Effectiveness of national pricing policies for patent-protected pharmaceuticals in the OECD: A systematic literature review

RUNNING TITLE: Effectiveness of Pharmaceutical Pricing Policies

AUTHORS:

First/corresponding author: Dominik J. Wettstein, M.A. HSG, Department of Health Sciences and Health Policy, University of Lucerne, Lucerne, Switzerland. Orcid: https://orcid.org/0000-0002-3085-212X

Co-author: Stefan Boes, Prof. Dr. oec. publ., Department of Health Sciences and Health Policy, University of Lucerne, Lucerne, Switzerland.

CONTACT INFORMATION FOR CORRESPONDING AUTHOR: Dominik Wettstein: <u>dominik.wettstein@stud.unilu.ch</u>.

FUNDING: This study has not been funded or supported by any public or private institution.

ACKNOWLEDGMENTS: none

COMPLIANCE WITH ETHICAL STANDARDS: Dominik Wettstein and Stefan Boes received no funding support. The first author is an external PhD student at the University of Lucerne and was employed at the pharmaceutical company Takeda Pharma while performing this research. Neither the former employer of the first author nor any other private or public entity supported or influenced the submitted research in any relevant manner.

KEYWORDS: pharmaceutical policy, pharmaceutical price regulation, reimbursement, pricing policies, reference pricing, value-based pricing

JEL CLASSIFICATION CODES: I180 Health: Government Policy; Regulation; Public Health

This is a post-peer-review, pre-copyedit version of an article published in Applied Health Economics and Health Policy. The final authenticated version is available online at: <u>https://doi.org/10.1007/s40258-018-0437-z</u>

Effectiveness of national pricing policies for patent-protected pharmaceuticals in the

OECD: A systematic literature review

Abstract

Objectives: The aim of this review is to assess the current state of empirical research regarding the effectiveness of national pricing regulations of the patent-protected market for prescription pharmaceuticals. Effectiveness is understood as the capacity of policies to have a desired impact on outcomes, such as health status, patient access, healthcare expenditure, and research investments, among others.

Methods: A systematic review of the published literature on pricing regulations in OECD countries was performed. The PubMed, MEDLINE, Scopus, Web of Science, Cochrane Library and the OECD iLibrary databases were searched in September 2016 and December 2017, with an update in August 2018. Interrupted time series studies and additional empirical studies were included, as well as systematic reviews if appropriate methods were applied. The risk of bias was assessed based on the recommendations of the BMJ guidelines, Cochrane EPOC criteria, QHES instrument, HTA good practice guidelines, CRD's guidance and the CHEC criteria. The quality of evidence was evaluated using the suggestions from EPOC and GRADE.

Results: Thirty-one publications met the inclusion criteria. Most of the assessed empirical research included therapeutic (TRP) and/or external reference pricing (ERP), with a clear majority focusing on TRP. The main outcomes that were analysed were drug prices, expenditures and drug use. For value-based pricing (VBP), only limited empirical data were found.

Conclusions: We found evidence that TRP may reduce pharmaceutical prices and expenditures in the short term. Furthermore, TRP may lead to substitution effects towards lower-priced pharmaceuticals. The effects of TRP on patient access, healthcare utilization and R&D investments

were found to be uncertain. No conclusions were drawn for ERP and VBP. No evidence was found for the effects on health outcomes for any of the analysed policies. There is a strong need for evidence generation regarding effective pricing policies, particularly

for value-based policies, managed entry agreements and non-financial outcomes.

Key Points for Decision Makers

- We found evidence that therapeutic reference pricing may reduce pharmaceutical prices and expenditures in the short term and may lead to substitution effects towards lower-priced drugs in the short term.
- Apart from the above, the existing research does not provide credible evidence that the current policies have an impact on healthcare utilization, patient access, health outcomes or R&D investments.
- There is a strong need for evidence generation regarding effective pricing policies, particularly for value-based pricing policies and for non-financial outcomes.
- Policy makers should systematically define the assessment of policy effectiveness during the policy formulation process. In addition, experimental research on the topic could augment the scarce amount of available evidence, especially for value-based pricing policies.

1. Introduction and background

1.1 Description of the policy issue

In most OECD (Organisation for Economic Co-operation and Development) countries, laws regulate the pricing of prescription pharmaceuticals. Parliaments and governments aim to control public spending on pharmaceuticals, while securing access to innovative treatments for their citizens. Desired policy outcomes of pricing and reimbursement regulations are focused on short-term reduction and mid-term stabilization of health expenditures [1]. In light of the financial and economic crisis, a majority of the countries in Western Europe in recent years decreed one-off as well as permanent, cost-containment policy measures to increase the control of spending on pharmaceuticals [1,2]. However, these policies face increasing criticism that they are not sufficiently effective, not only regarding impacts on public finances, but even more due to their potential consequences on access for patients to new treatment options [3,4], although new procedures for early access (conditional approval) and managed entry (coverage with evidence) have been introduced in Europe to make new therapies with "unsettled benefit–risk profiles" available [5].

Currently, the calls for reform are getting louder, in light of a growing number of new molecules and increasingly complex treatments, especially in oncology. According to IMS, the R&D pipeline for oncology "has expanded by more than 60% over the past decade", amounting to 710 late-phase therapies in 2017 [$\underline{6}$, $\underline{7}$]. Knowledge of the clinical benefits of the new therapies is often scarce at the time of marketing authorization [$\underline{8}$], and the promised survival benefits imply a longer therapy duration, and therefore, additional budget impacts. Additionally, an increasing number of molecules are used in combination with other medications [$\underline{6}$, $\underline{7}$]. Most of the national health systems have struggled to adapt to this new challenge, resulting in the reduced availability and coverage of new treatments [$\underline{6}$].

The current regulations might have not only adverse incentives for short-term availability, they are also claimed to have further undesirable effects on the long-term research decisions of industry, reducing related investments [9,10].

Finally, the ongoing change in the pharmaceutical sector, shifting from a "traditional blockbuster model" to more segmented markets offering therapies for smaller patient populations, leads to the discussion among authorities of whether current national policy approaches set the right incentives for industry to optimize research towards "value for money" [1,11,12]. In general, new drugs entering an established market can address previously unmet needs or target new populations for existing therapies (e.g., paediatric) and, consequently, increase treatment options [1]. While new therapies with high cure rates (e.g., for hepatitis) may be considered as cost-effective even at high nominal costs per patient and month, other innovations may seem hardly worth a premium compared to existing standards [13]. Most recently, OECD classified "many high-cost cancer drugs" as low-value ("type C") technologies, if value is "based solely on the cost per life year or per quality-adjusted life year" [13]. From a health system perspective there is a clear need for the evolvement of current reimbursement policies in industrialised countries to better reflect "value for money" of new treatments [14]. This calls for pricing regulations that promote fast access to essential innovations, while not incentivizing investments in "me-too" compounds that offer no additional benefit. The challenging part of such policy reforms towards a more value-based assessment is not only a technical but also a normative one: how to find consensus on which technologies are "essential" (funded on a system level) and which are "nice to have" (individual funding). The discussion on how to measure value for money and whether the new pricing schemes are increasing is still ongoing [15-17]. Figure 1 provides an overview of our policy analysis, summarizing the most common pricing policies and the most discussed policy outcomes. The latter were defined

with consideration to recent policy papers from the WHO and the OECD, as well as existing reviews of the topic [1,12,18-22]. We refined the effect taxonomy after the first abstract screenings. The differentiation between intermediate (behaviour, result) and ultimate policy effects represents our own proposal, which reflects the screened study designs.





Fig. 1 * includes affordability and availability (supply), P&R: pricing and reimbursement, MAH: marketing authorization holder

1.2 Description of current policy designs to address the policy issue

The most common pricing policies for pharmaceuticals in industrialised countries are therapeutic (internal) reference pricing, international (external) reference pricing and value-based assessments. These are generally combined with positive reimbursement lists (formularies), regular price reviews (individual or in groups) and tendering. These direct pricing policies are often supplemented with measures on the demand side to set desired incentives for prescribers, pharmacies and patients. Finally, authorities can link reimbursement authorisations to managed entry agreements, including coverage with evidence obligations and pay-for-performance schemes. The definitions below closely follow the suggestions of the "Glossary of Pharmaceutical Terms" issued by the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies.

Therapeutic (internal) reference pricing (TRP)

TRP is defined as the governmental practice of using the prices of identical (ATC 5 level) or similar medicines (ATC 4) or therapeutically equivalent treatments (beyond medicines) in a country. One or a set of therapies are used as benchmark or reference to set or negotiate the reimbursable price of a product in a given country. [20,23] The concrete mechanics can differ between the national systems (average or lowest of "equal" treatments, weighted for multiple indications, or not, measured per cycle, month or year). TRP can also be combined with other pricing instruments, such as ERP, and may also allow for an "innovation premium" for added therapeutic value (both are currently the case in Switzerland, based on Art. 65b KVV [24]). TRP sets the reimbursable price and thus implies that a third party, normally the patient (or insurance), has to cover the costs beyond the fixed price.

International (external) reference pricing (ERP)

ERP is the practice of using the prices of a medicine in one or several countries to derive a benchmark or reference to set or negotiate the price of a product in a given country [20,23]. All but two EU member countries (Sweden, UK) have implemented some type of ERP [15]. While the policy intends to affect the national market of the issuing state, its external effects are the subject of debate, since marketing authorization holders are incentivized to launch new therapies in countries with higher prices first and delay in others [15].

Value-based pricing (VBP)

The value-based assessment for pharmaceutical pricing is also referred to as "cost effectivenessbased", "outcome-based" or "pharma economic" pricing. There is still "no widely accepted definition" of the value part of this instrument [23]. Following the WHO glossary, when referring to VBP, we mean the practice of authorities of "setting prices for new medicines and/or deciding on reimbursement based on the therapeutic value which the medicine offers, usually assessed through a health technology assessment (HTA)". VBP can be combined with cost-effectiveness thresholds, such as in Sweden or the UK, to define a range for the acceptable price of a treatment. VBP agreements are predestined for combination with managed entry schemes (see below), such as the Patient Access Scheme (PAS) in the UK, which allows the manufacturer to adjust the offer to the authorities (bringing the ICER down). However, most MEAs and PASs are still volume-based and not value-based. [1,2,23,25,26]

Managed entry agreements (MEAs)

An MEA is an "arrangement between a manufacturer and a payer/provider that enables access to (coverage/reimbursement of) a health technology subject to specified conditions" [27]. It has established itself as the overarching term for arrangements such as "performance-based schemes", "risk-sharing agreements" (RSAs), "patient access schemes" (PASs) or "coverage with evidence" schemes. MEAs aim to address uncertainties of new health technologies regarding clinical performance, cost-effectiveness, effective use or long-term budget impacts. [23,27]

While some MEAs focus on real-world evidence collection after the market authorization, others are set up as profit controls, volume-based agreements or other forms of predefined ("capped") quantities or annual expenses for a new treatment. According to the ISPOR taxonomy, "cost-sharing" arrangements fall outside the definition of performance-based risk-sharing arrangements (PBRSA), since they are not linked to underlying cost-effectiveness [28]. While we do not limit our analysis to "financial schemes" [26], our focus lies on MEAs as part of or linked to pharmaceutical pricing regulations, following the WHO definition [23] (see inclusion criteria below under section 2.1).

Other pricing and reimbursement policies

In addition, the simple instrument of issuing a positive (or negative) reimbursement list is a widely used component of pharmaceutical pricing regulation. Further, in several countries, the official

reimbursement label is subject to negotiations for official reimbursement authorization. In addition to price, it often defines additional limitations of reimbursable use, e.g., the eligible population, sometimes including mandatory tests to prove eligibility, subject to approval by a medical examiner (insurance physician). This practice was recently applied to control costs of the new hepatitis C therapies, which led to a controversial discourse on politics and health sciences [1,13,29]. Finally, an interesting complement to TRP, VBP and other pricing policies under discussion is "indication-based pricing", which aims to "capture the differential value of drugs across indications or patient groups" [25]. Thus far, this has been applied to only a very few special therapies across the European countries [30]. One example is Bevacizumab, which in Switzerland has the same official list price for all of its seven reimbursable indications. However, for two of these, the official reimbursement label defines an indication-specific (renal cell carcinoma and breast cancer) payback that is reimbursable by the health insurance of the treated patient [31]. One common challenge for indication-based pricing is that existing administrative structures in many countries are not designed to "track patients' indications" for reimbursement purposes [32].

1.3 Why this review is important

Since the nineties, scientific interest in pharmaceutical pricing regulation has steadily increased, with a clear rise in publications in PubMed since 2013 [33]. In recent years, there have been a few systematic reviews published on existing evidence regarding pharmaceutical pricing regulation. Most of these reviews are limited to specific policies and have not been updated to reflect the most recent studies published on various health system and policy changes, especially regarding value-based pricing. The Cochrane Library has published seven systematic reviews in the research area in which we are interested. The review by Acosta et al. (2014) entitled "Pharmaceutical policies:

effects of reference pricing, other pricing, and purchasing policies" was found to be a very comprehensive, but was also a very restrictive, structured review [20].

Acosta et al. included only interrupted time series (ITS) and repeated measures (RM) studies. A more inclusive analysis of the existing body of research is necessary to provide a broader picture on current state of the discourse, which often takes place in the political arena. Otherwise, the analysis might reach only an exclusive expert audience. Finally, and most importantly, the previous reviews did not focus on the patent-protected market and did not simultaneously include all relevant policies. Most studies actually did the opposite—including or focusing on the off-patent market, while limiting the analysis to a single or a few selected policies. Against the background of the mentioned challenges for financing and incentivizing new, innovative health technologies, we consider the inverse focus to be essential.

1.4 Objectives

The aim of this review is to assess and summarize the current state of empirical research on the effectiveness of national pricing regulations on the patent-protected market for prescription pharmaceuticals. Effectiveness is understood to be the capacity of policies to have a desired impact on outcomes such as health state, patient access, drug use, healthcare utilization, drug prices, healthcare expenditure, research investment, individual or organizational benefit, overall welfare, behaviour other than drug use and equity.

The study aims to contribute to the discourse around reform options of pricing regulations for new ("innovative") pharmaceuticals in developed health systems with established public policies. Therefore, the analysis focuses on high-income OECD countries. There is undoubtedly a high need for health systems and related pharmaceutical policies to evolve in developing countries. However,

the majority of the respective policy settings and the data and evidence availability and quality were rated to not be supportive for the overarching research aims of this review.

2. Methods

2.1 Inclusion criteria for studies

Type of studies

Controlled before-after studies (CBA), interrupted time series studies (ITS) and repeated measures studies (RM) were included. Inclusion was generally based on the recommendations from the Effective Practice and Organisation of Care (EPOC) for review authors [34]. However, to gain a broader picture of the current research, empirical studies not fulfilling the EPOC criteria were included if appropriate quantitative data and methods for inductive statistics were used. Additionally, existing systematic reviews were included if appropriate methodologies were applied.

Type of policy designs

National pricing regulations for patent-protected pharmaceuticals, including international (external) reference pricing, therapeutic (internal) reference pricing, value-based pricing (based on clinical and pharma economic data), managed entry agreements, positive reimbursement lists (formularies), and regular price reviews (individual or in groups) were included if they were linked to price decisions. Not included were studies focusing on demand-side policies only, such as co-payments (patients), prescription quotas or budgeting (physicians), and substitution and margins (pharmacists).

Our definition of "pricing policies" follows the Glossary of Pharmaceutical Terms, published by the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies: "Regulations and processes used by government authorities to set the price of medicine as part of exercising price control" [23]. Based on this definition, we excluded analyses of MEAs not linked to price setting.

In contrast to the definition of the WHO CC and the Cochrane review by Acosta et al. [20], our scope was limited to official pricing policies issued by public authorities (i.e., national parliaments or governments, but not regulations issued by single health plans). Furthermore, effects of national pricing policies were considered only if they were realized in the addressed (sovereign) territory. In consequence, impact assessments of local policies on other countries, especially of ERP, were excluded. We acknowledge, however, that international effects are indirectly affecting the performance of national pricing policies [35].

Type of outcome measures

Outcomes of interest were policy effects such as health state (individual/societal), patient access, drug use, healthcare utilization, drug prices, healthcare expenditure, research and development (R&D) investments, welfare (economic benefit for an individual or organization, along with overall social welfare), behaviour other than drug use and equity (see Figure 1).

Scope of the studies: health systems considered

Only research focusing on "high-income" (World Bank classification) OECD countries was included, considering the historical changes of countries in their classification [<u>36</u>]. The reason for the defined scope is laid out above (1.4 Objectives).

2.2 Search methods

Published studies were identified by an electronic database search using the following sources: PubMed, MEDLINE, Scopus, Web of Science, Cochrane Library, and the OECD iLibrary. Searches with different word variations and combinations of "pharmaceutical" and "pricing" or "prices", as well as "policies" and "regulation" were performed. Publications on "reference pricing", "value-based pricing" and combinations with "patient access" and "innovative" were also searched. Further, a supplementary check on publications on "managed entry" or "risk sharing" agreements not flagged with "pricing" keywords was performed. The complete search strategy is listed in Table 3 of Appendix 1.

The searches were performed in September 2016, December 2017 and August 2018 (update of PubMed, Scopus and Web of Science search) and were restricted to records published in 2005 or later. No additional filters for language or quality of evidence (e.g., "peer-reviewed journal only") were applied at this stage. Only duplicate records (394) were excluded for initial abstract screening. Four additional publications not identified through the keyword search were added manually for abstract screening, since they were cited by at least one of the included systematic reviews on the topic.

2.3 Data extraction and analysis

As revealed in the PRISMA study flow [<u>37</u>] in Figure 2, the review was performed in five main phases: a) identification (electronic database searches), b) abstract screening, c) research categorization (full text), and d) assessment of risk of bias with e) subsequent qualitative synthesis. The first author (DJW) conducted the literature search and extracted the articles for initial abstract screening and research categorization. When articles met any of the exclusion criteria, they were excluded from further assessment. If the assignment was ambiguous or unclear, the first author (DJW) consulted with the second author (SB) to reach an agreement.

In the abstract screening, the exclusion criteria (Figure 2) were tested sequentially. If no exclusion criteria were met, then the publication was included in the research categorization step (c).

In the research categorization step (c), the full text of the selected publications were analysed, and they were classified according to "research type" (16 types, see Appendix 1, Table 4) and "research objective" (see Appendix 1, Table 5). If the publication was not classified as one of the six predefined research types, it was excluded. At the same time, the research objective of the publication was assigned to one of 24 predefined research objective pairs (see Table 5 in Appendix 1, based on the policy analysis layout in Figure 1). Studies were excluded if pricing policy was not the independent variable. Further, if no policy change was analysed (no change over time or no comparison with another country or district with a different policy setting), then the study was categorized as "descriptive" and was excluded.

For poster abstracts included after screening, research categorization was performed on the available abstract text. If, based on the available information, no exclusion criteria were applicable, then the abstract was included in the risk of bias assessment and qualitative synthesis.



Figure 2: Study flow (PRISMA diagram)

Fig. 2 *4 studies were added manually because they were cited by at least one of the included systematic reviews; DB: databases

2.4 Assessment of risk of bias

The assessment of the risk of bias was based on a synthesis of existing tools. The reason for this was that none of the commonly used tools were designed for an inclusive analysis of all of the types of research included in this analysis: empirical research, analytical microeconomic models and systematic literature reviews. The most common tools were designed for health interventions and had to be adjusted for health policy designs. The integrated questionnaire was based on a selection and synthesis of the recommendations from:

- the BMJ guidelines [38] and a later, additional questionnaire by Drummond et al. [39],
- the Cochrane EPOC criteria [40],

- the Quality of Health Economic Studies (QHES) instrument [41],
- the good practice guidelines for modelling in HTA by Philipps et al. [42],
- the CRD's guidance for reviews [43] and the criteria list from the Consensus on Health Economic Criteria (CHEC) project [44].

The questionnaire comprised of total 18 questions, four on the study design (S1-S4), four on the data source and handling (D1-D4), three for the analytical modelling (M1-M3) and seven on the empirical analysis, synthesis and conclusions (E1-E7). The full questionnaire is given in Appendix 1, Table 7.

For each publication and each question, the risk of bias was assessed with either low, unclear or high, following the EPOC suggestions [40]. Since the EPOC criteria were integrated with other assessment questionnaires, the scoring recommendation had to be adapted. In general, the score "unclear" was used restrictively. This was a necessary adaption for the rating of policy "interventions" compared to specific health interventions. If a question could not be answered since it was "not specified in paper" [40], the risk was rated high. The rating "unclear" was assigned only if credible arguments against relevant bias of the conclusion were indicated in the publication. For example, D4 (intervention dependent on other changes) was only rated low if it was plausible that the stated impact of the policy on the defined outcome was not influenced by other changes. It was rated unclear if efforts were displayed to control one or some of the most important confounders (e.g., other pharmaceutical policies implemented in parallel, other relevant healthcare policy measures in parallel, changes of the relevant market structure, relevant trends in technology, or relevant macroeconomic factors on the distribution or demand side).

Missing information from assessed poster abstracts was rated with a high risk of bias.

Low was scored with 2 points, unclear with 1 and high with 0. The final SCORE per record was the ratio of scored points to the total possible points, in percent. With the risk of bias defined as 1-

SCORE, the grouping was set as: 0% no risk, 1-19% low, 20-39% moderate, 40-59% medium, and 60-100% high risk of bias.

2.5 Synthesis of results

For each of the assessed publications all policy-outcome pairs analysed were listed and grouped into the four main policy designs (TRP, ERP, VBP, other), as described in section 1.2. The results per pair and publication were assigned to one of the following six policy-outcome effects:

- positive (\uparrow) ,
- negative (\downarrow) ,
- contradictory/inconclusive (\$),
- effect exists (different directions possible, \rightarrow),
- no effect (X),
- no conclusion (-).

The effects were contrasted with the risk of bias for the respective analysis for a qualitative synthesis per policy-outcome pair. We used the GRADE method [45] to rate the quality of evidence (high, moderate, low, very low), and based on that, followed the EPOC guidelines [46] to report the effect per pair.

3. Results

3.1 Included studies

A total of 31 publications met the inclusion criteria, and none were classified as CBA or RM. Eight publications were based on interrupted time series studies (ITS), and seven were included because they met the requirements for quantitative data and methods. A further four publications presenting analytical models were included, since empirical validation was performed. Finally, 12 systematic reviews were also included.

Included ITS: Armeni et al. 2016, Augurzky et al. 2009, Barros et al. 2010, Grootendorst et al. 2005, Grootendorst et al. 2006, Morgan et al. 2008, Stargardt 2010, Yfantopoulos 2007. [47-54] *Additional empirical research included (inductive statistics but no qualified ITS):* Golec et al. 2010, Kalo et al. 2012, Kanavos et al. 2011, Kyle 2007, Leopold et al. 2012, Stargardt 2011, von der Schulenburg et al. 2011. [10,55-60]

Included analytical models with empirical validation: Atella et al. 2012, Comanor et al. 2018, Kaiser et al. 2014, Koenig et al. 2011. [61-64]

Included systematic reviews: Acosta et al. 2014, Espin et al. 2011, Galizzi et al. 2011, Green et al. 2010, Lee et al. 2012, Lee et al. 2015, Morgan et al. 2009, Puig-Junoy 2005, Relakis et al. 2013 (poster abstract), Rémuzat et al. 2015, van der Gronde et al. 2017, Zhou et al. 2014 (poster abstract). [19-22,65-72]

Table 1 provides an overview of the included studies.

3.2 Excluded studies

Of the 871 publications included for initial abstract screening, 666 did not meet the inclusion criteria. Most of them (281) did not focus on pharmaceutical pricing regulations according to the definition. A total of 169 did not focus on OECD and/or on high-income countries; 82 focused on the off-patent market. Of the 205 records included for full-text research categorization, 174 were excluded because they did not analyse a policy change (134) and/or did not classify as an appropriate research type (147). Full details on every screened record and summary per criteria are given in Appendix 2, Table 9.

The main reasons for the exclusion of empirical studies, which were included in other systematic reviews on the topic (included in this review as well), were that they were either published before

the defined time frame (23), did not meet our definition of pricing policy (17), or focused on the off-patent (4) or free-pricing (2) market. Details are displayed in Appendix 1, Table 6.

Table 1: Overview of included publications

		•								ral	
					Scone / setting		~	~ ~	•	ene	5
Database	Publication	Type of economic research	Dependent variable	Methods	of analysis	Policy analysed	IRI	ERI	ΓR .	10 G	Outcomes
pubmed	Atella 2012 [61]	Economic model (analytic, empirical data)	Prices	OLS regression	US, Italy	Price controlls vs none		,,		X	Drug prices and drug quality (R&D invest)
scopus	Comanor 2018 [64]	Economic model (analytic, empirical data)	Prices	Ratio & linear regression	US, UK	Price controlls vs none			х	х	drug p rices
pubmed	Kaiser_2014 [62]	Economic model (analytic, empirical data)	Welfare***	Log-linear regression, random coefficients	Denmark 2005, statins	Change from external to therap. reference pricing	х				Drug prices, demand (drug use), expenditures, (co- pay ment)
pubmed	Koenig_2011 [63]	Economic model (analytic, empirical data)	Invest (R&D)	Random parameters logit model	27 European countries	External, therap. reference pricing, price controlls overall	х	х		х	Location choice (incl. R&D investment)
pubmed	Armeni_2016 [47]	Interrupted time series study (ITS)	Expenditures	ITS	Italy	Therap. reference pricing, quotas, [co-payment]	х				Drug expenditures
pubmed	Augurzky_2009 [48]	Interrupted time series study (ITS)	Prices	ITS	Germany	Therap. reference pricing	х				Drug prices
pubmed	Barros_2010 [49]	Interrupted time series study (ITS)	Expenditures	ITS	Spain	Administrated price reductions, therap. reference pricing	х			Х	C Drug exp enditures
pubmed	Grootendorst_2005 [50]	Interrupted time series study (ITS)	Expenditures	ITS	Canada, NSAIDs	Therap. reference pricing	х				Drug expenditures, drug use
pubmed	Grootendorst_2006 [51]	Interrupted time series study (ITS)	Prices	ITS	Canada, ACE Inh. & CCBs	Therap. reference pricing	х				Drug expenditures, drug use
pubmed	Morgan_2008 [52]	Interrupted time series study (ITS)	Invest (R&D)	ITS	Canada	Therap. reference pricing	х				R&D investment (local)
pubmed	Stargardt_2010 [53]	Interrupted time series study (ITS)	Usage**	ITS	Germany, statins	Therap. reference pricing	х				Drug use (adherence), healthcare utilization (visits), drug expenditures
pubmed	Yfantopoulos_2007 [54]	Interrupted time series study (ITS)	Prices	ITS	Greece	Positive list pricing				Х	C Drug expenditures
pubmed	Golec_2010 [10]	Statistical analysis - inductive (not ITS)	Invest (R&D)	OLS regression	US, EU	Price regulation by government vs none				х	Profitability, stock return, R&D investments
pubmed	Kalo_2012 [55]	Statistical analysis - inductive (not ITS)	Usage** & Exp	Aggregated linear regression	Hungary, asthma (2 prod.)	Therap. reference pricing	х				Drug expenditures (daily cost of therapy)
pubmed	Kanavos_2011 [56]	Statistical analysis - inductive (not ITS)	Prices	Random effects panel data analysis	OECD	Therap. & external reference pricing, free pricing	х	х			Drug prices
Scopus	Kyle_2007 [57]	Statistical analysis - inductive (not ITS)	Access*	Negative binomial regression	OECD	Price controlls vs none	х		х	хх	Patient access (countries launched, time to launch)
pubmed	Leopold_2012_II [58]	Statistical analysis - inductive (not ITS)	Prices	Linear regression model	14 EU countries, 14 products	External reference pricing		х			Drug prices
Scopus	Stargardt_2011 [59]	Statistical analysis - inductive (not ITS)	Prices	Hierarchical multi-level random intercept model	Germany	Therap. reference pricing, price freeze	х			Х	C Drug prices
pubmed	vonderSchulenburg_2011 [60]	Statistical analysis - inductive (not ITS)	Prices	Fixed/random effects panel data analysis	6 EU countries ACE Inhibitors	Therap. reference pricing, cost- effectiveness analysis (value-based), profit controlls, etc.	х		х	>	C Drug prices
pubmed	Acosta_2014 [20]	Systematic Review	Diverse	Systematic review of ITS, RM, CRM, CBA	18 articles included	Therap. & external reference pricing, maximum pricing, index pricing	х	Х		2	 K Health outcomes, healthcare utilization, drug expenditures and drug use
haiweb.org	g Espin_2011 [19]	Systematic Review	Prices	Systematic review [plus case studies]	21 articles included	External reference pricing		х			Drug prices
pubmed	Galizzi_2011 [65]	Systematic Review	Prices	Systematic review of theoretic and empiric research	35 articles included	Therap. reference pricing	х				Drug prices, drug expenditures, other effects
pubmed	Green_2010 [21]	Systematic Review	Diverse	Systematic review of ITS, RM, CRM, CBA	29 articles included	Restriction of reimbursement				2	C Drug use, healthcare utilization, health outcomes, drug expenditures
pubmed	Lee_2012 [66]	Systematic Review	Diverse	Systematic review of empiric research	16 articles included	Therap. reference pricing	x				Drug prices, drug expenditures, drug use and healthcare utilization
pubmed	Lee_2015 [22]	Systematic Review	Expenditures	Systematic review of ITS, RM	29 articles included	Policies to control expenditure (incl.	х			х	Drug expenditures, drug prices, drug use, healthcare
pubmed	Morgan_2009 [67]	Systematic Review	Diverse	Systematic review of ITS	3 [plus 12] articles included	Therap. reference pricing [and tiered formularies]	х				Drug expenditures (patient, insurer), drug use, healthcare utilization
pubmed	Puig-Junoy_2005 [68]	Systematic Review	Welfare***	Systematic review of empiric research	10 articles included	Therap. reference pricing	х				Overall social welfare, drug prices, healthcare utilization, [level of competition]
Web of Science	Relakis_2013 [69]	Systematic Review	Diverse	Systematic review of published evidence	na	Price controls				х	R&D investment, patient access (availability), drug expenditures, welfare
pubmed	Rémuzat_2015 [70]	Systematic Review	Prices	Systematic review of empiric research [plus survey]	234 articles included	External reference pricing		х			Drug prices, patient access, R&D investment, [international spill-over effects]
pubmed	vanderGronde_2017 [72]	Systematic Review	Diverse	Systematic review of scientific (peer-reviewed) and newspaper (journalistic) articles	221 (153+68) articles included	various	х	Х	х	хх	Drug prices, expenditures, access, various
pubmed	Zhou_2014 [71]	Systematic Review	Expenditures	Systematic review of theoretic and empiric	na	Therap. reference pricing	Х				Drug prices, drug use, drug expenditures, patient access

IST: Interrupted Time Series Study, TRP: Therapeutic Reference Pricing, ERP: External (International) Reference Pricing, VBP: Value-Based Pricing, R&D: Research and Development, na: not applicable [] not included in analysis, * includes affordability and availability (supply), ** includes drug use and healthcare utilization, *** includes individual benefit and overall welfare

3.3 Summary of risk of bias

Study design: For all the non-ITS empirical studies and empirically verified theoretical studies, the risk of bias was rated high. The main reasons for this were the lack of measures to control relevant underlying trends and confounding variables and limited time points before and after the analysed policy change. Further, the policy intervention for some of the studies was not clearly defined. [73-76] For example, Kaiser et al. defined the policy intervention as a "change from external to internal reference pricing" in Denmark in 2005 [62], while Atella et al. bundled "regulatory regimes" with or without price controls for the US and Italy [61]. In the latter, since effective (potentially interacting) policies remained unspecified, and no indication and justification for the data range was given, the risk of bias for the section study design was rated as high. Golec/Vernon investigated the impact of overall price controls on R&D spending and profitability of EU vs. US firms [10]. However, the basic design lacks plausible methods to isolate the policy effects from confounding drivers for R&D spending or stock market returns. Data: Most studies did not report techniques, evidence or plausible arguments to prevent outcomes from being influenced by other confounding variables during the analysed period. [40] Both Grootendorst/Steward and Morgan/Cunningham analysed the implementation of TRP policies in British Columbia [51,52]. The first study reports a negative (decreasing) effect on drug expenditures, while the latter concluded that there was no impact on local R&D spending. While the risk of bias for the analysis of Grootendorst/Steward was rated low overall, they admit that the introduction of low-cost generics during the analysed period could not be adequately controlled for [51]. Morgan/Cunningham neither control for nor discuss changes in the market in their analysis. Differences between the two systems regarding market structure (e.g., R&D intensity, companies entering/leaving the market) were neither controlled for, nor disclosed or discussed. [52]

Empirical analysis: Disaggregated results were missing for some of the studies and for some of the reviews. Additionally, some of the conclusions were enriched with opinion statements that were not founded on the analysed data and presented results. Yfantopoulos concludes that the introduction of positive list pricing in Greece was not effective in controlling pharmaceutical expenditures [54]. However, the underlying parameter is not significant, and many more details on the expenditure data that was used would be needed to reduce the risk of bias. The literature review from Espin/Rovira/Labry and that of Rémuzat et al. lacked an assessment of the evidence quality and risk of bias [19,70]. For both, it remains unclear whether the summary and the reported conclusions were based on the performed systematic review; additionally, no potential limitations of the analysis were disclosed.

Overall risk: The average risk of bias for the included ITS studies was rated low. Only the analysis from Yfantopoulos [54] left concerns, since information was missing on the independence of the effects from other changes, as well as on the aggregation of data and basis for conclusions, resulting in a medium risk of bias. The included analytical models with empirical verification scored lower, with moderate risk, mainly due to leaving doubts regarding the independence of the analysed changes and due to the lack of data reported on a disaggregated level. The non-ITS empirical studies were assessed only partly, since their risk of bias was judged as high after the initial assessment of the study design and data selection (except Kyle and Stargardt 2011, which was medium [57,59]). Most of the selected systematic reviews had a credible low risk of bias, with the exception of Rémuzat [70], Espin [19] and van der Gronde [72]. In Espin et al., more than half of the included studies were classified as opinions, while information on the included research designs was found to be incomplete. For the analysis of Relakis [69] and Zhou [71], no full results completing the published poster abstracts were found. Van der Gronde et al. [72] provided a comprehensive and up-to-date overview on the topic of pharmaceutical pricing; however, their paper did not disclose relevant information on the exclusion

criteria (screening, eligibility), criteria for additional inclusions, the chosen time period, and selection criteria for newspapers. Furthermore, no assessment of the risk of bias or the method of synthesis was disclosed (see PRISMA recommendations [37]), and central statements were either based on a single publication or not referred at all. An overview of the assessment of the risk of bias is provided in Appendix 1, Table 8.

3.4 Effects of the policy changes and quality of evidence

Table 2 provides an overview of the synthesized effects of the policy changes reported in the assessed empirical publications, as well as in the analysed systematic reviews. We found result statements for eight outcome categories. The only outcome category completely missing in the assessed publications was "equity". No research intention was formulated for seven potential policy-outcome pairs, leading to 17 potential effects for synthesis. A conclusive statement could be derived for only 11 pairs.

TRP on drug prices: Five of the empirical studies and six systematic reviews performed an analysis of the impact of TRP on drug prices. Three of the original studies found evidence for prices to decrease after the introduction of TRP, one study reported inconclusive results (increase as well as decrease) and one study did not find an impact. Four of the reviews concluded that the introduction of TRP was likely to have a negative (reducing) impact on prices, while one publication reported "minimal" impact, with no details. For a general statement of the respective correlations, the evidence quality was rated low. We conclude that TRP may reduce drug prices. [22,48,56,59,60,62,65,66,68,71,72]

TRP on healthcare expenditures: Seven of the empirical studies and six systematic reviews performed a respective analysis. Four of the original studies reported reduced reimbursed expenditures. One study stated a transitory reduction with no impact on the trend. Furthermore, one study found that TRP did not reduce expenditures, and a recent (2016) analysis concluded

that TRP leads to higher expenditures. Of the systematic reviews, all five reported that TRP reduced the amount of drug expenditures. However, the definition of savings and expenditures was heterogeneous, and uncertainties on sustainability of the effects were reported. Although the average risk of bias was moderate, the effect was ambiguous, and for half of the studies the evidence was limited to a specific therapy or substance. In consequence, the overall quality of evidence for a general statement was rated as low for short-term expenditures and very low for mid-term expenditures. We conclude that TRP may reduce drug expenditures in the short term, while the long-term effect is uncertain. [20,22,47,49-51,53,55,62,65-67,71] This finding is in line with that of Acosta et al. [20].

TRP on drug use: Four of the empirical studies and five systematic reviews reported a respective analysis. All of the publications reported, in some form, shifts, switches or substitutions due to TRP between reference and referenced drugs. Very limited information and evidence was reported on overall drug use for the affected therapies. The empirical studies were limited to four therapeutic/pharmacological subgroups: ACE inhibitors, calcium channel blockers, NSAIDS (ATC level 3) and statins (ATC level 4). Consequently, the overall quality of evidence for a general statement was found to be low, although the average risk of bias was low for the reported substitution effects. We found that for a "moderate" rating, broader empirical research is needed that includes different therapies. [20,22,50,51,53,62,66,67,71]

For TRP and the outcomes *healthcare utilization, patient access* and *R&D investment*, the quality of evidence was rated very low, and we conclude that it is uncertain whether a respective policy impact exists. No evidence was reported for effects on *health outcome* or overall *welfare*. As displayed in Table 2, the body of research was markedly limited for ERP and very limited for VBP policies. We found the negative impact of both policies on *prices* and *patient access* to be uncertain, similar to the impact of ERP on research investments. For all other possible outcomes, no clear conclusion (or no conclusion) was reported in the analysed literature.

Further effects were reported for other policies such as administered price reductions (Spain) [49], positive list pricing (Greece) [54], price freeze (Germany) [59] or profit controls [60]. A Cochrane review from 2010 found that "Implementing restrictions to coverage and reimbursement of selected medications can decrease third-party drug spending without increasing the use of other health services" based on the results from six ITS studies [21]. We found no evidence for impacts from MEA in the context of pricing policies. There is a growing interest, with a corresponding increase of publications, on "use, advantages and disadvantages" [77], while evidence on these outcomes remains scarce [26,78,79].

4. Conclusions and Discussion

OECD countries have implemented numerous policy reforms on pharmaceutical pricing in the last decade [1]. The scientific evidence of whether these policy adjustments have the desired or unwanted effects on debated outcomes is, however, still scarce. In particular, for patent-protected pharmaceuticals ("new innovative technologies"), qualified evidence on policy effects remains very limited. The majority of empirical studies and reviews included in this review focused on therapeutic reference pricing. We found evidence that TRP may reduce pharmaceutical prices and expenditures in the short-term and may lead to substitution effects towards lower priced drugs in the short term. Apart from that, the existing research does not provide certain evidence that the current policies have an impact on healthcare utilization, patient access, health outcomes or R&D investments.

The aim of this paper was to analyse qualified empirical research on the effectiveness of existing policies. It was not the aim to perform an impact analysis of the existing research on current policy debates. To consider potential reasons for the scarce evidence that we found, we investigated the inclusion of the analysed research in selected topical policy publications from the

OECD and the European Union. Of the 205 publications included in our initial research categorization, only two (Paris et al. [12] and Vogler et al. [80], both qualified as "descriptive") were referenced in the recent 231 page OECD paper on "New Health Technologies: Managing Access, Value and Sustainability" [13]. Additionally, the very recent report from the European Commission (Expert Panel on Effective ways of Investing in Health EXPH) on "Innovative payment models for high-cost innovative medicines" [14] refers only to one study (again, Paris et al. [12]). The cited OECD working paper No. 63 "Value in Pharmaceutical Pricing" [12] itself referrers to one of the categorized studies (Leopold [81], qualified as "descriptive"). The more recent OECD working paper No. 87 on "Pharmaceutical Expenditure And Policies" [1] makes reference to one of the included and assessed studies, the systematic review from Lee et al. [66], without placing it into context of other systematic reviews or original research.¹

For a general conclusion, a proper impact analysis would be needed that would consider the sequential influence of original research (e.g., using a "payback model", see [82,83]) in a broader selection of recent policy papers. Yet the conclusions might be noted for their discrepancy between imminent legislative discussions and available scientific evidence. While external and therapeutic reference pricing are still broadly applied and are not expected to be abandoned, new "innovative payment models for new medicines" are desired by authorities [14] and by the pharmaceutical industry [84]. There seems to be a high-level consensus that new models should reflect therapeutic value added for the society and focus on patient-relevant outcomes. Several OECD countries have already incorporated value-based elements into their pharmaceutical pricing policies; for example, Sweden has been doing this for more than 10 years [12,18]. The trend in OECD countries is clear, with HTA being "increasingly used to inform coverage decisions" [1]. In this context, the lack of evidence on value-based pricing policies is consternating, if not alarming, especially given the current scepticism of the European Parliament,

¹ The three papers from the OECD and EXPH refer to few of the recent literature on MEAs, which we excluded since none of them provides a policy effect analysis (see above).

where value-based pricing "can be misused as a profit maximizing economic strategy" [85]. As was very recently stated by Vogler (WHO) and Paris (OECD) et al. "regular reviews and evaluations of the impact of pricing and reimbursement policies" are critical to determine their effectiveness in "achieving the intended aims" [15]. There is a particular "need for impact assessments of managed entry agreements, value-based pricing and HTA" [15,77].

Why is the value-based pricing policy debate not informed by a more solid body of empirical evidence? There are admittedly methodological challenges with the empirical analysis of such policy changes in general. The different settings of the included studies in this paper reveal an unsurprising picture. The reported results (regarding TRP) with a lower risk of bias focused on only a few, established therapies or substances with a certain technological "stability" over a few years. Some of those studies could hardly be repeated for current oncologic treatments, where an increasing number of completely new therapies (e.g., targeted immune oncology) are coming to the market. This technological trend is "multiplied" by the increasing number of interdependent policy changes in recent years in most OECD healthcare systems.

These scientific challenges are confronted by the changing needs of the policy makers—the emerging legislative necessity to move from generally valid, static regulations to adaptive policies based on a mix of models [14]. In addition, the effort of designing and evaluating policy adaptions is a disproportionately higher burden for smaller countries [86].

Finally, value-based, performance-oriented agreements are often linked to MEAs and RSAs [78]. The resulting prices and conditions are, in the majority of countries, confidential and are therefore difficult to access for scientific evaluation [19,26,28,78,87].

It has never been more obvious that the interaction of health policy formulation and academic policy research needs to move beyond an "iterative" process (Habermas [88]) to a more "co-creative", "co-evolutionary" process (Jasanoff [89]). This could also increase legitimacy. In the

concrete example of value-based pricing of new pharmaceutical therapies, this should mean the following:

- Need for the early and regular involvement of policy makers in the design of new policy research. Define the concept of qualified policy effectiveness analysis in the policy formulation phase, and roll it out jointly with the regulation change in the policy implementation phase.
- Need for research institutions to proactively approach the changing needs of the policy formulation process with appropriate research tools. Promote applicable empirical tools to analyse smaller, faster and interdependent policy changes. Additionally, complement the classical empirical tools, such as interrupted time series studies, with economic (field or laboratory) experiments to test policy hypotheses at an early stage.
- Need for the pharmaceutical industry, healthcare providers and insurance companies to set up and cooperatively participate in health economic studies beyond established clinical trials (post-marketing authorization), using real-world data on clinical and non-clinical outcomes.

Main limitation: While our restrictive focus on qualified study designs and the chosen methodology to adjust for the risk of bias follows the current practices [34,40], it comes at a cost. The current state of the underlying policy reform might call for a broader analysis of survey data, discussion papers and policy statements—from scientific and from political stakeholders. These data were not included in the findings of our study. On the other hand, the broader selection of designs, as recommended by EPOC [34,40], and the inclusion of meta-literature might also have skewed our findings.

Nevertheless, we conclude that there is a high need for evidence generation on effective pricing policies. In particular, the emerging value-based pricing policies and managed entry agreements should be assessed continuously on a scientific basis to inform policy formulation processes in

OECD countries [15]. In general, it is recommended to define policy effectiveness analysis in the policy formulation and implementation process.

Compliance with Ethical Standards

Funding: No funding was received for the research performed or the writing of the manuscript. Conflict of interest: DJW is an external PhD student at the University of Lucerne and was employed at the pharmaceutical company Takeda Pharma while performing this research. Neither the former employer of the first author nor any other private or public entity supported or influenced this research in any relevant way. SB has no conflicts of interest to declare. All of the authors submitted a signed Conflict of Interest disclosure form.

Author contributions: All of the authors (DJW and SB) fulfilled the authorship criteria and contributed to the design of the study, review of the search protocol, analysis and interpretation of the results, and writing and review of the manuscript. DJW prepared the search protocol, performed the database searches, screenings, categorizations, and assessments and prepared the draft of the manuscript. All of the authors are aware of the submission and are in agreement with the manuscript.

		Orig.	Syst.						Quality of	
Policy	Outcome	studies	reviews	Effect			Risk of	f Bias ¹	evidence ²	Synthesis ³
	T			1					1	r
TRP	Drug prices	5		Kanavos_2011 [56]	not significant	-	69%	high	LOW	TRP may reduce
				vonderSchulenburg_2011 [60]	results inconclusive	Ţ	69%	high		drug prices.
				Kaiser 2014 [62]	Substantial reduction in prices	ī	10%	low		
				Augurzky 2009 [48]	no full but fast price adjustment	+ 	17%	low		
				14ugui2ky_2009 [40]	manufacturers seem to compensate	¥	1770	10 11		
					TRP prices with non-TRP prices					
				Stargardt 2011 [59]	TRP reduces prices	ī	44%	med		
			6	Galizzi 2011 [65]	After intro of TRP prices are likely	↓ 	8%	low		
			0	Cumpri_2011 [00]	to drop	¥	070	1011		
				Lee_2012 [66]	reduced drug prices	\downarrow	8%	low		
				Lee_2015 [22]	minimal impact on prices	\rightarrow	4%	low		
				vanderGronde_2017 [72]	lower prices	Ļ	96%	high		
				Zhou_2014 [71]	reference pricing could reduce	Ļ	92%	high		
				Puig-Junov 2005 [68]	prices (descriptive/no conclusion)	-	8%	low		
	Healthcare	7		Grootendorst 2005 [50]	reduced drug expenditures, due to	Ļ	0%	no	LOW for	TRP may reduce
	expenditures				substitution of lower cost for				short-term,	drug expenditures
					higher-cost drugs, coupled with					in the short term.
					cost drugs				VEDVIOW	It is up contain
				Grootendorst 2006 [51]	substitution of lower cost for	I	7%	low	for mid-term	whether TRP
					higher-cost drugs, coupled with the	¥				reduces drug
					reduced reimbursement of higher-					expenditures in the
					cost drugs, had the effect of					long-term.
					lowering arag expenditure					
				Stargardt_2010 [53]	decrease in expenditures	Ļ	10%	low		
				Kaiser_2014 [62]	Substantial reduction in healthcare	\downarrow	19%	low		
					expenditures					
				Kalo_2012 [55]	therap. reference pricing does not	Х	69%	high		
				Barros 2010 [49]	Impact on expenditures transitory:	⊥X	17%	low		
					on level but not trend	•				
				Armeni_2016 [47]	therap. reference pricing leads to	Î	10%	low		
			6	Galizzi 2011 [65]	higher expenditures saving effects (short-term) at least	1	8%	low		
			0		on molecule level, due to switches	¥	070	1011		
				Lee_2015 [22]	reference pricing may result in cost		4%	low		
				A	savings		00/			
				Acosta_2014 [20]	in the short term by shifting drug	Ļ	0%	по		
					use from cost share drugs to					
					reference drugs. effect on					
					expenditures of cost share drugs is					
				Morgan_2009 [67]	reduced expenditures	\downarrow	17%	low		
				Lee_2012 [66]	decreases in expenditures	\downarrow	8%	low		
				Zhou_2014 [71]	could reduce expenditures	Ļ	92%	high		
	Drug use	4		Grootendorst_2005 [50]	substitution of lower cost for	\rightarrow	0%	no	LOW	TRP may lead to
	(substitution/tot			Grootendorst 2006 [51]	higher-cost drugs substitution of lower cost for	\rightarrow	7%	low		substitution effects
	ai use)			Grootendorst_2000 [51]	higher-cost drugs		//0	10 11		towards lower
				Stargardt_2010 [53]	increase in switches and of non-	\rightarrow	10%	low		short term.
				Kaiser 2014 [62]	adherence reform induced consumers to	\rightarrow	19%	low		
					substitute away from branded	,	1770			
					drugs					
			5	Acosta_2014 [20]	drug use shifting from cost share	\rightarrow	0%	no		
				Morgan 2009 [67]	drugs to reference drugs increased switching reduced overall	→	17%	low		
				Lee 2012 [66]	increased switching.	÷	8%	low		
					no increased use	х				
				Lee_2015 [22]	shifts in use	\rightarrow	4%	low		
				Zhou_2014 [71]	increase use of lower priced drugs	\rightarrow	92%	high		

Table 2: Summary effects of policy changes and quality of evidence

TRP (cont.)	Healthcare utilization	1		Stargardt_2010 [53]	limited evidence that increased switching leads to increased visits in some sub-groups	ſ	10%	low	VERY LOW	It is uncertain whether TRP
			4	Lee 2015 [22]	(nothing reported)		4%	low		increases health-
			-	A costo 2014 [20]	affects on healthcare utilization are		00/	1011		care utilization.
				Acosta_2014 [20]	uncertain due to lack of evidence	-	070	110		
				M organ_2009 [67]	increase in short-term physician	¢	17%	low		
				Puig-Junoy_2005 [68]	(descriptive/no conclusion)	-	8%	low		
	Patient access	1		Kyle_2007 [57]	TRP leads to earlier launch	î	56%	med	VERY LOW	It is uncertain whether TRP leads
			1	Zhou_2014 [71]	no impact on patient access found	-	92%	high		to earlier launches.
	Health outcome	-	3	Lee_2015 [22]	(nothing reported)	-	4%	low	-	-
				Acosta_2014 [20]	no evidence found	-	0%	no		
				Morgan_2009 [67]	no evidence found	-	17%	low		
	Welfare	-	1	Puig-Junoy_2005 [68]	no evidence on found	-	8%	low	-	-
	Research	2	-	Koenig 2011 [63]	less investments for countries with	-	33%	mod	VERY LOW	It is uncertain
	investment				price controls, but not significant for R&D only					whether TRP has an effect on R&D
				Morgan_2008 [52]	reference pricing did not have impact on local R&D	Х	23%	mod		investments.
ERP	Drug prices	2		Kanavos_2011 [56]	not significant	-	69%	high	VERY LOW	It is uncertain
				Leopold_2012_II [58]	leads to lower prices, but price level not driven by ERP only	Ļ	75%	high		whether ERP reduces prices.
			3	Rémuzat_2015 [70]	inconclusive	¢	63%	high		
				Espin_2011 [19]	no evidence found	-	63%	high		
				vanderGronde_2017 [72]	(nothing reported)	-	96%	high		
	Healthcare expenditures	-	1	Acosta_2014 [20]	(nothing reported)	-	0%	no	-	-
	Drug use	-	1	Acosta_2014 [20]	(nothing reported)	-	0%	no	-	-
	Healthcare	-	1	Acosta_2014 [20]	(nothing reported)	-	0%	no	-	-
	utilization									
	Patient access		2	Rémuzat_2015 [70]	evidence for delay or avoidance of launches	Ļ	63%	high	VERY LOW	It is uncertain whether ERP has a
				vanderGronde 2017 [72]	countries with a lower willingness	Ţ	96%	high		negative effect on
					to pay could see a drug launch delayed or no launch at all	·		c		patient access.
	Health outcome	-	1	Acosta 2014 [20]	(nothing reported)	-	0%	no	-	-
	Research	1		Koenig 2011 [63]	less investments for countries with	-	33%	mod	VERYLOW	The effect of ERP
	investment	1		1.00mB_2011 [00]	price controls, but not significant for R&D only		5570	mou	VERT EO II	on R&D
			1	Rémuzat_2015 [70]	(descriptive/no conclusion)	-	63%	high		uncertain and unclear.
VBP	Drug prices	2		vonderSchulenburg_2011 [60]	cost-effectiveness analysis has a	Ļ	69%	high	VERY LOW	It is uncertain
				Comanor_2018 [64]	negative impact on price VBP leads to same prices as free-	х	97%	high		whether VBP reduces drug
					market pricing					prices.
			1	vanderGronde_2017 [72]	VBP incentivizes high prices for	Î	96%	high		
	Dationt	1		Kula 2007 [57]	nnovative drugs		5(0/	hicks	VEDVLOW	It is an east-in
	r auent access	1	-	Kyle_2007[57]	requirement seems to delay launch	Ļ	30%	mgu	VEKILUW	whether VBP has a negative effect on patient access

Policies: TRP: Therapeutic reference pricing, ERP: External reference pricing, VBP: Value-based pricing **Effect**: \uparrow positive effect, \downarrow negative effect, \updownarrow contradictory/inconclusive effect, \rightarrow effect (different directions possible), X no effect, - no conclusion

¹**Risk of bias:** 1-SCORE (0% <u>no</u> risk, 1-19% <u>low</u>, 20-39% <u>mod</u>erate, 40-59% <u>med</u>ium, 60-100% <u>high</u>), overall outcomes are per publication unless stated otherwise.

* Risk for this policy-outcome pair adjusted, since it was considerably higher than for the publication overall.

² Grades of evidence according to the GRADE Working Group [45]:

HIGH: We are very confident that the true effect lies close to that of the estimate of the effect.

MODERATE: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

LOW: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. VERY LOW: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

³ Synthesis of the effect following the EPOC guidelines on how to report the effects of interventions [46]. R&D: Research and Development

References

- 1. Belloni A, Morgan D, Paris V. Pharmaceutical Expenditure And Policies: PAST TRENDS AND FUTURE CHALLENGES. *OECD Health Working Papers*. 2016(87):0_1-4,8-73.
- 2. Garattini L, Curto A, Freemantle N. Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One? *PharmacoEconomics*. 2016;34(5):423-426.
- 3. Kheirandish M, Rashidian A, Kebriaeezade A, Cheraghali AM, Soleymani F. A review of pharmaceutical policies in response to economic crises and sanctions. *J Res Pharm Pract.* 2015;4(3):115-122.
- 4. Vogler S, Zimmermann N, Ferrario A, et al. Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. *Journal of pharmaceutical policy and practice*. 2016;9:9.
- 5. Banzi R, Gerardi C, Bertele V, Garattini S. Approvals of drugs with uncertain benefitrisk profiles in Europe. *European journal of internal medicine*. 2015;26(8):572-584.
- 6. Aitken M, Kleinrock M. *Global Oncology Trend Report A Review of 2015 and Outlook to 2020.* IMS Institute for Healthcare Informatics; June 2016 2016.
- 7. Aitken M, Kleinrock M, Simorellis A, Nass D. *Global Oncology Trends 2018, Innovation, Expansion and Disruption.* IQVIA Institute for Human Data Science; May 24, 2018 2018.
- 8. Grossmann N, Wild C. Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval? *ESMO open*. 2016;1(6):e000125.
- 9. Vernon JA. Examining the link between price regulation and pharmaceutical R&D investment. *Health Econ.* 2005;14(1):1-16.
- 10. Golec J, Vernon JA. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms. *PharmacoEconomics*. 2010;28(8):615-628.
- 11. Pani L, Montilla S, Nemeth G, Russo P, Viceconte G, Vogler S. Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR). *Pharmacological research*. 2016;111:247-250.
- 12. Paris V, Belloni A. Value in Pharmaceutical Pricing. OECD Publishing; 2013.
- 13. OECD. *New Health Technologies: Managing Access, Value and Sustainability*. OECD Publishing; 2017.
- 14. Expert Panel on effective ways of investing in Health (EXPH). *Innovative payment models for high-cost innovative medicines*. European Commission,; 2018.
- 15. Vogler S, Paris V, Ferrario A, et al. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. *Appl Health Econ Health Policy*. 2017;15(3):307-321.
- 16. Lorenzoni L, Murtin F, Springare L-S, Auraaen A, Daniel F. Which policies increase value for money in health care? 2018.
- 17. Cole A, Towse A, Lorgelly P, Sullivan R. *Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals*. 2018.
- 18. Panteli D, Arickx F, Cleemput I, et al. Pharmaceutical regulation in 15 European countries review. *Health Syst Transit.* 2016;18(5):1-122.
- 19. Espin J, Rovera J, Olry de Labry A. Review series on pharmaceutical pricing policies and interventions: working paper 1: external reference pricing. *WHO/HAI*. 2011.
- 20. Acosta A, Ciapponi A, Aaserud M, et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. *Cochrane Database Syst Rev.* 2014(10):CD005979.

- 21. Green CJ, Maclure M, Fortin PM, Ramsay CR, Aaserud M, Bardal S. Pharmaceutical policies: effects of restrictions on reimbursement. *Cochrane Database Syst Rev.* 2010(8):CD008654.
- 22. Lee IH, Bloor K, Hewitt C, Maynard A. International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry a systematic review. *J Health Serv Res Policy*. 2015;20(1):52-59.
- 23. Vogler S, Zimmermann N. Glossary of Pharmaceutical Terms. In: WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, ed. <u>http://whocc.goeg.at</u>: WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies,; 2016.
- 24. Verordnung über die Krankenversicherung (KVV). In: Bundesrat DS, ed. Vol 832.102. Systematische Sammlung des Bundesrechts (SR)1995.
- 25. Hughes DA. Value-based pricing: incentive for innovation or zero net benefit? *PharmacoEconomics*. 2011;29(9):731-735.
- 26. Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. 2013.
- 27. Klemp M, Fronsdal KB, Facey K, Forum HTP. What principles should govern the use of managed entry agreements? *Int J Technol Assess Health Care*. 2011;27(1):77-83.
- 28. Garrison LP, Jr., Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. *Value Health.* 2013;16(5):703-719.
- 29. Marshall AD, Cunningham EB, Nielsen S, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. *The lancet. Gastroenterology & hepatology.* 2018;3(2):125-133.
- 30. Flume M, Bardou M, Capri S, et al. Feasibility and attractiveness of indication valuebased pricing in key EU countries. *J Mark Access Health Policy*. 2016;4.
- 31. Spezialitätenliste: Avastin. BAG; 2018. <u>http://www.spezialitaetenliste.ch/</u>. Accessed 1. Aug. 2018.
- 32. Persson U, Norlin JM. Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations. *Appl Health Econ Health Policy*. 2018;16(2):157-165.
- 33. PubMed. PubMed search. 2018; <u>https://www.ncbi.nlm.nih.gov/pubmed/</u>. Accessed 31 Aug 2018.
- 34. Cochrane Effective Practice and Organisation of Care (EPOC). What study designs should be included in an EPOC review? *EPOC Resources for review authors*. Oslo: Norwegian Knowledge Centre for the Health Services; 2016.
- 35. Persson U, Jonsson B. The End of the International Reference Pricing System? *Appl Health Econ Health Policy*. 2016;14(1):1-8.
- 36. World Bank Country and Lending Groups. 2016; https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bankcountry-and-lending-groups. Accessed 31.12.2016, 2016.
- 37. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ (Clinical research ed.).* 2009;339:b2535.
- 38. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. *BMJ* (*Clinical research ed.*). 1996;313(7052):275-283.

- 39. Drummond M, Sculpher M, Torrance G, O'Brien BJ, Stoddart G, eds. *Methods for the Economic Evaluation of Health Care Programmes*. 3rd ed: Oxford University Press, U.S.A.; 2005.
- 40. Cochrane Effective Practice and Organisation of Care (EPOC). Suggested risk of bias criteria for EPOC reviews. *EPOC Resources for review authors*. Oslo: Norwegian Knowledge Centre for the Health Services; 2015.
- 41. Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. *Journal of managed care pharmacy : JMCP*. 2003;9(1):53-61.
- 42. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. *PharmacoEconomics*. 2006;24(4):355-371.
- 43. Tacconelli E. Systematic reviews: CRD's guidance for undertaking reviews in health care. *The Lancet Infectious Diseases*. Vol 102010.
- 44. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. *Int J Technol Assess Health Care*. 2005;21(2):240-245.
- 45. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *Journal of clinical epidemiology*. 2011;64(4):401-406.
- 46. Cochrane Effective Practice and Organisation of Care (EPOC). Reporting the effects of an intervention in EPOC reviews. *EPOC Resources for review authors*. Vol 24 August 20172017.
- 47. Armeni P, Jommi C, Otto M. The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study. *Eur J Health Econ.* 2016;17(8):963-977.
- 48. Augurzky B, Gohlmann S, Gress S, Wasem J. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach. *Health Econ.* 2009;18(4):421-436.
- 49. Barros PP, Nunes LC. The impact of pharmaceutical policy measures: an endogenous structural-break approach. *Soc Sci Med.* 2010;71(3):440-450.
- 50. Grootendorst PV, Marshall JK, Holbrook AM, Dolovich LR, O'Brien BJ, Levy AR. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs. *Health Serv Res.* 2005;40(5 Pt 1):1297-1317.
- 51. Grootendorst P, Stewart D. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. *Health Econ.* 2006;15(7):735-742.
- 52. Morgan S, Cunningham C. The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia. *Healthc Policy*. 2008;3(3):e128-153.
- 53. Stargardt T. The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. *Eur J Health Econ.* 2010;11(3):267-277.
- 54. Yfantopoulos J. Pharmaceutical pricing and reimbursement reforms in Greece. *Eur J Health Econ.* 2008;9(1):87-97.
- 55. Kalo Z, Abonyi-Toth Z, Bartfai Z, Voko Z. Pitfalls associated with the therapeutic reference pricing practice of asthma medication. *BMC Pulm Med.* 2012;12:35.
- 56. Kanavos PG, Vandoros S. Determinants of branded prescription medicine prices in OECD countries. *Health Econ Policy Law.* 2011;6(3):337-367.
- 57. Kyle MK. Pharmaceutical Price Controls and Entry Strategies. *Review of Economics and Statistics*. 2007;89(1):88-99.

- 58. Leopold C, Mantel-Teeuwisse AK, Seyfang L, et al. Impact of external price referencing on medicine prices a price comparison among 14 European countries. *South Med Rev.* 2012;5(2):34-41.
- 59. Stargardt T. Modelling pharmaceutical price changes in Germany: a function of competition and regulation. *Applied Economics*. 2011;43(29):4515-4526.
- 60. von der Schulenburg F, Vandoros S, Kanavos P. The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. *Health Econ Rev.* 2011;1(1):18.
- 61. Atella V, Bhattacharya J, Carbonari L. Pharmaceutical price controls and minimum efficacy regulation: evidence from the United States and Italy. *Health Serv Res.* 2012;47(1 Pt 1):293-308.
- 62. Kaiser U, Mendez SJ, Ronde T, Ullrich H. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark. *J Health Econ.* 2014;36:174-187.
- 63. Koenig P, Macgarvie M. Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe. *J Health Econ.* 2011;30(5):950-965.
- 64. Comanor WS, Schweitzer SO, Riddle JM, Schoenberg F. Value Based Pricing of Pharmaceuticals in the US and UK: Does Centralized Cost Effectiveness Analysis Matter? *Review of Industrial Organization*. 2018;52(4):589-602.
- 65. Galizzi MM, Ghislandi S, Miraldo M. Effects of reference pricing in pharmaceutical markets: a review. *PharmacoEconomics*. 2011;29(1):17-33.
- 66. Lee JL, Fischer MA, Shrank WH, Polinski JM, Choudhry NK. A systematic review of reference pricing: implications for US prescription drug spending. *Am J Manag Care*. 2012;18(11):e429-437.
- 67. Morgan S, Hanley G, Greyson D. Comparison of tiered formularies and reference pricing policies: a systematic review. *Open Med.* 2009;3(3):e131-139.
- 68. Puig-Junoy J. What is required to evaluate the impact of pharmaceutical reference pricing? *Appl Health Econ Health Policy*. 2005;4(2):87-98.
- 69. Relakis J, Maniadakis N, Kourlaba G, Shen J, Holtorf AP. Systematic Review on the Impacts of Strict Pharmaceutical Price Controls. *Value in Health.* 2013;16(7):A486.
- 70. Remuzat C, Urbinati D, Mzoughi O, El Hammi E, Belgaied W, Toumi M. Overview of external reference pricing systems in Europe. *J Mark Access Health Policy*. 2015;3.
- 71. Zhou W, Cui X, Qian Y. Review Of Reference Pricing Effects On Pharmaceuticals. *Value Health.* 2014;17(7):A787.
- 72. Gronde TV, Uyl-de Groot CA, Pieters T. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. *PLoS One*. 2017;12(8):e0182613.
- 73. Cochrane Effective Practice and Organisation of Care (EPOC). Interrupted time series (ITS) analyses. *EPOC resources for review authors*.2013.
- 74. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. *Int J Technol Assess Health Care*. 2003;19(4):613-623.
- 75. Shojania KG, Grimshaw JM. Evidence-based quality improvement: the state of the science. *Health affairs (Project Hope)*. 2005;24(1):138-150.
- 76. Eccles M, Grimshaw J, Campbell M, Ramsay C. Research designs for studies evaluating the effectiveness of change and improvement strategies. *Quality & safety in health care*. 2003;12(1):47-52.
- 77. Ferrario A, Araja D, Bochenek T, et al. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. *PharmacoEconomics*. 2017;35(12):1271-1285.

- 78. Piatkiewicz TJ, Traulsen JM, Holm-Larsen T. Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends. *PharmacoEconomics open*. 2018;2(2):109-123.
- 79. Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. *Soc Sci Med.* 2015;124:39-47.
- Vogler S, Vitry A, Babar ZU. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. *Lancet Oncol.* 2016;17(1):39-47.
- 81. Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HG, Laing R. Differences in external price referencing in Europe: a descriptive overview. *Health Policy.* 2012;104(1):50-60.
- 82. Banzi R, Moja L, Pistotti V, Facchini A, Liberati A. Conceptual frameworks and empirical approaches used to assess the impact of health research: an overview of reviews. *Health Res Policy Syst.* 2011;9:26.
- 83. Cohen G, Schroeder J, Newson R, et al. Does health intervention research have real world policy and practice impacts: testing a new impact assessment tool. *Health Res Policy Syst.* 2015;13:3.
- 84. EFPIA. *EFPIA response to Draft Opinion on Innovative payment models for high-cost innovative medicines*. 07/12/2017 2017.
- 85. European Parliament. European Parliament resolution of 2 March 2017 on EU options for improving access to medicines (2016/2057(INI)). European Parliament,; 2017.
- 86. Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? *Expert Rev Clin Pharmacol.* 2015;8(1):77-94.
- 87. Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. *BMC Health Serv Res.* 2010;10:153.
- 88. Habermas J. Verwissenschaftlichte Politik und öffentliche Meinung. Rentsch; 1964.
- 89. Jasanoff S. *States of knowledge : the co-production of science and the social order*. London Routledge; 2005.

Appendix 1

Table 3: Search strategy

#	descriptor	proceeding	PUBMED	MEDLINE	Scopus	Web of Science	OECD iLibrary	COCHRANE	Other	TOTAL
1	pharmaceutical OR medicine AND pricing OR prices	AND, OR, 2005-		162						
23	"pharmaceutical pricing" OR "* prices" OR "* price" "pharmaceutical pricing" OR "* prices" OR "* price" OR "med icine prices" OR "drug prices"	exact OR, 2005- l- exact OR, 2005-	180		131	101	19	5		
4	"medicine prices" OR "drug prices" AND NOT #2	exact OR, AND, 2005-	174							
5	pricing, pharmaceuticals, innovative	AND, 2005-	66							
6	patient access pricing pharmaceuticals policies	AND, 2005-	51							
7	pharmaceutical, "pricing policies"	AND, 2005-	24							
8	"pharmaceutical policies"	exact, 2005-	82							
9	"value-based pricing" OR "value based pricing"	exact, OR, 2005-	46							
10	pharmaceutical, pricing, policies	AND, 2005-					20			
11	"price regulation", pharmaceutical	exact, AND, 2005-	49							
12	"reference pricing"	exact, 2005-	151							
99	[manually added since cited by included systematic review]		1						3	
	Search results		824	162	131	101	39	5	3	1265
	duplicates		99	126	58	79	27	5	0	394
	Initial abstract screening		725	36	73	22	12	0	3	871
	excluded		550	31	64	15	4	0	2	666
	Initial research categorization		175	5	9	7	8	0	1	205
	excluded		149	5	6	6	8	0	0	174
	Assessment		26	0	3	1	0	0	1	<u>3</u> 1

Additional checks:

#	descriptor	proceeding	PUBMEI
Al	"managed entry" NOT #2 NOT #9 NOT #12	exact, OR, 2005-	44
	"risk sharing agreements" OR "risk sharing schemes" OR "risk		
A2	sharing contracts NOT #2 NOT #9 NOT #12	exact OR, 2005-	67
	"managed entry" OR "risk sharing" AND pharmaceutical OR		
A3	pharmaceuticals OR drugs NOT #2 NOT #9 NOT #12	AND, OR, 2005-	106
	Additional inclusions		0

Search fields: title, abstract, key words. Word variations if supported.

Table 4: Categorization type of research

Table 5: Categorization research objective

Type of economic research	Empirical/ analytical	excluded
Economic model (analytic)	analytic	Y
Economic model (analytic, empirical data)	combined	Ν
Cost-effectiveness analysis (CEA)	combined	Ν
Cost-utility analysis (CUA)	combined	Ν
Cost-benefit analysis	combined	Ν
RCT, NRCT	empiric	Ν
Controlled before-after study (CBA)	empiric	Ν
Interrupted time series study (ITS)	empiric	Ν
Repeated measures study (RM)	empiric	Ν
Statistical analysis - inductive (not RCT/NRCT, CBA or ITS)	empiric	Ν
Statistical analysis - descriptive	empiric	Y
(Retrospective) Observational study	empiric	Y
Survey / (Structured) Interviews	empiric	Y
Case study	empiric	Y
Systematic Review	empiric	Ν
Literature Review (not systematic)	empiric	Y
Legal analysis	empiric	Y
Synthesis/Comment	empiric	Y
Guideline	combined	Y

Research objective (independent > dependent var.)	excluded
Prices (descriptive)	Y
Prices > Behaviour	Y
Prices > Access*	Y
Prices > Health outcome	Y
Prices > Usage**	Y
Prices > Expenditures	Y
Prices > Equity	Y
Prices > Invest (R&D)	Y
Prices > Other	Y
Other (non_Policy) > Prices	Y
Other (non_Policy) > Other	Y
Policy (descriptive)	Y
Policy > Prices	Ν
Policy > Behaviour	Ν
Policy > Access*	Ν
Policy > Health outcome	Ν
Policy > Usage**	Ν
Policy > Expenditures	Ν
Policy > Usage** & Exp	Ν
Policy > Welfare***	Ν
Policy > Equity	Ν
Policy > Invest (R&D)	Ν
Policy > diverse	Ν
Policy implementation	Y

* includes affordability and availability (supply)
** includes drug use and healthcare utilization
*** includes individual benefit and overall welfare
Y: yes, N: no, R&D: Research and Development

Table 6: Reason for excluded studies included in other systematic reviews

PublicationPublicationReason for exclusionAronsson 2001XOut of defined time-frameBigrrum 2001XOut of defined time-frameBrekke 2003XOff-patent marketBrekke 2009XOff-patent marketBrekke 2000XOff-patent marketBursey 2000XOut of defined time-frameCarroll 2006XNo pricing regulation (search key words)Delate 2005XNo pricing regulation (search key words)Fischer 2004XNo pricing regulation (search key words)Fischer 2007XNo pricing regulation (search key words)Grootendorst 2002XXOut of defined time-frameHartung 2006XNo pricing regulation (search key words)Grootendorst 2002XXQut of defined time-frameHartung 2006XNo pricing regulation (search key words)Hartung 2006XNo pricing regulation (search key words)Keith 194XOut of defined time-frameJackevicious 2008XNo pricing regulation (search key words)Keith 194XOut of defined time-frameLaw 2008XNo pricing regulation (search key words)Marshall 2002XXNo pricing regulation (search key words)Marshall 2006XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Marshall 2006XNo pricing regulation (search key words)Marshall 2007XNo pricing r		2014	2010	12	
Publication\$\frac{2}{2}\$\$\frac{2}{3}\$Reason for exclusionAronsson 2001XOut of defined time-frameBjerrum 2001XOut of defined time-frameBrekke 2003XOut of defined time-frameBrekke 2009XOff-patent marketBrekke 2001XOut of defined time-frameBrekke 2001XOut of defined time-frameBrekke 2005XNo pricing regulation (search key words)Delate 2005XNo pricing regulation (search key words)Fischer 2004XOut of defined time-frameFischer 2007XNo pricing regulation (search key words)Fretheim 2007XNo pricing regulation (search key words)Grootendorst 2002XXHartung 2004XOut of defined time-frameHartung 2006XNo pricing regulation (search key words)Haztus 2002XXXVeith 1994XOut of defined time-frameIackevicious 2008XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameKephart 2005XNo pricing regulation (search key words)MacCara 2001XNo pricing regulation (search key words)Marshall 2002XXNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words) <t< th=""><th></th><th>osta_</th><th>en</th><th>20</th><th></th></t<>		osta_	en	20	
Aronsson 2001XOut of defined time-frameBjerrum 2001XOut of defined time-frameBrekke 2003XOut of defined time-frameBrekke 2003XOff-patent marketBrekke 2009XOff-patent marketBursey 2000XOut of defined time-frameCarroll 2006XNo pricing regulation (search key words)Delate 2005XNo pricing regulation (search key words)Farley 2008XNo pricing regulation (search key words)Fischer 2007XNo pricing regulation (search key words)Fretheim 2007XNo pricing regulation (search key words)Grootendorst_2002XXOut of defined time-frameFischer 2007XNo pricing regulation (search key words)Grootendorst_2004XOut of defined time-frameHartung 2004XOut of defined time-frameHartung 2004XNo pricing regulation (search key words)Keiht 1994XOut of defined time-frameJackevicious 2008XNo pricing regulation (search key words)Keiht 1994XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Marshall 2007XQMarshall 2006XNo pricing regulation (search key words)Marshall 2007XQMarshall 2007XQMoreno-Torres_2011XQMoren 2008X	Publication	Acc	Gre	Lee	Reason for exclusion
Bjerrum 2001XOut of defined time-frameBrekke 2003XOut of defined time-frameBrekke 2009XOff-patent marketBrekke 2011XOff-patent marketBursey 2000XOut of defined time-frameCarroll 2006XNo pricing regulation (search key words)Farley 2008XNo pricing regulation (search key words)Fischer 2004XOut of defined time-frameFischer 2007XNo pricing regulation (search key words)Fretheim 2007XNo pricing regulation (search key words)Grootendorst 2002XXGrootendorst 2004XOut of defined time-frameHartung 2006XXNo pricing regulation (search key words)Hartung 2006XXVout of defined time-frameHartung 2006XXVout of defined time-frameKephart 2005XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameKackar 2001XNo pricing regulation (search key words)Marshall 2002XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Marshall 2007XQui of defined time-frameMarshall 2007XQui of defined t	Aronsson 2001	Х			Out of defined time-frame
Brekke 2003XOut of defined time-frameBrekke 2009XOff-patent marketBursey 2000XOut of defined time-frameCarroll 2006XNo pricing regulation (search key words)Delate 2005XNo pricing regulation (search key words)Firsher 2004XNo pricing regulation (search key words)Fischer 2004XNo pricing regulation (search key words)Fretheim 2007XNo pricing regulation (search key words)Fretheim 2007XNo pricing regulation (search key words)Grootendorst 2002XXOut of defined time-frameHartung 2004XOut of defined time-frameHartung 2006XNo pricing regulation (search key words)Hazlet 2002XXQut of defined time-frameJackevicious 2008XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameJackavicious 2008XNo pricing regulation (search key words)Kibicho 2012XXOut of defined time-frameMarcara 2001XOut of defined time-frameMarcara 2001XOut of defined time-frameMarshall 2007XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Marshall	Bjerrum 2001		Х		Out of defined time-frame
Brekke 2009XOff-patent market Off-patent marketBrekke 2011XOff-patent marketBursey 2000XNo pricing regulation (search key words)Delate 2005XNo pricing regulation (search key words)Farley 2008XNo pricing regulation (search key words)Fischer 2004XOut of defined time-frameFischer 2007XNo pricing regulation (search key words)Grootendorst 2002XXGrootendorst 2004XOut of defined time-frameHartung 2006XNo pricing regulation (search key words)Hartung 2006XNo pricing regulation (search key words)Hartung 2006XNo pricing regulation (search key words)Hartung 2006XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameKephar 2005XNo pricing regulation (search key words)Kibicho 2012XFree pricing marketLaw 2008XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2008	Brekke 2003	Х			Out of defined time-frame
Brekke 2011XOff-patent marketBursey 2000XOut of defined time-frameCarroll 2006XNo pricing regulation (search key words)Farley 2008XNo pricing regulation (search key words)Fischer 2004XOut of defined time-frameFischer 2007XNo pricing regulation (search key words)Fretheim 2007XNo pricing regulation (search key words)Grootendorst 2002XXOut of defined time-frameHartung 2004XOut of defined time-frameHartung 2006XNo pricing regulation (search key words)Hartung 2005XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameKephart 2005XNo pricing regulation (search key words)Kibicho 2012XNo pricing regulation (search key words)KadawaXOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2007XXOut of defined time-frameMarshall 2007XNo pricing regulation (search key words)Morden 2008XOut of defined time-frameNarine 2001XOut of defined time-frameNarine 2001XOut of defi	Brekke 2009			Х	Off-patent market
Bursey 2000XOut of defined time-frameCarroll 2006XNo pricing regulation (search key words)Delate 2005XNo pricing regulation (search key words)Farley 2008XNo pricing regulation (search key words)Fischer 2004XNo pricing regulation (search key words)Fischer 2007XNo pricing regulation (search key words)Fretheim 2007XNo pricing regulation (search key words)Grootendorst 2002XXOut of defined time-frameHartung 2004XOut of defined time-frameHartung 2006XXNo pricing regulation (search key words)Keiht 1994XOut of defined time-frameJackevicious 2008XNo pricing regulation (search key words)Keiht 1994XOut of defined time-frameKephart 2005XNo pricing regulation (search key words)Kibicho 2012XFree pricing marketLaw 2008XNo pricing regulation (search key words)Marshall 2006XNo pricing regulation (search key words)Marshall 2007XQut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Morden 2008XOut of defined time-frameMorden 2008XNo pricing regulation (search key words)Morteni 2004XOut of defined time-frameNopricing regulation (search key words)Marshall 2007Morteni 2004XOut of defined time-frameMorden 2008XNo pricin	Brekke 2011	Х			Off-patent market
Carroll 2006XNo pricing regulation (search key words)Delate 2005XNo pricing regulation (search key words)Farley 2008XNo pricing regulation (search key words)Fischer 2004XOut of defined time-frameFischer 2007XNo pricing regulation (search key words)Grootendorst 2002XXGrootendorst 2004XOut of defined time-frameHartung 2004XOut of defined time-frameHartung 2006XNo pricing regulation (search key words)Hartung 2006XNo pricing regulation (search key words)Hartung 2006XNo pricing regulation (search key words)Hartung 2006XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameKackarcia 2005XNo pricing regulation (search key words)Kibicho 2012XFree pricing marketLaw 2008XNo pricing regulation (search key words)Marshall 2002XXMarshall 2007XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2004XOut of defined time-frameNarine 2001XOut of defined time-frameNarine 2001XOut of defined time-frameNarine 2	Bursey 2000		Х		Out of defined time-frame
Delate 2005XNo pricing regulation (search key words)Farley 2008XNo pricing regulation (search key words)Fischer 2004XOut of defined time-frameFischer 2007XNo pricing regulation (search key words)Fretheim 2007XNo pricing regulation (search key words)Grootendorst 2002XXOut of defined time-frameHartung 2004XOut of defined time-frameHartung 2006XNo pricing regulation (search key words)Haztus 2008XXVettoricus 2008XNo pricing regulation (search key words)Haztus 2005XNo pricing regulation (search key words)Haztus 2006XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameJackevicious 2008XNo pricing regulation (search key words)Kibicho 2012XFree pricing marketLaw 2008XNo pricing regulation (search key words)MacCara 2001XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Morden 2008XOut of defined time-frameNarine 2001XOut of defined time-frameNarine 2001X	Carroll 2006		Х		No pricing regulation (search key words)
Farley 2008XNo pricing regulation (search key words)Fischer 2004XOut of defined time-frameFischer 2007XNo pricing regulation (search key words)Grootendorst 2002XXOut of defined time-frameGrootendorst 2004XOut of defined time-frameHartung 2004XOut of defined time-frameHartung 2006XXNo pricing regulation (search key words)Hartung 2006XXOut of defined time-frameJackevicious 2008XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameJackevicious 2008XNo pricing regulation (search key words)Kibicho 2012XFree pricing marketLaw 2008XNo pricing regulation (search key words)MacCara 2001XOut of defined time-frameMarshall 2007XXOut of defined time-frameMarshall 2007XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2001XOut of defined time-frameMarine 2001XNo pricing regulation (search key words)Morden 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XNo pricing regulation (search key words)Sakabaug 2007XNo pricing regulation (search key words)Sakabaug 2007X	Delate 2005		Х		No pricing regulation (search key words)
Fischer 2004XOut of defined time-frameFischer 2007XNo pricing regulation (search key words)Fretheim 2007XXGrootendorst 2002XXGrootendorst 2004XOut of defined time-frameHartung 2004XOut of defined time-frameHartung 2006XXJackevicious 2008XNo pricing regulation (search key words)Hartung 2006XXJackevicious 2008XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameKephart 2005XNo pricing regulation (search key words)Kibicho 2012XFree pricing marketLaw 2008XNo pricing regulation (search key words)MacCara 2001XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2007XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2004XOut of defined time-frameMarshall 2007XNo pricing regulation (search key words)Morden 2004XOut of defined time-frameNopricing regulation (search key words)Morten 2004Morten 2004XOut of defined time-frameNopricing regulation (search key words)Morten 2004Morten 2004XOut of defined time-framePuig-Junoy 2007XX <td< td=""><td>Farley 2008</td><td></td><td>Х</td><td></td><td>No pricing regulation (search key words)</td></td<>	Farley 2008		Х		No pricing regulation (search key words)
Fischer 2007XNo pricing regulation (search key words)Fretheim 2007XNo pricing regulation (search key words)Grootendorst 2002XXOut of defined time-frameHartung 2004XOut of defined time-frameHartung 2006XNo pricing regulation (search key words)Hazlet 2002XXXValue of defined time-frameNo pricing regulation (search key words)Hazlet 2002XXXKeith 1994XOut of defined time-frameKeephart 2005XNo pricing regulation (search key words)Kibicho 2012XVFree pricing marketLaw 2008XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Marshall 2007XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2008XOut of defined time-frameNarine 2001XXOut of defined time-frameNarine 2001XOut of defined time-frameNarine 2001XOut of defined time-frameNarine 2001XOut of defined time-frameNarine 2002XOut of defined time-frameNarine 2001	Fischer 2004		Х		Out of defined time-frame
Fretheim 2007XNo pricing regulation (search key words)Grootendorst 2002XXOut of defined time-frameHartung 2004XOut of defined time-frameHartung 2006XNo pricing regulation (search key words)Hazlet 2002XXXJackevicious 2008XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameKephart 2005XNo pricing regulation (search key words)Kibicho 2012XFree pricing marketLaw 2008XNo pricing regulation (search key words)MacCara 2001XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2007XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2008XOut of defined time-frameNarine 2001XOut of defined time-frameNarine 2002XOut of defined time-frameNarine 2003XOut of defined time-frameSakshaug 2007XX<	Fischer 2007		Х		No pricing regulation (search key words)
Grootendorst 2002XXOut of defined time-frameHartung 2004XOut of defined time-frameHartung 2006XNo pricing regulation (search key words)Hartung 2006XXHazlet 2002XXJackevicious 2008XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameJackevicious 2008XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameKephart 2005XNo pricing regulation (search key words)Kibicho 2012XFree pricing marketLaw 2008XOut of defined time-frameMacCara 2001XOut of defined time-frameMarshall 2002XXNo pricing regulation (search key words)Marshall 2006XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2008XOut of defined time-frameNarine 2001XQuit of defined time-framePavenik 2002XQuit of defined time-frameSakshaug 2007XXOut of defined time-frame <tr<< td=""><td>Fretheim 2007</td><td></td><td>Х</td><td></td><td>No pricing regulation (search key words)</td></tr<<>	Fretheim 2007		Х		No pricing regulation (search key words)
Grootendorst_2004XOut of defined time-frameHartung 2004XOut of defined time-frameHartung 2006XNo pricing regulation (search key words)Hazlet 2002XXXJackevicious 2008XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameKephart 2005XNo pricing regulation (search key words)Kibicho 2012XYLaw 2008XNo pricing regulation (search key words)MacCara 2001XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2004XOut of defined time-frameNarine 2001XYOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXOff-patent marketRoughead 2006XNo pricing regulation (search key words)Sakshaug 2007XXOut of defined time-frameSchneeweiss 2003XXOut of defined time-frameSchneeweiss 2004XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frame <t< td=""><td>Grootendorst 2002</td><td>Х</td><td></td><td>Х</td><td>Out of defined time-frame</td></t<>	Grootendorst 2002	Х		Х	Out of defined time-frame
Hartung 2004XOut of defined time-frameHartung 2006XNo pricing regulation (search key words)Hazlet 2002XXXJackevicious 2008XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameKephart 2005XNo pricing regulation (search key words)Kibicho 2012XNo pricing regulation (search key words)Kacphart 2005XNo pricing regulation (search key words)MacCara 2001XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)McManus 2001XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2004XOut of defined time-frameNarine 2001XQuit of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXNo pricing regulation (search key words)Sakshaug 2007XXOut of defined time-frameSchneeweiss 2003XXOut of defined time-frameSchneeweiss 2004XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smal	Grootendorst_2004			Х	Out of defined time-frame
Hartung 2006XNo pricing regulation (search key words)Hazlet 2002XXXJackevicious 2008XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameKephart 2005XNo pricing regulation (search key words)Kibicho 2012XFree pricing marketLaw 2008XNo pricing regulation (search key words)MacCara 2001XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Marshall 2007XXOut of defined time-frameMarshall 2007XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Morden 2008XOut of defined time-frameNarine 2001XOut of defined time-frameNarine 2001XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXOff-patent marketRoughead 2006XNo pricing regulation (search key words)Sakshaug 2007XXOut of defined time-frameSchneeweiss 2002XXOut of defined time-frameSchneeweiss 2003XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-fram	Hartung 2004		Х		Out of defined time-frame
Hazlet 2002XXXXOut of defined time-frameJackevicious 2008XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameKephart 2005XNo pricing regulation (search key words)Kibicho 2012XFree pricing marketLaw 2008XOut of defined time-frameMacCara 2001XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Marshall 2007XOut of defined time-frameMorden 2008XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Moreno-Torres_2011XXNarine 2001XOut of defined time-frameNarine 2001XOut of defined time-frameNarine 2001XOut of defined time-framePavenik 2002XOut of defined time-framePavenik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXOff-patent marketRoughead 2006XNo pricing regulation (search key words)Sakshaug 2007XXOut of defined time-frameSchneeweiss 2003XXOut of defined time-frameSchneeweiss 2004XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 199	Hartung 2006		Х		No pricing regulation (search key words)
Jackevicious 2008XNo pricing regulation (search key words)Keith 1994XOut of defined time-frameKephart 2005XNo pricing regulation (search key words)Kibicho 2012XFree pricing marketLaw 2008XNo pricing regulation (search key words)MacCara 2001XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)McManus 2001XNo pricing regulation (search key words)Morden 2008XNo pricing regulation (search key words)Moreno-Torres_2011XXOut of defined time-frameNarine 2001XOut of defined time-frameNarine 2001XOut of defined time-frameNarine 2001XOut of defined time-framePavenik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXOff-patent marketRoughead 2006XNo pricing regulation (search key words)Sakshaug 2007XXOut of defined time-frameSchneeweiss 2003XXOut of defined time-frameSchneeweiss 2004XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regula	Hazlet 2002	Х	Х	Х	Out of defined time-frame
Keith 1994XOut of defined time-frameKephart 2005XNo pricing regulation (search key words)Kibicho 2012XFree pricing marketLaw 2008XNo pricing regulation (search key words)MacCara 2001XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Marshall 2007XOut of defined time-frameMarshall 2007XOut of defined time-frameMorden 2008XNo pricing regulation (search key words)Moreno-Torres_2011XXMarine 2001XOut of defined time-frameNarine 2001XOut of defined time-framePavenik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXOut of defined time-frameSakshaug 2007XNo pricing regulation (search key words)Sakshaug 2007XXOut of defined time-frameSchneeweiss 2002XXOut of defined time-frameSchneeweiss 2003XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)Namerai 2008XNo pricing regulation (search key words)Na	Jackevicious 2008		Х		No pricing regulation (search key words)
Kephart 2005XNo pricing regulation (search key words)Kibicho 2012XFree pricing marketLaw 2008XNo pricing regulation (search key words)MacCara 2001XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Marshall 2007XXNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)McManus 2001XOut of defined time-frameMorden 2008XNo pricing regulation (search key words)Moreno-Torres_2011XXNarine 2001XOut of defined time-frameNarine 2001XOut of defined time-framePavenik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXOff-patent marketRoughead 2006XNo pricing regulation (search key words)Sakshaug 2007XXOut of defined time-frameSchneeweiss 2002XXOut of defined time-frameSchneeweiss 2003XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)Na pricing regulation (search key words)No pricing regulation (search key words)Shaleweiss 2006XNo pri	Keith 1994		Х		Out of defined time-frame
Kibicho 2012XFree pricing marketLaw 2008XNo pricing regulation (search key words)MacCara 2001XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)McManus 2001XOut of defined time-frameMorden 2008XNo pricing regulation (search key words)Moreno-Torres_2011XXVanite 2004XOut of defined time-frameNarine 2001XOut of defined time-framePavenik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXOff-patent marketRoughead 2006XNo pricing regulation (search key words)Sakshaug 2007XXOut of defined time-frameSchneeweiss 2002XXOut of defined time-frameSchneeweiss 2003XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)Namley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)<	Kephart 2005		Х		No pricing regulation (search key words)
Law 2008XNo pricing regulation (search key words)MacCara 2001XOut of defined time-frameMarshall 2002XXNo pricing regulation (search key words)Marshall 2006XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)McManus 2001XOut of defined time-frameMorden 2008XNo pricing regulation (search key words)Moreno-Torres_2011XXNarine 2004XOut of defined time-frameNarine 2001XOut of defined time-framePavenik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXOut of defined time-frameSakshaug 2007XNo pricing regulation (search key words)Sakshaug 2007XXOut of defined time-frameSchneeweiss 2002XXOut of defined time-frameSchneeweiss 2003XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation	Kibicho 2012	Х			Free pricing market
MacCara 2001XOut of defined time-frameMarshall 2002XXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)McManus 2001XOut of defined time-frameMorden 2008XNo pricing regulation (search key words)Moreno-Torres_2011XXMotheral 2004XOut of defined time-frameNarine 2001XOut of defined time-frameNarine 2001XOut of defined time-framePavenik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXSakshaug 2007XNo pricing regulation (search key words)Sakshaug 2007XNo pricing regulation (search key words)Sawyer 1983XOut of defined time-frameSchneeweiss 2002XXOut of defined time-frameSchneeweiss 2003XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)NanceXNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation as definedPavenik 2000XOut of defined time-frame	Law 2008		Х		No pricing regulation (search key words)
Marshall 2002XXXOut of defined time-frameMarshall 2006XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)McManus 2001XOut of defined time-frameMorden 2008XNo pricing regulation (search key words)Moreno-Torres_2011XXMotheral 2004XOut of defined time-frameNarine 2001XOut of defined time-framePavcnik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXSakshaug 2007XNo pricing regulation (search key words)Sakshaug 2007XNo pricing regulation (search key words)Sakshaug 2007XNo pricing regulation (search key words)Sameeweiss 2002XXSchneeweiss 2003XXSchneeweiss 2004XXSchneeweiss 2005XSmalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation as definedPavenik 2000XOut of defined time-frame	MacCara 2001		Х		Out of defined time-frame
Marshall 2006XNo pricing regulation (search key words)Marshall 2007XNo pricing regulation (search key words)McManus 2001XOut of defined time-frameMorden 2008XNo pricing regulation (search key words)Moreno-Torres_2011XXMotheral 2004XOut of defined time-frameNarine 2001XOut of defined time-framePavcnik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXSakshaug 2007XNo pricing regulation (search key words)Sakshaug 2007XNo pricing regulation (search key words)Sakshaug 2007XNo pricing regulation (search key words)Sawyer 1983XOut of defined time-frameSchneeweiss 2002XXOut of defined time-frameSchneeweiss 2003XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)Nance 2006XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation as definedPavenik 2000XOut of defined time-frame <td>Marshall 2002</td> <td>Х</td> <td>Х</td> <td></td> <td>Out of defined time-frame</td>	Marshall 2002	Х	Х		Out of defined time-frame
Marshall 2007XNo pricing regulation (search key words)McManus 2001XOut of defined time-frameMorden 2008XNo pricing regulation (search key words)Moreno-Torres_2011XXMotheral 2004XOut of defined time-frameNarine 2001XOut of defined time-framePavenik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXSakshaug 2007XNo pricing regulation (search key words)Sakshaug 2007XNo pricing regulation (search key words)Sakshaug 2007XXSchneeweiss 2002XXSchneeweiss 2003XXSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation (search key words)Motherai 2008XNo pricing regulation (search key words)Soumerai 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation as definedPavenik 2000XOut of defined time-frame	Marshall 2006		Х		No pricing regulation (search key words)
McManus 2001XOut of defined time-frameMorden 2008XNo pricing regulation (search key words)Moreno-Torres_2011XXMotheral 2004XOut of defined time-frameNarine 2001XOut of defined time-framePavcnik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXXOff-patent marketRoughead 2006XNo pricing regulation (search key words)Sakshaug 2007XXSchneeweiss 2002XXSchneeweiss 2003XXSchneeweiss 2004XXXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)Van Driel 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation (search key words)	Marshall 2007		Х		No pricing regulation (search key words)
Morden 2008XNo pricing regulation (search key words)Moreno-Torres_2011XXOff-patent marketMotheral 2004XOut of defined time-frameNarine 2001XOut of defined time-framePavcnik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXSakshaug 2007XXSakshaug 2007XNo pricing regulation (search key words)Sakshaug 2007XNo pricing regulation (search key words)Sakshaug 2007XXSchneeweiss 2002XXSchneeweiss 2003XXSchneeweiss 2004XXSchneeweiss 2005XSchneeweiss 2006XSoumerai 2008XSoumerai 2008XSoumerai 2008XNamerai 2006XNo pricing regulation (search key words)Soumerai 2008XSoumerai 2006XSoumerai 2008XSoumerai 2008XSoumerai 2008XSoumerai 2008XSoumerai 2006XSoumerai 2006XSoumerai 2006XSoumerai 2008XSoumerai 2008XSoumerai 2006XSoumerai 2008XSoumerai 2008XSoumerai 2006XSoumerai 2006XSoumerai 2006XSoumerai 2006XSoumerai 2006 <td>McManus 2001</td> <td>Х</td> <td></td> <td></td> <td>Out of defined time-frame</td>	McManus 2001	Х			Out of defined time-frame
Moreno-Torres_2011XXOff-patent marketMotheral 2004XOut of defined time-frameNarine 2001XOut of defined time-framePavenik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXSakshaug 2007XNo pricing regulation (search key words)Sakshaug 2007XXSakshaug 2007XXSakshaug 2007XXSakshaug 2007XXSakshaug 2007XXSakshaug 2007XXSakshaug 2007XXSuger 1983XOut of defined time-frameSchneeweiss 2002XXXOut of defined time-frameSchneeweiss 2003XXXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)van Driel 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation as definedPavenik 2000XOut of defined time-frame	Morden 2008		Х		No pricing regulation (search key words)
Motheral 2004XOut of defined time-frameNarine 2001XOut of defined time-framePavcnik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXRoughead 2006XNo pricing regulation (search key words)Sakshaug 2007XXSawyer 1983XOut of defined time-frameSchneeweiss 2002XXSchneeweiss 2003XXSchneeweiss 2004XXOut of defined time-frameSchneeweiss 2006XXOut of defined time-frameSchneeweiss 2006XXNo pricing regulation (search key words)Smalley 1995XSumerai 2008XXNo pricing regulation (search key words)Smalley 1995XVan Driel 2008XXNo pricing regulation (search key words)Mabasa 2006XPavcnik 2000XXOut of defined time-frame	Moreno-Torres_2011	Х		Х	Off-patent market
Narine 2001XOut of defined time-framePavcnik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXRoughead 2006XNo pricing regulation (search key words)Sakshaug 2007XXSawyer 1983XOut of defined time-frameSchneeweiss 2002XXSchneeweiss 2003XXSchneeweiss 2004XXSchneeweiss 2005XSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XSoumerai 2008XNaNo pricing regulation (search key words)Samaley 1995XSoumerai 2008XNo pricing regulation (search key words)Namerai 2006XNo pricing regulation (search key words)Nabasa 2006XPavcnik 2000XOut of defined time-frameSchneeweis 2004XXNo pricing regulation (search key words)Smalley 1995XSoumerai 2008XXNo pricing regulation (search key words)XNo pricing regulation (search key words)XNo pricing regulation as definedPavcnik 2000XXOut of defined time-frame	Motheral 2004		Х		Out of defined time-frame
Pavcnik 2002XOut of defined time-framePuig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXRoughead 2006XNo pricing regulation (search key words)Sakshaug 2007XNo pricing regulation (search key words)Sawyer 1983XOut of defined time-frameSchneeweiss 2002XXSchneeweiss 2003XXSchneeweiss 2004XXSchneeweiss 2005XNo pricing regulation (search key words)Schneeweiss 2004XXSchneeweiss 2005XOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)van Driel 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation (search key words)Pavcnik 2000XOut of defined time-frame	Narine 2001	Х			Out of defined time-frame
Puig-Junoy 2004XOut of defined time-framePuig-Junoy 2007XXOff-patent marketRoughead 2006XNo pricing regulation (search key words)Sakshaug 2007XNo pricing regulation (search key words)Sawyer 1983XOut of defined time-frameSchneeweiss 2002XXSchneeweiss 2003XXSchneeweiss 2004XXSchneeweiss 2006XSchneeweiss 2006XSchneeweiss 2006XSchneeweiss 2006XSchneeweiss 2008XSchneeweiss 2008XSchneeweiss 2008XSoumerai 2008XSoumerai 2008XSoumerai 2008XSoumerai 2008XSoumerai 2006XSoumerai 2006XSoumerai 2006XSoumerai 2008XSoumerai 2008XSoumerai 2008XSoumerai 2006XSoumerai 2006XSamuerai 2006XSoumerai 2008XSoumerai 2008XSoumerai 2009XSoumerai 2006XSoumerai 2006XSou	Pavcnik 2002	Х			Out of defined time-frame
Puig-Junoy 2007XXXOff-patent marketRoughead 2006XNo pricing regulation (search key words)Sakshaug 2007XNo pricing regulation (search key words)Sawyer 1983XOut of defined time-frameSchneeweiss 2002XXSchneeweiss 2003XXSchneeweiss 2004XSchneeweiss 2006XSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XSoumerai 2008XVan Driel 2008XNo pricing regulation (search key words)Mabasa 2006XPuvcnik 2000XOut of defined time-frame	Puig-Junoy 2004			Х	Out of defined time-frame
Roughead 2006XNo pricing regulation (search key words)Sakshaug 2007XNo pricing regulation (search key words)Sawyer 1983XOut of defined time-frameSchneeweiss 2002XXSchneeweiss 2003XXSchneeweiss 2004XXSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)Van Driel 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation (search key words)Pavcnik 2000XOut of defined time-frame	Puig-Junov 2007	Х		Х	Off-patent market
Sakshaug 2007XNo pricing regulation (search key words)Sawyer 1983XOut of defined time-frameSchneeweiss 2002XXSchneeweiss 2003XXSchneeweiss 2004XXSchneeweiss 2004XSchneeweiss 2006XSmalley 1995XSoumerai 2008XVan Driel 2008XNo pricing regulation (search key words)Mabasa 2006XPavenik 2000XOut of defined time-frame	Roughead 2006		Х		No pricing regulation (search key words)
Sawyer 1983XOut of defined time-frameSchneeweiss 2002XXOut of defined time-frameSchneeweiss 2003XXOut of defined time-frameSchneeweiss 2004XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)van Driel 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation as definedPavcnik 2000XOut of defined time-frame	Sakshaug 2007		Х		No pricing regulation (search key words)
Schneeweiss 2002XXOut of defined time-frameSchneeweiss 2003XXOut of defined time-frameSchneeweiss 2004XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)van Driel 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation (search key words)Pavcnik 2000XOut of defined time-frame	Sawyer 1983	Х			Out of defined time-frame
Schneeweiss 2003XXOut of defined time-frameSchneeweiss 2004XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)van Driel 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation (search key words)Pavcnik 2000XOut of defined time-frame	Schneeweiss 2002	Х		Х	Out of defined time-frame
Schneeweiss 2004XXOut of defined time-frameSchneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)van Driel 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation as definedPavcnik 2000XOut of defined time-frame	Schneeweiss 2003	Х		Х	Out of defined time-frame
Schneeweiss 2006XNo pricing regulation (search key words)Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)van Driel 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation as definedPavcnik 2000XOut of defined time-frame	Schneeweiss 2004		Х	Х	Out of defined time-frame
Smalley 1995XOut of defined time-frameSoumerai 2008XNo pricing regulation (search key words)van Driel 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation as definedPavcnik 2000XOut of defined time-frame	Schneeweiss 2006		X		No pricing regulation (search key words)
Soumerai 2008XNo pricing regulation (search key words)van Driel 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation as definedPavcnik 2000XOut of defined time-frame	Smalley 1995		Х		Out of defined time-frame
van Driel 2008XNo pricing regulation (search key words)Mabasa 2006XNo pricing regulation as definedPavcnik 2000XOut of defined time-frame	Soumerai 2008		X		No pricing regulation (search key words)
Mabasa 2006XNo pricing regulation as definedPavcnik 2000XOut of defined time-frame	van Driel 2008		X		No pricing regulation (search key words)
Pavcnik 2000 X Out of defined time-frame	Mabasa 2006			Х	No pricing regulation as defined
	Pavenik 2000			X	Out of defined time-frame
Johnson 2011 X Free pricing market	Johnson 2011			Х	Free pricing market

Table 7: Questionnaire for assessment of risk of bias

				US)	
				study C	active.
			series	, is ino	
			A time	analys	modernpiticu
		TUPLE	stici	at some	Wilc or mati
		Inter	Statis	3th Bront and	a) She
tudy design	_				
S1	Research question stated and answerable?	Х	Х	Х	Х
S2	Intervention and potential alternative clearly defined and pre- specified?	Х	Х	Х	Х
\$3	Study design appropriate to adress question, following conventions?	Х	Х	Х	
S4	Setting and scope justified and appropriate to answer question (time frame, coverage)?	Х	Х	Х	Х
ata					
D1	Sources of data described and justified (quality, relevance, etc.)?	Х	Х	Х	Х
D2	Outcomes clearly stated, predefined & meaningful? Measures valid and reliable? Abstractions clear?	Х	Х	Х	Х
D3	Reasons for selection/ exclusion of data stated and plausible?	Х	Х	Х	Х
D4	Intervention independent from other changes?	Х	Х	Х	
lodel					
M1	Economic model (structure) displayed in a clear, transparent manner?			Х	
M2	Evidence for the model structure applied provided?			Х	
M3	Structural assumptions transparent and justified? Are they reasonable given the overall objective?			Х	
mpirical and	alysis				
E1	Shape of the intervention effect prespecified?	Х		Х	
E2	Major outcomes presented in disaggregated as well as aggregated form?	Х		Х	Х
E3	Data analysed appropriately? Details of statistical tests given?	Х		Х	Х
E4	Incomplete outcome data adressed?	Х		Х	Х
E5	Method of synthesis or meta-analysis of estimates described?	Х		Х	Х
E6	Conclusions & recommendations justified and based on the results (data) reported? Theoretical (model) conclusions valid given the data presented?	Х		Х	Х

IST: Interrupted Time Series Study, TRP: Therapeutic Reference Pricing, ERP: External (International) Reference Pricing, VBP: Value-Based Pricing

Table 8: Assessment risk of bias: scoring table

			STUDY DESI	IGN			DATA				MODEL			EMPIRICAL	ANALYSIS						1
			S1	S2	S3	S4	D1	D2	D3	D4	M1	M2	M3	E1	E2	E3	E4	E5	E6	E7	
			Research	and notential	Study design	Setting and	Sources of	Outcomes clearly stated	Reasons for	independent	Economic	Evidence for the model	Structural	Shape of the	Major	Data	Incomplete outcome data	Method of	Conclusions &	Limitation	
			stated and	alternative	to adress	justified and	described	predefined &	exclusion of	from other	(structure)	structure	transparent	effect	presented in	appropriately	adressed?	meta-analysis	s justified and	biases	
			answerable?	clearly	question,	appropriate	and justified	meaningful?	data stated	changes?	displayed in	a applied	and	prespecified?	disaggregate	?		ofestimates	based on the	discussed?	
				defined and	following	to answer	(quality,	Measures	and		clear,	provided?	justified?Are		d as well as	Details of		described?	results (data)	1	
				pre- specified?	conventions	<pre>? question (time frame)</pre>	relevance, etc.)?	valid and reliable?	plausible?		transparent manner?		they reasonable		aggregated form?	statistical tests given?			reported? Theoretical		
				speenieu.		coverage)?	e.e).	Abstractions					given the		101111.	tests given.			(model)		5
								clear?					overall						conclusions		
Publication	Type of economic research	Research objective											objective?						valid given the	I	Ŭ
Atella 2012	Economic model (analytic, empirical data)	Policy > Prices	Y(LOW)	N (HIGH)	N (HIGH)	N (HIGH)	unclear	unclear	Y(LOW)	N (HIGH)	Y(LOW)	Y(LOW)	unclear	N (HIGH)	N (HIGH)	Y(LOW)	unclear	Y(LOW)	N (HIGH)	N (HIGH)	44%
Comanor 2018	Economic model (analytic, empirical data)	Policy > Prices	unclear	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	3%
Kaiser 2014	Economic model (analytic, empirical data)	Policy > Welfare***	Y(LOW)	Y(LOW)	N (HIGH)	unclear	Y(LOW)	Y(LOW)	Y(LOW)	unclear	Y(LOW)	Y(LOW)	Y (LOW)	Y(LOW)	N (HIGH)	Y(LOW)	Y(LOW)	Y(LOW)	unclear	Y (LOW)	81%
Koenig 2011	Economic model (analytic, empirical data)	Policy > Invest (R&D)	Y(LOW)	unclear	N (HIGH)	Y(LOW)	N (HIGH)	unclear	unclear	N (HIGH)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	N (HIGH)	Y(LOW)	Y(LOW)	unclear	Y(LOW)	Y(LOW)	67%
Armeni 2016	Interrupted time series study (ITS)	Policy > Expenditures	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	unclear	-	-		Y(LOW)	unclear	Y(LOW)	Y(LOW)	unclear	Y(LOW)	Y(LOW)	90%
Augurzky_2009	Interrupted time series study (ITS)	Policy > Prices	Y(LOW)	Y(LOW)	Y(LOW)	Y (LOW)	Y(LOW)	unclear	Y(LOW)	N (HIGH)				Y(LOW)	Y(LOW)	Y(LOW)	Y (LOW)	Y(LOW)	N (HIGH)	Y (LOW)	83%
Barros_2010	Interrupted time series study (ITS)	Policy > Expenditures	Y(LOW)	unclear	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	N (HIGH)	unclear	-	-	-	unclear	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	83%
Grootendorst_2005	Interrupted time series study (ITS)	Policy > Expenditures	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	-		-	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y (LOW)	100%
Grootendorst_2006	Interrupted time series study (ITS)	Policy > Prices	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	N (HIGH)				Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	93%
Morgan_2008	Interrupted time series study (ITS)	Policy > Invest (R&D)	Y(LOW)	Y(LOW)	unclear	Y(LOW)	Y(LOW)	N (HIGH)	Y(LOW)	N (HIGH)	-		-	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	N (HIGH)	77%
Stargardt_2010	Interrupted time series study (ITS)	Policy > Usage**	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	unclear		-		Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	N (HIGH)	Y(LOW)	90%
Yfantopoulos_2008	Interrupted time series study (ITS)	Policy > Prices	Y(LOW)	Y(LOW)	Y(LOW)	Y (LOW)	unclear	Y(LOW)	unclear	N (HIGH)		-		Y(LOW)	N (HIGH)	N (HIGH)	unclear	Y(LOW)	N (HIGH)	N (HIGH)	57%
Golec_2010	Statistical analysis - inductive (not ITS)	Policy > Invest (R&D)	Y(LOW)	N (HIGH)	N (HIGH)	unclear	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	-	-		-		-	-	-	-		19%
Kalo_2012	Statistical analysis - inductive (not ITS)	Policy > Usage** & Exp	Y(LOW)	Y(LOW)	N (HIGH)	N (HIGH)	unclear	N (HIGH)	N (HIGH)	N (HIGH)		-		-		-		-	-	-	31%
Kanavos_2011	Statistical analysis - inductive (not ITS)	Policy > Prices	Y(LOW)	N (HIGH)	N (HIGH)	N (HIGH)	unclear	Y(LOW)	N (HIGH)	N (HIGH)		-	-	-		-	-	-	-	-	31%
Kyle_2007	Statistical analysis - inductive (not ITS)	Policy > Access*	Y(LOW)	N (HIGH)	N (HIGH)	Y(LOW)	Y(LOW)	N (HIGH)	unclear	N (HIGH)		-	-	-		-	-	-	-	-	44%
Leopold_2012_II	Statistical analysis - inductive (not ITS)	Policy > Prices	Y(LOW)	Y(LOW)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	-	-	-			-	-	-	-	-	25%
Stargardt_2011	Statistical analysis - inductive (not ITS)	Policy > Prices	Y(LOW)	Y(LOW)	N (HIGH)	N (HIGH)	unclear	Y(LOW)	Y(LOW)	N (HIGH)	-	-	-			-	-	-	-	-	56%
vonderSchulenburg_20]Statistical analysis - inductive (not ITS)	Policy > Prices	unclear	unclear	N (HIGH)	N (HIGH)	Y(LOW)	N (HIGH)	unclear	N (HIGH)	-		-	-		-	-	-	-	-	31%
Acosta_2014	Systematic Review	Policy > diverse	Y(LOW)	Y(LOW)	-	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)		-	-		-	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	100%
Espin_2011	Systematic Review	Policy > Prices	Y(LOW)	Y(LOW)	-	Y(LOW)	N (HIGH)	unclear	N (HIGH)			-		-	N (HIGH)	unclear	unclear	N (HIGH)	N (HIGH)	N (HIGH)	38%
Galizzi_2011	Systematic Review	Policy > Prices	Y(LOW)	Y(LOW)	-	Y(LOW)	Y(LOW)	Y(LOW)	unclear		-		-	-	Y(LOW)	Y(LOW)	Y(LOW)	unclear	Y(LOW)	Y(LOW)	92%
Green_2010	Systematic Review	Policy > diverse	Y(LOW)	Y(LOW)	-	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)			-		-	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	100%
Lee_2012	Systematic Review	Policy > diverse	Y(LOW)	Y(LOW)	-	Y(LOW)	Y(LOW)	Y(LOW)	unclear	-	-		-	-	Y(LOW)	Y(LOW)	Y(LOW)	unclear	Y(LOW)	Y (LOW)	92%
Lee_2015	Systematic Review	Policy > Expenditures	Y(LOW)	Y(LOW)	-	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)		-		-	-	Y(LOW)	Y(LOW)	Y(LOW)	unclear	Y(LOW)	Y (LOW)	96%
Morgan_2009	Systematic Review	Policy > diverse	Y(LOW)	Y(LOW)	-	Y(LOW)	unclear	Y(LOW)	unclear	-	-		-	-	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	N (HIGH)	Y (LOW)	83%
Puig-Junoy_2005	Systematic Review	Policy > Welfare***	Y(LOW)	Y(LOW)	-	Y(LOW)	unclear	Y(LOW)	Y(LOW)	-	-	-	-	-	unclear	Y(LOW)	Y(LOW)	Y(LOW)	Y(LOW)	Y (LOW)	92%
Relakis_2013	Systematic Review	Policy > diverse	Y(LOW)	unclear	-	Y (LOW)	Y(LOW)	N (HIGH)	N (HIGH)		-		-	-	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	29%
Rémuzat_2015	Systematic Review	Policy > Prices	Y(LOW)	Y(LOW)	-	Y(LOW)	unclear	unclear	unclear		-			-	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	38%
vanderGronde_2017	Systematic Review	Policy > diverse	unclear	N (HIGH)	-	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)		-	-		-	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	4%
Zhou_2014	Systematic Review	Policy > Expenditures	Y(LOW)	N (HIGH)	-	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	-	-	-	-	-	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	N (HIGH)	8%

Y: yes, N: no, IST: Interrupted Time Series Study, TRP: Therapeutic Reference Pricing, ERP: External (International) Reference Pricing, VBP: Value-Based Pricing * includes affordability and availability (supply), ** includes drug use and healthcare utilization, *** includes individual benefit and overall welfare

		b) A	bstract s	creening		c) Research categorization						
		, P	s	8								
	fa	<u> </u>	En lo	0				icy2				
		5 12	harr 8.8	5 9 9	e ce		ce2	Pol				
~	ble Date	9		dat Pat	er		den	<u> </u>				
E.	공' 육	,	0 0	0 <u>1</u> 0	s to	~,	8	ē,	m,			
AR	KC C	ಶೆ ಶೈ ಶೈ	g g	ਤੂਂ ਤੂੰ ਤੂੰ	gʻ gʻ	<u><u></u><u></u><u></u><u></u></u>	d'	ď	ರ		0.110.11	D. h.D.
10	20160828_OFCD il ihrary	1 E 10	ω u	ت تن ت	u u	 Type or economic research Synthesis/Comment 	v Policy (descriptive)	v	-	ID TITLE AUTOR (portes, portes, portes	2011	201
2	20172131 Scopus	y	v			n syndressy comment	y roncy (descriptive)	y		CCCC CCCC CCCCC CCCCC CCCCC CCCCC CCCCC CCCC	1011	201
2	20172131 Scopus	ý			y					EU judges overturns Rx price fixing: Foreign consignors must not abide by the Pharmaceutical Price Ordinal [No author name available] Deutsche Apotheker Zeitung		201
2	20172131 Scopus	y			y	n				Few regulations in pharmaceutical pricing [Per il prezzo dei farmaci poche regole da seguire] [No author name available] Giornale del Farmacista		200
2	20172131 Scopus	у			y	n				More and more drugs under the Pharmaceutical Prices Act (WGP) [Steeds meer geneesmiddelen onder de [No author name available] Pharmaceutisch Weekblad		201
7	20160828 pubmed	y	Y	Y		n			2523	272635 [Chapter 1. A contemporary history of the Japanese pharmaceutical industry (1980-2010). A contemporary [No authors listed] Yakushigaku Zasshi. 2014;49(1):18-38. Japanese. create date: 2014/10/03	03.10.2014	201
4	20160828 pubmed	y			y	n			2688	887181 A Campaign to Cut Drug Prices. [No authors listed] Sci Am. 2016 Jan;314(1):10. No abstract available. create date:2016/02/19	19.02.2016	201
4	20160828 pubmed	У		y		n			1912	127766 A few specialty drug prices fallall generics. [No authors listed] Manag Care. 2008 Dec;17[12]:46. No abstract available. create date:2009/01/09	09.01.2009	200
4	20160828 pubmed	Y			na	n			1611	110523 AIDS activists decry steady hikes in HIV drug prices. [No authors listed] AIDS Policy Law. 2005 Jul 29;20[14]:1, 4. No abstract avail create date: 2005/08/20	20.08.2005	200
4	20160828 pubmed	Y		_	y	n			1636	365977 Australia: new free trade agreement with US targets drug prices. [No authors listed] HIV AIDS Policy Law Rev. 2005 Aug;10(2):36, 38. No abstr create date:2005/12/22	22.12.2005	200
4	20160828 pubmed	Y	У	v		n			1567	672563 Commerce: Market-set drug prices abroad wouldn't cut U.S. prices. [No authors listed] Med Health. 2005 Jan 10;59[1]:1-2. No abstract available create date:2005/01/28	28.01.2005	200
4	20160828 pubmed	γ	У	v		n			2641	417639 Discounted drug prices for hospitals: result in prescriptions for expensive drugs in the community. [No authors listed] Prescript Int. 2015 Sep;24(163):223. create date:2015/09/30	30.09.2015	201
4	20160828 pubmed	Y	y	y	_	n			2044	446567 Drug prices on the rise as coverage gap looms. [No authors issted] Manag Care. 2010 Apr;19(4):55. No abstract available. create date:2010/05/08	08.05.2010	201
4	20160828 pubmed	Y		_	Y	n			2655	SP4733 Exorbitant drug prices narm research. [No authors issted] Prescrire int. 2015 Oct;24[164]:251. No astract available: create date:2015/12/26	26.11.2015	201
4	20160828 pubmed	Ŷ	y	Y .					203	552/4 How insurers barganing power affects or up prices in Medicate Part D. [Volumots issed] National Steed] National Steed (Sub-Sheet Steed) (Sub-Sheet Ste	01.01.2009	200
-	20100828 publied	Ŷ			y 				1638	SP35735 Interest of the matrix strength of the strength of	28.07.2010	20.
4	20100828 pubmed	y		w.	Y				162	290222 malaged as particles, drug inces tipe tot soving efforts. [Po autors issed] with relative 2005 (12) (25) (25) (25) (25) (25) (25) (25) (2	22.10.2005	200
4	20160828 pubmed	y 	y	,	na				1615	How and a segure of the other or top proceed and a segure of the other or top proceed and a segure of the other or top proceed and a segure of the other or top proceed and a segure of the other othe	15.09.2005	200
2	20160828 pubmed	y v				y Synthesis/Comment	v Policy (descriptive)	v	n 1817	179656 Better pharmaceutical price comparison studies are needed for meaningful evaluation of price-control poli [Schaffer et al] Value Health. 2008 Jan-Feb:11(1):129-30. doi: 10.1111/j. create date:2008/01/09	09.01.2008	200
2	20160828 pubmed	ý			Double, Up	n			1662	625648 Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Aaserud M, Dahlgren AT, Kå¶sters JP, Oxma Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005979. create date:2006/04/21 first author:Aaserud M	21.04.2006	200
2	20172131 Scopus	y	У	v		n				The cost of US pharmaceutical price regulation: A financial simulation model of R&D decisions Abbott T.A. Vernon J.A. Managerial and Decision Economics		200
2	20160828 pubmed	У				y Systematic Review	N Policy > diverse	N	Y 2531	318966 [Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (Review) Acosta A, Clapponi A, Aaserud M, Vietto V, A Cohrane Database Syst Rev. 2014 Oct 16;(10):CD00597: create date:2014/10/17 first author:Acosta A	17.10.2014	20
2	20172131 WebOfScience	y				y Statistical analysis - descriptive	y Policy > Prices	n	n	IMPACT OF AMNOG ON PHARMACEUTICAL PRICING TRENDS IN GERMANY Aggarwal, S VALUE IN HEALTH		201
7	20160828 pubmed	у у				n			2571	710043 Drug pricing policies in one of the largest drug manufacturing nations in the world: Are affordability and ao Ahmad A, Khan MU, Patel I. J Res Pharm Pract. 2015 Jan-Mar/4(1):1-3. doi: 10.4103/i create date:2015/02/25 first author:Ahmad A	25.02.2015	201
1	20160827 medline	у у				n			1915	150741 Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense Akaleephan C, Wibulpolprasert S, Sakulbumrungsil R, Luangruangrong P, Jitraknathee A, Aeksaengsri I create date: 2009/01/20 first author: Akaleephan C	20.01.2009	200
5	20160828 pubmed	γ	У	Y		n			2274	749874 Strategic funding priorities in the pharmaceutical sciences alled to Quality by Design (QbD) and Process An: Aksu B, De Beer T, Folestad S, Ketolainen J, L Eur J Pharm Sci. 2012 Sep 29;47(2):402-5. doi: 10.1016/j. create date:2012/07/04 first author:Aksu B	04.07.2012	201
2	20172131 WebOfScience	у у		_		n				EXTERNAL VERSUS INTERNAL REFERENCE PRICING: STRATEGIES FOR PHARMACEUTICAL PRICING IN THE AF AI Suwaidi, AS VALUE IN HEALTH		201
4	20160828 pubmed	Y	У	v		n			2742	423978 The state and consequences of dermatology drug prices in the United States. Albrecht J, Lebwohl M, Asgari MM, Bennett J Am Acad Dermatol. 2016 Sep;75(3):603-5. doi: 10.1016. create date:2016/07/18 first author:Albrecht J	18.07.2016	201
2	20172131 Scopus	у у				n				Pharmaceutical pricing in Ethiopia Ali E.E. Gilani AH. Gedif T. Pharmaceutical Prices in the 21st Century		201
4	20160828 pubmed	у у		_		n			2305	US /369 Controlling medicine prices in suban: the challenge of the recently established medicines regulatory author An GK, Yahia Y. Last Mediterr Health J. 2012 Aug;18(8):811-20. Create date:2012/10/13 [Inst author/Ail GK	13.10.2012	201
1	20160827 medline	Ŷ	y	v					218:	ssess Curronic nepatitis bit readments of control compared to simivale.	24.08.2011	20.
8	20160827 meunite 20160828 pubmed	y v	y	Ŷ					100	Subscription that used drug for the manifestion management of the standard drug standard	11 11 2009	20.
e .	20100828 publied	y y							1350	Subject Stopping the does not under a manufacture of advances to the subject velocity, and you introduced advances to the subject velocity. The subject velocity is the subject velocity intervelocity advances to the subject velocity. The subject velocity is the subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velocity is the subject velocity of the subject velocity. The subject velo	16 11 2005	200
2	20100828 pubmed	y	y	y v					2469	200509 Consultations in developing indeervalued account evaluation. In the second of t	02.04.2014	200
12	20160918 pubmed	y v	,	,		x Survey / (Structured) Interviews	v Policy (descriptive)	v	n 2653	532912 The Expansion of Use of Discounted Prices for International Reference Pricing Purposes. Ando G. Lockwood C. Izmirlieva M. Honore / Value Health. 2015 Nov:18/71:A519. doi: 10.1016/j.ival.2 create date:2015/11/05 first author:Ando G	05.11.2015	20
12	20160918 pubmed	ý			v	n		,	1740	401592 Economic aspects of the new Spanish laws on pharmaceutical preparations. AntoÄtanzas F, Oliva J, Pinillos M, JuÄ rez C, Eur J Health Econ. 2007 Sep;8(3):297-300. create date: 2007/04/03 first author: AntoÄtanzas F	03.04.2007	200
5	20160828 pubmed	y	У	v		n			2493	934980 Should the patent system for pharmaceuticals be replaced? A theoretical approach. AntoĀtanzas F, RodrĀ-guez-Ibeas R, JuĀ/rez Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5 create date:2014/06/18 first author:AntoĀtanzas F	18.06.2014	201
2	20160828 pubmed	у у				n			2159	598269 Post-Soviet transition: improving health services delivery and management. Antoun J, Phillips F, Johnson T. Mt Sinai J Med. 2011 May-Jun;78(3):436-48. doi: 10.1007. create date: 2011/05/21 first author: Antoun J	21.05.2011	201
4	20160828 pubmed	у			y	n			2092	929919 Most OECD countries could save money by improving clinical guidelines and negotiating better drug prices. Arie S. BMJ. 2010 Oct 7;341:c5552. doi: 10.1136/bmj.c5552. No create date:2010/10/12 first author:Arie S	12.10.2010	201
8	20160828 pubmed	y				y Interrupted time series study (ITS)	n Policy > Expenditures	n	y 2650	507643 The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case Armeni P, Jommi C, Otto M. Eur J Health Econ. 2015 Oct 27. [Epub ahead of print] create date: 2015/10/29 first author: Armeni P	29.10.2015	201
8	20160828 pubmed	У				y Economic model (analytic)	y Policy > Prices	n	n 2720	200978 The Simultaneous Effects of Pharmaceutical Policies from Payers' and Patients' Perspectives. Italy as a Case. Armeni P, Otto MH, Jommi C. Value Health. 2014 Nov;17(7):A405. doi: 10.1016/i.jval.2 create date:2014/11/01 first author:Armeni P	01.11.2014	201
2	20160828 pubmed	Y				 Fconomic model (analytic, empirical data) 	n Policy > Prices	n	y 2209	091623 Pharmaceutical price controls and minimum efficacy regulation: evidence from the United States and Italy. Atella V, Bhattacharya J, Carbonari L. Health Serv Res. 2012 Feb;47(1 Pt 1):293-308. doi: 10.11: create date:2011/11/19 first author:Atella V	19.11.2011	201
2	20160828 pubmed	Y				y Statistical analysis - descriptive	Y Policy (descriptive)	y	n 2653	533216 Comparison of Pharmaceutical Pricing and Reimbursement Systems In Turkey And Certain Other Eu Countr Atikeler K, Ozcelikay G. Value Health. 2015 Nov;18(7):AS72. doi: 10.1016/j.jval.2/ create date:2015/11/05 first author:Atikeler K	05.11.2015	201
12	20160918 pubmed	Y		_		y Interrupted time series study (ITS)	n Policy > Prices	n	y 1867	677725 Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data app Augurzky B, GA®himann S, Gress S, Wasem. Health Econ. 2009 Apr; 18(4):421-36. doi: 10.1002/hec.1; create date: 2008/08/05 first author: Augurzky B	05.08.2008	200
8	20160828 pubmed	Y	У	v		n			1825	254125 Pharmaceutical policies: effects of cap and co-payment on rational drug use. Austvoll-Dahlgren A, Aaserud M, Vist G, Rarr Cochrane Database Syst Rev. 2008 Jan 23;(1):CD007017. create date:2008/02/07 first author:Austvoll-Dahlgren A	07.02.2008	200
8	20160828 pubmed	у у				n			2496	96383 Makeholders' perspectives on access-to-medicines policy and research priorities in Latin America and the C Azeredo 1B, Luza VL, Oliveira MA, Emmenci Health Kes Policy Syst. 2014 Jun 25;12:31. doi: 10.1186/J Create date:2014/06/27 [Inst author:Azeredo 1B	27.06.2014	201
8	20160828 pubmed	у у				n			1/28	280037 [Preselection procedure for medical devices suppliers at the essential medicines and generic drugs purchas Babaley M. Med Trop (Mars). 2006 Dec;bo(b):523-30. French. create date:2007/020(19) [Inst author:Babaley M	09.02.2007	200
4	20100828 pubmed	y y							1726	BESKED Evaluation of use for database and the second se	29.02.2005	200
-	20100828 pubmed	y y	v	v		N			2661	Sector Evaluating up (cc), availability, and price components, improvements induces to unge in Leaving Co, infainting, spin, backan int, c. PCS sect. 2007 Mill 27,493,662.	01 12 2015	200
1	20160927 medline	y							2001	22222 Thys man by make 22222 The second and second and the second	2014	20
1	20160827 medline	× ×				n			2661	611893 Evaluating the effect of a proposed logistics fee cap on pharmaceuticals in South Africaa pre and post ana Bangalee V. Suleman F.	28.11.2015	20
12	20160918 pubmed	y y				 Economic model (analytic) 	v Policy > Welfare***	n	n 2005	053474 Retail price regulation and innovation: reference pricing in the pharmaceutical industry. Bardey D. Bornmier A. Jullien B. J Health Econ. 2010 Mar; 29(2):303-16. doi: 10.1016/i.ihe create date: 2010/01/08 first author:Bardey D	08.01.2010	20
12	20160918 pubmed	y				Y Economic model (analytic)	y Policy > Behaviour	N	n 2693	930001 Health insurance and diversity of treatment. Bardey D, Juliien B, Lozachmeur JM. J Health Econ. 2016 May; 47-50-63. doi: 10.1016/j.jhealer.create.date:2016/03/02 first author:Bardey D	02.03.2016	201
4	20160828 pubmed	y	У	v		n			2513	136254 Are specialty drug prices destroying insurers and hurting consumers?: a number of efforts are under way t Barlas S. P T. 2014 Aug;39(8):563-6. create date:2014/08/20 first author:Barlas S	20.08.2014	201
4	20160828 pubmed	У	У	v		n			2311	115461 'Gray market' not such a gray area anymore: why hospitals are paying exorbitant drug prices. Barlas S. P T. 2012 Oct;37(10):544. create date:2012/11/02 first author:Barlas S	02.11.2012	201
9	20160911 pubmed	У	у	v		n			2676	766890 Health Plans and Drug Companies Dip Their Toes Into Value-Based Pricing: The Pressure Is on P&T Committ Barlas S. PT. 2016 Jan;41(1):39-53. create date: 2016/01/15 first author: Barlas S	15.01.2016	201
12	20160918 pubmed	У				y Interrupted time series study (ITS)	n Policy > Expenditures	n	y 2062	621744 The impact of pharmaceutical policy measures: an endogenous structural-break approach. Barros PP, Nunes LC. Soc Sci Med. 2010 Aug;71(3):440-50. doi: 10.1016/j.socs_create date:2010/07/14 first author:Barros PP	14.07.2010	20
8	20160828 pubmed	γ		_		y Economic model (analytic)	y Policy > diverse	n	n 2057	575226 Pharmaceutical policies in European countries. Barros PP. Adv Health Scrv Res. 2010;22:3-27. Review. create date:2010/06/26 first author:Barros PP	26.06.2010	20
12	20160918 pubmed	γ	y	v		n		_	2054	S45588 Public drug expenditure in the Republic of Ireland. Barry M, Usher C, Tilson L. Expert Rev Pharmacoecon Outcomes Res. 2010 Jun; 10[3 create date: 2010/06/16 first author:Barry M	16.06.2010	20
12	20160918 pubmed	y				y Economic model (analytic, empirical data)	n Policy (descriptive)	y	n 2408	081570 [Mechanics and effects of European reference pricing for vaccines in Germany according to A§130a Abs. 2 Barth J, Hammerschmidt T, Vollmar J, Bierba Gesundheitswesen. 2014 Apr;76(4):e7-e13. doi: 10.1055 create date:2013/10/02 [first author:Barth J	02.10.2013	201
2	20100828 pubmed	у у				n			2607	u/soosy cummumy pharmacks: attruces toward the quarky and price of locally manufactured generic medicines Bashaar M, Hassali MA, Saleem F. J Pharm Policy Pract. 2015;8(1):15. doi: 10.1186/s40545-create.date.2015/06/17 [first author:Bashaar M	17.06.2015	201
2	20100828 pubmed	у у							2753	Subset Requirements and incentives for implementation or pharmaceutical Strategic Purchasing in Iranian Health : Bastani P, Uoshmangri L, Samadber M, Ding Giob J Health Sci. 2016 May 19;911;58/37. doi: 10.5539/ Create date:2016/09/18 first author@astani P 00/09/19 Desemble autointical audioicus autointical autointical autointical autointical audioicus autointical autointi	18.08.2016	201
12	20100328 pubmed	y y	W						2390	Stoop-s priming country by the store of primers mean instance companies in Station (Addom and Store of a primers mean instance companies) in Station (Addom and Store of a primers mean instance), as store in the store of primers mean instance companies in Station (Addom and Store of a primers). The Station (Addom and Store of a primers) in Station (Addom and Store of a primers) in Station (Addom and Store of a primers). The Station (Addom and Store of a primers) in Station (Addom and Store of a primers) in Station (Addom and Store of a primers). The Station (Store of a primers) in Station (Addom and Store of a primers) in Station (Addom and Store of a primers). The Station (Store of a primers) in Station (Store of a primers) in Station (Store of a primers). The Station (Store of a primers) is a station (Store of a primers) in Station (Store of a prime	21.08.2013	201
14	20160827 medline	y y	y						24/3	Second presente print meterical on fix expression pontation provided of provide of provi	25.04.2014	20.
1	20160827 medline	y y							224:	69748 The crisis in access to essential medicines in India: key issues which call for action. Bhravaya AL Kalanti SP. create date: 2012	2013	20.
2	20160828 pubmed	· · ·	v	v		n			2506	065814 Costs of telaprevir-based triple therapy for hepatitis C: \$189,000 per sustained virological response. Bichoupan K, Martel-Laferriere V, Sachs D, N Hepatology. 2014 Oct;60(4):1187-95. doi: 10.1002/hep.2 create date:2014/07/30 first author:Bichoupan K	30.07.2014	201
2	20160828 pubmed	y y	,			y Systematic Review	n Prices (descriptive)	v	n 2720	201014 The Grass is Always Greener on the Other Side or Why There Is Little Meaning in International Pharmaceuti Bierbaum M, DAVittmann S, Amier N, DAYpf Value Health. 2014 Nov. 17(7): A411. doi: 10.1016/j.jval.2 create date: 2014/11/01 first author:Bierbaum M	01.11.2014	20
5	20160828 pubmed	ý	v	v		n			2754	549327 Misoprostol Vaginal Insert in Labor Induction: A Cost-Consequences Model for 5 European Countries-An Ec Bierut A, DowglaÅ, Å-o-Smolarczyk J, Pienik, Adv Ther. 2016 Aug 22. [Epub ahead of print] create date: 2016/08/24 first author: Bierut A	24.08.2016	201
4	20160828 pubmed	у			na	n			2502	029784 The wrong prescription for drug prices. Birtwistle M. Health Serv J. 2014 Apr 25;124(6395):18. No abstract ava create date:2014/07/18 first author:Birtwistle M	18.07.2014	201
2	20160828 pubmed	γ	У	y		n			2494	943977 Are pharmacological properties of anticoagulants reflected in pharmaceutical pricing and reimbursement p Bochenek T, Czarnogorski M, Nizankowski R Eur Rev Med Pharmacol Sci. 2014 Jun;18(11):1649-56. create date: 2014/06/20 first author:Bochenek T	20.06.2014	201
2	20172131 WebOfScience	γ	_	у		n				ANALYSIS OF OUTPATIENT UTILIZATION AND COSTS OF ANTITHROMBOTIC DRUGS IN POLAND - IMPLICATI/ Bochenek, T; Nizankowski, R VALUE IN HEALTH		201
2	20160828 pubmed	γ	У			n			1596	Bodenheimer T. Ann Intern Med. 2005 Jun 21;142(12 Pt 1):996-1002. Rev create date: 2005/06/22 first author:Bodenheimer T	22.06.2005	200
12	20160918 pubmed	γ	у	Y		n			1676	761901 Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implication Boersma C, Athobari J, Gansevoort RT, de A Pharmacoeconomics. 2006;24(6):523-35. Review. create date: 2006/06/10 first author:Boersma C	10.06.2006	200
5	20160828 pubmed	γ	У	Y		n			2423	236878 How do patent rights affect regulatory approvals and data exclusivity rights for pharmaceuticals in the EU? Bogaert P. Van Keymeulen E. Pharm Pat Anal. 2012 Sep;14):393-405. doi: 10.4155/pp create date:2012/09/01 first author:Bogaert P	01.09.2012	201
12	20160918 pubmed	γ	у	Y		n			2501	Boland P. Manag Care. 2014 May;23(5):36-8. No abstract available. create date:2014/07/16 first author:Boland P	16.07.2014	201
11	20160918 pubmed	γ		У		n			2057	2/5228 Pharmaceuscal policy in the Netherlands: from price regulation towards managed competition.	26.06.2010	201
4	20100828 pubmed	Y	У	Y					2637	3/03/1 Jun warmarr make us nearmer r rescription arug prices and nearth Care utilization. Biorrescio-Higa F. J Health Lcon. 2015 Uc;44:37-33. doi:10.1016/j.jhealec.create.date.2015/09/17 [first author.Biorrescio-Higa F	17.09.2015	201
2	2010U828 pubmed	Ŷ	y	Y		Castinization and all a 199	V Delinus Deb		2630	30/13/2 Unit 200/From Financeurase Fine workUps and Wmy progs Lost More in the United States than in Mexce Device V An 1 Med. 2015 Dec;128(1):1265-7. doi: 10.1016/j.amj/created date:2015/08/251 [first author:Boyer LV	25.08.2015	201
12	20100828 pubmed	Y				y Statistical analysis - descriptive	Y Policy > Behaviour	n	n 2228	200139 (creative compliance in pharmaceurular markets: the case of profit controls. Expert Rev Pharmaceecon Outcomes Res, 2012 Feb;12(1 create date:2012)(7)[28] [first author@radley.j	28.01.2012	201
12	20100918 pubmed	Y	y	y Y		N			1917	1/21/22 [pupulation of the source use in one contrast system in the perspective of the statutory nearly in a fail of the source use in one contrast system in the perspective of the statutory nearly in the perspective of the statutory nearly in the source use in the source use in the source use in the perspective of the statutory nearly in the source use in the source us	29.01.2009	200
12	20100911 pubmed	y .	Y	v		N			2520	Aperatory wanning memory and an anti-approximation and a second second and a second	11.09.2014	201
99	20161222 sciencedirect.cor	y y		v					2/3	Regulation and regime of holograms/generation of regime (an regulation) Breake Kr, Lama L, Salawine GM. Intelline Cont. 2019 June 3. 004;Jin: 30107-02-01 (0)30/LI: (Tester Date: 2010)(0)(2) This authors Breake Kr.	01 07 1905	20.
99	20161127 sciencedirect cor	m v		v						Reference prioring, competition, and pharmaceutical expenditures: Theory and evidence from a natural exp Brekke (RA, Holmas TH, Stramma OR) in the create data-2007/02	03,07 1905	200
12	20160918 pubmed	, v		,		y Economic model (analytic)	v Policy > Behaviour		n 1716	188769 Reference prints of pharmaceuticals. Brekke KR, KÅfinebauer J, Krauma GR	26,12 2006	20
11	20160918 pubmed	7 V		v		D	, Shey & Denierrout		1625	2012 Direct to consumer advertising in pharmaceutical markets. Brekke KR, Kuhn M. J. Health Econ. 2006 Jan. 25(1):102-30. Epob 2005 Vec. 4 Freedand and Pharmaceutical markets.	11.11.2005	200
2	20172131 Scopus	y v	,			n			1010	Pharmaceutical pricing in Croatia: a comparison of ordinances in 2013 versus 2009 and their potential savin Brikicic LS. Godman B. Bogut M. Srden M. GaBl Journal		201
12	20160918 pubmed	y	У			n			2590	903495 Reference Pricing with Endogenous or Exogenous Payment Limits: Impacts on Insurer and Consumer Spent Brown TT, Robitson JC. Health Econ. 2016 Jun;25(6):740-9. doi: 10.1002/hec.31£ create date:2015/04/24 first author:Brown TT	24.04.2015	20
12	20160918 pubmed	y		у		n			1633	335081 Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures? Busse R, SchreyÄggg J, Henke KD. Int J Health Plann Manage. 2005 Oct-Dec;20(4):329-49. create date:2005/12/13 first author:Busse R	13.12.2005	20
2	20160828 pubmed	у	у	v		n			2518	180506 Using clinically nuanced cost sharing to enhance consumer access to specialty medications. Buxbaum J, de Souza J, Fendrick AM. Am J Manag Care. 2014 Jun 1;20(6):e242-4. create date:2014/09/03 first author:Buxbaum J	03.09.2014	201
2	20172131 Scopus	у		y		n				Impact of generic substitution on pharmaceutical prices and expenditures in OECD countries Buzzelli C. Kangasharju A. Linnosmaa I. Valto, Journal of Pharmaceutical Finance, Economics and Policy		20
2	20160828 pubmed	γ	у	y .		n			2330	303712 The determinants of pricing in pharmaceuticals: are US prices really so high? Cabrales A, JimÄDnez-MartÄ-n S. Health Econ. 2013 Nov;22(11):1377-97. doi: 10.1002/her create date:2013/01/11 first author:Cabrales A	11.01.2013	20

5 20160828 pubmed	У	У		n			27393500 Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients tr Cadranel J, Park K, Arrieta O, Pless M, Benda Lung Cancer. 2016 Aug;98:9-14. doi: 10.1016/j.lungcan.2 create date:2016/07/10 first author:Cadranel J	10.07.2016	2016
2 20172131 Scopus	у у			n			What role may pharmaceutical pricing and reimbursement in China? Cai Q, Salmon J.W. Journal of Pharmaceutical Finance, Economics and Policy		2005
8 20160828 pubmed	У	У		n			22432967 Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. Cameron A, Bansal A, Dua T, Hill SR, Moshe 1 Epilepsia. 2012 Jun;53(6):962-9. doi: 10.1111/j.1528-116 create date:2012/03/22 first author:Cameron A	22.03.2012	2012
8 20160828 pubmed	y	y		n			19042012 Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary a Cameron A, Ewen M, Ross-Degnan D, Ball D, Lancet. 2009 Jan 17;373(9659):240-9. doi: 10.1016/S014 create date:2008/12/02 first author:Cameron A	02.12.2008	2008
8 20160828 pubmed	y y			n			22867775 Switching from originator brand medicines to generic equivalents in selected developing countries: how m Cameron A, Mantel-Teeuwisse AK, Leufkens Value Health. 2012 Jul-Aug;15(5):664-73. doi: 10.1016/j.j create date:2012/08/08 first author:Cameron A	08.08.2012	2012
8 20160828 pubmed	v v			n			23128254 [Doctors, lawyers and pharmaceutical industry on health lawsuits in Minas Gerais, Southeastern Brazill. Campos Neto OH. Acurcio Fde A. Machado / Rev Saude Publica. 2012 Oct-46(5):784-90. Portuguese. create date:2012/11/07 first author:Campos Neto OH	07.11.2012	2012
2 20160828 pubmed	v			v Statistical analysis - descriptive	Y Policy > Access*	n n	26532742 What Makes A Pharmaceutical Pricing & Reimbursement Process Patient-Centric? A Comparative Analysis C Candotti-Besson B. Cozzone J. Value Health. 2015 Nov:18/71:A488. doi: 10.1016/j.iyal.2 create date:2015/11/05 first author:Candotti-Besson B	05.11.2015	2015
2 20160828 pubmed	v v						27564849 A comparative review of the pharmacoeconomic guidelines in South Africa. Carapinha JL. J Med Econ. 2016 Aug 26:1-8. [Epub ahead of print] create date:2016/08/27 first author:Carapinha JL	27.08.2016	2016
2 20160828 pubmed	v v			n			26707161 Comment on the implications of external price referencing of pharmaceuticals in Middle East countries. Carapinha JL. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):11 create date:2015/12/29 first author:Carapinha JL	29.12.2015	2015
4 20160828 pubmed	v	v		n			22478851 Regulators place spotlight on drug prices. Carroll J. Biotechnol Healthc. 2011 Summer 8/21:8-9. No abstract / create date:2012/04/06 first author:Carroll J	06.04.2012	2012
2 20160828 pubmed	,	, ,					24215848 The cost effectiveness of bevaring the added to canecitable with or without mitomycin-C in first II Carter HF Zannino D. John Simes B. Schoffel Fur L Carcer 2014 Feb-S031-535-43. doi:10.1016/j.jeiza.create.date-2013/11/13. J. first author:Carter HF	13 11 2013	2013
3 20160828 pubmed		,					19157250 (Cest astimutes of showing headling to the Dealing on Field headling ustance in 2005) Castale A Dave 7 AVC Devents TC Alver ME Dave Acad Med Dave (Cest) 2017 Han Dave 2017(2):125 (Cest asthe dave 2007) 201	25 12 2007	2007
2 20100828 publied	y y						1613/300 [Cost: Comments on Circlenic repairus o virus in orige analismi comment repairus o virus virus repairus o virus virus e advertage virus virus e	23.12.2007	2007
2 20100828 publied	y II	y					240011/6 [rear technology assessment and its impact on pharmaceutical pricing and remoursement powers]. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. Rev Web Clin. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First autori. Casimonaaou de C, sinvernantes Nr. First Autori. 2014/381,142 Suppl 1.35576. UR. 10/4007 (Create dealer2014/03/2) First	20.03.2014	2014
1 20160827 medline	УУУ			n			24363923 Availability, prices and attrotrability or essential medicines in Hait. Chanal HSJ, st Fort N2, Bero LS. Create date:2013	2013	2013
2 20172131 Scopus	уу			n			Pharmaceutical prices in india	24.04.2007	2015
8 20160828 pubmed	y	y		n			1/242/35 A proposal for measuring the degree of public nearth-sensitivity of patent legislation in the context of the V Chaves GC Universa MA. Built World Health Organ. 2007 Jan 25/(1/34-56). Create date: 2007/01/24 [hits author: Chaves GC	24.01.2007	2007
8 20160828 pubmed	у у			n			18405385 The influences of Tawan's generic grouping price policy on drug prices and expenditures: evidence from a Chen CL, Yang WC. BMC Public Health. 2008 Apr 12;8:118. doi: 10.1186/147 create date:2008/U4/15 [irst author:Chen CL]	15.04.2008	2008
4 20160828 pubmed	У	У		n			20575235 Drug prices, out-of-pocket payments, and insurer costs: how do payers vary? Chen J, Rizzo JA. Adv Health Scro Res. 2010;22:221-31. create date:2010/06/26 first author:Chen J	26.06.2010	2010
7 20160828 pubmed	у у			n			27123191 Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform. Chen Y, Hu S, Dong P, Kornfeld Ä., Jaros P, J Mark Access Health Policy. 2016;4. doi: 10.3402/imahp create date:2016/04/29 first author:Chen Y	29.04.2016	2016
2 20160828 pubmed	у у			n			18387056 Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region. Chen Y, Schweitzer SO. Value Health. 2008 Mar;11 Suppl 1:S124-9. doi: 10.1111/ create date:2008/04/17 first author:Chen Y	17.04.2008	2008
4 20160828 pubmed	У	У		n			26102457 Are high drug prices for hematologic malignancies justified? A critical analysis. Chhatwal J, Mathisen M, Kantarijan H. Cancer. 2015 Oct 1;121(19):3372-9. doi: 10.1002/cncr.25 create date:2015/06/24 first author:Chhatwal J	24.06.2015	2015
4 20160828 pubmed	У		У	n			23861432 Higher drug prices will boost development of personalised medicine, says new report. Chinthapalli K. BMJ. 2013 Jul 16;347:4549. doi: 10.1136/bmj.44549. No create date:2013/07/19 first author:Chinthapalli K	19.07.2013	2013
4 20160828 pubmed	у	У		n			15998928 Medicare-approved drug discount cards and prescription drug prices. Chisholm MA, Turner JC, Dipiro JT. Am J Health Syst Pharm. 2005 Jul 15;62[14]:1482-7. create date:2005/07/07 first author:Chisholm MA	07.07.2005	2005
2 20160828 pubmed	y	y		n			20446995 Recent case developments in health law. Pharmaceutical price-fixing and consumer protection: Blue Cross Clark S. J Law Med Ethics. 2010 Spring:38(1):160-2. doi: 10.1111/j create date:2010/05/08 first author:Clark S	08.05.2010	2010
9 20160911 pubmed	y			y Synthesis/Comment	Y Policy (descriptive)	V N	18244997 Value based pricing for NHS drugs: an opportunity not to be missed? Claston K, Briggs A, Buxton MJ, Culyer AJ, M BMJ. 2008 Feb 2;336(7638):251-4. doi: 10.1136/bmj.394 create date:2008/02/05 first author:Claxton K	05.02.2008	2008
2 20160828 pubmed	y.		na	n			17535009 OFT, VBP: QED? Claxton K. Health Econ. 2007 Jun;16(6):545-58. create date:2007/05/31 first author:Claxton K	31.05.2007	2007
4 20160828 pubmed	v		v	0			24239942 US trade agreement threatens to increase drug prices and withhold safety data. Cohen D. BMJ. 2013 Nov 15:347:16908. doi: 10.1136/bmi.16908. N. create date: 2013/11/19 first author: Cohen D.	19.11.2013	2013
6 20160828 pubmed	v	v		n			17132032 Comparing patient access to pharmaceuticals in the UK and US. Cohen J. Cairns C. Paquette C. Faden L. Appl Health Econ Health Policy. 2006;5(3):177-87. create date:2006/11/30 first author:Cohen J	30.11.2006	2006
12 20160918 pubmed	, ,		v				23389491 Transatiantic convergence with respect to the fourth burdle? Cohen L Pharmacoeconomics 2006 Dec:24 Suppl 2:87-94 doi:10.create date:2006/01/01.Liftst author:Cohen L	01 01 2006	2006
4 20160828 pubmed	7		,				19114449 Channes to the remulation of drum prices in the LW Colline L Philip Colline L Phil	21.12.2008	2008
2 20160828 pubmed	y		, v				1723125 Charles to the regulation of any price in the Ok. Control of the control	02.02.2007	2000
20160828 pubmed	7	N.	У				12226/07 Distrogramming and the Dation 2016 an	04.04.2009	2007
12 20160918 enhand	1	y					25555557 Implangation View Band Band Man Star Band Band Band Band Band Band Band Band	09.04.2008	2008
12 20160918 pubmed	Ý	y					203-30-20 Implementing value-based regimes regiment records and leaders and le	08.11.2015	2015
12 20100918 pubmed	У	Y		A.			203-90-41 the interview water-based organization to restrict care. Contrad DA Head Mark Mark Mark Mark Mark Mark Mark Mark	10.11.2015	2015
12 20100918 pubmed	У	Ŧ					2/V2090 reactors innuerosing ure vanisation in utits prescripting expenditure in reana.	31.03.2016	2016
6 20160828 pubmed	У	У		n			1922222 Quantifying the use of the statin antilipemic drugs: comparisons and contrasts between Nova Scotia, Canac Cooke C, Nissen L, Sketris I, Tett SE. Clin Ther. 2005 Apr;27(4):497-508. create date:2005/06/01 first author:Cooke C	01.06.2005	2005
11 20160918 pubmed	У	y		n			22.200940 Price regulation and relative dealys in generic drug adoption. Costa-Font J, McGuire A, Varol N. J Health Econ. 2014 Dec; 38:1-9. doi: 10.1016/j.jhealeco.i. create date:2014/09/10 first author:Costa-Font J	10.09.2014	2014
z 20160828 pubmed	у у	_		n			27358014 Regotating Pharmaceutical Prices: A Change in Chinese Health Policy. Costello MM. World Health Popul. 2016;16(4):5-8. create date:2016/07/01 first author:Costello MM	01.07.2016	2016
4 20160828 pubmed	У	У		n			17491288 Do P&T committees have enough power? Plans and PBMs are divided about sharing drug prices with clinici Cross M. Manag Care. 2007 Apr;16(4):39-42. No abstract available create date:2007/05/12 first author:Cross M	12.05.2007	2007
2 20160828 pubmed	У			 ¥ Literature Review (not systematic) 	 Policy (descriptive) 	y n	26533024 Methodology of International Comparison of Pharmaceutical Prices. Csanadi M, Fasseeh AN, Kalo Z. Value Health. 2015 Nov;18(7):A539. doi: 10.1016/j.jyal.2 create date:2015/11/05 first author:Csanadi M	05.11.2015	2015
2 20160828 pubmed	У			 Y Economic model (analytic, empirical dat 	ta) n Policy (descriptive)	y n	20831294 Cost-effectiveness analysis in markets with high fixed costs. Cutler DM, Ericson KM. Pharmacoeconomics. 2010;28(10):867-75. doi: 10.2165/ create date:2010/09/14 first author:Cutler DM	14.09.2010	2010
2 20172131 Scopus	у у			n			Equity in pharmaceutical pricing and reimbursement: Crossing the income divide in Asia Pacific Daems R. Maes E. Glaetzer C. Value in Health Regional Issues		2013
11 20160918 pubmed	y	y		n			16841230 [Price regulation and generic competition in the pharmaceutical market. Dalen DM, Str Ä, m S, Haabeth T. Eur J Health Econ. 2006 Sep;7(3):208-14. create date:2006/07/15 first author:Dalen DM	15.07.2006	2006
2 20160828 pubmed	y			 Economic model (analytic) 	y Policy > Welfare***	n n	24327269 Value-based differential pricing: efficient prices for drugs in a global context. Danzon P, Towse A, Mestre-Ferrandiz J. Health Econ. 2015 Mar;24(3):294-301. doi: 10.1002/hec. create date:2013/12/12 first author:Danzon P	12.12.2013	2013
2 20160828 pubmed	y.			y Economic model (analytic, empirical dat	ta) n Prices (descriptive)	y n	23156660 Effects of regulation on drug launch and pricing in interdependent markets. Danzon PM, Epstein AJ. Adv Health Econ Health Serv Res. 2012;23:35-71. create date:2012/11/20 first author:Danzon PM	20.11.2012	2012
2 20160828 pubmed	v v			n			24293058 Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement. Danzon PM, Mulcahy AW, Towse AK, Health Econ, 2015 Feb:24/21:238-52, doi: 10.1002/hec.3l create date:2013/12/03 first author:Danzon PM	03.12.2013	2013
4 20160828 pubmed	v			v Statistical analysis - descriptive	Y Prices (descriptive)	v n	21821570 Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor count: Danzon PM. Towse A. Mulcahv AW. Health Aff (Milkwood). 2011 Aug. 30/81:1529-38. doi: 10.1 create date:2011/08/09 first author:Danzon PM.	09.08.2011	2011
2 20172131 Scopus	, ,	v					Impact of direct-to-consumer advertising on pharmaceutical prices and demand Dave D. Saffer H Southern Economic Journal		2012
2 20160828 pubmed	, 	,					72202021 A Comparison of Asian and Global Disparsautical Dispars Line as EKC Mathod Disparsautical Dispars Line as EKC Mathod Disparsautical Disparse Line as EKC Mathod Disparsautical Disparse Line as EKC Mathod Disparsautical Disparse Line as EKC Mathod Disparse	01 11 2014	2014
4 20160828 pubmed	y y			K Statistical analysis - description	V Pricer (descriptive)	v n	2652/0 / Comparison of Applete Multi-interaction for the ford burger of the surface of the surfa	05 11 2015	2015
4 20100828 publied	y .			y Statistical analysis - descriptive	Prices (descriptive)	y n	2035062 A Companying the first wear and the second	25.05.2007	2013
4 20160918 publied	y .			y Elterature Review (not systematic)	y Policy (descriptive)	y II	173005212 Final direction and an electron between constraints of the standard	15.05.2007	2007
4 20160828 pubmed	Y	y					2/300600 The dimiculty of comparing orug prices between countries. De block M. Earcet Oricol. 2016 Apr;1/(4):E125. doi: 10.110/514/0- Create date:2016/06/15 Trist author/to ellock M	15.06.2016	2016
12 20160918 pubmed	У			y Legal analysis	y Policy > Access*	n n	2591547 Causes of drug shortages in the legal pharmaceutical tranework. De weerds t, similarity causes of drug shortages in the legal pharmaceutical tranework.	17.01.2015	2015
2 20160828 pubmed	У	У		n			187/1195 Patents or patients? Global access to pharmaceuticals and social justice. de Wildt G, Khoon CC. Med Confl Surw. 2008 Apr-Jun;24 Suppl 1:552-61. do: : create date:2008/09/06 [hrst author:de Wildt G	05.09.2008	2008
12 20160918 pubmed	У		na	n			21189519 [Reference pricing system for triptans: Chaos in the pharmac]. Diener HC. Med Monatsschr Pharm. 2010 Dec;33(12):451. German. create date:2010/12/31 first author:Diener HC	31.12.2010	2010
10 20160828 OECD iLibrary	У			y Synthesis/Comment	y Policy (descriptive)	y n	Achieving Better Value for Money in Health Care - Ensuring Efficiency in Pharmaceutical Expenditures Docteur E, Paris V create date:2009	01.07.1905	2009
12 20160918 pubmed	У		У	n			18368023 Australian pharmaceutical policy: price control, equity, and drug innovation in Australia. Doran E, Alexander Henry D. J Public Health Policy. 2008 Apr;29(1):106-20. doi: 10.10! create date:2008/03/28 first author:Doran E	28.03.2008	2008
5 20160828 pubmed	У		na	n			25256668 What is a new drug worth? An innovative model for performance-based pricing. Dranitsaris G, Dorward K, Owens RC, Schipp Eur J Cancer Care (Engl). 2015 May;24(3):313-20. doi: 10 create date:2014/09/27 first author:Dranitsaris G	27.09.2014	2014
2 20160828 pubmed	У			y Synthesis/Comment	 Policy (descriptive) 	y n	25274258 Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the Un Dranitsaris G, Papadopoulos G. Appl Health Econ Health Policy. 2015 Jun;13(3):291-302. create date:2014/10/03 first author:Dranitsaris G	03.10.2014	2014
9 20160911 pubmed	y Y			N			22589671 Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in malaysia Dranitsaris G, Truter I, Lubbe MS, Sriramana Malays J Med Sci. 2011 Oct;18(4):32-43. create date:2012/05/17 first author:Dranitsaris G	17.05.2012	2012
9 20160911 pubmed	y			Y Economic model (analytic)	y Prices > Health outcome	y n	21493060 The development of a value based pricing index for new drugs in metastatic colorectal cancer. Dranitsaris G, Truter I, Lubbe MS. Eur J Cancer. 2011 Jun;47(9):1299-304. doi: 10.1016/j.eji create date:2011/04/16 first author:Dranitsaris G	16.04.2011	2011
8 20160828 pubmed	y y			n			19082259 [Antibiotic use in Mexico: review of problems and policies]. Dreser A, Wirtz VJ, Corbett KK, EchĂļniz G. Salud Publica Mex. 2008;50 Suppl 4:5480-7. Review. Spai create date: 2008/12/17 first author: Dreser A	17.12.2008	2008
2 20160828 pubmed	y	v		n			25886175 Corporate social responsibility in global health: an exploratory study of multinational pharmaceutical firms. Droppert H, Bennett S. Global Health: 2015 Apr 9;11:15. doi: 10.1186/s12992-01 create date:2015/04/18 first author:Droppert H	18.04.2015	2015
5 20160828 pubmed	y.			y Statistical analysis - descriptive	Y Policy (descriptive)	y n	20803050 Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Drummond M, JĶnsson B, Rutten F, Starga Eur J Health Econ. 2011 Jun;12(3):263-71. doi: 10.1007/s create date:2010/08/31 first author:Drummond M	31.08.2010	2010
12 20160918 pubmed	v		v				17210939 European perspective on the costs and cost-effectiveness of cancer therapies. Drummond MF. Masion AR. J Clin Oncol. 2007 Jan 10:25(2):191-5. Review. create date: 2007/01/11 first author: Drummond MF.	11.01.2007	2007
9 20160911 pubmed	v			v Synthesis/Comment	Y Policy (descriptive)	V N	20705656 From a cancer drug fund to value based pricing of drugs. Duerden M. BMJ. 2010 Aug 12:341:c4388. Aci: 10.1136/bmi.c4388. N. create date:2010/08/14 first author:Duerden M	14.08.2010	2010
2 20172121 Scopus	y W						The effect of medicine part D on pharmaculical inviter and utilization During M Morton E S American Economic Review		2010
2 20172131 Scopus	y	, , , , , , , , , , , , , , , , , , ,					The product of the second product product and second product and secon		2011
12 201/2151 5copus	y	,					The meaning communication in the second data and the addentee contract to addentee contract t	08.01.2012	2012
12 20160918 pubmed	7	4					2/395231 Datiant paramitting of paramit methods to the control of	05.01.2013	2013
12 20100916 pubmed	y	Y					2000 a subscription of participants of generation and hadronic generation and	05.01.2014	2014
12 20160918 pubmed	γ'	Y					24033330 Detects, perceptions and veravours or ers vowarise generic medicines. Unime 32, shannon 6, cure w, Junne 42, June 34, June 44, Ju	05.06.2014	2014
12 20160918 pubmed	y'	Y					2333777 retrespons and activities on community priminicus unwards generic medicines. Unume Sy, shannon B, Luien W, Junne CP. J Manag Lare Spec Pharm. 2014 Nov20[1]:1138-40. Créate date:2014/10/30 hrt author:Dunne SS	30.10.2014	2014
1 20160827 medline	У	Y		n			21/97/280 Works the market share of generic medicines influence the price level/: a European analysis. Upist P, Simoens S. create date:2011/07/30 first author:Dyist P	30.07.2011	2011
12 20160918 pubmed	У	y	_	n			22/09/229/ The impact of reference-pricing systems in Europe: a iterature review and case studies. Dyst P, Vulto A, Simoens S. Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(£ create date:2011/11/22 first author:Dyst P	22.11.2011	2011
2 20160828 pubmed	У		У	n			19971177 European pnarmaceutkai priorig and reimbursement conterence. Enreth J. Williams D. Expert Rev Pharmaceocon Outcomes Res. 2009 Feb;9(1) create date:2009/04/18 first author:Ehreth J	18.04.2009	2009
2 20160828 pubmed	У	У		n			1/2004 Loordinating on lower prices: pnamaceutical pricing under political pressure. Ellison SF, Wolfram C. Rand J Econ. 2006 Summer;37(2):324-40. create date:2007/02/13 first author:Ellison SF	13.02.2007	2007
ь 20160828 pubmed	у у	_		n			1985/8949 How Alus runding strengthens nealth systems: progress in pharmaceutical management. Embrey M, Hoos D, Quick J. J Acquir Immune Defic Syndr. 2009 Nov;52 Suppl 1:534-: create date:2009/11/05 first author:Embrey M	05.11.2009	2009
8 20160828 pubmed	y	Y		n			24927816 Strengthening the capacity of managers in pharmaceutical services based on Primary Health Care (PHC) at c Emmerick IC, Chaves LA, Marin N, Luiza VL Hum Resour Health. 2014 Jun 13;12:34. doi: 10.1186/14: create date:2014/06/15 first author:Emmerick IC	15.06.2014	2014
8 20160828 pubmed	у у			n			25926990 FarmÄjcia Popular Program: changes in geographic accessibility of medicines during ten years of a medicini Emmerick IC, do Nascimento JM /r, Pereira Y J Pharm Policy Pract. 2015;8(1):10. doi: 10.1186/s40545- create date:2015/05/01 first author:Emmerick IC	01.05.2015	2015
8 20160828 pubmed	у у			n			26521237 Barriers in household access to medicines for chronic conditions in three Latin American countries. Emmerick IC, Luiza VL, Camacho LA, Vialle-V, Int J Equity Health. 2015 Oct 31;14:115. doi: 10.1186/s12 create date:2015/11/02 first author:Emmerick IC	02.11.2015	2015
8 20160828 pubmed	у у			n			23645920 Access to medicines in Latin America and the Caribbean (LAC): a scoping study. Emmerick IC, Oliveira MA, Luiza VL, Azeredo BMJ Open. 2013 May 3;3(5). doi:pii: e002224. 10.1136/t create date:2013/05/07 first author:Emmerick IC	07.05.2013	2013
4 20160828 pubmed	У	У		n			27270771 Use the Bayh-Dole Act to lower drug prices for government healthcare programs. Engelberg AB, Kesselheim AS. Nat Med. 2016 Jun 7;22(6):576. doi: 10.1038/nm0616-57; create date:2016/06/09 first author:Engelberg AB	09.06.2016	2016
99 20161127 haiweb.org	Y			y Systematic Review	n Policy > Prices	n y	Working Paper 1: External Reference Pricing (Review Series on Pharmaceutical Pricing Policies and Interven Espin J, Joan Rovira and Antonio Olry de Labry create date: 2011/05	03.07.1905	2011
-				n			Pharmaceutical pricing policies in China Fang Y. Pharmaceutical Prices in the 21st Century		2015
2 20172131 Scopus	y y						25104348 Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi F Fang Y1, Wagner AK2, Yane S3. Jiane M3. Zhane F2. Ross-Deenan D2. create date: 2013	2013	2013
2 20172131 Scopus 1 20160827 medline	y y y y			n				08 10 2005	2005
2 20172131 Scopus 1 20160827 medline 12 20160918 pubmed	y y y y		v				16209703 Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicin Faunce T. Doran E. Henry D. Drahos P. Searly Global Health 2005 Oct 6:1:15 create date: 2005/50/00 First author: Example T	00.10 71414	
2 20172131 Scopus 1 20160827 medline 12 20160918 pubmed 5 20160828 pubmed	y y y y y		y	n n Synthesis/Comment	v Policy (descriptive)	V D	16209703 Assessing the impact of the Australia-United States Fee Trade Agreement on Australian and global medicin Faunce T Joarna F, Jenny D, Drahos P, Searl Global Health. 2005 Ct 65:15. create date:2005/10/08 First author:Faunce T Joarna Health Agreement on Australian and global medicin Faunce T Joarna F, Jenny D, Drahos P, Searl Global Health. 2005 Ct 65:15. create date:2005/10/08 First author:Faunce T Joarna Health Agreement on Australian and global medicin Faunce T Joarna F, Jenny D, Drahos P, Searl Global Health. 2005 Ct 65:15. create date:2005/10/08 First author:Faunce T Joarna Health Agreement on Australian and global medicin Faunce T Joarna F, Jenny T Joarna H, Jenny T Joarna F, Jenny T Joarna H, Jenny T Joa	01.07.2009	2009
2 20172131 Scopus 1 20160827 medline 12 20160918 pubmed 5 20160918 pubmed 12 20160918 nubmed	у у у у у у		v	n y Synthesis/Comment	y Policy (descriptive)	y n	16209703 Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicin Faunce T. Doran E, Henry D, Drahos P, Seath Global Health. 2005 Oct 6;1:15. create date: 2005/10/08 Tist author:Faunce T 1956314 Policy Challenges of nanomedicine for Australiana Piers S. Active Teath Rev. 2009 May;32(2):256-67. create date: 2009/10/101 Tist author:Faunce T A 197631141 (Children Foundamer Faunce) Australiana Market S. Active Teath Market S. Ac	01.07.2009	2009
2 20172131 Scopus 1 20160827 medline 12 20160918 pubmed 5 20160828 pubmed 12 20160918 pubmed 13 2010918 pubmed	y y y y y y		y y	n y Synthesis/Comment	y Policy (descriptive)	y n	16097993 Aversing the impact of the Australia-United States Free Trade Agreement on Australian and global medicin Faunce T, Doran E, Henry D, Drahos P, Seeki (Cobal Health. 2005 Oct 6; 1:15. create date:2007/10/16 [Inst author Faunce T and the States Free Trade Agreement on Australian and global medicin Faunce T, Doran E, Henry D, Drahos P, Seeki (Cobal Health. 2005 Oct 6; 1:15. create date:2007/10/16 [Inst author Faunce T and the States Free Trade Agreement on Australian and global medicin Faunce T, Doran E, Henry D, Drahos P, Seeki (Cobal Health. 2005 Oct 6; 1:15. create date:2007/10/16 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/10/16 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/10/16 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/10/16 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/10/16 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/10/16 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/10/16 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/17/16 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/17/16 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/17/16 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/17/16 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/17 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/17 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/17 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/17 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/17 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/17 [Inst author Faunce T A aust Health Rev. (2005 Mars) 32(2):25. create date:2007/17 [Inst aut	01.07.2009 05.06.2007 15.06.2007	2009 2007 2007
2 20172131 Scopus 1 20160827 medline 12 20160918 pubmed 5 20160828 pubmed 12 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed	у У У У У У У		y y y	y Synthesis/Comment	y Policy (descriptive)	y n	15029703 Assessing the impact of the Australia-Unided States Free Trade Agreement on Australian and global medion Faurce T, Doran F, Jerrey D, Dahos P, Seel Coloral Health. 2005 Oct 6;1:15 create date:2007/10/81 [First authorFaurce T 1595113 Anisy Health Roots Faurce TA Aust Health Roots Oct 6;1:15 create date:2007/10/81 [First authorFaurce TA 1595113 Challenges for Australia's Holl Nanopharma Pickies: trade data, public goods and reference price in sourt Faurce TA Aust Health Roots Over Sign 2007 Juni 1;4:6. create date:2007/10/81 [First authorFaurce TA 1595113 Challenges for Australia's Holl Nanopharma Pickies: trade data, Preference Picking in sourt Faurce TA Aust Health Root 2007 Juni 1;4:6. create date:2007/10/81 [First authorFaurce TA 1595129 Peterme princip on phrametadias: in the Australia-Unide States Fer Task Agreement If Carefing Aust Faurce TA Aust Health Root 2007 Juni 1;4:6. create date:2007/10/81 [First authorFaurce TA	01.07.2009 05.06.2007 15.06.2007	2009 2007 2007
2 20172131 Scopus 1 20160827 medline 2 20160918 pubmed 5 20160828 pubmed 12 20160918 pubmed 2 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed	у У У У У У У У У У		y y y	n y Synthesis/Comment n n	y Policy (descriptive)	y n	16059793 Avesting the impust of the Australia-Unided States Free Trade Agreement no Australian and global medicin Faunce T, Doran E, Henry D, Drahos P, Sewi Global Health. 2005 Oct 6:1:15 create date:2007/10/8 [Inst authorFaunce T 19553114 Childenges of nonauticine for Australia's Inst PS. Faunce TA. Aust Health Rev. 2005 Mar;33(2):256-37. create date:2007/10/8 [Inst authorFaunce TA 19553114 Childenges of nonauticine for Australia's Inst PS. Cause Table create date:2007/10/8 [Inst authorFaunce TA 19563114 Childenges for Australia's Bio/Nanopharma Patcies: trade date: Jobs polic globs and reference pring in sust Faunce TA. Aust Health Rev. 2005 Mar;33(2):356-37. create date:2007/10/8 [Inst authorFaunce TA 19563518 Childenges for Australia's Bio/Nanopharma Patcies: trade date: Jobs and reference pring in sust Faunce TA. Aust Health Rev. 2005 Apr;24(2):38-42. create date:2007/10/8 [Inst authorFaunce TA 19564597 Reference pring in gost Jamanes TA Mexal Jausz TA Mexal Jausz TA Mexal Jausz TA 16000881 The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable a Faunce TS, Tomosy GF. Monath Bioeth Rev. 2005 Apr;24(2):38-42. create date:2005/10/9 [Inst authorFaunce TS	01.07.2009 05.06.2007 15.06.2007 08.10.2005	2009 2007 2007 2005
2 20172131 Scopus 1 20160827 medline 12 20160918 pubmed 5 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed 7 20160828 pubmed	y y y y y y y y y y	¥	y y y	n y Synthesis/Comment n n	y Policy (descriptive)	y n	16007093 Axessing the impust of the Australia-Underst States Free Trade Agreement on Australian and global medion Fazure T, Doran E, Henry D, Drahos P, Serel Gobal Health. 2005 Oct 6:1:5 create date:2007/10/8 [First author:Faxure:T A 1595131 Anisy Undergos of numerications for Australia's BiolyNacopharma Piloticies: trade desha, public goods and reference pricing in sunt F zamuer TA. Aust Health Rev. 2000 May;31(2):28-36. create date:2007/10/8 [First author:Faxure:TA 1595131 Charlenges for Australia's Biol/Nacopharma Piloticies: trade desha, public goods and reference pricing in sunt F zamuer TA. Aust Health Rev. 2000 May;31(2):28-36. create date:2007/10/8 [First author:Faxure:TA 15054579 Reference pricing for pharmaceuticals: the Australia's Biol/Nacopharma Piloticies: trade desha, public goods and reference pricing in sunt F zamuer TA. Aust Health Rev. 2000 Juni 1: create date:2007/10/8 [First author:Faxure:TA 16005881 The UN House of Commons report on the Influence of the pharmaceutical industry: Isoson for equilable # Raure: TS, Tomosy GF Main Biosin Rev. 2005 Apr;21/9]: create date:2007/10/8 [First author:Faxure:TA 16005881 The UN House of Commons report on the Influence of the pharmaceutical industry: Isoson for equilable # Raure: TS, Tomosy GF Comt Dem High Throughout Streeme. 2006 Pilot;91: Pilot create date:2007/10/18 [First author:Faxure:TS 16005881 The UN House of Commons report on the Influence of the pharmaceutical industry: Isoson for equilable # Raure: TS, Tomosy GF Comt Dem High Throughout Streeme. 2006 Pilot;92: Pilot create date:2006/10/18 [First author:Faxure:TS 160059687	01.07.2009 05.06.2007 15.06.2007 08.10.2005 16.02.2006	2009 2007 2007 2005 2006
2 20172131 Scopus 1 20160827 medline 12 20160918 pubmed 5 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed 4 20150828 pubmed	у у у у у у у у у у у у у у	y	y y y y	n y Synthesis/Comment n n n	y Policy (descriptive)	y n	16059793 Avesting the impust of the Australia-Unided States Free Trade Agreement no Australian and global median Fazure T, Doran E, Henry D, Drahos P, Sexié (clobal Health. 2005 Oct 6; 1:15) create date:2007/10/8 [Frist author Fazure T 19553134 Avesting the impust of the Australia-Unided States Free Trade Agreement Trade T	01.07.2009 05.06.2007 15.06.2007 08.10.2005 16.02.2006 31.07.2013	2009 2007 2007 2005 2006 2013
2 20172131 Scopus 20160827 medline 12 20160918 pubmed 2 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed 7 20160828 pubmed 4 20160828 pubmed 9 20160911 pubmed	y y y y y y y y y y y y y	У	y y y y	n y Synthesis/Comment n n y Synthesis/Comment	y Policy (descriptive) Y Policy (descriptive)	y n y N	16037903 Axessing the impusc of the Australia-Understated States Free Trade Agreement on Australian and jobal medicin Faurer, T. Jorna F. Jerroy, D., Draho P, Seari, G. Koll, Markan, Z. S. Cett, G. Li, S. Cetter, A. Cetter,	05.10.2003 01.07.2009 05.06.2007 15.06.2007 08.10.2005 16.02.2006 31.07.2013 27.05.2016	2009 2007 2007 2005 2005 2006 2013 2016
2 20172131 Scopus 1 20160927 medline 12 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed 12 20160928 pubmed 1 20160828 pubmed 1 20160828 pubmed 1 20160927 medline	у у у у у у у у у у у у у у у у у	y	y y y y	n y Synthesix/Comment n n y Synthesix/Comment y Synthesix/Comment y Survey/(Structured)Interviews	y Policy (descriptive) Y Policy (descriptive) y Prices > Behaviour	y n y N y n	16029703 Attesting the impact of the Australia-United States Free Trade Agreement on Australian and global medion. Faurue T, Doran E, Henry D, Danho P, Saet (Cold Health. 2005 Oct 6;1:15 create date:2007/10(8] Inst author Faurue T 1954112 Challenges for Australia's Michaegod amma Policies: Trade data), duble goods and reference price in sourt Faurue TA. Aust Health. 2005 Oct 6;1:15 create date:2007/10(8] First author Faurue TA 1954112 Challenges for Australia's Michaegod amma Policies: Trade data), duble goods and reference price in sourt Faurue TA. Aust Health. 2005 Oct 6;1:15 create date:2007/10(8] First author Faurue TA 1954112 Challenges for Australia's Michaegod amma Policies: Trade data), degreement affectores: Trade data First Australia-Since TA Aust Health. 2005 Oct 6;1:15 create date:2007/10(8] First author Faurue TA 10050081 Texa United Trade data First Australia Since TA Aust Health. 2005 Oct 6;1:15 create date:2007/10(8] First author Faurue TA 1005081 Texa United Trade data First Australia Since TA First Australia Since TA first author Faurue TA 1005081 Texa United Trade data First Australia First Australia First Australia first Australia Australia first Australia 1005081 Texa United Trade data First Australia First Australia First Australia First Australia 1005081 Texa United	01.07.2009 05.06.2007 15.06.2007 08.10.2005 16.02.2006 31.07.2013 27.05.2016 24.12.2014	2009 2007 2007 2005 2005 2013 2016 2014
2 20172131 Scopus 1 201608278 pubmed 2 201609218 pubmed 2 20160938 pubmed 2 20160938 pubmed 2 20160938 pubmed 2 20160938 pubmed 4 20160828 pubmed 9 20160931 pubmed 1 20160828 pubmed 2 20160931 pubmed	У У У У У У У У У У У У У У У У У У У	y y	y y y y	n y Synthesis/Comment n y Synthesis/Comment y Synthesis/Comment y Survey / (Structured) Interviews n	y Policy (descriptive) Y Policy (descriptive) y Prices > Behaviour	y n y N y n	16297903 Axessing the impact of the Australia-Unders States Free Trade Agreement in and global medicin Faure T, Doran F, Henry D, Draho P, Seal Colora Health. 2005 CH (5:1).5 create date:2007/10(8] [Fnt author-Faure T 1595311 Anisy Healtheges of nonuncing for Australia's Bio/Nanopharma Picioles: Trade date, Dollar goods and reference pricing in surts. Faure TA. Aust Health Pacco DMWa;3(2) 256-43. create date:2007/10(8] [Fnt author-Faure TA 15754577 Reference pricing of prafamenesticias: the Australia-Under State Detter Pacco DMWa;3(2) 256-43. create date:2007/10(8] [Fnt author-Faure TA 15754577 Reference pricing of prafamenesticias: the Australia-Under States Terma Agreement af Carleing Austr F Zaure TA. Aust Health Pacco Zu07/11(2) [Fnt author-Faure TA 15054578 The Influence Critic on Commons report on the Influence of the pharmaceutical Industry: Issung FTA. Montah licenti Aev. 2005 Apr;21(2):20:20 Tu 11: create date:2007/10(1) [Fnt author-Faure TS 15054578 The Influence of the Influence of the pharmaceutical Industry: Issung FTA. Montah licenti Aev. 2005 Apr;21(2):80:42 CH = 10:80:42007/11 [Fnt author-Finence TS 15075057 The Influence of Influence of the pharmaceutical Industry: Issung FTA. Montah licenti Aev. 2005 Apr;21(2):80:42 CH = 10:80:42007/11 [Fnt author-Finence TS 12975057 The Influence of Influence of the pharmaceutical Industry: Issung FTA. Montah licenti Aev. 2005 Apr;21(2):80:42 CH = 10:80:42007/11 [Fnt author-Finence TS 12975057 The Influence of Influence of Influence of The Influence of The Influence of The Influen	01.07.2009 05.06.2007 15.06.2007 08.10.2005 16.02.2006 31.07.2013 27.05.2016 24.12.2014 18.08.2012	2009 2007 2007 2005 2005 2013 2016 2014 2014 2012
2 20172131 Scopus 1 20160872 mediae 12 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed 2 20160918 pubmed 4 20160828 pubmed 1 20160918 pubmed 1 20160918 pubmed 1 20160918 pubmed 1 20160918 pubmed	У У У У У У У У У У У У У У У У У У У	y y	y y y y	n y Synthesis/Comment y y Synthesis/Comment y Survey / (Structured) Interviews y (Retrospective) Observational study	y Policy (descriptive) Y Policy (descriptive) y Prices > Behaviour Y Policy > Usage** & Exp	y n y N y n	15037993 Axessing the impost of the Australia-Unided States Free Trade Agreement on Australian and global medion. Fazure T, Doran E, Henry D, Draho P, Sewil Colobit Health. 2005 Oct 6;1:5 create date:2007/10(8] First author Fazure T 15951114 Challenges for Australia's Bio/Nacopharma Picicies: Trade data, builde godd and erference price in sust. Exam C TA. Aust Health Rev. 2005 Aug;312]: 236-42. create date:2007/10(8] First author Fazure TA 15951114 Challenges for Australia's Bio/Nacopharma Picicies: Trade data, builde godd and erference price in sust. Exam C TA. Aust Health Rev. 2005 Aug;312]: 236-42. create date:2007/10(8] First author Fazure TA 15951125 The UN House of Cammons regord on the Inhemes of the pharmacutcal industry issues for Austent Pice. create date:2007/10(8] First author Fazure TA 1605023 The UN House of Cammons regord on the Inhemes of the pharmacutcal industry issues for a equipation of the pharmacutcal issue for Australia States FS. First Auge FS. Control Bio States F	08.10.2003 01.07.2009 05.06.2007 15.06.2007 08.10.2005 16.02.2006 31.07.2013 27.05.2016 24.12.2014 18.08.2012 14.02.2013	2009 2007 2005 2006 2013 2016 2014 2014 2012 2013
2 20172131 Scopus 1 2016287 medilen 12 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed 12 20160918 pubmed 12 20160828 pubmed 12 20160828 pubmed 12 20160828 pubmed 12 20160938 pubmed 12 20160938 pubmed	у У у У у у у у у у у у у у у у у	y y y	У У У У	n Synthesis/Comment y Synthesis/Comment y Synthesis/Comment y Synthesis/Comment y Synthesis/Comment y Retrospective) Observational study n	y Policy (descriptive) Y Policy (descriptive) y Prices > Behaviour y Policy > Usage** & Exp	y n y N y n n n	16297903 Axessing the impact of the Australia-Undergo free Trade Agreement in adaption implicit a fautor F, Joronn F, Jerroy D, Daho P, Seal Columb 1420. Core Let 2007/10/8 [Inst author F, Annuer T 1595311 Anisy Undergo of Annuer T, Anis Sib O,Nanopharma Patioles: Trade de Balo, policit goods and reference pricing in surts. F Joanne TA Aust Health Rev. 2000 Myrs/31(2):SAS-0. crede date:2007/10/8 [Inst author F, Annuer TA 15754577 Reference pricing of prahamescularis: the Austation-Hole Shade Server Trade Agreement af Cale Strate (Taska Under Shauer TA Aust Health Rev. 2000 Myrs/31(2):SAS-0. crede date:2007/10/8 [Inst author F, Annuer TA 15654578 Reference pricing of prahamescularis: the Austation-Hole Shade Server Taska Organo Marka Under Shauer TS Monsh Bioch Rev. 2005 Apr;21/2):Sas-0. crede date:2007/10/8 [Inst author F, Annuer TS 1567958 The Inst News Conf Commons report on the Influence of the pharmaceutical Industry E source TS Formas Net	01072603 01072603 05.06.2007 08.10.2005 16.02.2006 31.07.2013 27.05.2016 24.12.2014 18.08.2012 14.02.2013 26.09.2013	2009 2007 2005 2006 2013 2016 2014 2014 2012 2013 2013
2 2017/2131 Scopus 1 2016/827 medilee 12 2016/938 pubmed 12 2016/938 pubmed	у У У У У У У У У У У У У У У У У У У У	y y y	y y y y	n y Synthesis/Comment n y Synthesis/Comment y Synthesis/Com	Y Policy (descriptive) Y Policy (descriptive) Y Policy > Behaviour Y Policy > Usage** & Exp	y n y N y n n n	16029703 Attesting the impust of the Australia-Underget States Free Trade Agreement on Australian and global medion. Faurce T, Dorn E, Henry D, Danho P, Sent (Cools Health. 2005 Oct 6:1:5 create date:2007/10/8 [Inst author:Faurce T A 15751114 Challenges of numerications in the Australia-Underget States Free Trade Agreement and reference pricing in surg T Faurce TA. Aust Health Rev. 2005 Aug;312 23:45. create date:2007/10/8 [Inst author:Faurce TA 15751114 Challenges for Australia's Bio/Nacopharma Policies: Trade Agreement af Categories in surg Tarake Agreement af Categories and reference pricing in surg Tarake Agreement af Categories and Territories Austra Faurce TA. Aust Health Rev. 2005 Aug;312 23:45. create date:2007/10/8 [Inst author:Faurce TA 15050355 The UK Noose of Commons report on the Influence of the pharmaceutical industry issues for author: States of the pharmaceutical industry issues for author: Faurce TA. Create date:2007/10/8 [Inst author:Faurce TA 15050355 The Influence of the pharmaceutical industry issues for author: Faurce TA Create date:2007/10/8 [Inst author:Faurce TA 15050355 The Influence of the pharmaceutical industry issues for author: Faurce TA Create date:2007/10/8 [Inst author:Faurce TA 15050355 The Influence of the pharmaceutical industry issues for author: Faurce TA Create date:2007/10/8 [Inst author:Faurce TA 15050356 The Influence of the pharmaceutical industry issues for author: Faurce TA Create date:2007/10/8 [Inst author:Faurce TA 15050356 The Influence issues for author: Faurce TA <td>01 07 2009 05 06 2007 15 06 2007 15 06 2007 08 10 2005 16 02 2006 13 07 2013 27 05 2016 24 12 2014 18 08 2012 14 02 2013 26 09 2013 03 04 2013</td> <td>2009 2007 2005 2006 2013 2016 2014 2012 2013 2013 2013</td>	01 07 2009 05 06 2007 15 06 2007 15 06 2007 08 10 2005 16 02 2006 13 07 2013 27 05 2016 24 12 2014 18 08 2012 14 02 2013 26 09 2013 03 04 2013	2009 2007 2005 2006 2013 2016 2014 2012 2013 2013 2013
2 20172131 Scopus 1 2016927 medilee 12 2016978 pubmed 12 2016978 pubmed 12 2016978 pubmed 12 2016978 pubmed 12 2016978 pubmed 12 2016978 pubmed 12 2016982 pubmed 12 2016988 pubmed 12 2016988 pubmed 12 2016988 pubmed 12 2016988 pubmed 12 2016988 pubmed 12 2016988 pubmed	у У у У у у у у у у у у у у у у у	y y y y	У У У У	n y Synthesis/Comment y Synthesis/Comment y Survey / [Structured] Interviews n y (Retrospective) Observational study n	Y Policy (descriptive) Y Policy (descriptive) Y Policy alebaviour Y Policy > Usage** & Exp	y n y N y n	16297903 Axessing the impact of the Australia-Unders States Steer Trade Agreement on Australian and global medicin Faure T, Doran E, Henry D, Draho P, Sear G Color Median. 2005 CH 6:1.15 crede date:2005/70(8] [Fnt author-Faure T 1595311 Anity Holeges of Anustralia's Bio/Nanopharma Patioles: Trade date, Jobili goods and reference pricing in surts. Tance TA. Aust Heaht Pacco DMws/33(2):2564-0. crede date:2005/70(8] [Fnt author-Faure TA 1754517 Reference pricing of prahamescularis: In Australia-Bio/Net State State. State Agreement af Center Relation Pacco DMWs. crede date:2007/70(8] [Fnt author-Faure TA 17545077 Reference pricing of prahamescularis: In Australia-Bio/Net State DMMS. crede date:2007/70(8] [Fnt author-Faure TA 1600881 The UK House of Commons report on the Influence of the pharmazeutical Industry: Fusions for equalities I: A surue TS. Monsh Bioeth Rev. 2005 Apr;242):8-42. crede date:2007/70(1) [Fnt author-Faure TS 12879058 The Instatutor Faure TA Fusions (DML) CML 2013 Seg. 3:15(2):15:574. doi: 10.1503/rms1) or crede date:2007/70(1) [Fnt author-Fined H 12879058 Forein Instatutor Faure TA Fusions (DML) Fusions (DML) CML 2013 Seg. 3:15(2):15:574. doi: 10.1503/rms1) or crede date:2005/707) [Fnt author-Fined H 1288058 Forein Instatutor Faure TA Fusions (DML) Fusions (DML) CML 2013 Seg. 3:15(2):15:574. doi: 10.1503/rms1) or crede date:2005/72] Free Hauthor-Fined H 12895058 Forein Instatutor Faure TA Fusions (DML) <td< td=""><td>06.10.2003 01.07.2009 05.06.2007 15.06.2007 08.10.2005 16.02.2006 31.07.2013 27.05.2016 24.12.2014 18.08.2012 14.02.2013 26.09.2013 03.04.2013 09.01.2008</td><td>2009 2007 2005 2006 2013 2016 2014 2012 2013 2013 2013 2013 2013</td></td<>	06.10.2003 01.07.2009 05.06.2007 15.06.2007 08.10.2005 16.02.2006 31.07.2013 27.05.2016 24.12.2014 18.08.2012 14.02.2013 26.09.2013 03.04.2013 09.01.2008	2009 2007 2005 2006 2013 2016 2014 2012 2013 2013 2013 2013 2013
2 2017;111 Scopus 1 2016/087; medilee 12 2016/097; medilee 12 2016/097; pubmed 12 2016/998; pubmed 12 2016/998; pubmed 12 2016/998; pubmed 12 2016/998; pubmed 12 2016/978; pubmed 12 2016/978; pubmed 12 2016/978; pubmed 12 2016/978; pubmed 12 2016/978; pubmed 14 2016/978; pubmed	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	y y y y y	у У У У	synthesis/Comment Synthesis/Comment Synthesis/Comment Synthesis/Comment (Retrospective) Observational study	Y Policy (descriptive) Y Policy (descriptive) Y Policy - Markov Y Policy > Usage** & Exp	y N y N n n	15029703 Alexisting the impust of the Australia-Unideg States Free Trade Agreement To Australian and global medion. Fazure T, Doran E, Henry D, Danho P, Sent G, Dolar Median. 2005 Oct 6:1:5. create date:2007/10/8 [Inst author:Fazure T 1595113 Alos Vielemings of noncontice for Australia's Bio/Nacopharma Pioleis: trade desh. public goods and reference pricing in sunt F. Tance TA. Aust Heahl P. 2005 Oct 6:1:5. create date:2007/10/8 [Inst author:Fazure TA 1595131 Alos Vielemings of noncontralia's Bio/Nacopharma Pioleis: trade desh. public goods and reference pricing in sunt F. Tance TA. Aust Heahl P. 2005 Aug; 21:10[2:3:0:2.10:2.007 Jml 1: 1:4:9. create date:2007/10/8 [Inst author:Fazure TA 1505035 The Viel Notace of Commons report on the infruence of the pharmaceutical industry issuon for equilable a Fazure TA. Tomosy GF. Month Bioeth Rev. 2005 Apr; 24:23:8-42. create date:2007/10/8 [Inst author:Fazure TA 12057955 The Inst Notace of the pharmaceutical industry issuon for equilable a Fazure TA. Tomosy GF. Comb Dem High Thomapolity Screen. 2005 6:6;12:3. create date:2007/10/11 [Inst author:Fazure TA 12057955 The Inst Notace of Tax Auge Commons resport on the Instence on direction viel Notace on Screen of Instence N Australia-Unidate N Australia-Unidate N Auge Common resport on the Instence TA Comb Dem High Thomapolity Screen. 2005 6:6;12:3. create date:2007/11 [Inst author:Fanes TA 12057955 The Instence N Auge Common resport on the Instence N Auge Common resport on the Instence N Auge Company Tax Auge Common resport on the Instence N Auge Company Tace N Auge Company Tace N Auge Company Tax Auge Common res	01 07 2009 05 05 2009 05 05 2007 15 06 2007 08 10 2005 16 02 2006 31 07 2013 27 05 2014 18 08 2012 14 02 2013 26 09 2013 03 04 2013 09 01 2008 15 10 2011	2009 2007 2005 2006 2013 2016 2014 2012 2013 2013 2013 2013 2013 2014
2 2017;131 Scopus 1 2016/827 mediae 2016/827 mediae 2 2016/828 pubmed 2 2016/828 pubmed 2 2016/828 pubmed 2 2016/828 pubmed 2 2016/828 pubmed 2 2016/828 pubmed 2 2016/938 pubmed	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	y y y y y	y y y	n y Synthesis/Comment y Synthesis/Comment y Survey / (Structured) Interviews n (Retrospective) Observational study n n	y Policy (descriptive) Y Policy (descriptive) Y Prices > Behaviour Y Policy > Lage** & Exp	y n y N y n	15029793 Axessing the impact of the Australia-Unideg States Free Trade Agreement in and global medion. Faurue T, Doran E, Henry D, Daho P, Sear J, Borna C, Henry D, Daho P, Sear J, Borna C, Henry D, Daho P, Sear J, Conte Health. 2005 Oct 6;1:15 create date:2007/VIGI [Inst author:Faurue:T 1 15951114 Challenges for Australia's liko Nanogharma Policies: Trade data), public goods and reference pricing in sourt Faurue: TA. Aust Health Rev. 2007 Juni; 1:4:3. create date:2007/VIGI [Inst author:Faurue:TA 15951114 Challenges for Australia's liko Nanogharma Policies: Trade data), public goods and reference pricing in sourt Faurue: TA. Aust Health Rev. 2007 Juni; 1:4:3. create date:2007/VIGI [Inst author:Faurue:TA 1595119 Definition Structure: Ta Mather Stru	06.10.2003 01.07.2009 05.06.2007 15.06.2007 08.10.2005 16.02.2006 31.07.2013 27.05.2016 24.12.2014 18.08.2012 14.02.2013 26.09.2013 03.04.2013 09.01.2008 15.10.2001 20.10.2009	2009 2007 2007 2005 2006 2013 2016 2014 2012 2013 2013 2003 2003 2001 2009
2 2017;111 Scopus 1 2016;827 medilee 12 2016;938 pubmed 12 2016	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	y y y y y	y y y y	synthesis/Comment Synthesis/Com	y Policy (descriptive) y Policy (descriptive) y Policy (descriptive) y Policy > Usage**& Exp y Policy (descriptive)	y n y N y n	15029703 Axessing the impact of the Australia-Undergo and Agreement on Australian and global medion. Faure T, Dorn E, Henry D, Danho P, Sensi Global Health. 2005 Oct 6:1:15 create date:2007/10/8 [Inst author:Faure:T A 15953114 Childnegs of numerications for Australia's Bio/Nacopharma Pixicies: trade desha, Datie goods and reference pricing in sunt X. Faure: TA. Aust Health Rev. 2000 May;31(2):236-7. create date:2007/10/8 [Inst author:Faure:TA 15754173 Allos Sensi Daties and Commons report on the Influence of the planmareutical industry issues for Australia's Bio/Nacopharma Pixicies: trade desha. Faure: TA. Aust Health Rev. 2000 May;31(2):236-7. create date:2007/10/8 [Inst author:Faure:TA 1505055 The Influence of the planmareutical industry issues for a Quitable & Faure: TA. Mast Health Rev. 2005 Apr;21(2):23-02 Durnt 1: create date:2007/10/8 [Inst author:Faure:TA 1505055 The Influence of the planmareutical industry issues for a Quitable & Faure: TA. Comb Dem High Throughout Screen. Create date:2007/10/8 [Inst author:Faure:TA 12059555 The Influence of Inclasmon segnet on the Influence of the planmareutical industry issues for a Quitable and autor:Faure:TS Comb Dem High Throughout Screen. Create date:2007/10/1 [Inst author:Faure:TS 12059555 The Influence of Commons report on the Influence of Inclasmon Barreers. Faure: TA. Comb Dem High Throughout Screen. Create date:2007/17/1 [Inst author:Faure:TS 12059555 The Influence of Common report on the Influence of Inclasmon Barreers. Faure: TA. Create date	06,102,2009 05,06,2007 15,06,2007 08,10,2005 16,02,2006 31,07,2013 27,05,2016 24,12,2014 18,08,2012 14,02,2013 03,04,2013 03,04,2013 09,01,2008 15,110,2011 20,10,2019 06,03,2016	2009 2007 2007 2005 2006 2013 2016 2014 2012 2013 2013 2013 2013 2008 2011 2009 2016
2 2017;131 Scopus 1 2016/827 medilee 12 2016/938 pubmed 12 2016	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	y y y y y	у У У У	n y Synthesis/Comment n y Synthesis/Comment n y (Rerospective) Observational study n y (Rerospective) Observational study n y y Synthesis/Comment y y Synthesis/Comment y y Synthesis/Comment y y y y y y y y y y y y y y y y y y y	Y Policy (descriptive) 0 Policy Prices	y n y N n n	15029703 Alexisting the impact of the Australia-Undergo and presence Theorem 1, Brance T, Doran E, Henry D, Danho P, Seen G Column Health. 2005 Oct 6:1:5 create date:2007/10(8] [Inst author-Finance T 15951114 Challenges for Australia's Bio/Nacopharma Picicies: Trade data, Date (Data Australia's Bio/Nacopharma Picicies: Trade data). 2005 Oct 6:1:5 create date:2007/10(8] [Inst author-Finance TA 15951114 Challenges for Australia's Bio/Nacopharma Picicies: Trade data, Date (Data Australia's Bio/Nacopharma Picicies: Trade data). 2005 Oct 6:1:5 create date:2007/10(8] [Inst author-Finance TA 15951114 Challenges for Australia's Bio/Nacopharma Picicies: Trade data (Data Under Sinance TA Aust New Pice 2abind Health Picicy. 2007 Jun; 1:4:9. create date:2007/10(8] [Inst author-Finance TA 1505125 The UN Nocae of Commons resport on the Influence of the pharmaceutical industry lesson for equilable a Austra TS, Comosty GF. Monanth Beacht Ber, 2005 Apr; 24(2):8-42. create date:2007/10(8) [Inst author-Finance TA 1505255 The UN Nocae of Commons resport on the Influence of the pharmaceutical industry lesson for equilable a Austra TS, Comosty GF. Monanth Beacht Ber, 2005 Apr; 24(2):8-42. create date:2007/10(8) [Inst author-Finance TA 15052555 Monanth Beacht Ber, 2005 Apr; 24(2):8-42. Monanth Beacht Ber, 2005 Apr; 24(2):8-42. create date:2005/27(1] [Inst author-Finance TA 15052555 Monanth Beacht Ber, 2005 Apr; 24(2):8-42. Frank Bio/Nemophare Frank Bio/Nemophare Actin Time Be, 2005 Apr; 24(2):8-42. Columont Beacht Ber,	0 1072009 01072009 05062007 150662007 08102005 16022006 31072013 27052016 24122014 18082012 14022013 26092013 03042013 09012008 15102001 22102009 06022016 15122010	2009 2007 2005 2006 2013 2016 2014 2012 2013 2013 2013 2013 2008 2011 2009 2016 2016
2 2012/2131 Scopus 1 2016/0372 mediate 12 2016/0378 pubmed 12 2016/0378 <	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	y y y y y	У У У У	n Synthesis/Comment y Synthesis/Comment y Survey/ (Fuctured) Interviews n y (Retrospective) Observational study n s s y Synthesis/Comment y Synthesis/Comment y Synthesis/Comment s Synthesis/Comment y Synthesis/Com y Synthesis/Com y Synthesis/Com y Synthesis/Com y Synthesis/Com	y Policy (descriptive) y Policy (descriptive) y Prices > Behaviour y Policy (descriptive) n Policy (descriptive) n Policy (descriptive)	y n y n n n	16029703 Alexisting the impact of the Australia-Undergo free Trade Agreement in and global medicin Faure T, Doran E, Jerroy D, Daho P, Sent G, Doran E, Jerroy D, Jano D, Hang J, Daro D, Jano D, Hang J, Jano	0.1072009 01.072009 05.06.2007 05.10.2005 15.06.2007 05.10.2005 16.02.2006 31.07.2013 27.05.2016 24.12.2014 18.08.2012 14.02.2013 05.01.2008 15.10.2011 20.10.2011 20.10.2015 15.10.2011 20.10.2016 15.12.2011 20.10.2015 15.12.2011 20.42.2015	2009 2007 2005 2006 2013 2016 2014 2012 2013 2013 2013 2013 2008 2011 2009 2016 2010 2010
2 2017;131 Scopus 1 2016/827 medilee 12 2016/938 pubmed 12 2016/938 pubmed 13 2016/938 pubmed 14 2016/938 pubmed 15 2016/938 pubmed 16 2016/938 pubmed 16 2016/938 pubmed 17 2016/938 pubmed 18 2016/938 pubmed 19 2016/938 pubmed 19 2016/938 pubmed 10 2016	У У У У У У У У У У У У У У У У У У У	y y y y y	у У У У	synthesis/Comment	y Policy (descriptive) y Policy (descriptive) y Prices > Behaviour y Policy > Uage**& Exp n Policy > Prices n Policy > Prices	y n y N n n y n y y	15029703 Alexisting the impact of the Australia-Undergo and parterement on Australian and global medion. Faurce T, Dorn E, Henry D, Danho P, Sens (Column Health, 2005 Oct 6,1:1.5 create date:2007/V0[6] [Inst author:Faurce TA 15951114 Challenges for Australia's Bio/Nacopharma Picicies: Trade does in policy goods and reference pricing in sunt. Faurce TA. Aust Health Rev. 2005 Aug;312 (236-2). create date:2007/V0[6] [Inst author:Faurce TA 15951114 Challenges for Australia's Bio/Nacopharma Picicies: Trade does in policy goods and reference pricing in partmenenticals: in the Australia-Under Saurce TA. Aust Health Rev. 2007 Aug;312 (236-2). create date:2007/V0[6] [Inst author:Faurce TA 1505031 The U. Noace of Commons reports on the Inhence of the pharmaculai industry issues for Australia Ta author:Faurce TA Montal Bioent Mer. 2005 Aug;312 (236-2). create date:2007/V0[7] [Inst author:Faurce TA 1505035 The U. Noace of Commons reports on the Inhence of the pharmaculai industry issues for S. (monsy OF. Montal Bioent Mer. 2005 Aug;312 (236-4). create date:2007/V0[7] [Inst author:Faurce TA 1505035 The U. Noace of Indication values based pricing in key UI countries. Faurce TA, Sonnos L, De Loi H, De Merey CR, Remmere R, Beance N, Canso TA, Sonnos L, De Loi H, De Merey CR, Remmere R, Beance TA, Canso TA, Sonnos L, De Loi H, De Merey CR, Remmere R, Beance TA, Beance TA, Canso TA, Sonnos L, De Loi H, De Merey CR, Remmere R, Beance TA, Beance TA, Sonnos L, De Loi H, De Merey CR, Beance TA, Beance TA, Canso TA, Sonnos L, De Loi H, De Merey CR, Beance TA, Beance TA, Canso TA, Beance	0.17.2003 0.107.2003 15.66.2007 0.61.02005 16.02.2005 16.02.2005 16.02.2005 16.02.2005 16.02.2005 17.05.2016 24.12.2014 18.08.2012 14.00.22013 05.02.2016 05.12.2014 05.02.2016 15.12.2010 15.64.2013 24.12.2014	2009 2007 2005 2006 2013 2016 2014 2013 2013 2013 2013 2013 2019 2016 2010 2010 2010
2 2012/131 Scoput 1 2016/827 mediate 12 2016/828 pubmed	УУ УУ У У У У У У У У У У У У У У У У	y y y y y	у У У У	n Synthesia/Comment Synthesia/	y Policy (descriptive) y Policy (descriptive) y Policy (descriptive) y Policy - > Behaviour y Policy - > Loge** & Lap y Policy (descriptive) n Policy > Policy) n Policy (descriptive)) n Policy (descriptive)) n Policy (descriptive)	y n y n n n y n y n	16029703 Alexisting the impact of the Australia-Undergo and approximation of Australia Marcel To Darker T, Darka T, Darker T, Darka T, Sella Marcel TA, Sella Marce	0.107.2009 0.56.2007 15.66.2007 15.66.2007 15.02.2005 16.07.2013 27.05.2015 24.12.2014 16.08.2012 24.12.2014 16.08.2012 16.02.2013 26.09.2013 05.04.2013 05.04.2013 25.12.2010 15.12.2011 25.12.2016 15.12.2	2009 2007 2005 2006 2013 2016 2014 2013 2013 2013 2008 2011 2009 2016 2010 2010 2013 2013 2013 2013

5 20160828 pubmed	У			Y Economic model (analytic, empirical data)	n Policy (descriptive)	y n	25327543 Convergence of decision rules for value-based pricing of new innovative drugs. Gandjour A. Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2 create date:2014/10/21 first	author:Gandjour A	21.10.2014	2014
12 20160918 pubmed	У			y Economic model (analytic)	y Policy (descriptive)	y n	23229599 Reference pricing and price negotiations for innovative new drugs : viable policies in the long term? Gandjour A. Gan	Lauthor:Gandjour A	19.01.2013	2013
2 20160828 pubmed	У			y Synthesis/Comment	Y Policy (descriptive)	y N	2682/0147 Pharmaceutical Price Schemes in turope: Time for a Continental One? Garattini L, Curto A, Freemantie N. Pharmaceeconomics. 2016 May;34(5):423-b. doi: 10.100 create date:2016/01/29 [tirs	author:Garattini L	29.01.2016	2016
9 20160911 pubmed	γ			y Synthesis/Comment	Y Policy (descriptive)	y N	24399/70 Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccines. Garattini L, Van de Vooren K, Freemantie N. J R Soc Med. 2014 Jan;10/(1):4-5. doi: 10.11///01410/6i create date:2014/01/09 [hrs	author:Garattini L	09.01.2014	2014
2 20160828 pubmed	У			y Economic model (analytic)	y Policy > Welfare***	n n	20577969 External referencing and pharmaceutical price negotiation. Garcia MariAtoso B, Jelovac I, Olivella P. Health Econ. 2011 Jun;20(6):737-56. doi: 10.1002/hec.1£ create date:2010/06/26 first	t author:Garcia MariA±oso B	26.06.2010	2010
8 20160828 pubmed	у у			n			19082251 [Pharmaceutical policies in Mexico: 20 years is nothing]. Gasman N. Salud Publica Mex. 2008;50 Suppl 4:5423-6. Spanish. No create date:2008/12/17 first	t author:Gasman N	17.12.2008	2008
1 20160827 medline	у у			n			21977842 The prices people pay for medicines in Zimbabwe. Gavaza P, Simoyi T, Makunike B, Maponga CC. create date:2009/01/01 first	t author:Gavaza P	01.01.2009	2009
4 20160828 pubmed	У	y		n			21682350 Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices. Gazzard B, Hill A, Anceau A. Appl Health Econ Health Policy. 2011 Jul 1;9(4):217-23. d create date:2011/06/21 first	t author:Gazzard B	21.06.2011	2011
4 20160828 pubmed	У	y		n			19178584 Variation in drug prices at pharmacies: are prices higher in poorer areas? Gellad WF, Choudhry NK, Friedberg MW, Br Health Serv Res. 2009 Apr;44(2 Pt 1):606-17. doi: 10.111: create date:2009/01/31 first	t author:Gellad WF	31.01.2009	2009
2 20160828 pubmed	У	y		n			18581187 What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savir Gellad WF, Schneeweiss S, Brawarsky P, Lips J Gen Intern Med. 2008 Sep;23(9):1435-40. doi: 10.1007, create date:2008/06/27 first	t author:Gellad WF	27.06.2008	2008
4 20160828 pubmed	У	y	_	n			16167399 One pill, many prices: variation in prescription drug prices in selected government programs. Gencarelli DM. Issue Brief George Wash Univ Natl Health Policy Forum.: create date:2005/09/20 first	t author:Gencarelli DM	20.09.2005	2005
9 20160911 pubmed	у			y Synthesis/Comment	Y Policy (descriptive)	y N	21671688 Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based p Gerber A, Stock S, Dintsios CM. Pharmacoeconomics. 2011 Jul;29(7):549-53. doi: 10.216! create date:2011/06/16 first	t author:Gerber A	16.06.2011	2011
12 20160918 pubmed	Y	v		n			23183986 The impact of generic reference pricing in Italy, a decade on. Ghislandi S, Armeni P, Jommi C. Eur J Health Econ. 2013 Dec;14(6):959-69. doi: 10.1007/: create date:2012/11/28 first	t author:Ghislandi S	28.11.2012	2012
12 20160918 pubmed	v	v		B			15760698 Pharmaceutical policy in Italy: towards a structural change? Ghislandi S. Krulichova I. Garattini L. Health Policy. 2005 Apr:72(1):53-63. create date:2005/03/12 first	t author:Ghislandi S	12.03.2005	2005
12 20160918 pubmed	v	ý		0			21937137 Competition and the Reference Pricing Scheme for pharmaceuticals. Ghislandi S. J Health Econ. 2011 Dec: 30(6):1137-49. doi: 10.1016/i.ih. create date: 2011/09/23 first	t author:Ghislandi S	23.09.2011	2011
12 20160918 pubmed	v v			0			24027849 [The reference pricine of pharmaceuticals in European countries]. Gildeveya GN. Starvkh DA. Probl Sotsialnoi Giz Zdravookhranennijai Istor Med. 2012 create date: 2013/09/14 first	t author:Gildeveva GN	14.09.2013	2013
8 20160828 pubmed	, ,		v	B			21123660 Pharmaceutical policies: effects of restrictions on reimbursement Gilliam MI Obstet General 2011 Jan: 117(1):122-3. doi: 10.1097/A0.create.date.2010/12/22 for	t author: Gilliam MI	22 12 2010	2010
4 20160828 pubmed	y N	v	,				1992751 Dr. Canadal Tarda's non-solution to the problem" of LLS drug prices " Gimen D Am Llaw Med 2005-2212-247.77 No shotpart wildb create date:2006/251 [10	t author: Gilman D	25.08.2006	2006
3 20172121 WebOffsiense	7	y .		Sunthania (Commont	· Deline (description)		TO STATE OF CONTRACT TALE AND	radiidi.diinan b	23.00.2000	2000
2 20172131 WebOfScience	y			y synthesis/comment	y Policy (descriptive)	y II				2013
2 20172131 WebOrscience	Y		Y		A. H A		LEGAL IMPACT OF PRAKMACED TICAL PRICING IN THE GERMAN'S TATUTON'T HEALTH INSURANCE STSTEM GSSP, C VALUE IN HEALTH			2012
2 201/2131 WebUrscience	Y			Economic model (analytic)	y Policy (descriptive)	y n	PHARMALEUTICAL PRILING BASED ON EARLT BENEFIT ASSESSMENTS GRS9, C VALUE IN HEALTH		25 40 2044	2012
8 20160828 pubmed	y .	Y		n			22025669 World Health Organization bits ablet to hans Hogerzei - ine dynamic Lifector of Essential Medicines and Gitanjali B. JPharmacol Pharmacol	author:Gitanjali B	26.10.2011	2011
2 20160828 pubmed	У	y	_	n	_		1/3/0319 Repackaged pharmaceuticals in the California workers' compensation system: from distribution and pricing Giflin M, Wilson L. Am Jind Med. 2007 Apr;50(4):303-15. create date:2007/03/21 [https://doi.org/10.1016/j.create.date:2007/03/21 [ht	Lauthor:Gitlin M	21.03.2007	2007
12 20160918 pubmed	Y		_	y Legal analysis	y Policy (descriptive)	y n	23992756 How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordab Gleeson D, Lopert R, Reid P. Health Policy. 2013 Oct;112(3):227-33. doi: 10.1016/j.he. create date:2013/09/03 first	t author:Gleeson D	03.09.2013	2013
2 20160828 pubmed	У	y	_	n			26968977 Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treat Glueck CJ, Shah P, Goldenberg N, Prince M, Lipids Health Dis. 2016 Mar 12;15:55. doi: 10.1186/s1294 create date:2016/03/13 first	t author:Glueck CJ	13.03.2016	2016
5 20160828 pubmed	У			y Synthesis/Comment	y Policy (descriptive)	y n	23322546 A new reimbursement system for innovative pharmaceuticals combining value-based and free market prici Godman B, Gustafsson LL. Appl Health Econ Health Policy. 2013 Feb;11(1):79-82. dc create date:2013/01/17 first	t author:Godman B	17.01.2013	2013
7 20160828 pubmed	У	У	_	n			21351864 Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Godman B, Sakshaug S, Berg C, Wettermark Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1 create date:2011/03/01 first	t author:Godman B	01.03.2011	2011
2 20160828 pubmed	У			y Economic model (analytic)	y Policy > Welfare***	n n	18180487 Drug licenses: a new model for pharmaceutical pricing. Goldman DP, Jena AB, Philipson T, Sun E. Health Aff (Millwood). 2008 Jan-Feb;27(1):122-9. doi: 10 create date:2008/01/09 first	t author:Goldman DP	09.01.2008	2008
12 20160918 pubmed	У	y		n			17609491 Prescription drug cost sharing: associations with medication and medical utilization and spending and healt Goldman DP, Joyce GF, Zheng Y. JAMA. 2007 Jul 4;298(1):61-9. Review. create date:2007/07/05 first	t author:Goldman DP	05.07.2007	2007
2 20160828 pubmed	Y			y Statistical analysis - inductive (not RCT/NR	n Policy > Invest (R&D)	n y	20617857 Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms. Golec J, Vernon JA. Pharmacoeconomics. 2010;28(8):615-28. doi: 10.2165/1 create date:2010/07/14 firs	t author:Golec J	14.07.2010	2010
2 20160828 pubmed	y	v		n			19014202 Measuring US pharmaceutical industry R&D spending. Golec J, Vernon JA. Pharmaceconomics. 2008;26(12):1005-17. doi: 10.2165 create date:2008/11/19 first	t author:Golec J	19.11.2008	2008
11 20160918 pubmed	v	v		B			19799470 Financial risk of the biotech industry versus the pharmaceutical industry. Golec J. Vernon JA. Appl Health Econ Health Policy. 2009;7(3):155-65. doi: 10 create date:2009/10/06 first	t author:Golec J	06.10.2009	2009
5 20160828 pubmed	, ,			 Economic model (analytic) 	v Policy > Invest (B&D)	N	26944633 Private versus social incentives for pharmaceutical innovation Gronzäller P. Macho-Statler J. På@rev-Castr. J. Health From 2016/Eeb 4. doi:nii: \$0162-6296/16/00025; create date:2016/03/06 fire	t author: Gonz Allez P	06.03.2016	2016
4 20160828 pubmed					,,		19201420 Concentration and drug prices in the ratal market for malaria treatment in grant Tenzania Grandman C Kachur SP, Abdulla S, Bioland P, Health Econ. 2009 Jun-19(5):727.42 doi:10.1010/Junc 1/ create date-2009(0/2/1) [fre	tauthor:Goodman C	21.02.2009	2009
4 20160828 pubmed	, ,	v		D			18774867 Differences in generic drug prices between the US and Canada Gool M Bell CM	t author: Gooi M	09.09.2008	2008
4 20160929 publicu	7	y					2017212 White Concession and a white and a white and a second and a se	Lauthor Conner M	16.03.2006	2008
 20100828 pubmed 20100828 pubmed 	У	y					20073323 Wing Cungerss muss user wwn orug prices. Goozener M. Mod Healthc. 2015 Dec 14;45(50):24. No abstract availab create date:2015/02/16 firs	author:Goozner M	10.02.2016	2016
12 20160918 pubmed	У	y		n			254U4U13 Parametimports and a managatory substrution reforms a kick or a mult for price competition in pharmaceut Graniund D, Koksal-Aynan MY. Eur J Health Econ. 2015 Dec;16(9):969-83. doi: 10.1007/j: create date:2014/11/19 [first	author:Granlund D	19.11.2014	2014
2 20172131 Scopus	У	Y		n			Lonsumer Information and Pharmaceutical Prices: Theory and Evidence Graniund D. Rudholm N. Oxford Bulletin of Economics and Statistics			2011
2 20172131 Scopus	у у		_	n		_	Pharmaceutical pricing in South Africa Gray A. Suleman F. Pharmaceutical Prices in the 21st Century			2015
8 20160828 pubmed	У			y Systematic Review	n Policy (descriptive)	Y n	26177819 The relevance of systematic reviews on pharmaceutical policy to low- and middle-income countries. Gray AL, Suleman F. Int J Clin Pharm. 2015 Oct;37(5):717-25. doi: 10.1007/s1: create date:2015/07/17 first	t author:Gray AL	17.07.2015	2015
8 20160828 pubmed	У			y Systematic Review	n Policy > diverse	n y	20687098 Pharmaceutical policies: effects of restrictions on reimbursement. Green CJ, Maclure M, Fortin PM, Ramsay CR Cochrane Database Syst Rev. 2010 Aug 4;(8):CD008654. I create date:2010/08/06 first	t author:Green CJ	06.08.2010	2010
8 20160828 pubmed	У	y	_	n			26365300 Pharmaceutical services cost analysis using time-driven activity-based costing: A contribution to improve cc Gregă ³ rio J, Russo G, LapÃeo LV. Res Social Adm Pharm. 2016 May-Jun;12(3):475-85. doi: create date:2015/09/15 first	t author:GregÃ ^a rio J	15.09.2015	2015
2 20160828 pubmed	у			y Economic model (analytic)	y Policy (descriptive)	y n	18806189 Decision analysis for resource allocation in health care. Griffin S, Claxton K, Sculpher M. J Health Serv Res Policy. 2008 Oct;13 Suppl 3:23-30. doi: create date:2008/11/14 firs	t author:Griffin S	14.11.2008	2008
12 20160918 pubmed	v			v Interrupted time series study (ITS)	n Policy > Prices	n v	16498702 A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Grootendorst P. Stewart D. Health Econ. 2006 Jul: 15/71:735-42. create date: 2006/02/25 first	t author:Grootendorst P	25.02.2006	2006
12 20160918 pubmed	v			v Interrupted time series study (ITS)	n Policy > Expenditures	n v	16174135 The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic. Grootendorst PV. Marshall JK. Holbrook AM. Health Serv Res. 2005 Qct:40(5 Pt 1):1297-317. create date:2005/09/22 first	t author:Grootendorst PV	22.09.2005	2005
7 20160828 pubmed	v v			B			15919633 [Measuring drug affordability (Senegal)]. Guimier JM. Candau D. Garenne M. Teulià ⁻ r Sante, 2005 Jan-Mar:15(1):53-62, French. create date:2005/05/28 first	t author:Guimier JM	28.05.2005	2005
4 20160828 pubmed	, , , , , , , , , , , , , , , , , , ,			B			1591962 (Why drug nrises are high in sub-Sahara Africa. Analysis of price structure: the case of Senepall Guimier IM. Candau D. Garenne M. Teuliã r. Sante 2005 Jan-Mar: 15(1):41-52. French create date: 2005/02/12 [sin	t author: Guimier IM	28.05.2005	2005
2 20160828 pubmed	, ,	W					22286562 Impact of parallel trade on pharmanutical firm's profile: rise or fall? Gran S kis B Zhone ki	tauthor:Guo S	21.01.2012	2012
12 20100010 publicu	,	y	_		A. R. AL. 1. M. N.				02.42.2000	2000
12 20160918 pubmed	y .			y Survey / (structured) interviews	y Policy (descriptive)	n n	19042052 Price control as a strategy for pharmaceutical cost containment - what has been achieved in worway in the Haakonsen H, Horn AW, Toverud EL. Health Policy. 2009 May;90[2-3]:77-85. doi: 10.1016/j.in create date:2008/12/02 This	zauthor:HA#konsen H	02.12.2008	2008
2 20160828 pubmed	У	y	_	n			246/7184 Cost analysis of sofosbuvir/ribavirin vérsus sofosbuvir/simeprévir for genotype 1 hepatitis C virus in interfe Hagan LM, Sulkowski MS, Schinazi RF. Hepatology. 2014 Jul;60(1):37-45. doi: 10.1002/hep.271! create date:2014/03/29 [https://doi.org/10.1002/hep.271! create date:2014/03/29 [https://do	Lauthor:Hagan LM	29.03.2014	2014
2 20172131 Scopus	γ			y Economic model (analytic)	y Policy (descriptive)	y n	The impact of the pharmaceutical pricing system on cost-effectiveness results: Finnish analysis Hallinen T. Soini E.J. Open Pharmaceeconomics and Health Economics Journal			2011
2 20160828 pubmed	Y	_		y Synthesis/Comment	y Policy (descriptive)	y N	27326322 High Drug Prices Hurt Everyone. Halpenny GM. ACS Med Chem Lett. 2016 Jun 9;7(6):544-6. doi: 10.1021 create date:2016/06/22 first	t author:Halpenny GM	22.06.2016	2016
2 20160828 pubmed	У	У		n			25889514 A comparison of estimated drug costs of potentially inappropriate medications between older patients recr Hamano J, Ozone S, Tokuda Y. BMC Health Serv Res. 2015 Feb 21;15:73. doi: 10.1186/s create date:2015/04/19 first	t author:Hamano J	19.04.2015	2015
1 20160827 medline	У	У		n			21110478 Implementing an essential medicines list: effects on pricing and utilization in West Bank, Palestine. Hamidi S1, Younis MZ, Forgione DA. create date:2008/07/01 first	t author:Hamidi S	01.07.2008	2008
8 20160828 pubmed	Y	v		n			27311827 Public health interventions to protect against falsified medicines: a systematic review of international, natic Hamilton WL, Doyle C, Halliwell-Ewen M, Lar Health Policy Plan. 2016 Jun 16. doi:pii: czw062. [Epub al create date:2016/06/18 first	t author:Hamilton WL	18.06.2016	2016
5 20160828 pubmed	y		na	n			22991869 [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals]. Hammerman A, Greenberg D. Harefuah. 2012 Jun;151(6):364-7, 376. Review. Hebrew. create date:2012/09/21 [first	t author:Hammerman A	21.09.2012	2012
7 20160828 pubmed	v v			0			23527456 Can price controls reduce pharmaceutical expenses? A case study of antibacterial expenditures in 12 Chine Han S, Liang H. Su W. Xue Y, Shi L Int J Health Serv. 2013;43(1):91-103. create date: 2013/03/27 fris	t author:Han S	27.03.2013	2013
2 20160828 pubmed		v		B			24029847 Price discrimination in essential medicines: evidence from International Drug Price Indicator Guide data Hanlon M Zhang R	t author: Hanlon M	14 09 2013	2013
2 20172121 Sconus	7	,	v				AMPraisV (Dharmanautical Drice Demulation): The clience of the lambe (AMDraisV: Das schwainen der limm; Hann W			2009
2 20172131 Scopus	y		y	-			Ammiest (internated at internation Council (CC) and the Table of and the Table of Ta			2005
2 20172131 3copus	y y						Finantaceuteal pircing polities in the doit council (dcc) and the onice Anate Finantace (ARE) — Haari K.S.t. Dessing C. Finantaceuteal Pirces in the 21st Century			2013
7 20160828 pubmed	y y			n			25328898 From generic scheme to brand-generic scheme: Have new Doicy influenced the efficiency of Iranian pharm Hashem-Weshkini A, Varmagnani M, Youse J Kes Pharm Pract. 2014 Jul; 3(3):38-95. doi: 10.4103/22/ Create date:2014/10/21 Titt	author:Hashemi-Meshkini A	21.10.2014	2014
2 20172131 Scopus	у у			n			A qualitative study exploring the impact of the pharmaceutical price war among community pharmacies in 1 Hassaii M.A. Shafie A.A. Al-Haddad M. Balam Journal of Clinical and Diagnostic Research			2010
2 20172131 Scopus	у у			n			A qualitative exploration of perceptions toward pharmaceutical price war among community pharmacists in Hassaii M.A. Siang T.C. Saleem F. Aljadhey H. Journal of Medical Marketing			2013
2 20172131 Scopus	у у			n			Pharmaceutical pricing in Malaysia Hassali M.A. Tan C.S. Wong Z.Y. Saleem F. Pharmaceutical Prices in the 21st Century			2015
4 20160828 pubmed	У	У		n			27200530 The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Models Du Hatswell AJ, Porter J, Hertel N, Lee D. Value Health. 2014 Nov;17(7):A323-4. doi: 10.1016/j.jval create date:2014/11/01 first	t author:Hatswell AJ	01.11.2014	2014
9 20160911 pubmed	У		y	N			23550084 Introduction of value based pricing may miss its 2014 target, NICE says. Hawkes N. BMJ. 2013 Apr 2;346:f2115. doi: 10.1136/bmj.f2115. No create date:2013/04/04 first	t author:Hawkes N	04.04.2013	2013
9 20160911 pubmed	у			Y Economic model (analytic)	y Policy > Health outcome	n n	20568075 Reimbursement and value-based pricing: stratified cost-effectiveness analysis may not be the last word. Hawkins N, Scott DA. Health Econ. 2011 Jun; 20(6):688-98. doi: 10.1002/hec.1t create date: 2010/06/23 first	t author:Hawkins N	23.06.2010	2010
4 20160828 pubmed	Y	v		n			24848043 Activists sound alarm on tiered drug prices. Hayden EC. Nature. 2014 May 22;509(7501):412. doi: 10.1038/50941 create date:2014/05/23 first	t author:Hayden EC	23.05.2014	2014
2 20160828 pubmed	у	y		n			27346189 International trade and determinants of price differentials of insulin medicine. Helble M, Aizawa T. Health Policy Plan. 2016 Jun 26. doi:pii: czw085. [Eoub al: create date:2016/06/28 first	t author:Helble M	28.06.2016	2016
4 20160828 pubmed	Y		v	n			16304078 Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme. Henry DA, Hill SR, Harris A. JAMA. 2005 Nov 23;294(20):2630-2. No abstract availabl create date: 2005/11/24 first	t author:Henry DA	24.11.2005	2005
2 20160828 pubmed	y.			y Synthesis/Comment	y Policy (descriptive)	y n	23339876 Structural changes in the German pharmaceutical market: price setting mechanisms based on the early ber Henschke C. Sundmacher L. Busse R. Health Policy. 2013 Mar: 10/31:263-9. doi: 10.1016/j.hea.reste date-2013/h1/24.16	t author:Henschke C	24.01.2013	2013
4 20160828 pubmed	v		v	0			25826837 ACA coverage expansion at riskbattle against high drug pricesgrowing government business. Herman B. Mod Healthc, 2015 Jan 5-45(1):20 No abstract available create date-2015/Jal/20 Life	t author:Herman B	02.04.2015	2015
4 20160828 pubmed			v	D			26642535 How drug prices and payment reform are changing the pharmary benefit husiness Herman B Mod Health: 2015 Sep 19-45(20)-9.0. No shortwart sublic create date 2015(12/0.0.1 Ext	t author: Herman B	09.12.2015	2015
4 20160828 pubmed	,		, ,	D			18784153 European concertation could be to forward and an 2006 and an 2007 and an 2006 and an	t author: Heymann TD	12 09 2008	2008
2 20172121 WabOfScience		v	,				Accounting for DBD. Many durbt the SOD million pharmanical price tan Haman B CHEMICALE ENGLISHEEPIN-CLUE		-1.03.1000	2005
2 20160828 pubmod	7	7		K Care study	v Policy (description)		2522018 The III Disamanufusi Drive Book minor previous pr	t author Hill CA	05 11 2015	2000
1 20160927 modine	7		-	Cure Study	 ancy (descriptive) 	y II	2005212 The out memory and the magnetized and the m	successful LA	2014	2013
1 20100827 medime	у У						44903317 Curanges to interaction property power in south Affred putting a Stop to everygreening? Hill JEL Créate date: 2014		2014	2014
a 20100828 pubmed	у	y					220/3433 Fitting installing insta	Laurior.mill S	08.00.2012	2012
8 20160828 pubmed	У	y		n			22461/19 Putting the priorities tirst: medicines for maternal and child health. Hill SR. Bull World Health Organ. 2012 Mar 1;90(3):236-8. doi: 11 create date:2012/03/31 first	¿author:Hill SR	31.03.2012	2012
1 20160827 medline	у у			n			24885/67 Enhancing medicine price transparency through price information mechanisms. Hinsch M1, Kaddar M, Schmitt S. create date: 2014		2014	2014
2 20172131 Scopus	У	y		n			How do brands" own generics" affect pharmaceutical prices? Hollis A. Review of Industrial Organization			2005
8 20160828 pubmed	у у			n			16320899 The World Bank, pharmaceutical policies, and health reforms in Latin America. Homedes N, Ugalde A, Forns JR. Int J Health Serv. 2005;35(4):691-717. create date:2005/12/03 first	t author:Homedes N	03.12.2005	2005
2 20160828 pubmed	У	У		n			27336585 Health and Ethical Consequences of Outsourcing Pivotal Clinical Trials to Latin America: A Cross-Sectional, E Homedes N, Ugalde A. PLoS One. 2016;11(6):e0157756. doi: 10.1371/journal.pc create date:2016/06/24 firs	t author:Homedes N	24.06.2016	2016
2 20160828 pubmed	у	У		n			27141308 Upstream solutions for price-gouging on critical generic medicines. Houston AR, Beall RF, Attaran A. J Pharm Policy Pract. 2016;9:15. doi: 10.1186/s40545-01/ create date: 2016/05/04 first	t author:Houston AR	04.05.2016	2016
12 20160918 pubmed	Y			Y Economic model (analytic)	y Prices (descriptive)	y n	25044582 Drug Launch Timing and International Reference Pricing. Hour N. Jelovac I. Health Econ. 2015 Aut: 24(8):578-89. doi: 10.1002/her.30.create date-2014//17/27 1 fire-	t author:Houy N	22.07.2014	2014
4 20160828 pubmed	, v			v Economic model (analytic empirical data)	n Policy (descriptive)	y n	21142275 Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis. How M Pharmacheronomics 2011 Jan 24(1):1-15 (doi: 10.2162/1-2014)/12/15 End	t author:Hovie M	15.12.2010	2010
4 20160828 pubmed	,			v Statistical analysis - inductive (not net full	n Policy (description)	× 0	18563950 Eutror drug noises and cost-effectiveness analyses Hoyde M Dismancements for a solution of the cost of th	t author: Hovie M	20.06.2008	2008
11 20160018 publicu	7			a statistical analysis - moutive (not RET/NR		, "	20052020 Drive candiding new entry, and information shork on nharmanautical market in Taiwan: a nationalide data brias PCT-2004 House VIC	t author birian EV	27 07 2010	2008
11 20160918 pubmed	y Y			-			20033777 First Exploration, new entry, and answired market in Talware and antionwise data inside Fr, isal IV, Plaang W-	Lauthor House C	27.07.2010	2010
11 20100318 pubmed	у у						44334024 Impacts on unugreminum senietit reductions on unitization and expenditures or oral antibiabetic medications insu JC, Lu CY, Wagner AK, Chan KA, Lai MS, Health Policy. 2014 Jun;116(2-3):196-205. doi: 10.1016/j create date:2013/12/10 [first	autoritisu Ju	10.12.2013	2013
2 20160828 pubmed	у у			n			2/UBU345 Pharmaceurcal pricing and reimbursement in Linitä: When the whole is less than the sum of its parts. Hu J, Mossaios E. Health Policy. 2016 May;120(5):519-34. doi: 10.1016/j.hr create date:2016/04/16 first	z autnor:eu J	16.04.2016	2016
2 20160828 pubmed	у у		_	n			26091710 A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators. Hu S, Zhang Y, He J, Du L, Xu M, Xie C, Peng 1 Appl Health Econ Health Policy. 2015 Aug;13 Suppl 1:S13 create date:2015/06/21 first	t author:Hu S	21.06.2015	2015
9 20160911 pubmed	У			y Synthesis/Comment	Y Policy (descriptive)	y N	21736392 Value-based pricing: incentive for innovation or zero net benefit? Hughes DA. Pharmacoeconomics. 2011 Sep;29(9):731-5. doi: 10.216! create date:2011/07/09 firs	t author:Hughes DA	09.07.2011	2011
9 20160911 pubmed	У			y Synthesis/Comment	Y Policy (descriptive)	y n	27201245 Sustainable Health Care Systems: The Role of Therapeutic Value and Value Based Pricing. Hulshof JA. Value Health. 2014 Nov;17(7):A452. doi: 10.1016/j.jval.2. create date: 2014/11/01 first	t author:Hulshof JA	01.11.2014	2014
6 20160828 pubmed	У	У		n			27149298 Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase ; Hurry M, Zhou ZY, Zhang J, Zhang C, Fan L, R J Med Econ. 2016 May 25:1-9. [Epub ahead of print] create date:2016/05/06 first	t author:Hurry M	06.05.2016	2016
2 20160828 pubmed	у	y		n			27202377 Differential Pharmaceutical Pricing: Are Prices Co-Related With GDP? lacobucci W, Mehta P, Marinoni G, Ando G, Value Health. 2014 Nov;17(7):A656. doi: 10.1016/j.iyal.2: create date:2014/11/01 first	t author:lacobucci W	01.11.2014	2014
2 20172131 WebOfScience	v	v		n			DRUG DEVELOPMENT AND PHARMACEUTICAL PRICING IN THE UNITED STATES: THE INFLUENCE OF DRUG I Jaconi, A: Khalidi, N: Olanrewaiu, O: Balkrish VALUE IN HEALTH			2011
2 20172121 Sconus		,					Pharmaceutical pricing policies in Optar Ibrahim MI M Diarmaceutical Drives in the 34 d Control			2015
2 20160828 pubmod	y y						22010/08 The Impact of Distance of Distanc	t author Imai S	01.11.2014	2013
2 20160929 publied	7	Y		-			252000 the impact of the impac	tauthorients: A	11.05.2012	2014
2 20100828 pubmed	У		na				2227/0900 [Initia sharing meturus in muldie mcome countries]. Initia (K alik * Z Acto Pharm Hung, 2012;82(1):45-32. Review. Hungarian. create date:2012/05/11 [first	autior:inotal A	11.05.2012	2012
5 20160828 pubmed	У	Y		n			21404477 [Instail&, MerA@sz G, KalA*Z. Acta Pharm Hung, 2010;80(4):162-72. Hungarian. create date:2010/01/01 first	author:Inotai A	01.01.2010	2010
5 20160828 pubmed	У	Y		n			243508bb3 Benetits of investment into modern medicines in Central-Eastern European countries. Inotai A, Petrova G, Vitezic D, KalA* Z. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1) create date:2013/12/20 first	author:Inotai A	20.12.2013	2013
ь 20160828 pubmed	У	У		n			1/1955 /b Reimbursement decision-making and prescription patterns of glitazones in treatment of type 2 diabetes mx Iversen PB, Vondeling H. Health Care Anal. 2006 Jun;14(2):79-89. create date:2007/01/02 first	¿author:lversen PB	02.01.2007	2007
2 20160828 pubmed	У	y		n			27243629 Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. Ilyengar S, Tay-Teo K, Vogler S, Beyer P, Wikit PLoS Med. 2016 May;13(5):e1002032. doi: 10.1371/jour create date:2016/06/01 first	t author:lyengar S	01.06.2016	2016
12 20160918 pubmed	У			y Statistical analysis - descriptive	Y Policy (descriptive)	y n	21682349 Design of patient access schemes in the UK: influence of health technology assessment by the National Inst JarosÅ, awski S, Tourni M. Appl Health Econ Health Policy. 2011 Jul 1;9(4):209-15. d create date: 2011/b6/21 first	t author:JarosÅ,awski S	21.06.2011	2011
12 20160918 pubmed	γ			y Literature Review (not systematic)	y Policy > Expenditures	n n	21982545 Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concept JarosÅ, awski S, Tourni M. BMC Health Serv Res. 2011 Oct 8;11:259. doi: 10.1186/1. create date:2011/10/11 first	t author:JarosÅ,awski S	11.10.2011	2011
4 20160828 pubmed	у у			n			25425142 Medicine prices, availability, and affordability in the Shaanxi Province in China: implications for the future. Jiang M, Zhou Z, Wu L, Shen Q, Lv B, Wang X Int J Clin Pharm. 2015 Feb;37(1):12-7. doi: 10.1007/s110! create date:2014/11/27 first	t author:Jiang M	27.11.2014	2014

1 20160827 medline									
	у у			n			23936471 Measuring access to medicines: a survey of prices, availability and affordability in Shaanxi province of Chini Jiang M1, Yang S, Yan K, Liu J, Zhao J, F	g Y. create date:2013	2013 20
2 20160828 pubmed	у	Y		n			25126231 Trends in pharmaceutical expenditures: the impact on drug benefit design. Joanne L, Leslie F, Brixner DI.	Am Health Drug Benefits. 2008 May;1(4):29-34. create date:2008/05/01 first author:Joanne L	01.05.2008 20
12 20160918 pubmed	У	y		n			21434697 Five-year examination of utilization and drug cost outcomes associated with benefit design changes includi Johnson JT, Neill KK, Davis DA.	J Manag Care Pharm. 2011 Apr;17(3):200-12. create date:2011/03/26 first author:Johnson JT	26.03.2011 20
4 20160828 pubmed	y		y	n			26882731 Healthcare leaders back feds stepping in to restrain drug prices. Johnson SR.	Mod Healthc. 2015 Nov 16;45(46):8-9. No abstract availa create date:2016/02/18 first author: Johnson SR	18.02.2016 20
11 20160918 pubmed	y			y Synthesis/Comment	y Policy > Invest (R&D)	n n	16824641 Public administration and R&D localisation by pharmaceutical and biotech companies: a theoretical framew Jommi C, Paruzzolo S.	Health Policy. 2007 Apr;81(1):117-30. Epub 2006 Jul 7. create date:2006/07/11 first author:Jommi C	11.07.2006 20
2 20172131 Scopus	v		v				Pharmaceutical pricing policies in Italy Jommi C. Minghetti P.	Pharmaceutical Prices in the 21st Century	20
4 20160828 pubmed	y y			n			16470978 Medicine prices and a medicine price index. Jones JS.	S Afr Med J. 2005 Dec:95(12):914. No abstract available. create date:2006/02/14 first author:Jones JS	14.02.2006 20
12 20160918 pubmed	v	v		n			20584355 Low-molecular-weight heparins: pharmacoeconomic decision modeling based on meta-analysis data. Kadusevicius E. Kildonaviciute G. Vara	vici Int J Technol Assess Health Care, 2010 Jul; 26(3):272-9. dr create date: 2010/06/30 first author: Kadusevicius E	30.06.2010 20
12 20160918 pubmed	,	,	v				25566846 The German Pharmaceutical Market Reorganization Act (AMNOG) from an economic point of view] Kajer K. Fetzer S	Bundessesundheitshlatt Gesundheitsforschung Gesundl create date 2015/01/09 first author:Kaier K	09.01.2015 20
2 20160828 pubmed	7		,	Economic model (analytic empirical data)	n Bolicy > Welfare***		Martors Republican of pharmacautical prices: existence from a reference price reform in Denmark Kaiser II. Mander SI. Då nde T. Illrich	Health Econ 2014 Jul-26-174-87, doi: 10.1016/j.ibaelec.create.dste.2014/06/01 first author:Kaiser II	01.05.2014 20
12 20160018 pubmed	y			n	in Toney > trenare		425672 Describe ways to enhance rank antistantin prescribing efficiency: Deniblic of Serie is so a see history? Kalaba M. Gordman B. Vubranniča A.	nni 10mm Eff Der 2012 Nurd-1165-520,40 doi: 10.1020/j.jmarc.cr.cr.anta.data-2012/11/19 first authors/salaha M	19 11 2012 20
12 20100010 publicu	y y						To allow why to enhance he in any occurring entering entering in the state of a for a state in start.	Periperinter and a 2012 the second and a second and a second	24.07.2012
12 20160918 pubmed	y			y statistical analysis - inductive (not RL1/NR	n Policy > Usage** & Exp	n y	22818402 Pittais associated with the therapeutic reference pricing practice or astrima medication. Kalo 2, Abonyi-1 otri 2, Bartrai 2, Voko 2	BMC Pulm Med. 2012 Jul 20;12:35. doi: 10.1186/14/1-22 Create date:2012/07/24 hrst author:Raid 2	24.07.2012 20
2 20160828 pubmed	у у			n			20089393 Implications of external price referencing of pharmaceuticals in Middle East countries. Kalo Z, Alabbadi I, Al Ahdab OG, Alowa	sh I Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):99 create date:2015/06/20 first author:KalA*2	20.06.2015 20
2 20160828 pubmed	У			y Synthesis/Comment	y Policy (descriptive)	y n	24219049 Differential pricing of new pharmaceuticals in lower income European countries. Kalo Z, Annemans L, Garrison LP.	Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(t create date:2013/11/14 tirst author:KalA*2	14.11.2013 20
12 20160918 pubmed	у у			n			16730848 Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Kaló Z, Muszbek N, Bodrogi J, BidlA ³ J.	Health Policy. 2007 Mar;80(3):402-12. Epub 2006 May 3C create date:2006/05/30 first author:KalA ^a Z	30.05.2006 20
2 20160828 pubmed	у у			n			26707267 Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East Kaló Z, VokA ² Z, Akhras KS, Kanavos P.	Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):15 create date:2015/12/29 first author:KalA ² Z	29.12.2015 20
10 20160828 OECD iLibrary	У			y Statistical analysis - descriptive	Y Policy (descriptive)	y n	Pharmaceutical Pricing and Reimbursement Policies in Slovakia Kaló Z., E. Docteur and P. Moïse	create date:2008	2008 20
9 20160911 pubmed	y			Y Economic model (analytic)	y Policy (descriptive)	Y n	26534098 Value-Based Pricing Scheme for new Technology in Consideration of Cost-Effectiveness Dominance to the I Kamae I, Sugimoto T, Yamabe K.	Value Health. 2015 Nov;18(7):A732. doi: 10.1016/j.jval.2) create date:2015/11/05 first author:Kamae I	05.11.2015 20
2 20172131 WebOfScience	y			y Statistical analysis - descriptive	y Prices (descriptive)	y n	THE SURVEY OF THE JAPAN-STYLE PREMIUM SCHEME IN PHARMACEUTICAL PRICING DECISIONS Kamae, I; Murata, T; Suman, D; Yamab	K; \$ VALUE IN HEALTH	20
4 20160828 pubmed	v	v					23569056 Higher US branded drug prices and spending compared to other countries may stem partly from quick uptr Kanayos P. Ferrario A. Vandoros S. And	rsor Health Aff (Millwood). 2013 Apr:32(4):753-61. doi: 10.13 create date:2013/04/10 first author:Kanavos P	10.04.2013 20
12 20160918 pubmed	, ,	, V					17764613 Pharmary discounts on generic medicines in France, is there room for further efficiency savings? Kanayos P. Taylor D.	Curr Med Res Onin 2007 Oct-23(10):2467-76 create date:2007/09/04 first author:Kanavos P	04.09.2007 20
8 20160928 pubmed	7	,					5201422 Measuring nerformance in off-natent drug markets - a methodological framework and empirical exclance f. Kanayor P	Health Policy, 2014 Nov-119(2):220-41, doi: 10.1016/j.bs.craste.dste.2014/00/10.1 First author: Kanayos P	10.09.2014 20
2 20172121 Sconus	, ,	,					Druge US- Are prices too high?: Measuring international pharmacultical price differences Kanaure D Vandoror S	Significance	20
2 201/2131 Scopus	y y						biographic received and receive	Agrimente Della de la contra de	47.05.2044
4 20160828 pubmed	y			y statistical analysis - inductive (not RL1/NR	n Policy > Prices	n y	11676345 Determinants of branded prescription medicine prices in OECD countries. Kanavos PG, Vandoros S.	Health Econ Policy Law. 2011 Jul (6)3:337-67. doi: 10.101 create date:2011/06/17 hrst author:kanavos PG	17.06.2011 20
7 20160828 pubmed	у у	_		n			23199963 Implementation of human papillomavirus immunization in the developing world. Kane MA, Serrano B, de SanjosA© S, V	tet Vaccine. 2012 Nov 20;30 Suppl 5:F192-200. doi: 10.1016. create date:2012/12/05 first author:Kane MA	05.12.2012 20
4 20160828 pubmed	У	y		n			24803662 High cancer drug prices in the United States: reasons and proposed solutions. Kantarjian H, Steensma D, Rius Sanjuar	Els J Oncol Pract. 2014 Jul;10(4):e208-11. doi: 10.1200/JOP.2 create date:2014/05/08 first author:Kantarjian H	08.05.2014 20
4 20160828 pubmed	У	y		n			24037953 Cancer drug prices and the free-market forces. Kantarjian H, Zwelling L.	Cancer. 2013 Nov 15;119(22):3903-5. doi: 10.1002/cncr. create date:2013/09/17 first author:Kantarjian H	17.09.2013 20
8 20160828 pubmed	у у			n			24098644 The market dynamics of generic medicines in the private sector of 19 low and middle income countries bet Kaplan WA, Wirtz VJ, Stephens P.	PLoS One. 2013;8(9):e74399. doi: 10.1371/journal.pone. create date:2013/10/08 first author:Kaplan WA	08.10.2013 20
11 20160918 pubmed	у	y		n			24511277 Financial aspects and the future of the pharmaceutical industry in the United States of america. Karamehic J, Ridic O, Ridic G, Jukic T, C	ic J, Mater Sociomed. 2013 Dec;25(4):286-90. doi: 10.5455/n create date:2014/02/11 first author:Karamehic J	11.02.2014 20
5 20160828 pubmed	y _			y Synthesis/Comment	Y Policy (descriptive)	y N	26994865 Implementation of the 2011 Reimbursement Act in Poland: Desired and undesired effects of the changes in Kawalec P, Sazan A. Stawowczyk E. Ko	lski Health Policy. 2016 Apr;120(4):356-61. doi: 10.1016/j.he create date:2016/03/21 first author:Kawalec P	21.03.2016 20
8 20160828 pubmed	y y			n			23805853 Trend analysis of the pharmaceutical market in Iran; 1997-2010; policy implications for developing countrie Kebriaeezadeh A. Koopaei NN. Abdolla	asl , Daru. 2013 Jun 28;21(1):52. doi: 10.1186/2008-2231-21- create date:2013/06/29 first author:Kebriaeezadeh A	29.06.2013 20
2 20172131 Scopus	y	v		n			A general-equilibrium analysis of public policy for pharmaceutical prices Kelton C.M.J. Rehelein R.P.	Journal of Public Economic Theory	20
4 20160828 nubmed	, v	v		D			27552619 The High Cost of Prescription Drugs in the United States: Origins and Presnerts for Reform Kescelheim X5 August 1 Surgeous August 1	JAMA, 2016 Aug 23-30:316(8):858-71, doi: 10.1001/jamg create date-2016/08/24 first author: Kesselhaim AS	24.08 2016 27
4 20160828 pubmed	,	y v		P			6034288 Do doug prices reflect development time and government investment? Keybani S Dianas-Wart M Down N	Med Care 2005 Aug: 43(8):753-62 create date: 2005/07/22 first author: Kashani S	22.07.2005 20
2 20160828 submod	7	,					22424505 The cost of observational inductions to astronomic modulus in the cost of observational inductions to astronomic formation and astronomic	Event Onio Drug Discov 2007 Nov-2/11):1421-4 doi: 10 create date:2007/11/01 List author Ker/Tahl S	01 11 2007 21
20100020 pubmed	у	y					A COMPANY OF PARTITAL COLLAR INTOVATION TO PARTITIS. KOSS JS.	copert openion of process 2007 nov 2017 149144 upt to 240 create date: 2007/11/01 first author: keyhani S	01.11.2007 20
2 20160828 pubmed	У			statistical analysis - descriptive	Y Policy > Invest (R&D)	n n	us pramaceurcal innovation in an international context. Keyhani S, Hebert P, Carpente	D, A Am J Public Health. 2010 Jun;100(b):1075-80. doi: 10.210 create date:2010/04/21 first author:Keyhani S	21.04.2010 20
2 20172131 Scopus	у у						Pharmaceucar Pricing Policies and Procedures in Saudi Arabia: A Narrative Review Khan T.M. Emeka P. Suleiman A.K. Alni	ary Linerapeutic innovation and Regulatory Science	20
8 20160828 pubmed	У			y Literature Review (not systematic)	y Policy > Access*	N n	26312250 A review of pharmaceutical policies in response to economic crises and sanctions. Kheirandish M, Rashidian A, Kebriaeez	le A J Res Pharm Pract. 2015 Jul-Sep;4(3):115-22. doi: 10.410: create date:2015/08/28 first author:Kheirandish M	28.08.2015 20
2 20160828 pubmed	У			y Synthesis/Comment	Y Policy (descriptive)	y N	26583303 European Pharmaceutical Pricing and Reimbursement-SMi's 21st Annual Meeting (October 5-6, 2015Lon Kibble A, D'Souza P.	Drugs Today (Barc). 2015 Oct;51(10):609-12. doi: 10.135 create date:2015/11/20 first author:Kibble A	20.11.2015 20
99 20161127 pubmed	у	y		n			22492899 Multiple drug cost containment policies in Michigan's Medicaid program saved money overall although son Kibicho J, Pinkerton SD.	Health Aff (Millwood). 2012 Apr create date:2012/04/12 first author:Kibicho J	12.04.2012 20
2 20172131 Scopus	y		y	n			Pharmaceutical pricing Kina S.H. Wosinska M.	Handbook of Pricing Research in Marketing	20
6 20160828 pubmed	v v			n			19966075 Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for Kirschenbaum BE.	Am J Health Syst Pharm. 2009 Dec 15;66(24 Suppl 7):S13 create date:2010/01/09 first author:Kirschenbaum BE	09.01.2010 20
5 20160828 pubmed	, ,	v					26085900 Breaking the Bank: Three Financing Models for addressing the Drug Innovation Cost Crisis Kleinke ID. McGee N	Am Health Drug Renefits 2015 May 8/3):118-26. Review create date:2015/06/19 first author:Kleinke ID	19.06.2015 20
11 20160918 pubmed	,	,		Economic model (analytic empirical data)	n Policy > Invest (R&D)	n v	1899905 Regulatory policy and the location of his-pharmaceutical foreign direct investment in Europe Koenia P. Margarvie M	Health From 2011 Sep 30/51-950-65, doi: 10.1016/j.ibe.create.date-2011/09/09 first author:Koenig P	09.09.2011 20
4 20160928 pubmed	y 	v		n	in Toney > invest (nab)		Education of the second	Clin lefert Dir 2016 Mar 15-52/6/292-4 doi: 10.1092///create date:2015/12/15 first author:Kongi P	15 12 2015 20
4 20100828 publied 0 20160011 submed	y	y		N.			2003/003 Eutona commissiona se uniona for agreerative medicine technical keverse de rendo in k koenig Sr, Pape Jw.	Chini hitect 05: 2010 Wai 15;02(0):7274. 00: 10:1053/04 Cleate date:2017/2715 Tisst dution.Koeling 3P	24.10.2012 20
3 20100311 publied	y	y		N			4147350 Early evaluation and value-based pricing of regenerative metaline technologies. Koerber P, kolauris B, kogowski W.	Regen Web. 2015 Woy, a(0):747-56. 001. 10.2217/1110-15 Create date: 2015/10/24 hist adultion. Kole bei P	24.10.2013 20
2 20160828 pubmed	y y			n			20238110 Does Pharmaceutical Pricing Transparency Matterr Examining Brazilis Public Procurement System. Koner JL, Mitsakakis W, Sadadi F, Byng	M Global Health. 2015 Aug 4;11:34. doi: 10.1186/512992-0. create date:2015/08/05 Tirst author:Konier Jc	05.08.2015 20
8 20160828 pubmed	У	y		n			21842577 Commercial influence and global nongovernmental public action in health and pharmaceutical policies. Koivusalo M, Mackintosh M.	Int J Health Serv. 2011;41(3):539-63. create date:2011/08/17 tirst author:Koivusalo M	17.08.2011 20
4 20160828 pubmed	У			 Y Economic model (analytic, empirical data) 	n Other (non_Policy) > Prices	y n	26531913 Determinants of Orphan Drug Prices in France: Regression Analysis. Korchagina D, Vataire A, Toumi M, Fali	Value Health. 2015 Nov;18[7]:A337. doi: 10.1016/j.jval.2 create date:2015/11/05 first author:Korchagina D	05.11.2015 20
12 20160918 pubmed	у	y		n			26054399 The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic mei Koskinen H, Ahola E, Saastamoinen LK,	likk Health Econ Rev. 2014 Dec;4(1):9. doi: 10.1186/s13561-C create date:2015/06/10 first author:Koskinen H	10.06.2015 20
12 20160918 pubmed	У	Y		N			26686797 Time Series Analysis on the Impact of Generic Substitution and Reference Pricing on Antipsychotic Costs in Koskinen H, Mikkola H, Saastamoinen	Ah Value Health. 2015 Dec;18(8):1105-12. doi: 10.1016/j.jva create date:2015/12/22 first author:Koskinen H	22.12.2015 20
5 20160828 pubmed	y		1	n			17211764 [Pharmacoeconomic analyseschance or 4th hurdle for innovative drugs]. Krammer H.	Wien Med Wochenschr. 2006 Dec;156(23-24):606-11. G create date:2007/01/11 first author:Krammer H	11.01.2007 20
2 20172131 Scopus	y y			n			An economic analysis of Indian pharmaceutical pricing policy: Drugs (prices control) order, 2013 Kumar P. Ramakrishanan S.	Law and Economics in India: Understanding and Practice	20
4 20160828 pubmed	y		v	n			21173063 Germany moves to lower drug prices. Kupferschmidt K.	CMAJ. 2011 Feb 8;183(2):E77-8. doi: 10.1503/cmaj.109-; create date:2010/12/22 first author:Kupferschmidt K	22.12.2010 20
2 20172131 Sconus				x Statistical analysis - inductive (not BCT/NR)	n Policy > Access*	n v	Pharmaceutical price controls and entry strategies Kyle M K	Beview of Economics and Statistics	20
7 20160828 pubmed	y			n national analysis - inductive protinciplin	ii Tuncy > Peccai		The machine in the control of the state gets of the state	MEDIC Rev 2011 Iul-12(2):16-22 create date-2011/07/22 first author:1are A	22.07.2011 20
6 20160828 pubmed	y y						Carrier and the second seco	Mark Longer 1 2017 Mark (2) (2) 202 day 10 1001/2000 create date 2012/07/12 mark anthen a ladawalle DA	17.07.2015 20
12 20100828 publied	y	y					Evaluating expected costs and benefits of Granung Avactist is high side and avacting estation costs of Provide the state of the state entry of of the state entr	A particular of the second sec	16.07.2013 20
12 20100918 publied	y .	y					1802.117 Do Ace minimuos an provide the same outcomes benefits in high-risk cardiovascular patients? Lata A, Wiczogrim MAR.	Curl hypertens kep. 2008 A0(2) (04) 280-52. Kewew. Create date: 2008/07/10 Tinst adultion cara A	10.07.2008 20
5 20160828 pubmed	Ŷ			y Statistical analysis - descriptive	Y Prices > Expenditures	y n	2084073 The impotence or price controls: failed attempts to constrain pharmaceutical expenditures in Greece. Lamoreiii D, O Donneii O.	Health Policy. 2011 Jul; 101(2):162-71. doi: 10.1016/j.healcreate.date:2010/10/05 hist author:Lambrein D	05.10.2010 20
9 20160911 pubmed	У	_		Y Synthesis/Comment	y Policy (descriptive)	Y N	2/201229 Whatever Happened To Nice Value-Based Pricing? Welcome, Value-Based Assessment. Langham S, Gemmell E, Kerrigan M, W	Value Health. 2014 Nov;17(7):A449. doi: 10.1016/j.jval.2 create date:2014/11/01 tirst author:Langham S	01.11.2014 20
12 20160918 pubmed	У	y		n			22002826 Using financial incentives to improve value in orthopaedics. Lansky D, Nwachukwu BU, Bozic KJ.	Clin Orthop Relat Res. 2012 Apr;470(4):1027-37. doi: 10. create date:2011/10/18 first author:Lansky D	18.10.2011 20
6 20160828 pubmed	у у			n			27527484 A population-based analysis of incentive payments to primary care physicians for the care of patients with Lavergne MR, Law MR, Peterson S, Ga	Son CMAJ. 2016 Aug 15. doi:pii: cmaj.150858. [Epub ahead o create date:2016/08/17 first author:Lavergne MR	17.08.2016 20
4 20160828 pubmed	y	y		n			23166285 The road to competitive generic drug prices in Canada. Law MR, Kratzer J.	CMAJ. 2013 Sep 17;185(13):1141-4. doi: 10.1503/cmaj.1. create date:2012/11/21 first author:Law MR	21.11.2012 20
4 20160828 pubmed	v	v		n			23968624 Money left on the table: generic drug prices in Canada. Law MR.	Healthc Policy. 2013 Feb;8(3):17-25. create date:2013/08/24 first author:Law MR	24.08.2013 20
9 20160911 pubmed							22078685 Value-based pricing: time for a NICEr way of measuring health? Lee H. King D. Darzi A. Dolan P.	Lancet, 2011 Nov 12:378(9804):1698. doi: 10.1016/S014_create date:2011/11/15 first author:Lee H	15.11.2011 20
	v	,	Y	N					
b 20160828 pubmed	y y	,	Y	N Systematic Review	N Policy > Expenditures	N	25092883 International experience in controlling pharmaceutical expenditure: influencing patients and providers and Lee IH. Bloor K. Hewitt C. Maynard A.	Health Serv Res Policy, 2015 Jan 20(1):52-9, doi: 10.117 create date:2014/08/06 first author:Lee IH	06.08.2014 20
6 20160828 pubmed	y y		Y	N Systematic Review	N Policy > Expenditures	NY	20092883 International experience in controlling pharmaceutical expenditure: influencing patients and providers and Lee IH, Bloor K, Hewitt C, Maynard A.	J Health Serv Res Policy. 2015 Jan;20(1):52-9. doi: 10.117 create date:2014/08/06 first author:Lee IH	06.08.2014 20
6 20160828 pubmed 6 20160828 pubmed 7 20160828 pubmed	y y y	y y	Y	N Systematic Review	N Policy > Expenditures	N Y	25092883 International experience in controlling pharmaceutical expenditure: influencing patients and providers and Lee IH, Bloor K, Hewitt C, Maynard A. 2000099 The effects of new pricing and copayment schemes for pharmaceuticals in South Korea. Lee IH, Bloor K, Hewitt C, Maynard A. 2019/2019/2019 Applications for the influence ordinal influence and the influence of the influence ordinal influence ordinal influence and the influence ordinal influence ordina	J Health Serv Res Policy. 2015 Jan;20(1):52-9. doi: 10.117 create date:2014/08/06 first author:Lee H Health Policy. 2012 Jan;104(1):40-9. doi: 10.1016/j.healtl create date:2011/10/18 first author:Lee H Am L Mang Care, 2012 May 119/811he40-27. Pauliew.create date:2012/12/10/16 first author:Lee H	06.08.2014 20 18.10.2011 20 04.12.2012 20
6 20160828 pubmed 6 20160828 pubmed 7 20160828 pubmed 5 20160828 pubmed	y y y y	y y	Y	N Y Systematic Review n Y Systematic Review	N Policy > Expenditures N Policy > diverse	N Y	5502833 International experience in controlling pharmaceutical expenditure: influencing patients and providers and Lee Hi, Bloor K, Hewitt C, Maynard A. 2003099 The effects of new pricing and posyment schemes for pharmaceutical isoluch forea. 20139972 A systematic review of reference pricing: implications for US prescription drug spending. 20139991 A systematic review of reference pricing: implications for US prescription drug spending.	J Health Serv Res Policy. 2015 Jan;20(1):52-9. doi: 10.117 create date:2014/08/06 first author:Lee IH Health Policy, 2012 Jan;20(1):40-9. doi: 10.1016/j.healtl create date:2011/0/18 first author:Lee IH M. Ann J Mang Care. 2012 Nov 118(11):429-37. Review. create date:2012/12/18 first author:Lee II below Mengh 2014 Jan;21(4):65 doi:10.1016/first create date:2012/12/18 first author:Lee II below Mengh 2014 Jan;21(4):65 doi:10.1016/first create date:2012/12/18 first author:Lee II	06.08.2014 20 18.10.2011 20 04.12.2012 20 28.06.2014 22
6 20160828 pubmed 6 20160828 pubmed 7 20160828 pubmed 5 20160828 pubmed	у У У У У	y	Y	N Y Systematic Review N Systematic Review	N Policy > Expenditures N Policy > diverse	N Y	552283) international experience in controlling pharmaceutical expenditore: influencing patients and providers and Lee Hi, Bloor K, Hewitt G, Maynard A. 200599 The effects of new princing and coopyment schemes for pharmaceutical in storation. Increa. 218472 A systematic review of reference princip: implications for US prescription drug spending. 2006000 Media device inclusionement coverage and princip runs in Korea: current practice and Assume Mind Rescute Lee K. Bloor K. Advanta MV, Pointal 2006000 Media device inclusionement coverage and princip runs in Korea: current practice and Assume Mind Rescute SS 34, Sala E. C.	Health Serv Res Policy, 2015 Jan;20(1):52-9, doi: 10.117 create date:2014/08/06 [first author:Lee IH Health Policy, 2012 Jan;104(1):40-9, doi: 10.1016/j.healtl.create date:2011/10/18 [first author:Lee IH M. an J Manag Care: 2012 Nov 1;81(1):e429-37. Review. create date:2014/10/18 [first author:Lee IL Value Health. 2014 Jun;174(1):476-81. doi: 10.1016/j.ival. create date:2014/06/28 [first author:Lee SS Value Health. 2014 Jun;174(1):476-81. doi: 10.1016/j.ival.	06.08.2014 20 18.10.2011 20 04.12.2012 20 28.06.2014 20
201608228 pubmed 20160828 pubmed 20160828 pubmed 20160828 pubmed 20160828 pubmed 201609318 pubmed	у у у у у у у у у у	y	Y	N y Systematic Review y Systematic Review	N Policy > Expenditures N Policy > diverse	N Y	592283) international experience in controlling pharmaceutical expenditors: influencing patients and providers and Lee H, Bloor K, Hewitt C, Maynard A. 200399 The effects of new princing and cosyment schemes for parameturicalis in book forces. Lee H, Bloor K, Hewitt C, Maynard A. 20139721 A systematic review of reference princip implications for US prescription drug spending. Lee H, Einster K-MA, Strank WH, Polinsi 20049000 Medical device minimum entropy of the strange and principal schemester and schemest the strange and principal schemester. 2014 Schemester Schemester Schemester and principal schemester and sche	Health Sarv Res Folio, 2015 Ana/2015-23- doi:10.1117 create date.2014/08/66 [inst authorize H Health Folio, 2023 Jan.2016]13-69. doi: 10.1016/j.had.creater date.2011/07/86 [Inst authorize H M, Ami Mang Care. 2012 Nor 128111e429-37. Review. create date.2012/07/86 [Inst authorize H Value Health Tolio, 2021 Nor 128111e429-37. Review. create date.2012/07/86 [Inst authorize H Value Health Tolio, 2021 Nor 128111e429-37. Review. create date.2012/07/86 [Inst authorize H Value Health Tolio, 2021 Nor 128111e429-37. Review. create date.2016/07/86 [Inst authorize H Value Health Tolio, 2021 Nor 128111e429-37. Review. create date.2016/07/86 [Inst authorize H Value Health Tolio, 2021 Nor 128111e429-37. Review. create date.2016/07/86 [Inst authorize H Value Health Tolio, 2021 Nor 128111e429-37. Review. create date.2016/07/86 [Inst authorize H Value Health Tolio, 2021 Nor 128111e429-37. Review. create date.2016/07/86 [Inst authorize H Value Health Tolio, 2021 Nor 128111e429-37. Review. create date.2016/07/86 [Inst authorize H Value Health Tolio, 2021 Nor 128111e429-37. Review. create date.2016/07/86 [Inst authorize H Value Health Tolio, 2021 Nor 128111e429-37. Review. create date.2016/07/86 [Inst authorize H Value Health Tolio, 2021 Nor 128111e429-37. Review. create date.2016/07/86 [Inst authorize H Value Health Tolio, 2021 Nor 128111e429-37. Review. create date.2016/07/86 [Inst authorize H Value Health Value H Value Health Val	06.08.2014 20 18.10.2011 20 04.12.2012 20 28.06.2014 20 01.09.2006 20
b 20160828 pubmed 6 20160828 pubmed 7 20160828 pubmed 5 20160828 pubmed 12 20160918 pubmed 5 20160828 pubmed	y y y y y y y y y	y	Y	N y Systematic Review n n n	N Policy > Expenditures N Policy > diverse	N Y	552283) International experience in controlling pharmaceutical expenditore: Influencing patients and providers and Lee Hi, Bloor K, Hewitt C, Maynard A. 200599 The effects of new princing and copyment schemes for pharmaceutical in shorth Korea. Lee Hi, Bloor K, Hewitt C, Maynard A. 2018972 A systematic review of reference princip: implications for US prescription drug spending. Lee H. Bloor K, Hewitt C, Maynard A. 20189001 Medical device inclusionment or coverse and anticing runks in Korea: current practica and kause with a secsion schemes and anticing and the Medical Coverse and anticing runk and a starks review your en actess to inconse L Lee HV, Bloor K, Hewitt C, Maynard A. 2018eb The impacts of cost containment strategies on pharmaceutical ad escuel wither on access to inconse L Lee HV, Pang KG, Huang YT, Lu OY, Ch 2018eb The implication of the Medicine Control clouding and data-track review your on access to inconse L Lee HV, Pang KG, Huang YT, Lu OY, Ch 2018eb The implication of the Medicine Control clouding and data-track review your on access to inconse L Lee HV, Pang KG, Kasang YT, Lu OY, Ch 2018eb The implication of the Medicine Control clouding and data-track review your on access to inconse L Lee HV, Pang KG, Kasang YT, Lu OY, Ch 2018eb The implication of the Medicine Control clouding and data-track review your on access to inconse L Lee HV, Pang KG, Kasang YT, Lu OY, Ch 2018eb The implication of the Medicine Control clouding and data-track review your on access to inconse L Lee HV, Pang KG, Kasang YT, Lu OY, Ch 2018eb The implication of the Medicine Control clouding and data-track review your on access to inconse L Lee HV, Pang KG, Kasang YT, Lu OY, Ch 2018eb The implication of the Medicine Control clouding and data-track review your on access to inconse L Lee HV, Pang KG, Kasang YT, Lu OY, Ch 2018eb The implication of the Medicine Control clouding and data-track review your on access to inconse L Lee HV, Pang KG, Kasang YT, Lee HV, Pang KG, Huang YT, Lee HV, Pang KG, Huang YT, Huang YT, Lu HV, Pa	Health Serv Res Folicy, 2015 Jan 20(1):52-9. doi:10.1111/create date.2014/00(6) [first authorizet H Health Neiky, 2013.2014(1):43-0. doi:10.1016/j.hadi/created/act2011/01/8] [first authorizet H M, Ami Manag Cze. 2012 Noi:13(1):142-93-7. Review.create.date.2012/10/8] [first authorizet A Manag Cze. 2012 Noi:13(1):142-93-7. Review.create.date.2012/10/8] [first authorizet A Vaule Health.2014 [Jin:174:167-68.10].10.1016/j.hadi.org/active Create.date.2014/01/8] [first authorizet A Saft Med: 2016 Nei 73:166(1):45-64.00:12734/2014 (first authorizet Y Saft Med: 2016 Nei 73:166(1):45-64.00:12734/2014 (first authorizet Y	06.08.2014 20 18.10.2011 20 04.12.2012 20 28.06.2014 20 01.09.2006 20 02.04.2016 20
b 2016/08/28 pubmed 2 2016/08/28 pubmed 2 2016/08/28 pubmed 2 2016/08/28 pubmed 12 2016/08/28 pubmed 2 2016/08/28 pubmed 2 2016/08/28 pubmed 4 2016/08/28 pubmed	y y y y y y y y	Y	Υ ¥	N y Systematic Review n n n n	N Policy > Expenditures N Policy > diverse	N Y	592283) international experience in controlling pharmaceutical expenditors: influencing patients and provides and Lee Hi, Bloor K, Hewitt C, Maynard A. 20099 The effects of new princing and cosyment schemes for patimaceutical is also buth foreas. 2018/0721 Agreematic review of reference princip implications for US prescription drug spending. 2018/2010 Media device inclusionsement coverage and princip runis foreas current can advance Media Schemes Lee H. Bloor K, Hewitt C, Maynard A. 2018/2012 Media device inclusionsement coverage and princip runis foreas current particle and statuse Media Schemes Lee SC. Schemes Lee SC. 2018/2012 Media device inclusionsement coverage and princip runis foreas current particle and statuse Media Schemes Lee SC. Alarge MC, Huang YT, Liu OH, Ch. 2018/2012 Ministry and the Medicines Control Council Dackog and Basi-track review system on access is innovative Lee VC, Yang MC, Huang YT, Liu OH, Ch. 2018/2012 Ministry and Johed Coverage and princip runis Linking State-An Alexen for and scheme Scheme Scheme Schemes JM, Wagner AM, Strack MM, Polinski Media Schemes JM, Wagner AM, Strack MM, Strack	Health Sarv Res Folicy, 2015 Jan.2011;52-9. doi:10.1117/create date.2014/09(6) [first authorice H Health Folicy, 2013 Jan.2011;13-09, doi:10.1016/j.healt/created/act2011/07(8) [first authorice H M, Ami Manag Care. 2012 Nor 118(11):e429-37. Review. create date.2012/07(8) [first authorice Ja Vulae Health.2014;01:7341-784. doi:10.1006/j.kul.2rceated.act2014/07(8) [first authorice SS S8] Planmarcosconomics.2002.49(9):831-902. create date.2016/07(8) [first authoric.evg MM Valae Health.2015 Jali Jari;91(3):14-6. doi:10.1016/j.kul.2rceated.att2-2016/07(8) [first authoric.tegg MM Valae Health.2015 Jali Jari;91(3):14-6. doi:10.1016/j.kul.2rceated.att2-2016/07(8) [first authoric.tegg MM Valae Health.2015 Jali Jari;91(3):14-6. doi:10.1016/j.kul.2rceated.att2-2016/07(8) [first authoric.tegg MM	06.08.2014 20 18.10.2011 27 04.12.2012 22 28.06.2014 20 01.09.2006 27 02.04.2016 22 23.01.2016 20
b 2016/08/28 pubmed 6 2016/08/28 pubmed 7 2016/08/28 pubmed 12 2016/08/28 pubmed 12 2016/08/28 pubmed 5 2016/08/28 pubmed 4 2016/08/28 pubmed 2 2016/08/28 pubmed 2 2016/08/28 pubmed 2 2016/08/28 pubmed	у У У У У У У У У У У У	¥	Y Y	N y Systematic Review n y Systematic Review n n y Statistical analysis - inductive (not RCT/NR,	N Policy > Expenditures N Policy > diverse n Policy > Prices	N Y	592283 International experience in controlling pharmaceutical expenditore: influencing patients and providers and Lee IN, Bior Y, Hewitt C, Maynard A. 20059 The effects of new princing and copyment schemes for pharmaceutical in solution forcea. Lee IN, Bior Y, Hewitt C, Maynard A. 2018972 A systematic review of reference princip: implications for US prescription drug spending. Lee IN, Einster NA, Shrank NV, Polnsi Maynobiol Medical device inclusionsement coverage and princip rules in Kores: current anricicate and issues MH sceles Lee SS, Salee A. Shrank NV, Polnsi 201226 The impacts of cost containment strategies on pharmaceutical ad equivalent term context and sceles SS, Salee A. Sharek NV, Polnsi 201226 The impacts of cost containment strategies on pharmaceutical expension frame context and sceles with term context and sceles SS, Salee A. Sharek NV, Polnsi 201226 The impact of the Medicine Control Council Saledge and Bartskic review phare on access to innovate: Lee JNN, Polnsi A. Sharek NV, Barka MJ, Sharek NV, Barka MJ, Barka M	Heath Serv Res Folicy, 2015 Auto,2015;3-9. doi:10.1117/cetate/deta2014/00/66 [first authorizet H Heath Neiky, 2021;an:01(114:0-6) doi:10.1056/j.hadi/cretate/deta2011/01/86 [first authorizet H M, Ami Manag Czer. 2021 Noi:118(11):e420-37. Review. create/deta2010/21/86 [first authorizet J M, Jani Manag Czer. 2021 Noi:118(11):e420-37. Review. create/deta2010/21/86 [first authorizet J Juda Heath.2015 auto:11.0106/j.j.doi:10.1016/j.hadi.createdate2010/01/86 [first authorizet J Juda Heath.2015 Auto:11.0106/j.j.doi:10.1016/j.j.doi:10.1016/j.j.doi:10.1016/j.j.doi 58 Piarmacoconomics.2006;240(9):951-902. create/deta2010/01/86 [first authorizet Y Value Heath.2015 2012 Cetz;27:34-41. doi:10.1016/j.j.doi:	06.08.2014 20 18.10.2011 20 28.06.2014 20 28.06.2014 20 01.09.2006 20 02.04.2016 20 23.01.2016 20 28.03.2013 20
6 2016/03/28 pubmed 7 2016/03/28 pubmed 7 2016/03/28 pubmed 12 2016/03/18 pubmed 12 2016/03/18 pubmed 12 2016/03/28 pubmed 2 2016/03/28 pubmed 2 2016/03/28 pubmed 2 2016/03/28 pubmed	у У У У У У У У У У У У У У	Y	Y	N y Systematic Review n y Systematic Review n n y Statistical analysis - inductive (not RCT/NR y Statistical analysis - decriptive	N Policy > Expenditures N Policy > diverse n Policy > Prices Y Policy > Expenditures	N Y N Y	5022833 Unternational experience in controlling pharmaceutical expenditors: influencing patients and providen and Lee H, Bloor K, Hewitt C, Maynard A. 200299 The effects of new princing and comparent schemes for pharmaceutical in south foreas. 20049 Line effects of new princing and comparent schemes for pharmaceutical in south foreas. 20049 Line effects of the subscription of the speed of the subscription of the subscription of the speed of the subscription of the speed of the subscription of the speed of the subscription of the subscriptio	Heath Serv Res Foliz, 2015 Jan 20(1):52-9. doi: 10.1117 create date:2014/W0(6 [first authorize H heath Folicy. 2015 Jan 2011;13-94. doi: 10.1116/j.hasti create date:2011/V0[8 [first authorize H M, Am J Manag Care. 2012; Nor 11;21(1):62:93-77. Review. create date:2017;17/18 [first authorize H B M, Am J Manag Care. 2012; Nor 11;21(1):62:93-77. Review. create date:2016;17/18 [first authorize H B M M, Am J Manag Care. 2012; Nor 11;21(1):62:93-77. Review. create date:2016;17/18 [first authorize H B M M M, Am J	06.08.2014 20 18.10.2011 27 28.06.2014 27 28.06.2014 27 01.09.2006 27 23.01.2015 27 28.03.2013 27 08.11.2014 27
b 2016/02/28 pubmed c 2016/02/28 pubmed c 2016/02/28 pubmed c 2016/09/18 pubmed c 2016/09/18 pubmed c 2016/09/18 pubmed c 2016/09/28 pubmed c 2016/08/28 pubmed c 2016/08/28 pubmed c 2016/08/28 pubmed c 2016/08/28 pubmed	y y y y y y y y y y y	Y	Y Y	N y Systematic Review n y Systematic Review n y Statistical analysis - inductive (not RCT/NR y Statistical analysis - descriptive y Statistical analysis - descriptive	N Policy > Expenditures N Policy > diverse n Policy > Prices Y Policy > Prices Y Policy > Prices	N Y N Y n n y n	5928283 International experience in controlling pharmaceutical expenditore: influencing patients and providers and Lee IN, Bloor K, Hewitt C, Maynard A. 200599 The effect on leve princing and copyment schemes for pharmaceutical in South Korea. Lee IN, Bloor K, Hewitt C, Maynard A. 2018972 (A systematic review of reference princip: implications for US prescription drug spending. Lee JA, Escher MA, Shrank NV, Polnia Media Control and	Hieabi Sarv Bes Foliz, 2015 Jan.20(1):52-9. doi:10.1117/cetal-date.2014/00/66 [fint authorice H Heabih Telky: 2012 Jan.2014(1):43-60 doi:10.1016/j.hadi/cretade/date.2011/01/86 [fint authorice H M, Ami Mang Czer. 2012 Noi:118(1):e32-93-78. Review. create date.2016/27(8/ [fint authorice J, Vauke Heabih.2016 Jan.178(1):74-64 doi:10.1016/j.had/createddate.2016/07(8/ [fint authorice YC SAF Med. 2016 Noi:11.2016/sAF doi:10.2016/j.had/createddate.2016/07(8/ [fint authorice W Vauke Heabih.2016 Jan.178(1):74-64 doi:10.1016/j.j.du/createddate.2016/07(8/ [fint authorice W Vauke Heabih.2016 Jan.178(1):74-64 doi:10.1016/j.j.du/createddate.2016/07(8/ [fint authorice W Vauke Heabih.2016 Jan.178(1):14-64 doi:10.1016/j.j.du/createddate.2016/07(8/ [fint authoricegold C S, VaukW Optio Jan.2012 DC: 27: createddate.2016/07(8/ [fint authoricegold C S, VaukW Doi:1803:1832-22. createddate.2016/17(8/ [fint authoricegold C S, VaukW Doi:1803:1822-22. createddate.2016/17(8/ [fint authoricegold C S, VaukW Doi:1803:1822-23. createddate.2016/17(8/ [fint authoricegold C S) Doi:1803:1822-23. createddate.2016/17(8/ [fint authoricegold C S) Doi:1803:1822-1823. createddate.2016/17(8/ [fint authoric	06.08.2014 22 18.10.2011 24 04.12.2012 22 28.06.2014 22 01.09.2006 22 02.04.2016 22 23.01.2015 22 28.03.2013 22 08.11.2014 22
b 2016/03/28 pubmed 6 2016/03/28 pubmed 7 2016/03/28 pubmed 12 2016/03/28 pubmed 12 2016/03/28 pubmed 2 2016/03/28 pubmed	y y y y y y y y y y y	y	Y Y	N Y Systematic Review n Y Systematic Review n n Y Statistical analysis - inductive (not RCT/NR Y Statistical analysis - descriptive Y Statistical analysis - descriptive Statistical analysis - descriptive	N Policy > Expenditures N Policy > diverse n Policy > Prices Y Policy > Prices	N Y N Y n n y n	 Biorgania de experience in controlling pharmaceutical expenditore: Influencing patients and providen and Lee Hi, Bior K, Hewit C, Maynard A. Biorgania D. & Charles M. (2000) Control and Control an	Heath Sarv Mes Foliz, 2015 Am.20(1):52-9. doi: 10.1117 credit delta:2014/00/66 [first authorize H Heath Foliz, 2012.1016/114-09. doi: 10.1016/j.hasti credit delta:2011/01/86 [first authorize H M, Amil Manag Care. 2012. Not 118(1):642-07. Review.credit delta:2013/01/86 [first authorize Ls Valuer Heath, 2012. Anno 118(1):643-06. doi:10.1016/j.hudi.credit delta:2013/01/86 [first authorize Ls Valuer Heath, 2015. Heat 118(1):642-07. Review.credit delta:2014/01/86 [first authorize Ls Saft Med 1.2015.Met 17:00166/j.hudi.credit delta:2016/01/86 [first authorize JM Valuer Heath, 2015.Heat 17:0166/j.hudi.credit delta:2016/01/86 [first authorize JM Valuer Heath, 2015.Heat 17:0166/j.hudi.credit delta:2016/01/86 [first authorize JM Heath 2015.Heath 20	06.08.2014 22 18.10.2011 22 04.12.2012 22 28.06.2014 22 01.09.2006 22 23.01.2016 22 23.02.2013 22 08.02.2013 22 08.11.2014 22 10.10.2014 22 22.0.2013 22 22.0.2013 22 22.0.2014 22 22.0.2011 22
201108/25 pubmed 20168/25 pubmed	y y y y y y y y y y y y y	Y	¥ ¥	N y Systematic Review n y Systematic Review n n y Statistical analysis - inductive (not NC/I/NR y Statistical analysis - descriptive y Statistical analysis - descriptive n	N Policy > Expenditures N Policy > diverse n Policy > Prices Y Policy > Spenditures Y Policy > Expenditures Y Policy > Prices Y Policy (descriptive)	N Y N Y n n y n y n	 Biorgani, Biorgani, Bio	Hieabi Sarv Bes Foliz, 2013 Jan.2011;53-9. doi: 10.1117 create date.2014/00/66 [first authorize H Heabih Telky: 2012 Jan.2011;14:3-9. doi: 10.1165/j.hadi create date.2011/2018 [first authorize H M, Ami Mang Czer. 2012 Noi: 1181(1):e420-37. Review. create date.2016/21/08 [first authorize J Vauke Heabih. 2013 Jan.218(1):e42-60: 10.1016/j.hadi create date.2016/2018 [first authorize V SAF Med. 2016 Noi: 10.1016/j.hadi create date.2016/2018 [first authorize V SAF Med. 2016 Zize Sci23-44. doi: 10.1016/j.j.bl.21 create date.2016/07/81 [first authorize V Vauke Heabih. 2015 Jan.218(1):e42-66 doi: 10.1016/j.j.bl.22 create date.2016/07/81 [first authorize Qid Vauke Heabih. 2015 Jan.218(1):e42-66 doi: 10.1016/j.j.bl.22 create date.2016/07/81 [first authorize Qid Vauke Heabih. 2015 Jan.218(1):e42-66 doi: 10.1016/j.j.bl.22 create date.2016/07/81 [first authorize Qid Vauke Heabih. 2015 Jan.218(1):e54-66 doi: 10.1016/j.bl.22 create date.2016/07/81 [first authorize Qid Vauke Heabih.2015 Jan.218(1):e54-66 doi: 10.1016/j.bl.22 create date.2016/07/81 [first authorize Qid Vauke Heabih.2015 Jan.218(1):e54-66 doi: 10.1016/j.bl.22 create date.2016/07/81 [first authorize Qid Vauke Heabih.2015 Jan.218(1):e54-66 doi: 10.1016/j.bl.22 create date.2016/07/81 [first authorize Qid Vauke Heabih.2015 Jan.218(1):e54-66 doi: 10.1016/j.bl.22 create date.2016/71/81 [first authorize Qid Vauke Heabih.2015 Jan.218(1):e54-66 doi: 10.1016/j.bl.22 create date.2016/71/81 [first authorize Qid Vauke Heabih.2015 Jan.218(1):e54-66 doi: 10.1016/j.bl.22 create date.2016/71/81 [first authorize Qid Vauke Heabih.2015 Jan.218(1):e54-66 doi: 10.1016/j.bl.22 create date.2016/71/81 [first authorize Qid Vauke Heabih.2015 Jan.218(1):e54-66 doi: 10.1016/j.bl.22 create date.2016/71/81 [first authorize Qid Vauke Heabih.2015 Jan.218(1):e54-66 doi: 10.1016/j.bl.22 create date.2016/71/81 [first authorize Qid Vauke Heabih.2015 Jan.218(1):e54-66 doi: 10.1016/j.bl.22 create date.2016/71/81 [first authorize Qid Vauke Heabih.2015(J):e56-66 doi: 10.1016/j.bl.22 create date.2016/71	06.08.2014 22 18.10.2011 26 28.06.2014 27 28.06.2014 27 20.04.2016 22 20.04.2016 22 20.02.2013 27 20.02.2013 27 20.02.2013 27 20.02.2013 27 20.02.2013 27 20.02.2014 22 22.10.2011 27 25.08.2015 27 25.08.2016 27 25.08.2014 27 25.08.2014 27 25.08.2015 27 25.08.
201108/25 pubmed 20108/25 pubmed	y y y y y y y y y y y y y y y y	y y y	Y Y	N Y Systematic Review Y Systematic Review N N Statistical analysis - inductive (roc RC/I)RR Statistical analysis - descriptive Statistical analysis - descriptive Statistical analysis - descriptive	N Policy > Expenditures N Policy > Mores N Policy > Prices Y Policy > Prices	N Y N Y n n y n y n	502283 Dimetrational experience in controlling pharmaceutical expenditore: Influencing patients and providers and Lee HI, Bloor K, Hewitt C, Maynard A. 20029 The effects of new pricing and coopyment schemes for pharmaceutical in south foreat. 2014 Lee HI, Bloor K, Hewitt C, Maynard A. 20149 Dimetric review of reference pricing: implications for US prescription drug spending. 2014 Lee HI, Bloor K, Hewitt C, Maynard A. 20149 Dimetric review of reference pricing: implications for US prescription drug spending. 2014 Lee HI, Bloor K, Hewitt C, Maynard A. 2014 Lee HI, Bloor K, Hewitt C, Maynard A. 2014 Dimetric and Jacuare Winter Course and princing rules forea: current princice and Assume Winter Sciences Lee SK. Saled A. 2014 Sciences and an annual and the schesk review years on access to imnovate Lee HI, Honer K, Haung YL, Lo CY, D 2014 Thing varia of Adedia Coursiga on High Dong Prices in the United States A: Never Ending Stary or a Time FL coopold. Chamber JD. 2014 Sciences and Jacce references on High Dong Prices in the United States A: Never Ending Stary or a Time FL coopold. Chamber JD. 2014 Sciences and Jacce references on High Dong Prices in the United States A: Never Ending Stary or a Time FL coopold. Chamber JD. 2014 Sciences and Jacce references on High Dong Prices in the United States A: Never Rules Sciences and Sciences and Sciences The Net Sciences A: Never Neurosciences and Net Sciences A: Neurosciences A: Neuroscien	Health Siev Nes Foliz, 2015 Jan 20(1):52-9. doi: 10.1117 create date.2014/00(6) [fint authorize H Health Foliz, 2012 and 10(1):40-9. doi: 10.1016/j.hasti create date.2011/01(8) [fint authorize H M, Ami Mang Care. 2012 Not 138(1):e8/20-37. Review. create date.2012/01(8) [fint authorize L Vaula Health.2015 Jan 2012 Not 138(1):e8/20-37. Review. create date.2014/01/91 [fint authorize L Si Pharmaceconomics.2002,40(9):91-902. create date.2016/01/91 [fint authorize K Mark Health.2015 Jan 2015 Jan 2016 [fint authorize K Mark Health.2015 Jan 2015 Jan 2016 [fint authorize K Mark Health.2015 Jan 2015 Jan 2016 [fint authorize K Mark Health.2012 Desc133]:4-11. Gath 2012 Desc 27. create date.2016/07(2) [fint authorize H Mark Health.2012 Desc133]:4-11. Gath 2012 Desc 27. create date.2016/07(2) [fint authorize H Mark Health.2012 Desc133]:4-11. Gath 2012 Desc 27. create date.2016 [fint 2] [fint authorize H Mark Health.2012 Desc133]:4-11. Gath 2012 Desc 27. create date.2016 [fint 2] [fint authorize H Mark Health.2012 Desc133]:4-12. Gath 2016 [fint 2] [fint authorize H Mark Health.2012 Desc133]:4-12. Gath 2016 [fint 2] [fint authorize H Mark Health.2012 Desc133]:4-12. Gath 2016 [fint 2] [fint authorize H Mark Health.2015 Desc133]:4-12. Gath 2016 [fint 2] [fint authorize H Mark Health.2015 Desc133]:4-12. [fint authorize H Mark Health.2015 Desc133]:4-12. Gath 2016 [fint 2] [fint authorize H Mark Health.2015 Desc133]:4-12. Gath 2016 [fint 2] [fint authorize H Mark Health.2015 Desc134]:4-12. [fint authorize H Mark Health.2015 Desc134]:5-12. [f	06.08.2014 22 18.10.2011 22 28.08.2014 22 28.08.2014 23 20.09.2006 23 20.09.2006 24 20.01.2016 24 28.03.2013 24 28.03.2016 24 28.03.2016 24 28.03.2016 24 27.10.2014 24 27.08.2015 24 27.08.2015 24 27.08.2015 24 27.08.2015 24 27.08.2015 24 27.08.2015 24 27.08.2015 24 27.08.2015 24 27.08.2014 24 27.08.
21104825 pubmed 2016825 pubmed 2016828 pubmed	y y y y y y y y y y y y y y y y y y y	y y y y	Ŷ	N y Systematic Review y Systematic Review n y Statistical analysis - inductive (not RCT/NR y Statistical analysis - descriptive Statistical analysis - descriptive statistical analysis - descriptive	N Policy > Expenditures N Policy > diverse	N Y N Y n n y n y n	 Biorgania depertence in controlling pharmaceutical expenditors: Influencing patients and providers and Lee H, Bloor K, Hewitt C, Maynard A. Biorgania D, Santa D, Sant	Health Siew Ves Foliz, 2015 ana/2011;52:4. doi: 10.1111/create date.2014/00/66 [first authorize H health Visiku, 2012;10:1011;10:36, 10:1011;61;10:100;10:100;10:101;10:101;10:101;10:101;10:100;10:100;10:101;10:101;10:101;10:100;10;10;10;10:100;10;10;10;10;10;10;10;10;10;10;10;10;	06.08.2014 21 18.10.2011 22 04.1.2012 24 20.08.2014 25 20.08.2016 25 20.0.2016 25 20.0.2016 25 20.0.2016 25 20.0.2016 25 20.0.2018 25 20.0.2018 25 20.0.2014 25 20.0.2014 25 20.0.2014 25 20.0.2015 27 10.0.2015 27 20.0.2015 27 20.0.2016 27 20.0.2015 27
2010825 pubmed	y y y y y y y y y y y y y y y y y y y	y y y y	Ŷ	N y Systematic Review y Systematic Review n statistical analysis - inductive (not RCT/NR y Statistical analysis - descriptive y Statistical analysis - descriptive n n n n y Statistical analysis - descriptive n n n	N Policy > Expenditures N Policy > Mores n Policy > Prices Y Policy (descriptive)	N Y N Y n n y n y n	 Bioremational experience in controlling pharmaceutical expenditore: Influencing patients and providers and Lee IN, Bior K, Hewitt C, Maynard A. Biorematical experience in controlling pharmaceutical information for the provide patients and providers and Lee IN, Bior K, Hewitt C, Maynard A. Biorematical experience in controlling pharmaceutical information for the provide patients and providers and Lee IN, Bior K, Hewitt C, Maynard A. Biorematical experience in the provide on convergence and princing running in Korea: current practical and kasses White Routical AM, Sharka NH, Pohrai Maynard A. Biorematical experience in the Medicine Convergence and princing running in Korea: current practical and kasses White Leg MM, Pohraid AM, Sharka NH, Pohrai Maynard A. Biorematical experience in the Medicine Convergence and princing running and track review growth market and kasses where the langes of the Medicine Convergence on high Drug Prices in the United States - Alveer-Finding Stary or a Time F L topolo C. Chambers JD, Wagner AK. Biord Diale Convergence on pharmaceutical policy and medicine aals in eight European countries. Leopold C, Chambers JD, Wagner AK. Biord Intercons in external price reference for public policy and medicine aals in eight European countries. Leopold C, Martel T-Eerowaks AK. Voja Biorematical Biord Research and the reference for public policy and medicine aads in eight European. Research Rese	Heath Serv Res Foliz, 2015 Jan 2010;3-2-9. doi: 10.1101 create date.2014/00(6) [first authorize H Heath Neiko, 2012. Not 13:016():hash created date.2011/01(8) [first authorize H M, Ami Mang Care. 2012. Not 13:016():hash created date.2011/01(8) [first authorize L Value Heath.2012. Not 13:016():hash created date.2012 [hash created date.2016 (hash model):2012 [hash created date.2016 [hash created date.2016] (hash model):2012 [hash created date.2016 [hash created date.2016] Value Heath.2012 [hash created date.2016 [hash created date.2016] (hash model):2012 [hash created date.2016 [hash created date.2016 [hash created date.2016] Value Heath.2012 [hash created date.2016 [hash created date.2016] Value Heath.2012 [hash created date.2016 [hash created date.2016] (hash hash hash hash hash hash hash hash	06.08.2014 22 18.10.2011 22 26.06.2014 22 26.06.2014 22 20.09.2006 22 20.09.2006 22 20.09.2006 22 20.09.2016 22 20.0016 22 20.
201108258 pubmed 20108258 pubmed 7 20108258 pubmed 20108258 pubmed pubmed 2010918 pubmed pubmed 2010918 pubmed pubmed 2010928 pubmed 2010928 2010918 pubmed 2010918	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	y y y y y	Y	N Systematic Review Systematic Review Statistical analysis - inductive (not RCT/NR Statistical analysis - inductive (not RCT/NR Statistical analysis - descriptive Statistical analysis - descriptive	N Policy - Expenditures N Policy - Averse N Policy - Proces Y Policy - Proces Y Policy - Proces Y Policy - Proces Y Policy - Proces	N Y N Y n n Y n y n	 Bierranitoni experience in controlling pharmaceutical expenditore: Influencing patients and providers and Lee IH, Bioor K, Hewitt C, Maynard A. Bierranito enverying and coopyment systemes for pharmaceutical in spont horea. Lee IH, Bioor K, Hewitt C, Maynard A. Bierranito enverying and coopyment systemes for the provident in Korea: current and coopyment systemes for the provident and the coopyment and the pharmaceutical in spont and the coopyment systemes for the National Head System and Coopyment Systemes for National Systemes for the National Head System and Coopyment Systemes for National Head System Andrea Systems and Coopyment Systemes for National Head System Andrea Systems and Coopyment Systemes Systems and Coopyment Systems Systems and Coopyment Systems Systems and Coopyment Systems Systems and Coopyment Systems and Coopyme	Health Siev Ves Foliz, 2013 Am.20(1):53-9. doi: 10.1111/create date.2014/00(6) [first authorize H Health Folizy, 2012; and 2014; 30-40 doi: 10.1016/j.hasti create date.2011/01(8) [first authorize H M, Am J Manag Care. 2012; Not 11; 2014; 30-40 doi: 10.1016/j.hasti create date.2013/01(8) [first authorize L B) [first statuber of the s	06.08.2014 22 8.1.02011 22 2.0.62.2014 22 2.0.62.2014 22 2.0.62.2014 22 2.0.62.2014 22 2.0.02.016 22 2.0.0216 22 2
201108/25 pubmed 20108/25 pubmed	y y y y y y y y y y y y y y y y y y y	y y y y y y	Ŷ	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive first RCT/NR Systematic analysis - inductive first RCT/NR Systematic analysis - descriptive Systematic analysis - descri	N Policy - Expenditures N Policy - Avene Policy - Proces Y Policy - Proces Y Policy - Proces Y Policy - Proces Y Policy - Proces	N Y N Y n n y n	5022833 International experience in controlling pharmaceutical isogendture: Influencing patients and providers and Lee IN, Bior K, Hewitt C, Maynard A. 5022835 The effect of new pricing and corpusmeris tohenes for pharmaceutical is individual for a set of the effect of the economic receivable of the effect of the economic recenivable of the economic receivable of the economic receivable	Health Serv Kes Foliz, 2013 Ana/2011;52:4: doi: 10.1111/create date.2014/00(6) [first author:Lee H Health Neiky. 2012. No: 13.1015(h).ebd (created create date.2011/01(8) [first author:Lee H M, Am/ Mang Care. 2012 No: 13.1015(h).ebd (created create date.2012)(A)[first author:Lee H Value Health.2012 Ani:13.1015(h).ebd (created created	06.08.2014 22 18.10.2011 22 20.02.2014 22 20.02.2014 22 20.02.2016 22 20.02.2016 22 20.03.2016 22 20.03.
0 01108828 pubmed 0 01108828 pubmed 0 01108828 pubmed 1 01108828 pubmed 2 01108918 pubmed 2 0110918 pubmed	y y y y y y y y y y y y y y y y y y y	y y y y y	Y Y	N Systematic Review Y Systematic Review Y Systematic Review S Statistical analysis - inductive (not RCT/NR Stat	N Policy - Dependitures N Policy - Avere Policy - Proces Y Policy - Proces Y Policy - Proces Y Policy (descriptive)	N Y N Y n n y n y n	502283 International experience in controlling pharmaceutical expenditore. Influencing patients and providers and Lee IN, Bior K, Hewit C, Maynard A. 502283 The effects of new pricing and consymmers stremes for pharmaceutical in stork forces. Lee IN, Bior K, Hewit C, Maynard A. 513872 Anyternatic review of reference pricing: implications for US prescription drug spending. Lee IN, Bior K, Hewit C, Maynard A. 504800 Media diverse implications for US prescription drug spending. Lee IN, Bior K, Hewit C, Maynard A. 504912 Immunos of cass containment strategies on pharmaceutical is appending resonance and tax in the strate and stass with house. Lee IN, Bior K, Haung YT, Lu CY, D. 5049123 Immunos of the Medicine Control caucito and the strate verwey more macraces in immunos: Lee 194 M, Pichard M, Sandes DJ. 5049124 Immunos of the Medicine Control caucito and the strate verwey more macraces in immunos: Lee 194 M, Pichard M, Sandes DJ. 5049124 Immunos of the Medicine Control caucito and the strate verwey more macraces in immunos: Lee 194 M, Pichard M, Sandes DJ. 50592705 Iffect of the modicine Control caucito and the strate verwey more in the functionan countrite. Leopaid C, Vapares T-Eronavison A. Markange D, Pannalise metal on the modicine Control caucito and the strate	Health Serv Ves Foliz, 2013 Am.20(1):53-9. doi: 10.1111/create date.2014/00(6) [first authorize H Health Foliz, 2012; 2012; 2014):143-95. doi: 10.1016/j.hadi/created/act2011/01(8) [first authorize H M, Amil Mana, Care. 2012; Not 12(1):143-127. Review.create date.2013/01/80] [first authorize L Valuer Health, 2014; Amil 12(1):143-143. doi:10.1016/j.hadi/created/act2013/01/81 [first authorize L Valuer Health, 2014; Not 12(1):143-163. doi:10.1016/j.hadi/created/act2013/01/81 [first authorizes S S Afr Med 1. 2015 Mer 17:0016/j.hadi 2014; Care L Control (1):143-143. doi:10.1116/j.hadi/created/act2013/01/81 [first authorizes M S Afr Med 1. 2015 Mer 17:0016/j.pvi20; Create date:2016/01/81 [first authorizes M Valuer Health, 2015; Ling 10:131-64. doi:10.1016/j.j.pvi20; Create date:2016/01/81 [first authorizes M M Health Neizy, 2012 Dec;137(1):31-32. U (Health Neizy, 2012 Dec;137(1):34-55. U (Health Neizy, 2012 Dec;137(1):3	06.08.2014 22 81.10.2011 22 20.62.2014 22 20.62.2014 22 20.02.2016 22 20.10.2016 22 20.10.2016 22 20.10.2016 22 20.10.2016 22 20.10.2016 22 20.10.2016 22 21.10.2014 22 21.00.2011 22 22.08.2015 22 21.00.2012 22 20.02.2014 22 22.08.2015 22 23.08.2015 22 24.09.2016 22 25.08.2015 22 25.08.
0 0100820 pubmed 0 01008710 pubmed	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	y y y y y	Y	N Systematic Review Systematic Review Systematic Review N Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not NC/NR Statistical analysis - inductive (not NC/NR	N Policy - Expenditures N Policy - Averse P Policy - Proces P Policy - Proces P Policy - Resentatures P Policy - Strentatures P Policy - Welfare*** P Policy - Welfare*** P Policy - Welfare***	N Y N Y N Y n Y n Y n Y n	 Biorerational experience in controlling pharmaceutical expenditore: Influencing patients and providers and Lee IN, Biorer K, Hewitt C, Maynard A. Biorerational experience in controlling pharmaceutical in South Norea. Lee IN, Biorer K, Hewitt C, Maynard A. Biorerational experience in controlling pharmaceutical in South Norea. Lee IN, Biorer K, Hewitt C, Maynard A. Biorerational experience in controlling pharmaceutical in South Norea. Lee IN, Biorer K, Hewitt C, Maynard A. Biorerational experience in control and south Reveal experiments and South Norea. Lee IN, Biorer K, Hewitt C, Maynard A. Biorerational experiment strategies on pharmaceutical expenditories of the National Networks. Biorerational C, Maynard A. Biorerational experiment strategies on pharmaceutical expenditories of the National Networks. Biorerational C, Cavarga on Nigh D rug Pices in the United States - A Never-Finding Story on Timer F. Leopold C, Manher JL, Lui CY, D Thity Years of Media Coverage on pharmaceutical policy and mediance sales in earth Tampean countries. Leopal M, Channers JD, Wagner AK. Biord M, Berdona M, Barterational experimental expension mong Life Lorgeno countries. Leopal C, Manher T-Eenwisse AK, Voja Direreration of Healt Societic Ref P orability Cring and reindrumenternal antitris & A' A narry and Life Lorgeno A. Biorden D Healt Societic Ref P orability Cring and reindrumenter and antitris & A' A narry and Life Lorgeno A. Biorden D Healt Societic Ref P coulding Cring and reindrumenter and antitris & A' Cavargeno H. Lessing C, Athaton T, Davis P. Biorden D Healt Societic Ref Lorgeno Life Lorgeno A. Biorden D Hea	Heath Serv Res Folg, 2015 ana/2015-28. doi: 10.1111/create date:2014/0016 Instantor-tee H Heath Vielk, 2012 and 0114-36. doi: 10.1016/j.hadi: create date:2011/0118 Instantor-tee H Ann J. Mang Care. 2012 Not 12.1015/j.hadi: create date:2011/0118 Instantor-tee H Mark J. Mang Care. 2012 Not 12.1015/j.hadi: create date:2011/0118 Instantor-tee H Mark J. Mang Care. 2012 Not 12.1015/j.hadi: create date:2011/0118 Instantor-tee H Mark J. Mark J. 2016 Mer 17,008/14-16. doi: 10.7396/JAM.create date:2016/0121 Instantor-tee N SAM Med L. 2016 Mer 17,008/14-16. doi: 10.7396/JAM.create date:2016/0121 Instantor-tee N SAM Med Rev. 2012 Dec;52/31-44.1 Epub 2012 Dec; 7. create date:2016/1/211 Instantor-teeged C Li, Sonth Med Rev. 2012 Dec;52/31-44.1 Epub 2012 Dec; 7. create date:2015/0/211 Instantor-teeged C J. Mall Wolf Leader J. 2016 Mer 21, 2016 Dec 2014 (2016 Binst Instantor-teeged C Instantor-teeged C J. Mall Wolf Leader J. 2016 Mer 21, 2016 Dec 2014 (2016 Binst Instantor-teeged C Instantor-teeged C J. Mall Wolf Leader J. 2016 Mer 21, 2016 Dec; 10.01016/j.j.pai2 Coreate date:2015/0711 Instantor-teeged C All Healt Rev. 2014 Dec; 1219: 157-64.1 Instantor-teeged C All Healt Rev. 2014 Dec; 1219: 157-64.1 All Healt Rev. 2015 All 12: 10.01016/j.j.pai2 Coreate date:2015/0711 Instantor-teeged C	06.08.2014 22 18.10.2011 22 20.02.2014 22 20.02.2014 22 20.02.2016 22 20.02.2016 22 20.02.2016 22 20.02.2016 22 20.03.2016 22 20.03.
0 0108828 pulmed 0108828 pulmed 0108828 0108828 pulmed 0108878 0108888 pulmed 0108888 0108888 pulmed 0108888 0108888 pulmed 0108888 0108888 pulmed 0108888	y y y y y y y y y y y y y y y y y y y	Y Y Y Y Y	Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not RCT/NR Systematic analysis - inductive (not	N Policy > Dependences N Policy > Proces Policy > Proces Policy > Proces Policy > Proces Policy Adverses Policy Policy Adverses Policy Policy Adverses Policy Po	N Y N Y n n y n y n y n y n	1920283 The international experience in controlling pharmaceutical is expenditore. Influencing patients and providers and Lee NH, Bior K, Hewit C, Maynard A. 1920295 The effect of new pricing and corpurent schemes for pharmaceutical is insolution. Noncea. Lee NH, Bior K, Hewit C, Maynard A. 1920295 The effect of new pricing and corpurent schemes for pharmaceutical is insolution. Noncea. Lee NH, Bior K, Hewit C, Maynard A. 1920295 The effect of new pricing and corpurent schemes for the instress: current pricine and skause with works. Lee NH, Bior K, Hewit C, Maynard A. 1920286 The impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Lee YC, Yang MC, Huang YL, Lo CY, D. 1920286 The impact of octs containment strategies on pharmaceutical expenditures of the National Health Insurance in Lee YC, Yang MC, Huang YL, Lo CY, D. 1920290 Insert of National Scote on medicine prices a price comparison and LE Looped control. Lee NH, Bior K, Magner AK, Massler SD, Massler	Heath Serv Res Foliz, 2013 Am.20(1):53-9. doi: 10.1111/create date.2014/00(8) [first authorize H leath Folizy, 2013.10(1):14)-80. doi: 10.1016/j.hadi created date.2011/01(8) [first authorize H M. Ami Mang Care. 2012. Not: 13(1):16(1):461. doi:10.1016/j.hadi.created.40210/018 [first authorize L Vaular Heath.2015.10(1):16)-160. doi:10.1016/j.hadi.created.40210/018 [first authorize L Vaular Heath.2015.10(1):16)-160. doi:10.1016/j.hadi.created.40210/018 [first authorize H Vaular Heath.2015.10(1):16)-160. doi:10.1016/j.hadi.created.40210/018 [first authorize H Vaular Heath.2015.10(1):15)-60. doi:10.1016/j.judi.20 created.402103(1)/18 [first authorize H Vaular Heath.2015.10(1):15)-60. doi:10.1016/j.judi.20 created.402103(1)/18 [first authorizengoli C L]. Sonth Med Rev 2012 Dec:53313-44. Gu hz) 2012 Dec:27 created.4022.10(1)/2013 [first authorizengoli C value Heath.2015.10(1):15)-60. doi:10.1016/j.judi.20 created.4022.10(1)/2013 [first authorizengoli C value Heath.2015.10(1):15)-70.46 created.4022.10(1)/2013 [first authorizengoli C value Heath.2015 Judi.18):15:15-70.46 created.4022.10(1)/2013 [first authorizengoli C value Heath.2015 Judi.18):15:15:70.46 created.4022.10(1)/2013 [first authorizengoli C value Heath Rev.2015 Judi.18):15:15:74.46 created.4022.10(1)/2013 [first authorizengoli C value Heath.2015 Judi.18):15:15:74.46 created.4022.10(1)/2013 [first	06.08.2014 22 8.1.02011 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2016 22 2.0.02.2016 22 2.0.02.2016 22 2.0.02.2016 22 2.0.02.2018 22 2.0.02.2018 22 2.0.02.2018 22 2.0.02.2018 22 2.0.02.2018 22 2.0.02.2014 2.0.02 2.0.02.2014 2.0.02 2.0.02.2014 2.0.02 2.0.02.2014 2.0.02 2.0.02.2014 2.0.02 2.0.02.2014 2.0.02 2.0.02.2014 2.0.02 2.0.02.2014 2.0.02 2.0.02.2014 2.0.02 2.0.02.2014 2.0.02 2.0.02.2014 2.0.02 2.0.02.2014 2.0.02 2.0.02 2.0.02.2014 2.0.02 2.0
6 01108028 pubmed 7 20108028 pubmed 8 20108028 pubmed 2 20108078 pubmed 2 201080787 pubmed <t< td=""><td>Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y</td><td>Y Y Y Y Y</td><td>Y</td><td>N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Statistical analysis inductive from RECT/NR Statistical analysis inductive from RECT/NR</td><td>N Policy - Dependences N Policy - Proces P Policy - Proces P Policy - Proces P Policy (descriptive) P Policy (descriptive) P Policy (descriptive) P Policy (descriptive)</td><td>N Y N Y n n y n y n y n y n</td><td>502283 International experience in controlling pharmaceutical in expenditore. Influencing patients and providers and Lee Hi, Bloor K, Hewitt C, Maynard A. 502283 The effects of new pricing and consegures ischemes for pharmaceutical in stork forces. Lee Hi, Bloor K, Hewitt C, Maynard A. 502872 Anytematic review of reference pricing: implications for US prescription drug spending. Lee Hi, Bloor K, Hewitt C, Maynard A. 502872 Maynet and consegure inclusions for US prescription drug spending. Lee Hi, Bloor K, Hewitt C, Maynard A. 502872 Implicit of cost containment strategies on pharmaceutical in expending end that humanes in Lee YC, Jing KC, Hang YC, Li O L C. 5028720 They reserve in other conserve in end price price parameters of the National Health Immanes in Lee YC, Jing KC, Hang YC, Li O L C. 5028720 They reserve in other conserve in end price price in the United States - A National National Health Immanes in Lee States - A National Natio</td><td>Heath Siev Kes Folg, 2015 ana 20(1):52-9. doi: 10.1111/create date.2014/00(8) [first author:Lee H heath Neiky, 2012 and 2014 0-04. doi:10.1016/j.hadi create date.2011/01(8) [first author:Lee H heath Neiky, 2012 host 12(1):62-97. Review. reste date.2017/01[first author:Lee H heath Neiky, 2012 host 12(1):62-97. Review. reste date.2017/01[first author:Lee H heath Neiky, 2012 host 12(1):62-97. Review. reste date.2017/01[first author:Lee H heath Neiky, 2012 host 12(1):62-97. Review. reste date.2016/12(1):62-97. Review. reste date.2016/12(1):61-97. Review. Review. Review. reste date.2016/12(1):61-97. Review. Review.</td><td>06.08.2014 22 06.18.2013 22 06.12.2013 22 28.06.2014 22 29.06.2014 22 29.06.2014 22 29.06.2014 22 29.07.2015 22 20.07.2015 22 20.07.2015 22 21.07.2014 22 25.08.2015 22 21.02.0714 22 25.08.2015 22 21.02.0714 22 20.07.2014 22 20.07.2015 22 20.07.2014 22 20.07.2014 22 20.07.2014 22 20.07.2015 22 20.07.2014 22 20.07.2015 22 20</td></t<>	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y	Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Statistical analysis inductive from RECT/NR	N Policy - Dependences N Policy - Proces P Policy - Proces P Policy - Proces P Policy (descriptive) P Policy (descriptive) P Policy (descriptive) P Policy (descriptive)	N Y N Y n n y n y n y n y n	502283 International experience in controlling pharmaceutical in expenditore. Influencing patients and providers and Lee Hi, Bloor K, Hewitt C, Maynard A. 502283 The effects of new pricing and consegures ischemes for pharmaceutical in stork forces. Lee Hi, Bloor K, Hewitt C, Maynard A. 502872 Anytematic review of reference pricing: implications for US prescription drug spending. Lee Hi, Bloor K, Hewitt C, Maynard A. 502872 Maynet and consegure inclusions for US prescription drug spending. Lee Hi, Bloor K, Hewitt C, Maynard A. 502872 Implicit of cost containment strategies on pharmaceutical in expending end that humanes in Lee YC, Jing KC, Hang YC, Li O L C. 5028720 They reserve in other conserve in end price price parameters of the National Health Immanes in Lee YC, Jing KC, Hang YC, Li O L C. 5028720 They reserve in other conserve in end price price in the United States - A National National Health Immanes in Lee States - A National Natio	Heath Siev Kes Folg, 2015 ana 20(1):52-9. doi: 10.1111/create date.2014/00(8) [first author:Lee H heath Neiky, 2012 and 2014 0-04. doi:10.1016/j.hadi create date.2011/01(8) [first author:Lee H heath Neiky, 2012 host 12(1):62-97. Review. reste date.2017/01[first author:Lee H heath Neiky, 2012 host 12(1):62-97. Review. reste date.2017/01[first author:Lee H heath Neiky, 2012 host 12(1):62-97. Review. reste date.2017/01[first author:Lee H heath Neiky, 2012 host 12(1):62-97. Review. reste date.2016/12(1):62-97. Review. reste date.2016/12(1):61-97. Review. Review. Review. reste date.2016/12(1):61-97. Review.	06.08.2014 22 06.18.2013 22 06.12.2013 22 28.06.2014 22 29.06.2014 22 29.06.2014 22 29.06.2014 22 29.07.2015 22 20.07.2015 22 20.07.2015 22 21.07.2014 22 25.08.2015 22 21.02.0714 22 25.08.2015 22 21.02.0714 22 20.07.2014 22 20.07.2015 22 20.07.2014 22 20.07.2014 22 20.07.2014 22 20.07.2015 22 20.07.2014 22 20.07.2015 22 20
0 0108828 pulmed 0108828 pulmed 0108828 pulmed 0108828 pulmed 0108828 pulmed 11 0108828 pulmed 0108828 0108828 pulmed 0108828 pulmed 0 0108828 pulmed 0108828 0 0108928 pulmed 0108828 0 0108928 pulmed 0108828 0 0108928 pulmed 0108827 0 0108827 meline 0108827	y y y y y y y y y y y y y y y y y y y	y y y y y	¥ ¥	N Systematic Review Systematic Review N Systematic Review N Systematic Review Systematic Review Systematic analysis - inductive (not RC/I/IR Statistical analysis - inductive (not RC/I/IR Statistical analysis - descriptive Statistical analysis - descriptive Systematic analysis -	N Policy - Expenditures N Policy - Avers Policy - Proces P P Policy - Proces P P Policy - Proces P P P Policy - Proces P P P P P P P P P P P P P P P P P P P	N Y N Y n n y n y n y n y n	502283 International experience in controlling pharmaceutical isogenditure. Influencing patients and providers and Lee NL, Biorr K, Hewit C, Maynard A. 5022863 The effect of new pricing and coopyment schemes for pharmaceutical isolation for access the involution of the schemic Maynard A. 502876 Media Coopyment schemes for pharmaceutical isolation for access the involution of the schemic Maynard A. 502876 Media Coopyment schemes for the involution of the schemic and skause with access the involution of the schemic Maynard A. 502887 Media Coopyment schemes for the involution of the schemic Maynard A. 502887 Media Coopyment schemes for the schemic maynary schemic and skause with where its coopyment schemes for the schemic Maynard A. 502887 Ministry schemic Maynard A. 5029887 Ministry schemic Maynard A. 502988787 Ministry schemic Maynard A. 50298879788 Ministry schemic Maynard A. 5029887 Ministry schemic Maynard A. 5029887 Ministry schemic Maynard A. 5029887 Ministry schemic Maynard A.	Heath Serv Res Foliz, 2013 Am.20(1):53-9. doi: 10.1111/create date.2014/00(8) [fint authorize H Heath Pelicy. 2013 an:01(1):40-9. doi: 10.1016/j.hadi/created.edu211/01/8 [fint authorize H M, Am/ Mang Care. 2012 Not:131(1):46-03-7. Review. create date.2013/01/91 [fint authorize L Value Heath.2013 Not:131(1):46-03-7. Review. create date.2013/01/91 [fint authorize H M, Am/ Mang Care. 2012 Not:131(1):46-03-7. Review. create date.2013/01/91 [fint authorize H M, Am/ Mang Care. 2012 Not:131(1):46-03-7. Review. Create date.2013/01/91 [fint authorize H M, Am/ Mang Care.2012 Not:131(1):46-03-9. Review. et al. Samt Med. 2016 Not:131(1):46-03-03. Review. et al. Samt Med. 2016 Not:131(1):46-03. Review. et al. Samt Med. 2016 Not:131(1):46-03. Review. et al. Samt Med. 2016 Not:131(1):46-03. Review. et al. Samt Med. 2016 Not:131:46-03. Review. et al. Samt Med. 2016 Not:131(1):46-03. Review. et al. Samt Med. 2016 Not:131(1):46-03. Review. et al. Samt Med. 2016 Not:131:46-03. Review. et al. 2016 Not:131:46-03. Review.	06.08.2014 22 81.10.2011 22 20.62.2014 22 20.62.2014 22 20.63.2005 22 20.63.2005 22 20.03.2005 22 20.03.2016 22 20.03.2016 22 20.03.2016 22 20.03.2013 22 20.03.2014 22 20.03.2014 22 20.07.2015 22 20.07.2014 22 20.07.2015 22 20.07.2014 22 20.07.2014 22 20.07.2014 22 20.07.2014 22 20.07.2014 22 20.07.2014 22 20.07.2014 22 20.07.2014 22 20.07.2014 22 20.07.2015 22 20.07.2014 22 20.07.2015 22 20.07.
0 0108828 pubmed 0 0108918 pubmed 0 0108918 pubmed 1 0108918 pubmed 1 0108918 pubmed 1 0208927 meline 1 0208927 meline 1 0208927 meline	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	y y y y y y	Y Y	N Systematic Review Systematic Review N Systematic Review N Satistical analysis - inductive (not RCT/NR Satist	Ν Policy > Dependences Ν Policy > Prices Υ Policy > Molicine*** γ Policy > Prices	N Y N Y n n n n y n y n n n n n n n n	502283 International experience in controlling pharmaceutical expenditore. Influencing patients and providers and Lee NH, Bior K, Hewitt C, Maynard A. 502283 The effects of new pricing and consequence storage and principal influencing spending. Lee NH, Bior K, Hewitt C, Maynard A. 502875 Micro Start Constraints and Start	Heath Reiv, 2012. And 2012 Additional and 2012 certification of the control of t	06.08.2014 22 8.1.02011 22 2.0.6.2014 22 2.0.6.2014 22 2.0.6.2014 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2011 22 2.0.0.2011 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22 2.0.0015 22
0 0100820 pubmed 0 0100830 pubmed 0 0008007 medine 0 000	Y Y	¥ ¥ ¥ ¥	Y	N Systematic Review Systematic Review N Systematic Review N Systematic Review Systematic Review Systematic analysis - inductive (not RC//NR Systematic ana	N Policy - Expenditures N Policy - Avera Policy - Proces P Policy - Proces P Policy - Proces P Policy - Wolfare*** P Policy - Wolfare*** P Policy (descriptive) P Policy - Proces P Policy (descriptive) P Policy - Proces	N Y N Y n n y n y n y n y n y n y n	1920283 The international experience in controlling pharmaceutical isogendators. Influencing patients and providers and Lee NH, Biorr K, Hewitt C, Maynard A. 1920295 The effect of new pricing and corpurent schemes for pharmaceutical isofaxion forces. Lee NH, Biorr K, Hewitt C, Maynard A. 1920295 The effect of new pricing and corpurent schemes for pharmaceutical isofaxion forces. Lee NH, Biorr K, Hewitt C, Maynard A. 1920296 The effect of new pricing and corpus manaceutical expendition. Forces. Level Partice and Assume What Schemett C, Maynard KA, Shandes JD. 1920286 The impact of cost containment strategies on pharmaceutical and schemet What on access to innovate. Lengt MP, Roland AK, Shandes JD. 1920287 The impact of cost containment strategies on pharmaceutical and scherk review yearon access to innovate. Lengt MP, Roland KA, Shandes JD. 1920287 Their scheme and incre efference probabilis corpus and increasive man more L4 Guoropan contrille: Leopoid C, Anather JB, Wagner AG. 1920298 Their scheme and incre efference probabilis corpus and increasive man more latic corpoan controlle: Leopoid C, Martle Telewavise AK, Vojd 19203400 Differences in celebrating to force acception conview. Leopoid C, Vogle Y, Shutt MH Telewavise AK, Vojd 19203400 Differences in celebrating in force acception conview. Leopoid C, Vogle Y, Shutt MH Telewavise AK, Vojd 19203400 Differences in celebrating in theit	Heath Serv Mes Foliz, 2013 ana/2013-28. doi: 10.1111/create date:2014/W08 [first author:Lee H eath Vielky. 2013;20:104114-09. doi: 10.1116/j.hadd1 create date:2013/W18 [first author:Lee H meath Vielky. 2013;20:104114-09. doi: 10.1116/j.hadd1 create date:2013/W18 [first author:Lee H meath Vielky. 2013;20:104114-09. doi: 10.1116/j.hadd1 create date:2013/W18 [first author:Lee H meath Vielky. 2013;20:104114-09. doi: 10.2116/j.hadd1 create date:2013/W18 [first author:Lee H meath Vielky. 2013;20:104114-09. doi: 10.2116/j.hadd1 create date:2013/W18 [first author:Lee H meath Vielky. 2013;20:104114-01. doi: 10.2116/j.hadd1 create date:2013/W18 [first author:Lee H Mest J. 2016 Mer 17;050(H);40:20 create date:2013/W18 [first author:Leegold C k, Sont Med Rev. 2012;20:cc;27:31-44. Equi 2012;20:cc; 7: create date:2013/W18 [first author:Leegold C k, Sont Med Rev. 2012;20:cc;27:31-44. Equi 2012;20:cc; 7: create date:2013/W18 [first author:Leegold C k, Sont Med Rev. 2012;20:cc;27:31-44. Equi 2012;20:cc; 7: create date:2013/W18 [first author:Leegold C k, Sont Med Rev. 2012;20:cc;27:31-44. Equi 2012;20:cc; 7: create date:2013/W18 [first author:Leegold C k, Sont Med Rev. 2012;20:cc;27:31-44. Equi 2012;20:cc; 7: create date:2013/W18 [first author:Leegold C k, Sont Med Rev. 2012;20:cc;27:31-44. Equi 2012;20:cc; 7: create date:2013/W18 [first author:Leegold C k, Sont Med Rev. 2012;20:cc;27:31-46. doi: 10.1016/j.j.pacc; Create date:2013/W178 [first author:Leegold C k, Auth Health. 2013;14:21:42. doi: 10.1016/j.j.pacc; Create date:2013/W178 [first author:Leegold C k, Create date:2014;179 [first author:Leegold C k, Create date:2014;17	06.08.2014 22 81.10.2011 22 20.62.2014 22 20.62.2014 22 20.02.2016 22 20.02.2016 22 20.02.2016 22 20.03.2016 22 20.03.2016 22 20.03.2016 22 20.03.2018 22 21.03.2014 22 21.03.2015 22 21.03.2015 22 20.03.2015 22 20.03.2015 22 20.03.2015 22 20.03.2015 22 20.03.2015 22 20.03.2015 22 20.03.2015 22 20.03.2014 22 20.03.2014 22 20.03.2014 22 20.03.2014 22 20.03.2015 22 20.03.2014 22 20.03.2015 22 20.03.2015 22 20.03.2014 22 20.03.2015 22 20.03.2014 22 20.03.2015 22 20.03.2014 22 20.03.2015 22 20.03.2015 22 20.03.2014 22 20.03.2015 22 20.03.2016 22 20.03.
6 01108826 pubmed 7 01108826 pubmed 7 01108826 pubmed 2 01108816 pubmed 2 01108817 pubmed 2 011088827 medine <t< td=""><td>Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y</td><td>¥ ¥ ¥ ¥ ¥</td><td>Y</td><td>N Systematic Review Systematic Review Systematic Review Systematic Review Statistical analysis - inductive (not RCT/NR Statistical analysis - inductive (not RCT/NR Statistical analysis - inductive (not RCT/NR Statistical analysis - descriptive Statistical analy</td><td>N Policy > Dependences N Policy > Prices Policy > Prices Policy > Spendences Policy > Spendences Policy (descriptive) Policy (descriptive) Policy (descriptive) Policy (descriptive) Policy > Welfarge*** Policy (descriptive) Policy > Policy > Prices Policy (descriptive) Policy > Policy > Prices Policy (descriptive) Policy = Prices Pol</td><td>N Y N Y n n y n y n y n n y n</td><td>1920283 The intervational experience in controlling pharmaceutical is expenditore. Influencing patients and providers and Lee NH, Bior K, Hewit C, Maynard A. 1920295 The effects of new princing and consumers schemes for pharmaceutical is insoft horeas. Lee NH, Bior K, Hewit C, Maynard A. 1920295 The effects of new princing and consumers schemes for pharmaceutical is insoft horeas. Lee NH, Bior K, Hewit C, Maynard A. 1920296 Mediad device reinhousement coverage and princing runs forces: current prince and assum with most cover and princing runs forces and scars with most cover and scars. Lee NH, Bior K, Hewit C, Maynard A. 1920286 The impact of acts containment strategies on pharmaceutical is paid and scals. New your on Thirties. Leg NH, Ficher MA, Shanka KM, Sahaka SM, Sahaka SM,</td><td>Heath Neiko, 2021. and 2015 Adv. 2015 (Adv. 2015) Adv. 2015 (Adv.</td><td>06.08.2014 22 8.1.02011 22 2.0.6.2014 22 2.0.6.2014 22 2.0.6.2014 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.1.0.2014 22 2.1.0.2014 22 2.1.0.2014 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2014 22 2.0.0.2015 22 2.0.0.2014 2.0.0.2014 2.0.00</td></t<>	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	¥ ¥ ¥ ¥ ¥	Y	N Systematic Review Systematic Review Systematic Review Systematic Review Statistical analysis - inductive (not RCT/NR Statistical analysis - inductive (not RCT/NR Statistical analysis - inductive (not RCT/NR Statistical analysis - descriptive Statistical analy	N Policy > Dependences N Policy > Prices Policy > Prices Policy > Spendences Policy > Spendences Policy (descriptive) Policy (descriptive) Policy (descriptive) Policy (descriptive) Policy > Welfarge*** Policy (descriptive) Policy > Policy > Prices Policy (descriptive) Policy > Policy > Prices Policy (descriptive) Policy = Prices Pol	N Y N Y n n y n y n y n n y n	1920283 The intervational experience in controlling pharmaceutical is expenditore. Influencing patients and providers and Lee NH, Bior K, Hewit C, Maynard A. 1920295 The effects of new princing and consumers schemes for pharmaceutical is insoft horeas. Lee NH, Bior K, Hewit C, Maynard A. 1920295 The effects of new princing and consumers schemes for pharmaceutical is insoft horeas. Lee NH, Bior K, Hewit C, Maynard A. 1920296 Mediad device reinhousement coverage and princing runs forces: current prince and assum with most cover and princing runs forces and scars with most cover and scars. Lee NH, Bior K, Hewit C, Maynard A. 1920286 The impact of acts containment strategies on pharmaceutical is paid and scals. New your on Thirties. Leg NH, Ficher MA, Shanka KM, Sahaka SM,	Heath Neiko, 2021. and 2015 Adv. 2015 (Adv. 2015) Adv. 2015 (Adv.	06.08.2014 22 8.1.02011 22 2.0.6.2014 22 2.0.6.2014 22 2.0.6.2014 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.1.0.2014 22 2.1.0.2014 22 2.1.0.2014 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2014 22 2.0.0.2015 22 2.0.0.2014 2.0.0.2014 2.0.00
0 0110820 pubmed 0 0110820 pubmed 0 0110820 pubmed 1 0110820 pubmed 2 0100510 pubmed 2 0100502 pubmed 2 0100503 pubmed 2 0100503 pubmed 2 0100503 pubmed 2 0100504 pubmed 2 0100505 pubmed 2 0100505 pubmed 2 0100507 pubmed 2 0100507 pubmed 2 0100507 meline 2 0100507 meline 2 0100507 meline 2 0100507 pubmed 2 0100507 pubmed 2 010	, a	¥ ¥ ¥ ¥ ¥	Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Statistical analysis - inductive from RC2/NR Statistical analysis - inductive from RC2/NR Statistical analysis - inductive Statistical anal	N Policy - Dependences N Policy - Poes P Policy - Poes P Policy - Poes P Policy - Poes P Policy (descriptive)	N Y N Y n n n n y n y n n n n n n n n y n	502283 International experience in controlling pharmaceutical in expenditors: Influencing patients and providers and Lee Hi, Bloor K, Hewitt C, Maynard A. 502283 The effects of new pricing and consegures ischemes for pharmaceutical in south forces. Lee Hi, Bloor K, Hewitt C, Maynard A. 502872 March effects environment concernage and princip inprice in forces and source with an environment concernage and princip inprice and source with an environment concernage and princip inprice and force with the source and source and source with the source and source and source with the source	Heath Siev Ves Foliz, 2013 ana 20(1):52.4. doi: 10.1111/create date:2014/00(6) [fint author:Lee H heath Neiko, 2012 and 2014 0-0-0. doi:10.1016/h.hadi create date:2011/10/10 [fint author:Lee H heath Neiko, 2012 and 2014 0-0-0. doi:10.1016/h.hadi create date:2011/10/10 [fint author:Lee H heath Neiko, 2012 and 2014 0-0-0. doi:10.1016/h.hadi create date:2014/10/10 [fint author:Lee H heath Neiko, 2012 and 2014 0-0-0. doi:10.1016/h.hadi create date:2016/10/10 [fint author:Lee H heath Neiko, 2013 and 2014 0-0-0. doi:10.1016/hudi create date:2016/10/10 [fint author:Lee H heath Neiko, 2013 and 2014 0-0-0. doi:10.1016/hudi create date:2016/10/10 [fint author:Lee H heath Neiko, 2013 Dec;131313-12. doi:10.1016/hudi create date:2016/10/10 [fint author:Leegodd C had teah. 2013 Dec;131313-12. doi:10.1016/hudi create date:2016/10/10 [fint author:Leegodd C had teah. 2013 Duc;131313-12. doi:10.1016/hudi create date:2016/10/10 [fint author:Leegodd C had teah. 2013 Duc;131313-12. doi:10.1016/hudi create date:2016/10/10 [fint author:Leegodd C had teah. 2013 Duc;131313-12. doi:10.1016/hudi create date:2016/10/10 [fint author:Leegodd C had teah. 2013 Duc;131313-12. doi:10.1016/hudi create date:2016/10/10 [fint author:Leegodd C had teah. 2013 Duc;131313-12. doi:10.1016/hudi create date:2016/10/10 [fint author:Leegodd C had teah. 2013 Duc;131313-12. doi:10.1016/hudi create date:2016/10/10 [fint author:Leegodd C had teah. 2015 Author:Leegodd C had teah. 2013 Duc;13131-12. doi:10.1016/hudi create date:2016/10/10 [fint author:Leegodd C had teah. 2013 Duc;1313-12. doi:10.1016/hudi create date:2016/10/10 [fint author:Leegodd C had teah. 2013 Duc;1313-12. doi:10.1016/hudi create date:2016/10/10 [fint author:Leegodd C had teah. 2014 Author:Leegodd C had teah	06.08.2014 22 06.08.2014 22 06.02.2011 22 28.06.2014 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2015 23 20.02.2014 23 20.02.2014 23 22.08.2015 24 10.02.2014 23 22.08.2015 24 10.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 20.02.2014 2
0 0108828 pubmed 0108828 pubmed 0108828 0108828 pubmed 0108827 0108827 meline 0108827 0108827 pubmed 0108827	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	y y y y y y y y y y y y y y y y y y y	Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not RC/I/NR Systematic analysis - inductive (not RC/I/NR Systematic analysis - descriptive Systematic analysis - descri	N Policy - Dependences N Policy - Poes Policy - Poes Policy - Poes Policy - Poes Policy Lessophile Policy - Poes Policy - Policy - Poes Policy - Policy - Poes Policy - Policy - Poes Policy - Poes Policy - Poes Policy - Policy - Poes Policy - Poes Policy - Po	N Y N Y n n y n y n y n y n y n y n	1920283 International experience in controlling pharmaceutical isopendium: influencing patients and providers and Lee NL, Bloor K, Hewit C, Maynard A. 1920295 The effects of new pricing and corpusment schemes for pharmaceutical is hown for an access of more increment of the Net Corpus of the Net	Health Serv Res Folia, 2013 ana/2013-29. doi:10.1016/healt create date.2014/2016 [Inst author:Lee H Health Neiz, 2012. Not 31:0113-04:00.10156/healt create date.2011/2016 [Inst author:Lee H M, Ami Mang Care, 2012. Not 31:0113-04:01.01056/healt create date.2013/2016 [Inst author:Lee H M, Ami Mang Care, 2012. Not 31:0113-04:01.01056/healt create date.2013/2016 [Inst author:Lee L Value Health.2015. Not 31:0113-64: doi:10.1016/j.jud2: Create date.2013/2016 [Inst author:Lee H M, Ami Mealth Rev. 2015 [Inst 31:013-64: doi:10.1016/j.jud2: Create date.2013/2016 [Inst author:Lee N Value Health.2015 [Inst 31:013-64: doi:10.1016/j.jud2: Create date.2013/2016 [Inst author:Lee N Value Health.2015 [Inst 31:013-64: doi:10.1016/j.jud2: Create date.2013/2016 [Inst author:Lee N Value Health.2015 [Inst 31:013-64: doi:10.1016/j.jud2: Create date.2013/2016 [Inst author:Lee N Value Health.2015 [Inst 31:013-64: doi:10.1016/j.jud2: Create date.2013/2016 [Inst author:Lee N Value Health Neiz, 2015 (Inst 30:013-85: doi:10.1016/j.jud2: Create date.2013/2016 [Inst author:Lee N Value Health Neiz, 2015 (Inst 30:013-85: doi:10.1016/j.jud2: Create date.2013/2016 [Inst author:Lee N Value Health Neiz, 2015 (Inst 30:013-85: doi:10.1016/j.jud2: Create date.2013/2016 [Inst author:Lee N Value Health Neiz, 2015 (Inst 30:013-85: doi:10.1016/j.jud2: Create date.2013/2016 [Inst author:Lee N Value Health Neiz, 2015 (Inst 30:013-85: doi:10.1016/j.jud2: Create date.2013/2016 [Inst author:Lee N Value Health Neiz, 2016 (Inst 30:013-85: doi:10.1016/j.jud2: Create date.2013/2017 [Inst author:Lee N C, Soi:Si Med.2014/2016 [Inst 30:013-85: doi:10.1016/j.jud2: Create date.2013/2017 [Inst author:Lee N C, Soi:Si Med.2014/2016 [Inst 30:01:01:01/2016 [Inst 30:01:01:01/2016 [Inst 30:01:01:01/2016 [Inst 30:01:01:01/2016 [Inst 30:01:01/2016 [Inst 30:01:01:01/2016 [Inst 30:01:01:01/2016 [Inst 30:01:01/2016 [Inst 30:01:01:01/2016 [Inst 30:01:01/2016 [Ins	06.08.2014 22 8.10.2011 22 2.06.2014 22 2.06.2014 22 2.06.2014 22 2.06.2016 22 2.00.2016 22 2.00.2016 22 2.00.2016 22 2.00.2016 22 2.00.2016 22 2.00.2016 22 2.00.2016 22 2.00.2016 22 2.00.2016 22 2.00.2016 22 2.00.2016 22 2.00.2016 22 2.00.2016 22 2.00.2016 22 2.00.2014 22 2.0012 22 2.0
0 0108828 pubmed 0210828 pubmed<	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y		y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive fron PCT/NR Statistical analysis - inductive fron PCT/NR Statistical analysis - descriptive Statistical analysis - descriptive Systematical systematic	N Policy > Dependences N Policy > Prices Y Policy > Volicine*** Y Policy > Volicine*** Y Policy > Prices Y Policy > Prices Y Policy > Prices	N Y N Y n n y n n y n y n	502283 International experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee Hi, Bloor K, Hewitt C, Maynard A. 502283 The effects of new pricing and consequence storage and principation drug spending. Lee Hi, Bloor K, Hewitt C, Maynard A. 502875 Micro Televice insthumement concernage and principations in Kores. Lee Hi, Bloor K, Hewitt C, Maynard A. 502872 Micro Televice insthumement concernage and principa ingrines for the National Hewitt Instance: In Lee TC, Tang MG, Haung TJ, Li O'L CD. 5028720 They resonance in the concerner concernage and principa ingrines of the National Hewitt Instance: In Lee TC, Tang MG, Haung TJ, Li O'L CD. 5028720 They resonance in the concerner concernage and principa ingrines for the National Hewitt Instance: In Lee TC, Tang MG, Haung TJ, Li O'L CD. 5028720 They resonance interacting in the organ calce principa ingrine ingrindia ingrine ingrine ingrindia ingrine ingrine ingri	Heath Neiko, 2021 and 2014 an	06.08.2014 22 8.1.02011 22 2.0.62.2014 22 2.0.62.2014 22 2.0.62.2014 22 2.0.62.2016 22 2.0.02.2016 22 2.0.02.2016 22 2.0.02.2016 22 2.0.02.2016 22 2.0.02.2016 22 2.0.02.2011 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2014 22 2.0.02.2015 22 2.0.02.20
0 0108020 pubmed 0 0108030 pubmed 0 0108030 pubmed 0 0108030 pubmed 0 0108030 medine 0 010	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	¥ ¥ ¥ ¥ ¥ ¥ ¥	Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not RC//NR Statistical analysis - inductive (not RC//NR Statistical analysis - descriptive Statistical analysis - descriptive Statistical analysis - descriptive Systematical a	N Policy - Expenditures N Policy - Proces P Policy - Proces P Policy - Proces P Policy - Proces P Policy (descriptive)	N Y N Y n n y n y n y n y n y n	502283 International experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee Hi, Bloor K, Hewitt C, Maynard A. 502287 Therefore for every roigs and consequence schemes for the prescription drug spending. Lee Hi, Bloor K, Hewitt C, Maynard A. 502878 Marcia Consequence schemes and princing units forces: current principa and space schemes. Lee Hi, Bloor K, Hewitt C, Maynard A. 502879 Medical device insthus-memor consequence and princing units forces: current principa and space schemes. Lee Hi, Bloor K, Hewitt C, Maynard A. 502879 Their operator of the Medical currence on principa and principa	Heath Serv Res Folg, 2015 an:20(1):52-9. doi: 10.1112 create date:2014/00(8) Instantor-tee H Heath Viely, 2012 an:01(1):40-9. doi: 10.1016/j.hadi create date:2011/01(1) Instantor-tee H Am J Meang Cee, 2012 Nor L12(1):42-93-7. Nerview, create date:2011/01(1) Instantor-tee H Mark J Meang Cee, 2012 Nor L12(1):42-93-7. Nerview, create date:2011/01(1) Instantor-tee H Mark J Meang Cee, 2012 Nor L12(1):42-93-7. Nerview, create date:2011/01(1) Instantor-tee H Mark J Meang Cee, 2012 Nor L12(1):42-93-7. Nerview, create date:2012 Nor L12(1):43-93-7. Nerview, create date:2015/01/21 Instantor-tee H Pharmacoccocomous 2002;49(9):890-1005/pluid 20 create date:2015/01/21 Instantor-tee N SAM Med Rev. 2022 Dec;52(3):44-1. Epub 2012 Dec; 27. create date:2015/01/21 Instantor-teepold C Li, Sonth Med Rev. 2012 Dec;13(3):13-92. create date:2015/01/21 Instantor-teepold C Value Health. 2013 Dec;13(3):13-92. create date:2015/01/21 Instantor-teepold C Adm Folge Molt, Molta Dec;13(1):410-000 Dec;13(1):410-000 Instantor-teepold C Adm Folge Molta Dec;13(1):411-191-000 Dec;13(1):410-000 Instantor-teepold C Adm Folge Molta Dec;13(1):411-191-000 Create date:2011/01/21 Instantor-teepold C Adm Folge Molta Molta: Molta:00-000 Oct 10.010/1/1000 Creat	06.08.2014 22 81.10.2011 22 2.06.2014 22 2.06.2014 22 2.06.2014 22 2.06.2016 22 2.01.09.2006 22 2.01.2016 22 2.01.2016 22 2.01.2016 22 2.01.2014 2.0114 22 2.0114 2.014 22 2.0114 2.014 2.0
0 0108828 pubmed 0 0108918 pubmed 0 0108918 pubmed 0 0108918 pubmed 0 0108918 pubmed 1 0108928 pubmed 1 010	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y		Y Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not RCT/NR Systematic analysis - inductive (not	N Policy - Dependences N Policy - Prices Policy - Prices Policy - Specializes Policy - Specializes Policy (descriptive) Policy (descrip	N Y N Y n n y n y n n n n n y n	1923283 International experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee IN, Bior K, Hewit C, Maynard A. 1923295 The effects of new pricing and consumers schemes for pharmaceutical in softwohr fores. Lee IN, Bior K, Hewit C, Maynard A. 1933297 Effect of new pricing and consumers schemes for pharmaceutical in softwohr fores. Lee IN, Bior K, Hewit C, Maynard A. 1934297 Anyternatic review of reference pricing: implications for US prescription drug spending. Lee IN, Bior K, Hewit C, Maynard A. 1934210 The impacts of cast containment strategies on pharmaceutical in a local dist-cal a scaw with more in Lee ST, Shade AM, Shankes XD, Shade SJ, Sha	Heath Neik, 2021. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee H heath Neik, 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee H heath Neik, 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee B water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee B water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee B water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee B water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee B water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee B water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee B water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 13105(heat) create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 12105/heat. Create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 12105/heat. Create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 12105/heat. Create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Not 12105/heat. Create date 2021/00(8) [Instantor-tee gM Water Medh. 2021. Sol 12102. Not 10. Sol 10. Sol 10(100(1)(1) [Instantor-tee hateree 1011/10(1) [I	06.08.2014 22 8.1.0.2011 22 2.0.6.2014 22 2.0.6.2014 22 2.0.6.2014 22 2.0.0.2040 21 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2014 22 2.0.0.2015 22 2.0.0.2014 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2014 22 2.0.0.2015 22 2.0.0.2014 22 2.0.0.2015 22 2.0.0.2015 22 2.0.0.2014 22 2.0.0.2015 22 2.0.0.2014 22 2.0.0.2015 22 2.0.0.2014 22 2.0.0.2015 22 2.0.0.2014 22 2.0.001 22
0 0108828 pubmed 0 0108828 pubmed 0 0108828 pubmed 1 0108828 pubmed 2 0108918 pubmed 2 0108917 meline 2 0108927 pubmed 2 0108927 pubmed 2 0206928 pubmed 2 0206928 pubmed 2 0206928 pubmed 2 020	Y Y Y	¥ ¥ ¥ ¥ ¥ ¥ ¥	Y	N Systematic Review Statistical analysis - inductive from NCC/NR Systematical analysis - inductive from SCC/NR Systematical analysis - inductive	N Policy - Dependences N Policy - Proces Y Policy - Proces Y Policy - Proces Y Policy - Proces Y Policy (descriptive)	N Y N Y N Y N Y N N Y N N N N N N	192283 International experience in controlling pharmaceutical in expenditors. Influencing patients and providers and Lee Hi, Bloor K, Hewitt C, Maynard A. 1928724 Other of the experision and comparent schemes for patients in forces. current or prices and comparing the influencing appendix. Lee Hi, Bloor K, Hewitt C, Maynard A. 1928725 Medication in the experision of comparent schemes for patients in forces. current prices and scalars with the schemes in the experision of the patients of the schemes and price market in the schemes and patient price market and schemes with the schemes in the scheschemes in the schemes in the schemes in the schemes	Heath Serv Res Folg, 2013 ana 20(1):53:4. doi: 10.1016/j.heati create date:2011/2016 Instantor-tee H Heath Neiko, 2013 ana 2013 As doi: 10.1016/j.heati create date:2011/2016 Instantor-tee H Mark Manag Care, 2013 Nov 11,2013 (J.heat) create date:2011/2016 Instantor-tee H Mark Manag Care, 2013 Nov 11,2013 (J.heat) create date:2011/2016 Instantor-tee H Mark Manag Care, 2013 Nov 11,2013 (J.heat) create date:2011/2016 Instantor-tee H Pharmacocconcomposition Constantor-tee H Instantor-tee H Pharmacocconcomposition Constantor-tee H Instantor-tee H SAM Med J. 2016 Mar 17,056(1):456, doi: 10.7365(2)MAC create date:2016(7/2) (Finst author-tee)GIC Instantor-tee)GIC Li, South Med Rev, 2012 Dec;137,131:42. Create date:2016(7/2) (Finst author-tee)GIC instantor-tee)GIC instantor-tee)GIC Value Health, 2013 Ling 10;34:53:43:13:122 Create date:2016(7/2) (Finst author-tee)GIC instantor-tee)GIC Value Health, 2013 Ling 10;34:53:43:13:122 Create date:2016(7/2) (Finst author-tee)GIC instantor-tee)GIC Value Health, 2013 Ling 10;34:53:43:43:43:43:43:43:44:44:44:44:44:44:44	06.08.2014 22 06.08.2014 22 06.02.2011 22 28.06.2014 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2015 23 20.02.2014 23 20.02.2014 23 22.08.2015 24 14.09.2015 24 14.09.2015 24 14.09.2015 24 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 20.02.2014 20.02.2014 20.02.2014 20.02.2014 20.02.2014 20.02.2014 20.02.2014 20.02.2014 20.02.2014 20.02.201 20.02.2014 20.02.
0 0.000320 pubmed 1 0.000320 pubmed <td< td=""><td>Y Y Y Y Y</td><td>× 2 2 2</td><td>y y</td><td>N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not RC/IVIR Systematic analysis - inductive (not RC/IVIR Statistical analysis - descriptive Systematic analysis - descr</td><td>N Policy > Dependences N Policy > Poess P Policy > Poess P Policy > Poess P Policy > Mediates P Policy (descriptive) P Policy > Welfare*** P Policy > Mediate*** P Policy > Poess P Policy = Poess P Po</td><td>N Y N Y n n y n y n n n n y n</td><td>1920283 The intervational experience in controlling pharmaceutical is expenditore. Influencing patients and providers and Lee HI, Bloor K, Hewit C, Maynard A. 1920295 The effects of new princing and consymmers stremes for pharmaceutical is hown for an access the involvement of the material constraints of the stream stream stress of the stream strea</td><td>Heath Reiv, 2013. and 2013. Set of the set</td><td>06.08.2014 22 81.10.2011 22 24.06.2014 22 24.06.2014 22 24.06.2016 22 24.01.2016 22 24.01.2016 24 24.01.2016 24 24.01.2011 24 24.01.2011 24 24.01.2011 24 25.08.2015 24 24.01.2011 25 25.08.2015 24 24.01.2014 25 25.08.2015 24 26.01.2014 25 26.02.201 26.02.201 26.02 26.02.201 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02 26.02.201 26.02 26.0</td></td<>	Y Y Y Y Y	× 2 2 2	y y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not RC/IVIR Systematic analysis - inductive (not RC/IVIR Statistical analysis - descriptive Systematic analysis - descr	N Policy > Dependences N Policy > Poess P Policy > Poess P Policy > Poess P Policy > Mediates P Policy (descriptive) P Policy > Welfare*** P Policy > Mediate*** P Policy > Poess P Policy = Poess P Po	N Y N Y n n y n y n n n n y n	1920283 The intervational experience in controlling pharmaceutical is expenditore. Influencing patients and providers and Lee HI, Bloor K, Hewit C, Maynard A. 1920295 The effects of new princing and consymmers stremes for pharmaceutical is hown for an access the involvement of the material constraints of the stream stream stress of the stream strea	Heath Reiv, 2013. and 2013. Set of the set	06.08.2014 22 81.10.2011 22 24.06.2014 22 24.06.2014 22 24.06.2016 22 24.01.2016 22 24.01.2016 24 24.01.2016 24 24.01.2011 24 24.01.2011 24 24.01.2011 24 25.08.2015 24 24.01.2011 25 25.08.2015 24 24.01.2014 25 25.08.2015 24 26.01.2014 25 26.02.201 26.02.201 26.02 26.02.201 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02.201 26.02 26.02 26.02.201 26.02 26.0
0 0108828 pubmed 0 0108828 pubmed 0 0108828 pubmed 1 0108828 pubmed 2 01089828 pubmed 2 01089818 pubmed 2 </td <td></td> <td>v v v v v</td> <td>Y Y</td> <td>N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Statistical analysis - inductive (not RCT/NR Systematical analysis - inductive (not RCT/NR Systematical analysis - descriptive Systematical analysis - des</td> <td>N Policy > Dependences N Policy > Prices Y Policy > Molicae*** Y Policy > Molicae*** Y Policy > Prices Y Policy > Prices Y Policy and Policae*** Y Policae*** Y Policae*** Y Policae***</td> <td>N Y N Y n n y n n y n y n</td> <td>1923283 International experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee Hi, Bloor K, Hewitt C, Maynard A. 1923297 International experience in controlling pharmaceutical in synth forms. Lee Hi, Bloor K, Hewitt C, Maynard A. 1923297 International experience in controlling pharmaceutical in synth forms. Lee Hi, Bloor K, Hewitt C, Maynard A. 1923297 Anyternatic review of reference princip: implications for US prescription drug spending. Lee Hi, Bloor K, Hewitt C, Maynard A. 1923220 They reference princip: implications for US prescription drug spending. Lee S, Salade Lee</td> <td>Heath Serv Kes Folg, 2013 Am 20(1):53-9. doi: 10.1016/heati create date:2014/2016 [Inst author:Lee H heath Neiky, 2012 and 2014 ob 49. doi:10.1016/heati create date:2011/2016 [Inst author:Lee H heath Neiky, 2012 and 2014 ob 49. doi:10.1016/heati create date:2011/2016 [Inst author:Lee H heath Neiky, 2012 and 2014 ob 49. doi:10.1016/heati create date:2016/12016 [Inst author:Lee H heath Neiky, 2013 and 2014 ob 49. doi:10.1016/heati create date:2016/12016 [Inst author:Lee H heath Neiky, 2013 and 2014 ob 49. doi:10.1016/heati create date:2016/12016 [Inst author:Lee H heath Neiky, 2013 Dec;1313]13-22. doi:10.1016/heati create date:2016/12016 [Inst author:Lee gold C kylae Heath. 2015 Audit 2015 ob 40. doi:10.1016/hylae2 create date:2016/12016 [Inst author:Lee gold C kylae Heath. 2015 Juni 2013 Juni 2013 Juni 2012 Dec;232] Juni 2014 Juni 201</td> <td>06.08.2014 22 81.10.2011 22 24.06.2014 22 24.06.2014 22 24.06.2014 22 24.06.2016 24 24.07.2016 24 24.07.2016 24 24.07.2016 24 24.07.2016 24 24.07.2016 24 24.07.2016 24 24.07.2016 24 24.07.2011 24 25.08.2015 24 24.08.2015 24 24.08.2015 24 24.08.2016 24 25.08.2015 24 26.07.2051 24 26.07.2051 24 26.07.2051 24 26.07.2051 24 26.07.2051 24 27.08.2015 24 27.08.2015 24 27.08.2016 24 27</td>		v v v v v	Y Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Statistical analysis - inductive (not RCT/NR Systematical analysis - inductive (not RCT/NR Systematical analysis - descriptive Systematical analysis - des	N Policy > Dependences N Policy > Prices Y Policy > Molicae*** Y Policy > Molicae*** Y Policy > Prices Y Policy > Prices Y Policy and Policae*** Y Policae*** Y Policae*** Y Policae***	N Y N Y n n y n n y n y n	1923283 International experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee Hi, Bloor K, Hewitt C, Maynard A. 1923297 International experience in controlling pharmaceutical in synth forms. Lee Hi, Bloor K, Hewitt C, Maynard A. 1923297 International experience in controlling pharmaceutical in synth forms. Lee Hi, Bloor K, Hewitt C, Maynard A. 1923297 Anyternatic review of reference princip: implications for US prescription drug spending. Lee Hi, Bloor K, Hewitt C, Maynard A. 1923220 They reference princip: implications for US prescription drug spending. Lee S, Salade Lee	Heath Serv Kes Folg, 2013 Am 20(1):53-9. doi: 10.1016/heati create date:2014/2016 [Inst author:Lee H heath Neiky, 2012 and 2014 ob 49. doi:10.1016/heati create date:2011/2016 [Inst author:Lee H heath Neiky, 2012 and 2014 ob 49. doi:10.1016/heati create date:2011/2016 [Inst author:Lee H heath Neiky, 2012 and 2014 ob 49. doi:10.1016/heati create date:2016/12016 [Inst author:Lee H heath Neiky, 2013 and 2014 ob 49. doi:10.1016/heati create date:2016/12016 [Inst author:Lee H heath Neiky, 2013 and 2014 ob 49. doi:10.1016/heati create date:2016/12016 [Inst author:Lee H heath Neiky, 2013 Dec;1313]13-22. doi:10.1016/heati create date:2016/12016 [Inst author:Lee gold C kylae Heath. 2015 Audit 2015 ob 40. doi:10.1016/hylae2 create date:2016/12016 [Inst author:Lee gold C kylae Heath. 2015 Juni 2013 Juni 2013 Juni 2012 Dec;232] Juni 2014 Juni 201	06.08.2014 22 81.10.2011 22 24.06.2014 22 24.06.2014 22 24.06.2014 22 24.06.2016 24 24.07.2016 24 24.07.2016 24 24.07.2016 24 24.07.2016 24 24.07.2016 24 24.07.2016 24 24.07.2016 24 24.07.2011 24 25.08.2015 24 24.08.2015 24 24.08.2015 24 24.08.2016 24 25.08.2015 24 26.07.2051 24 26.07.2051 24 26.07.2051 24 26.07.2051 24 26.07.2051 24 27.08.2015 24 27.08.2015 24 27.08.2016 24 27
0 0100820 pulmed 0 0100820 pulmed 0 0100820 pulmed 1 0100820 pulmed 2 0100820 medine 2 010	Y Y Y Y Y Y Y Y	* * * * *	Y Y	N Systematic Review P Systematic Review N Systematic Review N Statistical analysis - inductive from RC//NR V Statistical analysis - inductive from RC//NR N Survey / Statistical analysis - inductive from RC//NR N Survey / Structured] Interviews	N Policy - Expenditures N Policy - Pores Y Policy - Pores Y Policy - Pores P Policy - Wafare*** P Policy - Wafare*** P Policy - Wafare*** P Policy - Pores P Policy (descriptive) P Policy (descriptive) P Policy (descriptive)	N Y N Y n n y n y n y n y n y n y n	1920283 International experience in controlling pharmaceutical in expenditors. Influencing patients and providers and Lee H, Bloor K, Hewitt C, Maynard A. 1920297 There of text in the comparison of compare is schemes for parametrical in a loss of the comparison on pharmaceutical in comparison among. 14 European comparison comparison of the comparison of the comparison on pharmaceutical comparison among. 14 European comparison comparison of the comparison on pharmaceutical comparison among. 14 European comparison comparison of the comparison of the comparison of the comparison on pharmaceutical comparison among. 14 European comparison comparison comparison among. 14 European comparison compari	Heath Serv Res Folg, 2013 ana 20(1):52-9. doi: 10.1113/create date:2014/00(8) Instantor-tee H Heath Viely, 2013 and 2014 3-0. doi: 10.1016/j.hadi create date:2011/01(8) Instantor-tee H Ann J Meang Care, 2013 Nor 12(1):s28-93.7 Nerview, create date:2011/01(8) Instantor-tee H Mark J Meang Care, 2013 Nor 12(1):s28-93.7 Nerview, create date:2011/01(8) Instantor-tee H Mark J Meang Care, 2013 Nor 12(1):s28-93.7 Nerview, create date:2011/01(8) Instantor-tee H Mark J And Key J 2016 Mer 17:0504 (J-84.6 doi: 10.7395/JAM) Instantor-tee H S Mr Med Rev, 2012 Onc; 253-94.1 Epub 2012 Dec; 27. create date:2016/1/21 [Inst anthor-teepold C Instantor-teepold C Li, Sonth Med Rev, 2012 Dec; 133-13-12. Create date:2016/1/21 [Inst anthor-teepold C Instantor-teepold C Ant Healt Neury, 2012 Dec; 133-13-12. Create date:2016/1/21 [Inst anthor-teepold C Instantor-teepold C Ant Healt Neury, 2013 Dec; 133-13-12. Create date:2016/1/21 [Inst anthor-teepold C Instantor-teepold C Ant Healt Neury, 2014 Dec; 131-13-12. Create date:2016/1/21 [Inst anthor-teepold C Instantor-teepold C Ant Healt Neury, 2014 Dec; 131-12. Create date:2016/1/21 [Inst anthor-teeping C Anth Healt Neury, 2014 Dec; 131-12. Sci Gi Med, 2014 Feb: 10.073.7 A doi: 10.0106/j.paccirc create date:2011/1/201 [Inst anthor-teeping C Sci	06.08.2014 22 06.08.2014 22 06.12.2013 22 26.06.2014 23 27 26.06.2014 23 27 26.06.2014 23 27 26.06.2014 23 27 26.02.2015 23 27 26.02.2014 22 27 26.02.2014 22 27 26.02.2014 23 27 26.02.2015 23 26.02.2014 23 27 26.02.2014 23 27 26.02.2012 23 27 27 27 27 27 27 27 27 27 27 27 27 27
0 0108828 pulmed 0 02108828 pulmed 2 02108827 medine 2 0200827 pulmed 2 0200827 pulmed 2 0200828 pulmed 2 0200828 pulmed 2 0200828 pulmed 2 <td>Y Y Y</td> <td></td> <td>Y Y</td> <td>N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not RCC/NR Systematic analysi</td> <td> N Policy - Dependences N Policy - Prices Policy - Prices Policy - Prices Policy - Prices Policy (descriptive) Policy (descriptive) Policy (descriptive) Policy (descriptive) </td> <td>N Y N Y n n y n y n n y n y n y n y n</td> <td>1920283 International experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee HI, Bloor K, Hewit C, Maynard A. 1920295 The effects of new princing and consegurent schemes for pharmaceutical in softwohr forces. Lee HI, Bloor K, Hewit C, Maynard A. 192030 Media feet device reinducement concernage and princing inplacement in forces: current princips inplacement in strate current princips and the schemes of the Mational Evolutional Schemes and Bard Schemes and Bard Schemes and Schemes</td> <td>Heath Reiv, 2012. Not 13101(1-34). So that 1310 credit date 2014/0016 [Inst authors tere H heath Reiv, 2012. Not 13101(1-34). So that 13101(1-34). So that 1310(1-34). So that 1310(1-34)</td> <td>06.08.2014 22 8.1.02011 22 2.0.6.2014 22 2.0.6.2014 22 2.0.6.2014 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2011 22 2.0.0.2011 22 2.0.0.2011 22 2.0.0.2014 22 2.0</td>	Y Y Y		Y Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not RCC/NR Systematic analysi	 N Policy - Dependences N Policy - Prices Policy - Prices Policy - Prices Policy - Prices Policy (descriptive) Policy (descriptive) Policy (descriptive) Policy (descriptive) 	N Y N Y n n y n y n n y n y n y n y n	1920283 International experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee HI, Bloor K, Hewit C, Maynard A. 1920295 The effects of new princing and consegurent schemes for pharmaceutical in softwohr forces. Lee HI, Bloor K, Hewit C, Maynard A. 192030 Media feet device reinducement concernage and princing inplacement in forces: current princips inplacement in strate current princips and the schemes of the Mational Evolutional Schemes and Bard Schemes and Bard Schemes and Schemes	Heath Reiv, 2012. Not 13101(1-34). So that 1310 credit date 2014/0016 [Inst authors tere H heath Reiv, 2012. Not 13101(1-34). So that 13101(1-34). So that 1310(1-34). So that 1310(1-34)	06.08.2014 22 8.1.02011 22 2.0.6.2014 22 2.0.6.2014 22 2.0.6.2014 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2016 22 2.0.0.2011 22 2.0.0.2011 22 2.0.0.2011 22 2.0.0.2014 22 2.0
0 0108828 pulmed 0 0108828 pulmed 0 0108828 pulmed 1 0108828 pulmed 2 0108918 pulmed 2 0108918 pulmed 2 0108928 pulmed 2 0108918 pulmed 2 0108917 pulmed 2 010	v v v v		Y Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not RCUNR Statistical analysis - inductive (not RCUNR Statistical analysis - descriptive Statistical analysis - descriptive Systematical analysis - descripti	N Policy - Dependences N Policy - Poes Y Policy - Poes Y Policy - Poes Y Policy - Poes Y Policy (descriptive)	N Y N Y N Y N Y N N Y N N Y N Y Y N	1923283 International experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee Hi, Bloor K, Hewitt C, Maynard A. 1924290 The effects of new pricing and consegures ischemes for pharmaceutical in software international in software international in software international in software and pharmaceutical in software and pharmaceutical in software international in software international internatinternatinterenational international international international i	Li esabi Servi des Foliz, 2013 ana 20(1):52.9. doi: 10.1016/j.hadi Create date:2014/2016 Instantor-tee H Marci Manag Care. 2012 Nor 1,21(1):e3/29-37. Review. Create date:2011/2016 Instantor-tee H Marci Manag Care. 2012 Nor 1,21(1):e3/29-37. Review. Create date:2011/2016 Instantor-tee H Marci Manag Care. 2012 Nor 1,21(1):e3/29-37. Review. Create date:2016/2016 Instantor-tee H Paramacocconscional Constraints. S AM Med J. 2016 Mar 17,066(1):e3/6. doi: 10.10786/JMAC create date:2016/2016 Instantor-tee H Li Sonth Med Rev. 2012 Dec; 13/31.31-22. create date:2016/2016 Instantor-tee gold C Li Sonth Med Rev. 2012 Dec; 13/31.31-32. create date:2016/2016 Instantor-tee gold C Value Health. 2015 Jul.21(5):06-400. do create date:2015/07016 Instantor-tee gold C Value Health. 2015 Jul.21(5):06-400. do create date:2015/07016 Instantor-tee gold C Value Health. 2015 Jul.21(5):06-400. do create date:2016/2016 Instantor-tee gold C Value Health. 2015 Jul.21(5):06-400. do create date:2016/2016 Instantor-tee gold C Value Health. 2015 Jul.21(5):06-416. do create date:2016/2016 Instantor-tee gold C Value Health. 2015 Jul.21(5):06-416. do create date:2016/2016 Instantor-tee gold C Value Health. 2015 Jul.21(5):06-416. do create date:2011/2016 Instantor-tee gold C <	06.08.2014 22 06.18.2013 22 06.12.2013 22 26.06.2014 23 20.10.2016 22 20.10.2016 22 20.10.2016 22 20.10.2016 22 20.10.2014 22 20.10.2014 22 20.10.2014 22 20.10.2014 22 20.10.2014 22 20.10.2014 22 20.10.2015 22 20.10.2012 22 20.10.2013 22 20.10.2013 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2013 22 20.10.2013 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2013 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2013 22 20.10.2013 22 20.10.2013 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2013 22 20.10.2012 22 20.10.2013 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2012 22 20.10.2012 20.10.2012 20.10.2013 22 20.10.2013 20.10 20.10 20.10 20.10 20.10 20.10 20.10 20.10 20.10 20.10 20.10 20.10 20.10 20.
0 0108828 pulmed 0 02168828 pulmed 0 02168828 pulmed 1 02168828 pulmed 2 02169818 pulmed 2 02169828 pulmed 2 02169819 pulmed 1 02169827 medine 2 02169828 pulmed 2 02169827 pulmed 2 02169828 pulmed 2 02169828 pulmed 2 02169829 pulmed	y y y y y y	* * * *	Y Y Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not RCC/NR Systematic analysis - inductive inductiv	N Policy - Dependences N Policy - Proces P Policy - Proces P Policy - Weifare*** P Policy - Proces P Policy (descriptive) P	N Y N Y n n y n n y n y n y n y n	1920283 International experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee IN, Bior K, Hewit C, Maynard A. 1920295 The effects of new princing and convergence systems for the sime for the stress of the stres stress of the stress of the stres stres of the stress of the st	Heath Neik, 2021. 2021. Not 13101(J-84). 2021.	06.08.2014 22 8.16.2011 22 2.06.2014 22 2.06.2014 22 2.06.2014 22 2.06.2016 22 2.01.09.2006 22 2.01.2016 22 2.01.2016 22 2.01.2016 22 2.01.2014 22 2.01.2014 22 2.02.2014 22 2.02.2014 22 2.02.2014 22 2.02.2014 22 2.01.2014 22 2.02.2014 22 2.01.2014 22 2.02.2014 22 2.01.2014 22 2.02.2014 22 2.01.2014 22 2.02.2014 22 2.01.2014 22 2.02.2014 22 2.01.2014 22 2.02.2014 22 2.01.2014 22 2.02.2014 22 2.01.2014 22 2.02.2014 22 2.02.2014 22 2.02.2014 22 2.02.2014 22 2.02.2014 22 2.02.2014 22 2.02.2014 22 2.02.2014 22 2.02.2014 22 2.02.2014 22 2.02.2014 22 2.02.2014 22 2.01.2014 22 2.01.2014 22 2.01.2015 22 2.01.2014 2.01.2014 22 2.01.2014 22 2.01.2014 22 2.01.2014 22 2.01
0 0100820 pubmed 0 0100820 pubmed 0 0100820 pubmed 1 0100820 pubmed 2 0100810 pubmed 2 0100810 pubmed 2 0100820 pubmed 2 0100827 meline 2 010	v v v	* * * *	Y Y Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Statistical analysis - inductive (not RCT/NR Statistical analysis - inductive (not RCT/NR Statistical analysis - descriptive Statistical analysis - descriptive Systematical analysis - descri	 N Policy - Dependences N Policy - Proces Y Policy - Proces Y Policy - Proces Y Policy (descriptive) Y Policy (descriptive) Y Proces (descriptive) Y Policy (descriptive) Y Policy (descriptive) 	N Y N Y N Y N Y N N N Y N N Y N	 Bierrantional experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee IN, Bior K, Hewit C, Maynard A. Bierrantional experience in controlling pharmaceutical in spenditors. Lee IN, Bior K, Hewit C, Maynard A. Lee IN, Bior K, Hang YG, Lu C Y. Di Marchaet and State and Sta	Heath Serv Res Folg, 2013 ana 20(1):53-9. doi: 10.1016/j.hadi create date.2011/2016 Instantor-tee H Heath Neiko, 2013 ana 2013 43-9. doi: 10.1016/j.hadi create date.2011/2016 Instantor-tee H Mark Manag Care. 2013 Nov 11.2013 (J.hadi SJ. Resive. create date.2011/2016 Instantor-tee H Mark Manag Care. 2013 Nov 11.2013 (J.hadi SJ. Resive. create date.2011/2016 Instantor-tee H Mark Manag Care. 2013 Nov 11.2013 (J.hadi SJ. Resive. create date.2011/2016 Instantor-tee B Shif Med J. 2016 Mar 37.0680 (J.SG. Ross) create date.2016/2016 Instantor-tee B Shif Med Rev. 2020 Ces;213-34-1. Epub 2012 Dec; 27. create date.2016/1/2016 Instantor-teepoid C Instantor-teepoid C Li, South Med Rev. 2012 Dec;133.131-32.2 create date.2016/1/2016 Instantor-teepoid C Instantor-teepoid C Value Health 2015 Jul:10(1):56-0040 create date.2011/2017 Instantor-teepoid C Instantor-teepoid C Value Health 2015 Jul:10(1):56-0040 create date.2011/2017 Instantor-teepoid C Instantor-teepoid C Value Health 2015 Jul:10(1):56-0040 create date.2011/2017 Instantor-teepoid C Instantor-teepoid C Value Health 2015 Jul:11(1):51-57-57 create date.2011/2017 Instantor-teepoid C Instantor-t	06.08.2014 22 8.1.02011 22 2.0.6.2014 22 2.0.6.2014 22 2.0.6.2014 22 2.0.6.2016 22 2.0.02016 22 2.0.2016 22 2.0.2016 22 2.0.2016 22 2.0.2016 22 2.0.2016 22 2.0.2016 22 2.0.2016 22 2.0.2016 22 2.0.2016 22 2.0.2016 22 2.0.2014 22 2.0.2014 22 2.0.2014 22 2.0.2014 22 2.0.2014 22 2.0.2014 22 2.0.2014 22 2.0.2014 22 2.0.2015 22 2.0.2015 22 2.0.2015 22 2.0.2015 22 2.0.2015 22 2.0.2014 22 2.0.2015 22 2.0.2014 22 2.0.2014 22 2.0.2014 22 2.0.2015 22 2.0.2014 22 2.0.2015 22 2.0.1.2013 22 2.0.1.2013 22 2.0.1.2013 22 2.0.2014 22 2.0.2014 22 2.0.2015 22 2.0.1.2013 22 2.0.1.2013 22 2.0.1.2013 22 2.0.1.2013 22 2.0.1.2013 22 2.0.1.2013 22 2.0.2014 22 2.0.2015 22 2.0.2014 22 2.0.2015 22
0 0100020 pubmed 0 0100020 pubmed 0 0100020 pubmed 1 0100020 pubmed 2 010	Y Y Y	* * * * *	Y Y Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not RC/)/R Systematic analysis - inductive (not RC/)/R Systematic analysis - descriptive Systematic a	N Policy - Dependences N Policy - Poess P Policy - Poess P Policy - Poess P Policy (descriptive) P Policy (descrip	N Y N Y n n y n y n n y n y n y n	 Bierrantional experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee H, Bloor K, Hewitt C, Mynard A. Bierrantional experience in controlling pharmaceutical in system for horses. Lee H, Bloor K, Hewitt C, Mynard A. Bierrantional experience in controlling pharmaceutical in system for horses. Lee H, Bloor K, Hewitt C, Mynard A. Lee M, Hande AM, Shanki W, Polndi A. Lee M, Bloor K, Hewitt C, Mynard A. Lee M, Bloor K, Hande AM, Shanki W, Polndi A. Lee M, Hande AM, Shanki W, Polndi A. Lee M, Bloor K, Mante Ferwisse K, Seri Galland M, Bloor K, Mante Ferwisse K, Seri Galland M, Bloor K, Shanki H, Bennes JD, Wagne J. A. Leepaid C, Vagder S, Natto F. Heuwisse K. Seri Galland Berrice Impact Compact proton and reinformation and parametrical control and control on control and control on control and control and control and control and control and control on control and control	Heath Serv Res Folg, 2013 an:20(1):32-9. doi: 10.11) create date:2014/00(8 [first author:Lee H] Heath Vielk, 2013 an:01(1):43-9. doi: 10.1101/hashi create date:2011/01(1) [first author:Lee H] Mark Manag Care, 2013 Nor 1.21(1):42(3):7. Nervix. create date:2011/01(1) [first author:Lee H] Mark Manag Care, 2013 Nor 1.21(1):42(3):7. Nervix. create date:2011/01(1) [first author:Lee H] Mark Manag Care, 2013 Nor 1.21(1):42(3):7. Nervix. create date:2011/01(1) [first author:Lee K] Pharmacocconcomposition create date:2011/01(1) [first author:Lee K] SAM Med Par, 2016 Mar 17,000(1); 430 (first author) create date:2016/01(2) [first author:Leeged C] Li, Sonth Med Rev. 2012 Dec;15(2):431-44. Equid 2012 Dec; 7. create date:2013/01(2) [first author:Leeged C] create date:2016/01(2) [first author:Leeged C] Author Neikey, 2013 Dec;11(3):131-32. create date:2013/01(2) [first author:Leeged C] Author Neikey, 2013 Dec;11(3):131-32. create date:2013/01(2) [first author:Leeged C] Author Neikey, 2013 Dec;11(3):131-32. create date:2013/01(2) [first author:Leeged C] Author Neikey, 2013 Dec;11(3):131-32. create date:2013/01(2) [first author:Leeged C] Author Neikey, 2013 Dec;11(3):131-32. create date:2013/01(2) [first author:Leeged C] Author Neikey, 2014 Dec;12(1):57-64. doi: 10.1001/joaccirc create date:2013/01(2) [first author:Leeged C] Au	06.08.2014 22 81.10.2011 22 24.06.2014 22 24.06.2014 22 24.06.2016 22 24.01.2016 24 24.01.2016 24 24.01.2016 24 24.01.2016 24 24.01.2011 24 24.01.2011 24 24.01.2011 24 24.01.2011 24 24.01.2011 24 24.02.2014 24 24.02.2014 24 24.02.2014 24 25.02.2014 24 26.02.2014 24 27
0 0108828 pulmed 0 0210828 pulmed 0 0210828 pulmed 1 0210828 pulmed 2 0210978 pulmed 2 021	y y y y	- 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	Y Y Y Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Statistical analysis - inductive (not RCT/NR Systematical analysis - inductive (not RCT/NR Systematical analysis - decorptive Sectors and statistical analysis - decorptive Sectors and statistical analysis - decorptive Sectors and (analysic) Economic model (analysic) Economic model (analysic) Economic model (analysic) Systematical analysis - decorptive Systematical analysis - d	 N Policy - Dependences N Policy - Proces Policy - Proces Policy - Proces Policy (descriptive) Policy (descriptive) Policy (descriptive) Proces (descriptive) Policy (descriptive) Policy (descriptive) 	N Y N Y n n y n y n y n y n y n	 Bierrantional experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee IP, Bior K, Hewit C, Mynard A. Bierrantional experience in controlling pharmaceutical in synth forces. Lee IP, Bior K, Hewit C, Mynard A. Bierrantional experience in controlling pharmaceutical in synth forces. Lee IP, Bior K, Hewit C, Mynard A. Bierrantional experience in controlling pharmaceutical in synth forces. Lee IP, Bior K, Hewit C, Mynard A. Bierrantional E. S., Salet S.	Heath Teily, 2021an:201139-89, doi:10.1016/h.hadi create date.2011/2016 [Inst author:Lee H heath Teily, 2021an:201131-96, 2021an;2016/h.hadi create date.2021i/2016 [Inst author:Lee H heath Teily, 2021an;201131-96, 2021an;2016/h.hadi create date.2021i/2016 [Inst author:Lee H heath Teily, 2021an;201131-96, 2021an;2016/h.hadi create date.2021i/2016 [Inst author:Lee H heath Teily, 2021an;201134-06, 2010an;2016 [Inst author:Lee H heath Teily, 2021an;201134-06, 2010an;2017an;2	06.08.2014 22 81.10.2011 22 24.06.2014 22 24.06.2014 22 24.06.2014 22 24.06.2016 24 24.07.2015 24 24.07.2015 24 24.07.2015 24 24.07.2014 24 24.07.2014 24 25.08.2015 24 24.08.2015 24 24.08.2015 24 24.08.2015 24 24.08.2015 24 24.08.2016 24 25.08.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.07.2015 24 26.07.2015 24 26.07.2015 24 26.07.2016 24 27.07.2015 24 26.07.2015 24 27.07.2015 24 27.07.2015 24 27.07.2015 24 27.07.2015 24 27.07.2015 24 27.07.2015 24 27.07.2015 24 27.07.2015 24 27.07.2015 24 27.07.2015 24 27.07.2016 24 27.07.2010 24
0 0100820 pubmed 0 0100820 pubmed 0 0100820 pubmed 1 0100820 pubmed 2 0100820 medme 2 0100820 pubmed 2 0100820 pubmed 2 0100820 pubmed 2 0100820<	y y y y y y	* * * * *	Y Y Y Y	N Systematic Review P Systematic Review N Systematic Review N Systematic Review N Systematic Review N Statistical analysis - Inductive front RC//NR V Statistical analysis - descriptive Statistical analysis - descriptive Statistical analysis - descriptive N Scommic model (snalyfic) Commic model (snalyfic) Legal snalysis N Synthesis/Comment N Survey / (Structured) Interviews N Survey / (Structured) Interviews N Survey / Structured) Interviews	N Policy - Dependences N Policy - Poes Y Policy - Poes Y Policy - Poes Y Policy - Poes Y Policy (descriptive)	N Y N Y N Y N Y n N Y n N Y n Y n Y n	 Bierrantional experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee PH, Bioor K, Hewitt C, Maynard A. Bierrantional experience in controlling pharmaceutical in software interface and subserval historics. Lee PH, Bioor K, Hewitt C, Maynard A. Lee Data C, Maynard A.<	Heath Serv Res Folg, 2013 ana 20(1):52-9. doi: 10.1113/create date:2014/2016 First author:tee H Heath Neik, 2013 ana 20(1):52-9. doi: 10.1116/j.hadi create date:2011/2016 Instantor:tee H Mark Mean, Gree, 2013 Nor 12(1):52-97. Neixe. create date:2011/2016 Instantor:tee H Mark Mean, Gree, 2013 Nor 12(1):52-97. Neixe. create date:2011/2016 Instantor:tee H Mark Mean, Gree, 2013 Nor 12(1):52-97. Neixe. create date:2016/2016 Instantor:tee H Pharmacocconcomposition, 2002.349(1989) Nor. create date:2016/2016 Instantor:tee H SAF Med J. 2016 Mer 17:060(1):43-6. doi: 10.7386/2040 create date:2016/2017 Instantor:teegod C EL, Sonth Med Rev. 2012 Dec; 12(3):31-32-2. create date:2016/2016 instantor:teegod C Mark Med Rev. 2012 Dec; 12(3):31-32-2. create date:2016/2016 instantor:teegod C Appl Neiky, 2013 Dec; 13(3):31-32-2. create date:2016/2017 Instantor:teegod C Appl Neiky, 2013 Dec; 13(3):31-32-2. create date:2016/2016 instantor:teegod C Appl Neiky, 2013 Dec; 13(3):31-32-2. create date:2016/2016 instantor:teegin C Appl Neiky, 2013 Dec; 13(3):31-32-2. create date:2016/2016 instantor:teegin C Appl Neiky, 2013 Dec; 13(3):31-32-2. <td< td=""><td>06.08.2014 22 06.08.2014 22 06.02.2011 22 26.06.2014 23 20.06.2014 23 20.02.2015 23 20.02.2015 23 20.02.2015 23 20.02.2011 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2015 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2015 23 20.02.2015 23 20.02.2015 23 20.02.2013 23 20.02.2013 23 20.02.2013 23 20.02.2013 23 20.02.2015 23 20</td></td<>	06.08.2014 22 06.08.2014 22 06.02.2011 22 26.06.2014 23 20.06.2014 23 20.02.2015 23 20.02.2015 23 20.02.2015 23 20.02.2011 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2015 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2014 23 20.02.2015 23 20.02.2015 23 20.02.2015 23 20.02.2015 23 20.02.2013 23 20.02.2013 23 20.02.2013 23 20.02.2013 23 20.02.2015 23 20
0 0108828 pulmed 0 02168828 pulmed 0 02168828 pulmed 1 02168828 pulmed 2 02169828 pulmed 2 02169818 pulmed 2 02169819 pulmed 2 02169818 pulmed	y y y y y y	• • • • •	Y Y Y Y Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not RC/IVI8 Systematic analysis - inductive (not analysis) Systematic analysis - inductive (no	 N Policy - Dependences N Policy - Prices Policy - Prices Policy - Prices Policy - Prices Policy (descriptive) Policy (descriptive) Policy (descriptive) Policy (descriptive) 	N Y N Y n n y n y n n y n y n y n	1920283 International experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee HI, Bloor K, Hewit C, Maynard A. 192029 The effects of new pricing and concernage and pricing inplanzaeutical in soft horeas. Lee HI, Bloor K, Hewit C, Maynard A. 192030 Media Effects environment concernage and pricing inplanzaeutical in soft and concernage and pricing inplanzaeutical expension and cases to innovate Lee SK, Makel A., Sharkes D. 1920210 The impact of cast containment strategies on planmaceutical expension and casts to innovate Lee SK, Makel A., Sharkes D. 19202170 The other Machines Concolumplication and the chask newse way more access to innovation. Lee W, Bloor K, Haurey YL, OV, Ch 19202170 The other Machines Concolumplication and the chask newse way more and casts to innovation. Leopal C, Yager K, Haurey YL, OV, Ch 2021221 The other Machines Concolumplication and on-planzaeutical concerptive environ. Leopal C, Yager S, Haure T, Haurey K., Matter Terewisse AC, Marter T, Davis R. 2021240 Discingent A, Marter M, Barter	 Heath Neik, 2021. Not 12101(A): 4.6 (i): 10.1016 (heat) create date 2021/0/18 (ii): fauthor: ten H enth Neik, 2021. Not 12101(A): 4.6 (ii): 10.1016 (heat) create date 2021/0/18 (ii): fauthor: ten L when Neik, 2021. Not 12101(A): 4.6 (iii): A (iiii): A (iii): A (ii): A (iii): A (i	06.08.2014 22 81.10.2011 22 24.06.2014 22 24.06.2014 22 24.06.2014 22 24.06.2014 22 24.06.2016 24 24.01.2016 24 24.01.2016 24 24.01.2016 24 24.01.2014 24 24.01.2016 24 24
0 0100820 pubmed 0 0100820 pubmed 0 0100820 pubmed 1 0100820 pubmed 2 0100910 pubmed 2 010	y y y y y y	· · · ·	Y Y Y Y Y	N Systematic Review Systematic Review Systematic Review Systematic Review Systematic Review Systematic analysis - inductive (not RC//NR Systematic analysis - inductive (not RC//NR Statistical analysis - descriptive Statistical analysis - descriptive Systematical analysis - descript	 N Policy - Dependitures N Policy - Proces Y Policy - Proces Y Policy - Proces Y Policy (descriptive) 	N Y N Y N Y N A N N N N N N N N N N N N N N N N N N	 Bierrantional experience in controlling pharmaceutical expenditors: Influencing patients and providers and Lee IP, Bioor K, Hewitt C, Maynard A. Bierrantional experience in controlling pharmaceutical in source and patients in forces. Lee IP, Bioor K, Hewitt C, Maynard A. Lee A. Linkar M, Shrak MW, Folndi M, Biother M,	Heath Serv Res Folg, 2013 ana 20(1):53: 4. doi: 10.1016/.heati create date:2011/2016 Instantor-tee H Heath Neiko, 2013 ana 20(1):53: 4. doi: 10.1016/.heati create date:2011/2016 Instantor-tee H Mark Manag Care, 2013 Not 1,21(1):e3:25: 7. Review. create date:2011/2016 Instantor-tee H Mark Manag Care, 2013 Not 1,21(1):e3:25: 7. Review. create date:2011/2016 Instantor-tee H Mark Manag Care, 2013 Not 1,21(1):e3:25: 7. Review. create date:2016/2016 Instantor-tee B SM Med J. 2016 Mar 17:06:01(1):e3:05: 60:400. create date:2016/2016 Instantor-tee B S M Med Rev. 2021 Dec; 17:23:13-41. Fuo 2012 Dec; 7: create date:2016/2016 Instantor-tee B Instantor-tee B Li, South Med Rev. 2012 Dec; 17:33:13:12:2. create date:2016/2016 Instantor-tee B Instantor-tee B A (H) Health, 2013 Dec; 17:33:13:12:2. create date:2016/2016 Instantor-tee B Instantor-tee B A (H) Health, 2013 Dec; 17:33:13:12:2. create date:2016/2016 Instantor-tee B Instantor-tee B A (H) Health, 2013 Dec; 17:33:13:12:2. create date:2016/2016 Instantor-tee B Instantor-tee B A (H) Health, 2013 Dec; 17:33:13:12:2. create date:2016/2016 Instantor-tee B Instantor-tee B A (H) H	06.08.2014 22 06.08.2014 22 06.02.2014 22 28.06.2014 22 28.06.2014 22 29.06.2014 22 29.06.2014 22 29.07 20.11.2015 22 20.07 20.11.2014 22 29.08.2015 22 20.07 20.11.2014 22 20.07 20.11.2014 22 20.07 20.12.2014 22 20.07 20.0

4 20160828 pubmed										
	y	y		n			7393865 [The generics reform lowered drug prices]. Lundin D, Jacob J, EngstrĶm A. Lakartidningen. 2007 Feb.	8-Mar 6;104(9):680-1. Swedis create date:2007/03/31 first author:Lundin D	31.03.2007	2007
11 20160918 pubmed	у	Y		N			16693494 Regulatory Solutions to the Problem of High Generic Drug Costs. Luo J, Sarpatwari A, Kesselheim AS. Open Forum Infect Dis. 20	5 Dec;2(4):ofv179. doi: 10.10 create date:2015/12/23 first author:Luo J	23.12.2015	2015
2 20160828 pubmed	У			 ¥ Economic model (analytic, empirical data) 	n Policy (descriptive)	y n	8634650 Funding pharmaceutical innovation through direct tax credits. Lybecker KM, Freeman RA. Health Econ Policy Law. 20	07 Jul;2(Pt 3):267-84. doi: 10.1 create date:2008/07/19 first author:Lybecker KM	19.07.2008	2008
4 20160828 pubmed	у	y		n			13795158 BC government reveals plans to lower generic drug prices to 20% of brand-name price by April 2014. Lynas K. Can Pharm J (Ott). 2013 Ja	;146(1):13. doi: 10.1177/171! create date:2013/06/26 first author:Lynas K	26.06.2013	2013
4 20160828 pubmed	y	v		n			3509514 BC to chart new path for generic drug prices after cancelling 2010 agreement with pharmacy. Lynas K. Can Pharm J (Ott). 2012 M	y;145(3):104. doi: 10.3821/14 create date:2013/03/20 first author:Lynas K	20.03.2013	2013
4 20160828 pubmed	v	v		n			3509540 PEI moves to lower generic drug prices. Lynas K. Can Pharm J (Ott). 2012 Ju	145(4):160. doi: 10.3821/191 create date:2013/03/20 first author:Lynas K	20.03.2013	2013
4 20160828 pubmed	v	v		n			3795174 Provincial/territorial governments join forces to make further cuts to generic drug prices. Lynas K. Can Pharm J (Ott). 2013 M	r:146(2):68-70. doi: 10.1177/ create date:2013/06/26 first author:Lynas K	26.06.2013	2013
11 20160918 nubmed	y y	,					0486360 [Mechanism and implication of resulation of the pricing of essential medicines in the private pharmaceutic: Maārea D. Maārea S. Maārea MD. Med Trop (Mars) 2010 an	-70(2):184-8 Review French create date:2010/05/22 first author: Maã-ga D	22.05.2010	2010
12 20160918 pubmed	y y	W					Proceeding the second s	lun:12/5):271-6 create date:2005/05/24 first author:Mahasa //ii	24.06.2006	2006
6 20160928 pubmed	y	,		-			Effective Encode a interspectre maximum anomatic cost prime provide and a proton party matching and for the set of the se	51/20E 12 dei: 10.12E8/imm_sreate.date.2008/06/02 First author/Maddate.Maskeenie B	03.06.2000	2000
2 20160828 publied	y	y .					3313776 Webla influence on hercepuri sousiouzation in Australia. application or one of the onescentizer of chapman 3, Sateria S, Houley S, Societa J, Bolano J, Bolano J, Societa J, Bolano	0/.303-12. 001. 10.1230/jisili. create date:2008/00/05 hist author:Mackenzie K	15 10 2012	2008
2 20160828 pubmed	Ŷ	Y		n			4120330 Prescription drug coupons: evolution and need for regulation in direct-to-consumer adventsing. Mackey 1K, Yagi N, Liang BA. Res Social Adm Pharm. 20.	4 May-Jun; 10(3):588-94. doi: create date:2013/10/15 first author:Mackey IK	15.10.2013	2013
12 20160918 pubmed	У	У		n			5/8/956 Drug insurance utilization management policies and reference pricing : an illustrated commentary on the a Maclure M. Milbank Q. 2005;83(1):133	47. Review. No abstract avails create date:2005/03/25 first author:Maclure M	25.03.2005	2005
4 20160828 pubmed	у у			n			US12232 Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. Madden JM, Meza E, Ewen M, Laing RO, Stell Rev Panam Salud Publica.	010 Apr;27(4):291-9. Erratum create date:2010/06/01 first author:Madden JM	01.06.2010	2010
12 20160918 pubmed	У		na	n			6838556 [Statin therapy: cost-effectiveness and evaluation of evidence as criterium for improving expenditure withi Magi L, Sforza P, Rafaiani S, Settembri P, Mo Recenti Prog Med. 2006 N	y;97(5):257-61. Italian. create date:2006/07/15 first author:Magi L	15.07.2006	2006
11 20160918 pubmed	У	y		n			1154203 [Competition between branded and generic drugs in Austria: evidence from the market for ACE inhibitors] Mahlich JC, Stadler I. Gesundheitswesen. 2012.	an;74(1):23-8. doi: 10.1055/s- create date:2010/12/15 first author:Mahlich JC	15.12.2010	2010
4 20160828 pubmed	У	У		n			17149663 Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. Mailankody S, Prasad V. JAMA. 2016 Jul 19;316(3):	71-2. doi: 10.1001/jama.2016 create date:2016/05/06 first author:Mailankody S	06.05.2016	2016
12 20160918 pubmed	У	У		n			6027743 Dihydropyridines, felodipine, and PHARMAC. Mann S. N Z Med J. 2005 Jul 15;118	1218):U1569. create date:2005/07/20 first author:Mann S	20.07.2005	2005
4 20160828 pubmed	у	y		n			14480618 Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England. Mansfield SJ. Aust Health Rev. 2014 Feb	38(1):6-15. doi: 10.1071/AH1. create date:2014/02/01 first author:Mansfield SJ	01.02.2014	2014
12 20160918 pubmed	У			Y Survey / (Structured) Interviews	y Policy > Behaviour	Y N	17503281 Patients' knowledge and attitude towards therapeutic reference pricing system in Slovenia. MarĂ'etko N, Kos M. Int J Clin Pharm. 2016 Aug	 [Epub ahead of print] create date:2016/08/10 first author:MarĂ'etko N 	10.08.2016	2016
5 20160828 pubmed	у	y		n			2013144 An innovative approach to pharmacy management in a state correctional system. Marcoux RM, Simeone JC, Colavita M, Larrat J Correct Health Care. 201	Jan;18(1):53-61. doi: 10.1177 create date:2011/10/21 first author:Marcoux RM	21.10.2011	2011
12 20160918 pubmed	y			Y Survey / (Structured) Interviews	y Policy > Behaviour	Y N	16532916 External Reference Pricing from the Perspective of Slovenia. Mardetko N, Kos M. Value Health. 2015 Nov;18	7]:A520. doi: 10.1016/j.jval.2 create date:2015/11/05 first author:Mardetko N	05.11.2015	2015
12 20160918 pubmed	y.			Y Survey / (Structured) Interviews	y Policy > Behaviour	Y N	16534159 Therapeutic Reference Pricing System In Slovenia From The Patients' Perspective. Mardetko N, Kos M. Value Health. 2015 Nov;18	7):A742. doi: 10.1016/j.jval.2 create date:2015/11/05 first author:Mardetko N	05.11.2015	2015
12 20160918 pubmed	y			 Economic model (analytic) 	y Policy > Prices	n n	7201192 The Inverse Correlation Between Internal And External Risk Under International Reference Pricing: An Anal Marinoni G, Lockwood C, Ando G. Value Health. 2014 Nov;17	7):A443. doi: 10.1016/j.jval.2 create date:2014/11/01 first author:Marinoni G	01.11.2014	2014
1 20160827 medline	v	v					8489199 Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Ca. Marshall DA, Douglas PR, Drummond MF, Torrance GW, Macleod S, Ma	ti O. Cheruvu L. Corvari R. create date:2008/05/21 first author:Marshall DA	21.05.2008	2008
4 20160828 pubmed	, V		v	0			16122057 Trans-Pacific trade part triggers fears over drug prices McCall C Lancet 2015 Jun 20-385/9	86):2450-1_doi: 10.1016/S01_create.date:2015/07/01 first author:McCall C	01.07.2015	2015
4 20160828 pubmed	, V		, v	0			7553038 Drug prices are kent high in LIS by protection and price pendiations, study finds. McCarthy M BMI 2016 Aug 23-354-i66	0. doi: 10.1136/bmi.id640. Nr. create date:2016/08/25 first author:McCarthy M	25.08.2016	2016
4 20160828 pubmed	,	v	,				6224223 Medicate could save up to \$16bp if allowed to perotiate drug prices, paper finds McCarthy M BMI 2015 Jul 29-351 hd1	doi: 10.1136/bmi b4112. Nu create date: 2015/08/01 first author: McCarthy M	01.08.2015	2015
4 20160828 pubmed	, ,						5646508 Bising drug prices drug US manufacturary' revenues analysis finds McCarthy M BMI 2015 Oct 7:251-552	doi: 10.1136/bmi.h5276. Nr. create.date:2015/10/09.Lfirst author:McCarthy M	09 10 2015	2015
4 20160828 publica	y	y		-			1110024 Dana Deleva A believ Devale	= 21(2)-59, 70, 1. No obstract / create date: 2015/20/05 first author: McCarthy M	20.04.2016	2015
4 20100828 publied	y		y				712222 Diugrines Arbite Pazze. Preatore ze zo o marganización de la companya de	2010101012 52 doi:10.20151/create date:2010/04/25 hist author:NicLaughin DB	25.04.2010	2010
2 20160828 pubmed	y			y Economic model (analytic, empirical data)	N Policy (descriptive)	y n	U031292 The economics of comparative effectiveness studies: societa and private perspectives and their implication Meltzer D, Basu A, Conti R. Pharmacoeconomics. 2011	28(10):843-53. doi: 10.2165/ create date:2010/09/14 first author:Weitzer D	14.09.2010	2010
11 20160918 pubmed	у у			n			7546309 The availability and affordability of selected essential medicines for chronic diseases in six low- and middle- Mendis S, Fukino K, Cameron A, Laing R, Filig Bull World Health Organ.	207 Apr;85(4):279-88. create date:2007/0b/05 first author:Mendis S	05.06.2007	2007
2 20160828 pubmed	у у						109491/10 A pricing poincy towards the sourcing of cheaper drugs in Cyprus. Merkur S, Mossialos E. Health Policy, 2007 May,8	(2-3):308-75. Epub 2000 Sep : create date:2006/09/05 tirst author:Merkur S	05.09.2006	2006
9 20160911 pubmed	У			y synthesis/Comment	 Policy (descriptive) 	y N	2/21942/ Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inade Messori A. Clin Drug Investig. 2016 Ar	giso(a):599-bus. doi: 10.1007 create date:2016/05/25 first author:Messori A	25.05.2016	2016
4 20160828 pubmed	У		Y	n			2/0/3004 High drug prices emerge as 2015's top issue. Meyer H. Mod Healthc. 2015 Dec 21	28;45(51):17-23. No abstract create date:2016/04/16 first author:Meyer H	16.04.2016	2016
5 20160828 pubmed	У	y		0			7491596 Governmental influences on drug development: striking a better balance. Miller HI, Henderson DR. Nat Rev Drug Discov. 2007	lul;6(7):532-9. Review. create date:2007/05/12 first author:Miller HI	12.05.2007	2007
12 20160918 pubmed	У			y Economic model (analytic)	y Policy > Behaviour	n n	9038465 Reference pricing and firms' pricing strategies. Miraldo M. J Health Econ. 2009 Jan;28	1):176-97. doi: 10.1016/j.jhez create date:2008/11/29 first author:Miraldo M	29.11.2008	2008
6 20160828 pubmed	у у			n			13579000 Latvia: Health system review. Mitenbergs U, Taube M, Misins J, Mikitis E, I Health Syst Transit. 2012;1	4(8):xv-xxii, 1-191. create date:2013/04/13 first author:Mitenbergs U	13.04.2013	2013
11 20160918 pubmed	у у			n			6083945 Problems in the regulatory policy of the drug market. Miziara NM, Coutinho DR. Rev Saude Publica. 2015;4	:35. create date:2015/06/18 first author:Miziara NM	18.06.2015	2015
2 20160828 pubmed	y y			n			9082262 [Policies concerning pharmaceutical prices and reimbursement in Mexico, Organization for Co-operation at MoA-se P, Docteur E. Salud Publica Mex. 2008;5	Suppl 4:S504-10. Spanish. N create date:2008/12/17 first author:MoA se P	17.12.2008	2008
1 20160827 medline	v v			n			9082261 [Competition and prices in the Mexican pharmaceutical market]. Molina-Salazar RE. GonzĂilez-MarĂ-n E. Carbaial-de Nova C.	create date:2008/12/17 first author:Molina-Salazar RE	17.12.2008	2008
2 20172131 Scopus	v v			n			The impact of Ghana's National Health Insurance Scheme median pharmaceutical pricing methodology and Mordi D.O. Exhan K. Rankin J. Journal of Pharmaceutical	Policy and Practice		2015
2 20160828 pubmed	, ,			v Statistical analysis - descriptive	Y Prices (descriptive)	v n	1921527 The level of income ampairs to have no consistent basing on pharmaceutical prices across countries Morel CM McGuire & Moreilas E Health &ff (Milleonor) 201	Aug-30(8):1545-52 doi: 10.1 create date:2011/08/09 first author: Morel CM	09.08.2011	2011
0 30160011 pubmod	,			Y Example model (analysis)	Delivery Invest (0.8 D)		The value of inner the conductive decay of print machine and print machine of an and the conductive of maximum of the second back back of the second back of the sec	2015-4 dei: 10.2402/imohn sreate date:2016/04/20 Erst authorshiferens 5/	20.04.2016	2016
12 20160018 pubmed	y			Economic model (analytic)	y Policy > lifvest (R&D)	N U	5 125125 The value of inflorence of antibio and back state of the second part of the second state of the s	2010;4: 00: 10:3402/jinalip create date:2010/04/23 hist author/Moreno 36	23.04.2010	2010
12 20100518 publied	y	y		in the second size a second study (CTC)	- Delinus Invest (08 D)		3005502 The implact on repeated toxic containment policies on phramaceutical status exception care study for the implact on repeated toxic containment policies on phramaceutical status exception care study for the implact on repeated toxic containment policies on phramaceutical status exception care study for the implact on repeated toxic containment policies on phramaceutical status exception care study for the implact on repeated toxic containment policies on phramaceutical status exception care study for the implact on repeated toxic containment policies on phramaceutical status exception care study for the implact on repeated toxic containment policies on phramaceutical status exception care study for the implact on repeated toxic containment policies on phramaceutical status exception care study for the implact on repeated toxic containment policies on phramaceutical status exception care study for the implact on repeated toxic containment policies on phramaceutical status exception care study for the implact on repeated toxic containment policies on phramaceutical status exception care study for the implact on repeated toxic containment policies on phramaceutical status exception care study for the implact on repeated toxic containment policies on phramaceutical status exception care study for the implact on th	2)ve128_E2	24.03.2000	2010
12 20100918 publied	y			y interrupted time series study (113)	ii Policy > livesc (R&D)	пу	3505700 The effect of evidence based drug coverage policies on pharmaceutical rad, a case study non-britsh color worgans, cummignantic.	5).6128-55. Create date.2009/05/24 Tirst aution.Morgan 5	24.03.2009	2009
12 20100918 publied	y		Doubl, short t				3503766 The effect of excerne based drug coverage pointes on prantaceutan act, a case study infinite instruction worgans, Customeranian C. Press	5).54-05. Create date.2009/05/24 Tirst aution.Morgan 5	24.03.2009	2009
7 20160828 pubmed	Ŷ			y Systematic Review	N Policy > diverse	N	1003047 Companson or terea formularies and reference pricing policies: a systematic review. Morgan S, Hanley G, Greyson D. Upen Med. 2005;3(3):e13	-9. Epub 2009 Aug 4. create date:2009/01/01 first author:Morgan 5	01.01.2009	2009
4 20160828 pubmed	У			y Statistical analysis - descriptive	Y Policy > Prices	n n	9305/47 Influencing Drug Prices through Formulary-Based Policies: Lessons from New Zealand. Morgan S, Hanley G, McMahon M, Barer M. Healthc Policy. 2007 Aug;a	1):e121-40. create date:2007/08/01 first author:Morgan S	01.08.2007	2007
12 20160918 pubmed	У	y		n			10614652 Prescription drug accessibility and affordability in the United States and abroad. Morgan S, Kennedy J. Issue Brief (Commonw Fun	d). 2010 Jun;89:1-12. create date:2010/07/10 first author:Morgan S	10.07.2010	2010
2 20160828 pubmed	У			y Survey / (Structured) Interviews	y Policy (descriptive)	y n	Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discount Morgan SG, Thomson PA, Daw JR, Friesen M, Health Policy. 2013 Oct;11	(3):248-54. doi: 10.1016/j.he. create date:2013/07/03 first author:Morgan SG	03.07.2013	2013
4 20160828 pubmed	У		y	n			17551037 Canada's high drug prices under review. Moulton D. CMAJ. 2016 Aug 22. doi:pi	cmaj.109-5311. [Epub ahead create date:2016/08/24 first author:Moulton D	24.08.2016	2016
4 20160828 pubmed	у у			n			3034857 India's capping of drug prices will leave drugs costing near the market price. Mudur G. BMJ. 2012 Oct 3;345:e664	. doi: 10.1136/bmj.e6649. Nc create date:2012/10/05 first author:Mudur G	05.10.2012	2012
5 20160828 pubmed	у у			n			4612518 Local production of pharmaceuticals in Africa and access to essential medicines: "urban bias" in access to im Mujinja PG, Mackintosh M, Justin-Temu M, Global Health. 2014 Mar 1	;10:12. doi: 10.1186/1744-86 create date:2014/03/13 first author:Mujinja PG	13.03.2014	2014
6 20160828 pubmed	y y			n			3902994 Lithuania: health system review. Murauskiene L, Janoniene R, Veniute M, var Health Syst Transit. 2013;1	5(2):1-150. Review. create date:2013/08/02 first author:Murauskiene L	02.08.2013	2013
8 20160828 pubmed	V I	v		0			7599634 Sources of medicine information in Finland Nätrhi LL Helakomi S Health Policy 2007 Nov-8	1):51-7 Epub 2007 Jun 27 create date: 2007/06/30 first author: Nātrhi II	20.05.2007	2007
		,							20110121017	
8 20160828 nubmed	v	v		n			7479353 Sources of medicine information and their reliability evaluated by medicine users Natro III Pharm World Sci 2007 De	29(6):688-94 Epub 2007 Mar create date:2007/05/05 first author:Nātrhi II	05.05.2007	2007
8 20160828 pubmed 4 20160828 pubmed	y V	Y		n			7479333 Sources of medicine information and their reliability evaluated by medicine users. Nätrchi U. Pharm World Sci. 2007 De 1965547 The impact of reduced drue prices on the costs affectiveness of MART in South Africa. Natrosci N. Geffen N. Afri AIDS Res. 2005 Marc	29(6):688-94. Epub 2007 Mar create date:2007/05/05 first author:NÄ#rhi U 1):55-7 doi: 10.2889/160859 create date:2005/05/01 first author:Nattracs N	05.05.2007	2007
8 20160828 pubmed 4 20160828 pubmed 2 20172131 Scores	y y y	У		n n			7479353 Sources of medicine information and their reliability evaluated by medicine users. NÄerhi U. Pharm World Sci. 2007 De S865643 The impact of reduced drug prices on the cost-effectiveness of HAART in South Africa. Nattras N, Geffen N. Afri ADS Res. 2005 May: Destinguished information in Valence. Destinguished and the cost-effectiveness of HAART in South Africa. Natures T. & Boundead C. & Destinguished and the cost of the cost-effectiveness of HAART in South Africa.	29(6):688-94. Epub 2007 Ma create date:2007/05/05 first author:NÄisrhi U 1):65-7. doi: 10.2989/160859 create date:2005/05/01 first author:Nattrass N a 11# Centure	05.05.2007 01.05.2005	2007 2005 2015
8 20160828 pubmed 4 20160828 pubmed 2 20172131 Scopus 2 20150828 pubmed	у у у у у	Y		n n			7479335 Sources of medicine information and their reliability evaluated by medicine users. Nahr IU. Pherm World Sci. 2007 De Natrices N Ceffers N Afri J AGS Des. 2005 March Martines N Ceffers N Afri J AGS Des. 2005 March Phermacentical pricing policies in Vietnam Martine N Ceffer N Afri J AGS Des. 2005 March Martines N Ceffers N Afri J AGS Des. 2005 March Phermacentical pricing policies in Vietnam Phermacentical pricing policies in Vietnam	29(6):688-94. Epub 2007 Ma create date:2007/05/05 first author:NÄIRrhi U 1):65-7. doi: 10.2989/160859 create date:2005/05/01 first author:Nattrass N 21st Century 00/10/57. Bol date:10.1002/create date:2016/00/1/61 Eist author:Naturass TA	05.05.2007 01.05.2005	2007 2005 2015
8 20160828 pubmed 4 20160828 pubmed 2 20172131 Scopus 2 20160828 pubmed 1 20160828 pubmed	у у у у у у у	Y		n n n			273233 Sources of medicine information and their reliability evaluated by medicine users. Nahrin U. Pherm World's Sci. 2007 De 265845 The impact of reduced drug prices on the cost effectiveness of MAXE Ti South Africa. Nattrass N. Geffen N. Afri JAS DE Re. 2005 Mayre 266846 The impact of reduced drug prices on the cost effectiveness of MAXE Ti South Africa. Nattrass N. Geffen N. Afri JAS DE Re. 2005 Mayre 267846 The impact of reduced regular prices and model inclusion econtexts. Nattrass N. Geffen N. Marine exited in Price and prices and p	29(6):688-94. Epub 2007 Mar create date:2007/05/05 first author:Nåarhi U 1):657. doi:10.2989/160393 create date:2005/05/01 first author:Natriss N 2:31x Century r;30(2):267-80. doi: 10.1093/create date:2014/01/16 first author:Natriss 1M	05.05.2007 01.05.2005 16.01.2014	2007 2005 2015 2014
8 20160828 pubmed 4 20160828 pubmed 2 20172131 Scopus 2 20160828 pubmed 1 20160827 medline	У У У У У У У У У	У		n n n			2747335 Sources of medicine information and their reliability evaluated by medicine users. Narin U. Pherm World Sci. 2007 De 2763356 The import of noticed display reliability evaluated by medicine users. Narin U. Pherm World Sci. 2007 De 2763356 The import of noticed display reliability evaluated by medicine users. Nattrass N. Geffers N. Aff 20 SER 2005 Object 2763356 The import of noticed display reliability evaluated by medicine. Nattrass N. Geffers N. Aff 20 SER 2005 Object 2763356 The import of notice display reliability evaluated by medicine. Nattrass N. Geffers N. Nattrass N. Phermacentical pricing policies in Vietnam 2763376 Object options for pharmaceutical pricing and purchasing: issues for low- and middle-income counties. Nagyere TA. Knight R. Roughead EE, Broosk C. (Heath Policy Plan. 2015 M 2763376 Object options for pharmaceutical pricing infects of purchasing: medicine: a cross-country comprison of the affordati. Vietnis LM, Cameron A, Van de Polic F, Seren M, Borower WB, Laing K. Nattrass N, Cameron A, Van de Polic F, Seren M, Borower WB, Laing K.	296(5):894 Epub 2007 Mar create date:2007/05/05 first author:NAImH U 11557 . doi:10.2989/160859 create date:2005/05/01 first author:Nattras N 21si Century ;;30(2):267-80. doi: 10.1093/ create date:2010/05/09 first author:Naims IM create date:2010/09/09 first author:Naims IM	05.05.2007 01.05.2005 16.01.2014 09.09.2010	2007 2005 2015 2014 2010
20160828 pubmed 20160828 pubmed 20172131 Scopus 20160828 pubmed 20160828 pubmed 20160827 medline S 20160828 pubmed	y y y y y y y y y	y y		n n n n			ZAT9325 Sources of medicine information and their reliability evaluated by medicine users. Nikmin U. Pherm World's Sci. 2007 De States N. Center Torking of professional information and their reliability evaluated by medicine users. Nattras N. Center N. Afri John Sen. 2005 Mym. Bit Informatic of profused Torking of any professional information and their reliability evaluated by medicine users. Nattras N. Center N. Martines N. Ma	290(568-4) (pa) 207 Me create date 2007/50/6 First author-Nikerh U 1165 - doi: 10.297/60169 create date:2007/50/6 First author-Nikerh U 2134 Century 2134 Century 2132 Century 2012/2078 doi: 10.1039/ create date:2014/01/16 first author:Nikern IM 268 Suppl:1513-7 doi: 10.1 create date:2014/01/16 first author:Nikern IM 268 Suppl:1513-7 doi: 10.1 create date:2014/01/16 first author:Nikern IM	16.01.2007 05.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011	2007 2005 2015 2014 2010 2011
8 20160828 pubmed 2 20172131 Scopus 2 20172131 Scopus 2 20160828 pubmed 1 20160827 medline 5 20160827 medline 9 20160828 pubmed	y y y y y y y y y y	y		n n n n y Synthesis/Comment	Y Policy > Invest (R&D)	n N	747935 Sources of medicine information and their reliability evaluated by medicine users. Narhu U. Pherm World Sci. 2007 De 767935 Sources of medicine information and their reliability evaluated by medicine users. Nattrass N. Geffen N. Aff 205 Es. 2005 Mp. 767936 The manaceutical pricing policie in Velnam The South Aff 201 South	298(548.4 5, 50a) 2007 Mer create date:2007/55/05 [First author:Niterite U 11657 dei: 10.2989/56058 Greate date:2005/55/01 [First author:Niteris U 2 137 Century 2)212 Feb doi: 10.1033/ create date:2016/15/15 [First author:Niteris IM create date:2010/99/09 [First author:Niteris IM 668 Suppl:5133-7. doi: 10.1 create date:2011/80/09 [First author:Niteris M 11372-96 doi: 10.1000/00 create date:2011/80/04 [First author:Niteris M	05.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2016	2007 2005 2015 2014 2010 2011 2016
8 20160828 pubmed 4 20160828 pubmed 2 20172131 Scopus 2 20160828 pubmed 1 20160827 medline 5 20160828 pubmed 9 20160911 pubmed 1 20160827 medline	у у у у у у у у у у у у у	y y		n n n y Synthesis/Comment	Y Policy > Invest (R&D)	n N	X197313 Sources of medicine information and their reliability evaluated by medicine users. Nikrit IU. Pherm World's X1: 2007 De Key State The impact of relaxed drug prices on the cost effectiveness of MAXI Ti Soukh Mrfria. Nattrass IX, Geffen N. Afri JAG Fes. 2003 Myrri Key State The impact of relaxed drug prices on the cost effectiveness of MAXI Ti Soukh Mrfria. Nattrass IX, Geffen N. Afri JAG Fes. 2003 Myrri Key State Topic state s	236(568-44 (pa) 2007 Mer credet date:2007/65/67 [Frist author-Nikerh U 11657 - doi: 10.293/6610699 credet date:2005/65/61 [Frist author-Nikerh U 2143 Century 2143 Century 2143 Century 2143 Century 2143 Century 2143 Century 2143 Century 2143 Century 2144 Cenu	05.05.2007 01.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2016 2013	2007 2005 2015 2014 2010 2011 2016 2013
20160828 pubmed 20160828 pubmed 20160828 pubmed 20172131 Scopus 20160827 medline	у у у у у у у у у у у у	y y		n n n n n s Synthesk/Comment n	Y Policy > Invest (R&D)	n N	2747335 Sources of medicine information and their reliability evaluated by medicine users. Narrh U. Pharm World Sci. 2007 De 2763356 The impect of networld engine process of HAAPT in South Africa. Nattrass N, Geffers N. Africa SEe, 2003 Object 2763356 The impect of networld engine process of HAAPT in South Africa. Nayyers TA. Roughead E.E. Pharmaceutical pricing optics in Vietnam 276356 Point genetic reliability evaluating: Kuess for low- and middle-income countrie. Nayyers TA. Roughead E.E. Pharmaceutical pricing optics in Vietnam 276357 Quantifying the impoverabing effects of purchasing medicines: a cross-country comparison of the affordal Netris LM. Cannoc Life. Sauth Pharmaceutical 2013 Sep 2761711 Nord Vietname Channel Channe	298(548)4 (pa) 2007 Me create date:2007/8/5(6) [First author-Nillerik U 11657 dei: 10.298(5)50595 create date:2005/8/5(1) [First author-Nillerik U 2 134 Century 302(12)67 dei: 10.1093) create date:2016/9/16 [First author-Nillerik M 686 Suppl: 51.313-7. doi: 10.1 create date:2010/8/9/09 [First author-Nillerik M 11327-9 doi: 10.1090/00 create date:2011/8/0/V6 [First author-Nillerik M 11327-9 doi: 10.1090/00 create date:2013 002 (200-40. create date:2013)	0.05.2007 01.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2016 2013 14.09.2007	2007 2005 2015 2014 2010 2011 2016 2013 2007
2 20160828 pubmed 2 20160828 pubmed 2 20172131 Scopus 2 20160828 pubmed 1 20160827 medline 9 20160911 pubmed 1 20160827 medline 2 20160827 medline 1 20160827 medline 2 20160827 medline 2 20160827 medline	у у у у у у у у у у у у	y y y		n n n n ynthesis/Comment n	Y Policy > Invest (R&D)	n N	747933 Sources of medicine information and their reliability evaluated by medicine users. Nikrit IU. Pherm World's 221, 2007 De 767935 Sources of medicine information and their reliability evaluated by medicine users. Nikrit IS. Nikr	296(568-4 (spa) 207 Mer create date:2007/65/6 [Fris author-Nikerh U 1157 - doi: 10.297 Mer Create date:2007/65/6 [Fris author-Nikerh U 2143 Century 2143 Century 2143 Century 2152(237-84) doi: 10.1039/ create date:2014/01/16 [Fris author-Nikerh M 665 Suppl: 5133 - doi: 10.1034 (create date:2014/01/16 [Frist author-Nikerh M 11:3127-96 doi: 10.1158/0001 create date:2016/07/20 [Frist author-Nikerh M 11:3127-96 doi: 10.1158/0001 create date:2016/07/20 [Frist author-Channa A mer (Hanton K, Peneth K) create date:2017/8/17 [Frist author:20 formel TP 021:205-40. create date:2007/8/74 [Frist author:20 formel TP 9,12159:33-48. create date:2007/8/74 [Frist author:20 formel TP 9,12159:33-48. create date:2007/8/74 [Frist author:20 formel TP	30.00,2007 05.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2016 2013 14.09.2007 15.07.2015	2007 2005 2015 2014 2010 2011 2016 2013 2007 2015
20160828 pubmed 20160828 pubmed 20160828 pubmed 20172131 Scopus 20160828 pubmed 20160828 pubmed 20160827 medline 20160828 pubmed	у у у у у у у у у у у у у у у	y y y y	y	n n n y Synthesi/Comment n n	Y Policy > Invest (R&D)	n N	2013215 Sources of medicine information and their reliability evaluated by medicine users. Natritus N, Ceffen N. Pharma World's Sci. 2007 De Vision 2014 2014 The improvement of information and their reliability evaluated by medicine users. Natritus N, Ceffen N. Africa Sci. 2007 De Vision 2014 2014 The improvement of information and their reliability evaluated by medicine users. Natritus N, Ceffen N. Africa Sci. 2007 De Vision 2014 2014 Discipoticies of information and their reliability evaluated by medicine users of their information and their reliability evaluated by medicine users of their information and their reliability evaluated by medicine users of the information and their reliability evaluated by medicine users of the information and their reliability evaluated by medicine users of the information and their reliability evaluated by medicine users of the information and their reliability evaluated by medicine users of the information and their reliability evaluated by medicine users of their information and their reliability evaluated by medicine users of their information and their reliability evaluated by medicine users of their information and their reliability evaluated by medicine users of their information and their reliability evaluated by medicine users of their information and their reliability evaluated by medicine users of their information and their reliability evaluated by medicine users of their information and their reliability evaluated by medicine users of their information and their reliability evaluated by medicine users of their information and their reliability evaluated by medicine users of their information and their reliability evaluated by medicine users of their information and thei	290(588-4 (apa 2007 Me create date-2007/50/5) [Fris author-Nikmh U 1557 - doi: 10.293/50/5059 create date-2007/50/5) [Fris author-Nikms N 2134 Century 2134 Century 21	05.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2016 2013 14.09.2007 15.07.2015 01.05.2010	2007 2005 2015 2014 2010 2011 2016 2013 2007 2015 2010
2016/6828 pubmed 2016/828 pubmed 2017131 Scopus 2016/828 pubmed	y y y y y y y y y y y y y y	Y Y Y	y	n y Synthesi/Comment n y southesi/Comment n y southesi/Comment n y southesi/Comment southes	Y Policy > Invest (R&D) n Prices > Expenditures	n N Y n	7479335 Sources of medicine information and their reliability evaluated by medicine users. Narhari N, Leffen N. Pharm World's Sci. 2007 De 7679356 The impact of reduced drug process of MAXE Till South Africa. Nattrass N, Genet N. Africa Sci. 2007 De 7678356 The impact of reduced drug process of MAXE Till South Africa. Nayers TA, Knight R, Rosynded EL, E. Pharmaceutical pricing policies in Vietnam 7678356 Quantifying the importanting effects of partametal pricing and purchasing medicines: a cross country comparison of the affordal Niets NL, Cameron A, Van de Policy E, Seven N, Horower WJ, Lang R. 7678357 Quantifying the importanting effects of partametal polici health Amagement. Noviet M, Lameron A, Van de Policy E, Seven N, Horower WJ, Lang R. 7678357 Voorand Value-Based Pricing to Boott Cancer Research and Innovation. Conand A, Amir C, Francok T, Hurrose C, Policabil Le Abith Thanapari market. O Conand KLA, Polycer S, Solomon T, Hurrose C, Policabil Le Abith Thanapari Market. 7678358 Precipition or proscription The general Tabler of attempts to liggtar and legislate against PBMS at fiduca U Optiche MA, Nu L, Market A, Market C, Market M, Mang Lere Z, Stöll 7678358 Precipition or proscription The general Tabler of Pattempts to Biggtar and legislate against PBMS at fiduca U Optiche M, Nu L, Market M, Mang Lere Z, Stöll 7678359 Stender Level of Patted Research and Innovation	296(568.4 (spa) 207 Me: create date:2007/65/6 [First author-Niterit U 1157 - doi: 10.297 Me: create date:2006/65/01 [First author-Niterits N 2143 Century (77)(2376 40: 01.297 Me: Control (117)(116) [First author-Niterits N (78)(2376 40: 01.1016)(24)(78) [First author-Niterits M (78)(25)(78)(78)(78)(78)(78)(78)(78)(78)(78)(78	30.00.2007 05.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2016 2013 14.09.2007 15.07.2015 01.05.2010 17.09.2013	2007 2005 2015 2014 2010 2011 2016 2013 2007 2015 2010 2013
2016/0828 pubmed 2016/0828 pubmed 2017131 Scopus 2016/0828 pubmed	y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y	Y Y Y	у	n n s synthesid/Comment n Economic model (analytic, empirical data)	Y Policy > Invest (R&D) n Prices > Expenditures	n N y n	2013 Sources of medicine information and their reliability evaluated by medicine users. Natritus N, Celler NA Pharma Work 52:1, 2007 De 2014 The information and their reliability evaluated by medicine users. Natritus N, Celler NA MATA 56 Ex. 2005 May 2014 The information and their reliability evaluated by medicine users. Natritus N, Celler NA MATA 56 Ex. 2005 May 2014 Markine N of relaxed source in the cost efficiences of MAX in South MArica. Natritus N, Celler NA MATA 56 Ex. 2005 May 2014 Natritus N, Celler NA Natritus N, Celler NA Natritus N, Celler NA Natritus N, Celler NA Natritus N, Celler NA, Van 6 Poly RA 10, 2014 Natritus N, Celler NA, Van 6 Poly RA 10, 2014 Natritus N, Celler NA, Van 6 Poly RA 10, 2014 Natritus N, Celler NA, Van 6 Poly RA 10, 2014 Natritus N, Celler NA, Van 6 Poly RA 10, 2014 Natritus N, Celler NA, Van 6 Poly RA 10, 2014 Paramacul 2015 Bay Paramacul 2015 Ba	290(588-4) (apa 2007 Me create date:2007/05/05 [Fris author-Nikerh U 1165 - doi: 10.299/arceate date:2014/07/15 [Fris author-Nikers M 2134 Century 2134 C	30.06.1207 05.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2016 2013 14.09.2007 15.07.2015 01.05.2010 17.09.2013 08.02.2006	2007 2005 2015 2014 2010 2011 2016 2013 2007 2015 2010 2013 2006
2016/0828 pubmed 2016/0828 pubmed 2017131 Scopus 2016/0828 pubmed 1 2016/0828 pubmed 2016/0828 pubmed 2016/0828	y y y y y y y y y y y y y y y y y y y	Y Y Y	y	n n y Synthesi/Comment y y synthesi/Comment n n n n n n n n n n y synthesi/Comment n n n n n n n n n n n n n	Y Policy > Invest (R&D) n Prices > Expenditures	n N y n	2479335 Sources of medicine information and their reliability evaluated by medicine users. Narharis N, Gelfen N. Pherrar World's Sci. 2007 De 267836 The impact of reduced drug process of MAXE Till South Africa. Nattrass N, Gelfen N. Africa File. 2007 De 267837 Marmaceutical pricing policies in Vietnam Naparo TA, Foughead EL. Pherrareceutical pricing policies in Vietnam 26840 Marging Configuration of the state of the	296(568.4 (pa) 207 Me create date 2007/6/05 [frs author-Nikerh U 1157 - doi: 10.297 (doi: 10.693 create date 2005/6/01 [frst author-Nikers M 2143 Century 702)2376 840 doi: 10.1033/ create date-2014/01/16 [frst author-Nikers M 666 Suppl S131 - 74.0 : 10.1 create date-2014/01/16 [frst author-Nikers M 11.1127 - 94.0 : 10.1 create date-2014/01/16 [frst author-Chains A 11.1127 - 94.0 : 10.1 create date-2015/07/20 [frst author-Chains A 11.1127 - 94.0 : 10.1 create date-2015/07/20 [frst author-Chains A 11.1127 - 94.0 : 10.1 create date-2015/07/20 [frst author-Chains A 11.1127 - 94.0 : 10.1 create date-2015/07/20 [frst author-Chains A 11.1127 - 94.0 : 10.1 create date-2015/07/20 [frst author-Chains A 11.1127 - 94.0 : 10.1 create date-2015/07/20 [frst author-Chains A 11.1127 - 94.0 : 10.1 create date-2015/07/20 [frst author-Chains A 11.1127 - 94.0 : 10.1 create date-2015/07/20 [frst author-Chains A 11.1127 - 94.0 : 10.1 create date-2015/07/20 [frst author-Chains A 11.1127 - 94.0 : 10.1 create date-2003/07/20 [frst author-Chains A 11.1127 - 94.0 : 10.1 create date-2005/07/20 [frst author-Chains A 11.1127 - 94.0 : create date-2005/07/20 [frst author-Chains A 11.1127 - 11.1127 - 11.1127 - 11.1127 - create date-2005/07/20 [frst author-Chains A 11.1127 - 11.1127 - 11.1127 - 11.1127 - 11.1127 - create date-2005/07/20 [frst author-Chains A 11.1127 - 21.1127 - 11	30.00.2007 05.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2016 2013 14.09.2007 15.07.2015 01.05.2010 17.09.2013 08.02.2006 10.10.2009	2007 2005 2015 2014 2010 2011 2016 2013 2007 2015 2010 2013 2000 2013 2006 2009
2016/6828 pubmed 20171131 \$Copus 20171131 \$Copus 2016/6828 pubmed	y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y y	Y Y Y Y	y	n n n y y Synthesia/Comment n c Economic model (analytic, empirical data) n	Y Policy > Invest (R&D) n Prices > Expenditures	n N y n	2019 Sources of medicine information and their reliability evaluated by medicine users. Nutritus N, Celler NA Pharma WorkS12, 12007 De 2019 Sources of medicine information and their reliability evaluated by medicine users. Nutritus N, Celler NA M120 Sec. 2007 De 2019 Marma exitical pricing ond purchasing medicines: screen on the cost effectiveness of MAXIF is South Mrica. Nutritus N, Celler NA M120 Sec. 2007 De 2019 Source of paramaceutical pricing and purchasing medicines: a cross-country comparison of the alfordal NRINK N, Cameron A, Van de Poel N, Fougher AL E, Levis N, Bouyene AL E, Levis N, Bouwene YN, Lang R, Ling R,	296(588-44 (pa) 2007 Mer crede date:2007/05/05 [Frist author-Nikerh U 1165 - doi: 10.293/crede date:2005/05/01 [Frist author-Nikerh U 2114 Century 2012 Genetary 2012 G	30.06.1207 05.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2016 2013 14.09.2007 15.07.2015 01.05.2010 17.09.2013 08.02.2006 10.10.2009 02.04.2015	2007 2005 2014 2010 2011 2016 2013 2007 2015 2010 2013 2006 2009 2015
2016/0828 pubmed 2016/0828 pubmed 20171313 [Scopus 2016/0828 pubmed	y y y y	Y Y Y Y Y	у	n n n y synthesi/Comment n c c conomic model (analytic, empirical data) n	Y Policy > Invest (R&D) n Prices > Expenditures	n N y n	2013215 Sources of medicine information and their reliability evaluated by medicine users. Natrita N, Ceffen N, Martina S, Martina	296(568/4, Equa 2007 Mer crede date:2007/65/6 [First author:Niterh U 1156 - Aio: 12.039/ Crede date:2005/65/01 [First author:Niters N 214 Century 7:02(3267 840 date:10.1039/ crede date:2014/01/16 [First author:Niters N 665 Sup[15137 - Ao: 10.239/ crede date:2014/01/16 [First author:Niters N 665 Sup[15137 - Ao: 10.1116/01/16 [First author:Niters N 665 Sup[15137 - Ao: 10.1116/01/16 [First author:Niters N 665 Sup[15137 - Ao: 10.1116/01/16 [First author:Object] 665 Sup[15137 - Ao: 10.1116/01/16 [First author:Object] 667 Sup[15147 - Ao: 10.1116/01/16 [First author:Object] 667 Sup[151467 Ao: 00.1116/01/16 [First author:Object] 671 Sup[151467 Ao: 00.1116/01/16 [First author:Object] 672 Sup[15147 Ao: 00.1116/01/16 [First author:Object] 720 Sup[15147 Ao: 00.1116/01/16 [First author:Object] 721 Sup[15147 Ao: 00.1116/01/16 [First author:Object] 721 Sup[15147 Ao: 00.1116/01/16 [First author:Palse Ai: 10.1011/16/21407 Ao: 00.1116	30.00.12007 G1.05.2007 G1.05.2005 G1.05.2005 G1.05.2005 G1.05.2016 2013 A4.08.2011 A4.08.2007 15.07.2015 G1.05.2010 17.09.2013 08.02.2006 10.10.2009 G2.04.2015 O7.05.2015	2007 2007 2015 2014 2010 2011 2016 2013 2007 2015 2010 2013 2006 2009 2015 2015 2015
2 20160828 pubmed 2 2010828 pubmed 2 2012111 Stopps 2 2012111 Stopps 2 20120828 pubmed 1 20160827 mediae 2 20120828 pubmed 2 20160828 pubmed	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Υ Υ Υ Υ Υ	y	n n y Synthesi/Comment n c c v v Sunthesi/Comment v v v v v v v v v v v v v v v v v v v	Policy > Invest (R&D) Policy > Invest (R&D) Policy > Expenditures Policy (descriptive)	n N y n	Yangsa Sources of medicine information and their reliability evaluated by medicine users. Number IU Pherr World's Sci. 2007 De Sector of relaxed and process on the cost effectiveness of MAKIT is Soukh Africa. Nattras N, Geller N. Africa Sci. 2007 De Marmaceutical pricing policies in Vietnam Naparo TA. Roughead E.E. Pherrometerskical Pricing policies in Vietnam Naparo TA. Roughead E.E. Pherrometerskical Pricing policies in Vietnam Status N, Ceder of pharmaceutical pricing and purchasing medicines: a cross country comparison of the affordal Nietna NA, Cameron A, Van de Policies J, Forwork I, Househ Pall, Camero M, Juang E. Naparo TA. Koughead E.E. Pherrometerskical Pricing policies in Vietnam Pharmace.2016 (Figure N, Browert NI, Lang R. Vandri Value Elsend Pricing to Boost Cancer Research and Innovation. Ocranal A, Amir F, Trannock F.T. Cancer Res. 2016 (Sinual E - N, Naparo TA, Sourghead E.E. Pharmace.2016 (Sinual E - N, Naparo TA, Sourghead E.E. Pharmace.2016 (Sinual E - N, Naparo TA, Sourghead E.E. Pharmace.2016 (Sinual E - N, Naparo TA, Sourghead E.E. Pharmace.2016 (Sinual E - N, Naparo TA, Sourghead E.E. Pharmace.2016 (Sinual E - N, Naparo TA, Sourghead E.E. Pharmace.2016 (Sinual E - N, Naparo TA, Sourghead E.E. Pharmace.2016 (Sinual E - N, Naparo TA, Sourghead E.E. Pharmace.2016 (Sinual E - N, Naparo TA, Sourghead E.E. Pharmace.2016 (Sinual E - N, Naparo TA, Sourghead E.E. Pharmaceutical Pricing and Market Acceso Southol Gospito and Naparo TA,	296(588-44 (pa) 207 Mer crete date:2007/50/51 [Frist author-Nikerh U 1167-7, doi: 10.297/610699 crete date:2005/60/11 [Frist author-Nikerh U 2143 Century 2143 Century 2144 Century	30.00.12007 G5 05.2007 G1 05.2005 G1 05.2005 G1 05.2005 G1 05.2005 G1 05.2010 G4 08.2011 2015.2016 G1 05.2010 17.09.2013 G8 02.2006 10.10.2009 02.04.2015 G7 05.2015 J4 06.2016	2007 2005 2015 2014 2010 2011 2016 2013 2007 2015 2010 2013 2006 2009 2015 2015 2015 2015
2 2016823 pubmed 2 2016823 pubmed 2 2016823 pubmed 2 2016827 mediat 2 2016827 pubmed 2 2016827 pubmed 2 2016887 pubmed 2 2016888 pubmed	Y Y Y Y	Y Y Y Y Y	y	n n y Synthesi/Comment n n s s s s s s s s s s s s s s s s s	Y Policy > Invest (R&D) Prices > Expenditures Prices > Expenditures Prices > Expenditures Policy (descriptione) Policy (descriptione)	n N y n y N	2013 Sources of medicine information and their reliability evaluated by medicine users. Nativa N, Cell Phenrol Work Sci. 2007 De 2014 Marmaceutical pricing ond purchasing insues of MAXIF in South Mrica. Nativa N, Cell Marmaceutical pricing ond purchasing insues of MAXIF in South Mrica. Nativa N, Cell Phenrol Work Sci. 2007 De 2014 Marmaceutical pricing ond purchasing insues of MAXIF in South Mrica. Nativa N, Cell Phenrol Work Sci. 2007 De 2014 Marmaceutical pricing ond purchasing insues for New and middle-income countrie. Nativa N, Cell Roley ond LE, Rousset I, Rousset I	290(589.4 (apa 207 Me create date:207/50/5 [Fris.author:Nitren U 11567. doi: 10.293/create date:2014/01/16 [Fris.author:Nitren N 2134 Century 2134 Centur	3.0.00.2.007 01.05.2005 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2016 20.13 20.13 20.15.2010 11.05.2010 11.05.2010 10.10.2009 02.04.2015 10.06.2016 12.099 12.009 10.05.2015 12.009 10.05.2015 12.009 10.05.2015 10.05.2016 10.05.2015	2007 2005 2015 2014 2010 2011 2016 2013 2006 2013 2006 2009 2015 2016 2009 2015 2016 2009
2 20106823 pubmed 2 2010582 pubmed 2 2010582 pubmed 2 2010682 pubmed 2 2010682 pubmed 2 20106827 pubmed 2 20106828 pubmed 2 20106828 pubmed 2 20106828 pubmed 2 20106828 pubmed 2 20106882 pubmed 2 </td <td>Y Y Y Y</td> <td>y y v v</td> <td>Y</td> <td>n Synthesia/Comment Synthesia/</td> <td>Policy > Invest (R&D) Policy > Invest (R&D) Prices > Expenditures Policy (description) Policy (description) Policy (description)</td> <td>n N y n y N y n</td> <td>2479325 Sources of medicine information and their reliability evaluated by medicine users. Natrita N, Celler N. Pharm World Sci. 2007 De 268 The import of relaxed drug prices on the cost effectiveness of MAKIT is South Africa. Natrita N, Celler N. Africa Field Sci. 2007 De 268 The import of relaxed circuit of relaxed and prices and maximum sci. 2007 De Natrita N, Celler N. Africa Field Sci. 2007 De 268 Policy of relaxed circuit of relaxing and prices in the difference countrie. Natrita N, Celler Cell A, North Policy R, Roughed EL, Event M, Horower MJ, Lang R. 268 Sci of relaxed circuit of a sprach king in difference so country comparison of the affordad Nitros M, Cameron A, Van de Policy F, Scionon T, Murres E, France K-E. Devauer Value Sci of a sprach king in difference so country comparison of the affordad Nitros M, Sci of Accer Res. 2016 Sci on 17.6 278428 Montries frameworks in difference access from the animaliani market. Occamel A, Amir E, Trancek T, Marce E, Francek T, Marce C, Francek T, Marcek T, Prancek T, Marcek T, Prancek T, Marcek T, Marce</td> <td>296(568-44 (pa) 207 Mer crete date 2007/50/51 [Frist author-Nikerh U 1167-7 doi: 10.297/610699 crete date 2005/60/11 [Frist author-Nikerh U 2143 Century 2143 Century 2144 Century</td> <td>3.000.12007 01.05.2005 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2016 20.13 20.05.2016 10.05.2010 17.09.2013 08.02.2006 10.10.2009 02.04.2015 07.05.2015 27.09.2015 20.0015 20.0015</td> <td>2007 2005 2015 2014 2010 2011 2016 2013 2007 2015 2010 2009 2015 2015 2015 2016 2016 2013</td>	Y Y Y Y	y y v v	Y	n Synthesia/Comment Synthesia/	Policy > Invest (R&D) Policy > Invest (R&D) Prices > Expenditures Policy (description) Policy (description) Policy (description)	n N y n y N y n	2479325 Sources of medicine information and their reliability evaluated by medicine users. Natrita N, Celler N. Pharm World Sci. 2007 De 268 The import of relaxed drug prices on the cost effectiveness of MAKIT is South Africa. Natrita N, Celler N. Africa Field Sci. 2007 De 268 The import of relaxed circuit of relaxed and prices and maximum sci. 2007 De Natrita N, Celler N. Africa Field Sci. 2007 De 268 Policy of relaxed circuit of relaxing and prices in the difference countrie. Natrita N, Celler Cell A, North Policy R, Roughed EL, Event M, Horower MJ, Lang R. 268 Sci of relaxed circuit of a sprach king in difference so country comparison of the affordad Nitros M, Cameron A, Van de Policy F, Scionon T, Murres E, France K-E. Devauer Value Sci of a sprach king in difference so country comparison of the affordad Nitros M, Sci of Accer Res. 2016 Sci on 17.6 278428 Montries frameworks in difference access from the animaliani market. Occamel A, Amir E, Trancek T, Marce E, Francek T, Marce C, Francek T, Marcek T, Prancek T, Marcek T, Prancek T, Marcek T, Marce	296(568-44 (pa) 207 Mer crete date 2007/50/51 [Frist author-Nikerh U 1167-7 doi: 10.297/610699 crete date 2005/60/11 [Frist author-Nikerh U 2143 Century 2143 Century 2144 Century	3.000.12007 01.05.2005 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2016 20.13 20.05.2016 10.05.2010 17.09.2013 08.02.2006 10.10.2009 02.04.2015 07.05.2015 27.09.2015 20.0015 20.0015	2007 2005 2015 2014 2010 2011 2016 2013 2007 2015 2010 2009 2015 2015 2015 2016 2016 2013
2 2016828 pulmed 2 2010121 Sopus 2 2010125 pulmed 2 2010125 <td>Y Y Y Y</td> <td>Y Y Y Y Y</td> <td>y</td> <td>n o o o o Spinbesk/Comment o o Spinbesk/Comment o o S Spinbesk/Comment o S Spinbesk/Comment o Spinbesk/Comme</td> <td>Y Policy > Invest (R&D) Prices > Expenditures Prices > Expenditures Vices > Expenditures Vices (descriptive) Vices (descriptive) Vices (descriptive) Vices (descriptive) Vices (descriptive)</td> <td>n N y n y n y n y n</td> <td>2019216 Sources of medicine information and their reliability evaluated by medicine users. Nutritus N, Cerlin M, Sources OF, Martina SN, Sources OF, Sour</td> <td>290(589.4 (pa) 207 Me create date:207/50/5 [Frist author:Niterin U 1165 / doi: 10.297/2 create date:2014/01/15 [Frist author:Niterin M 2134 Century 2134 Century 2134 Century 2134 Century 2134 Century 2134 Century 2134 Century 2134 Device date:2014/01/15 [Frist author:Niterin M 868 Suppl:S133-7 doi: 10.1 create date:2014/01/15 [Frist author:Niterin M 8134 DF 40 doi: 10.1158/000 Create date:2014/01/27 [Frist author:Chana A 1134 DF 40 doi: 10.1158/000 Create date:2015/01/27 [Frist author:Chana A 1134 DF 40 doi: 10.1158/000 Create date:2015/01/25 [Frist author:Chana A 1134 DF 40 doi: 10.1158/000 Create date:2015/01/25 [Frist author:Chana A 1134 DF 40 doi: 10.1158/000 Create date:2013/09/27 [Frist author:Chana A 0054 Jug/262/13747. create date:2013/09/27 [Frist author:Chenha M 059 Aug/262/13747. create date:2013/09/27 [Frist author:Chenha M 509 Aug/262/13747. create date:2013/09/27 [Frist author:Chenha M 509 Aug/262/13747. create date:2013/09/27 [Frist author:Chenha M 509 Aug/262/13747. create date:2013/00/27 [Frist author:Pails B 1131/2146 doi: 10.1039/ create date:2013/00/27 [Frist author:Pails B 113</td> <td>2005 05 2007 01:05 2005 16:01 2044 06:09 2010 04:08 2011 20:05 2016 10:02 2016 10:02 2016 10:02 2016 10:02 2016 10:02 2016 10:02 2016 10:02 2016 10:02 2006 02:04 2015 10:02 2005 10:02 2005 10:02 2005 10:02 2015 10:06 2015 10:06 2016 10:06 200 10:06 200 10:06 200 1</td> <td>2007 2005 2015 2014 2010 2011 2016 2013 2007 2015 2010 2013 2006 2009 2015 2015 2015 2016 2015 2015 2016</td>	Y Y Y Y	Y Y Y Y Y	y	n o o o o Spinbesk/Comment o o Spinbesk/Comment o o S Spinbesk/Comment o S Spinbesk/Comment o Spinbesk/Comme	Y Policy > Invest (R&D) Prices > Expenditures Prices > Expenditures Vices > Expenditures Vices (descriptive) Vices (descriptive) Vices (descriptive) Vices (descriptive) Vices (descriptive)	n N y n y n y n y n	2019216 Sources of medicine information and their reliability evaluated by medicine users. Nutritus N, Cerlin M, Sources OF, Martina SN, Sources OF, Sour	290(589.4 (pa) 207 Me create date:207/50/5 [Frist author:Niterin U 1165 / doi: 10.297/2 create date:2014/01/15 [Frist author:Niterin M 2134 Century 2134 Century 2134 Century 2134 Century 2134 Century 2134 Century 2134 Century 2134 Device date:2014/01/15 [Frist author:Niterin M 868 Suppl:S133-7 doi: 10.1 create date:2014/01/15 [Frist author:Niterin M 8134 DF 40 doi: 10.1158/000 Create date:2014/01/27 [Frist author:Chana A 1134 DF 40 doi: 10.1158/000 Create date:2015/01/27 [Frist author:Chana A 1134 DF 40 doi: 10.1158/000 Create date:2015/01/25 [Frist author:Chana A 1134 DF 40 doi: 10.1158/000 Create date:2015/01/25 [Frist author:Chana A 1134 DF 40 doi: 10.1158/000 Create date:2013/09/27 [Frist author:Chana A 0054 Jug/262/13747. create date:2013/09/27 [Frist author:Chenha M 059 Aug/262/13747. create date:2013/09/27 [Frist author:Chenha M 509 Aug/262/13747. create date:2013/09/27 [Frist author:Chenha M 509 Aug/262/13747. create date:2013/09/27 [Frist author:Chenha M 509 Aug/262/13747. create date:2013/00/27 [Frist author:Pails B 1131/2146 doi: 10.1039/ create date:2013/00/27 [Frist author:Pails B 113	2005 05 2007 01:05 2005 16:01 2044 06:09 2010 04:08 2011 20:05 2016 10:02 2016 10:02 2016 10:02 2016 10:02 2016 10:02 2016 10:02 2016 10:02 2016 10:02 2006 02:04 2015 10:02 2005 10:02 2005 10:02 2005 10:02 2015 10:06 2015 10:06 2016 10:06 200 10:06 200 10:06 200 1	2007 2005 2015 2014 2010 2011 2016 2013 2007 2015 2010 2013 2006 2009 2015 2015 2015 2016 2015 2015 2016
2 2016828 pulmed 2 2016828 pulmed 2 2016928 pulmed 2 2016928 pulmed 3 2016928 pulmed 2 2016927 pulmed 3 2016927 pulmed 2 2016928 pulmed 2 201	Y Y Y Y	Y Y Y Y	Y	n n y y synthesi/Comment n s s s s s s s s s s s s s	Yolcy > Invest (I&D) Prices > Expenditures Prices > Expenditures Prices > Expenditures Prices (descriptive) Prices (descr	n N y n y n y n y n y n y n	Autors II. Nummer Nummer Perm Worlds St. 2007 De 2019 Sources of medicine information and their reliability evaluated by medicine users. Nummer Vol. 2017 De Nummer Vol. 2017 De 2019 Marmaceutical price optices in Vietnam Nummer Vol. 2017 De Nummer Vol. 2017 De 2019 Marmaceutical price optices in Vietnam Nummer Vol. 2017 De Nummer Vol. 2017 De 2019 Marmaceutical price optices in Vietnam Nummer Vol. 2017 De Nummer Vol. 2017 De 2019 Marmaceutical price optices in Vietnam Nummer Vol. 2017 De Nummer V	296(568.44 (pa) 207 Mer crete date 2007/65/05 [Fris author-Nikerh U 1157-7 doi: 10.297/610699 crete date 2005/65/01 [Fris author-Nikerh U 2143 Century 2143 Century 2143 Century 2143 Century 2143 Century 2144 Century 2145 Century 21	0 40.6 2007 01.05 2005 16.0.12.004 09.09.2010 04.08.2011 20.05.2016 20.03.2016 20.03.2016 15.07.2015 01.05.2010 01.02.2006 02.04.2015 10.02.2006 02.04.2015 11.46.62.016 12.05.2015 11.46.62.016 12.05.2015 12.05	2007 2005 2015 2014 2010 2011 2016 2013 2007 2015 2010 2015 2010 2015 2015 2015 2015
2 2016828 pubmed 2 2010828 pubmed 2 2010828 pubmed 2 2010828 pubmed 3 2010828 pubmed 3 2010828 pubmed 3 2010828 pubmed 3 2010828 pubmed 1 2010828 pubmed 2 2010828 pubmed	Y Y Y Y	Y Y Y Y	y	n s s s spinbesi/Comment s s s s s s s s s s s s s	Policy > Invest (R&D) Policy > Invest (R&D) Prices > Expenditures Prices > Expenditures Policy (descriptive) Policy (desc	n N y n y n y n y n y n	Variant Number 0. Number 0. Perm World's X1:007 De Variants N, Central Fordical drag process on the cost efficiences of MART in South MAria. Nutras N, Central N, References M, Aldris South MAria. Nutras N, Central N, Roughead EL, Central N, Borghead EL, Central N, Borgh	296(588-44 (pa) 207 Mer crete date:2007/50/51 [Frist author:Niterin U 1165 - dio: 10.293/crete date:2005/60/11 [Frist author:Niterin M 2131 Century 2131 Century 2132	3000 2007 0155 2005 150 2014 0909 2010 04 09 2010 04 09 2010 14 09 2011 14 09 2017 15 07 2015 10 05 2010 10 05 2010 10 05 2010 10 02 2015 10 02 200 10 02 200 10 02 200 10 02 200 10 00 200	2007 2005 2015 2014 2010 2011 2016 2013 2016 2013 2016 2013 2016 2006 2009 2015 2016 2015 2016 2015 2016 2015 2016 2005 2015 2016 2006 2006 2006 2007 2017 2017 2017 2017 2017 2017 2017
2 2016828 pubmed 2 2016827 medine 2 2016927 pubmed 2 2016928 pubmed 2 201	Y Y Y Y	Y Y Y Y	×	n n y Synthesi/Comment y Synthesi/Comment y Synthesi/Comment y Y Cenomic model (analytic, empirical data) n y Synthesi/Comment y Y Cenomic model (analytic, empirical data) n y Synthesi/Comment y Statistical analysi - descriptive Statistical analysi - descriptive Statistical analysi - descriptive	Policy > Invest (R&D) Policy > Invest (R&D) Policy > Expenditures Policy (descriptive) Policy (descr	n N Y n Y n Y n Y n Y n Y n Y n Y n	2019215 Sources of medicine information and their reliability variated by medicine users. Natrita N, Gerlen N. Phorem World's X1: 2007 De Normal Net State	290(589.4 (Jan 2007 Me create date:2007/50/6 [Frist author:Nitren U 1567. doi: 10.293/create date:2014/01/16 [Frist author:Nitren M 2134 Century 2134 Century 213	0 616 2007 01.05 2005 16.0.1.2014 06.08.2010 20.05 2016 20.05 2016 20.03 2010 20.03 2016 20.03 2016 20.03 2016 15.07 20.015 01.05.2010 01.05.2010 01.05.2010 02.04.2015 20.05 20.06 20.06 20.06 20.06 20.06 20.06 20.06 20.06 20.06 20.06 20.06 20.06 20.06 20.06 20.06 20.06 20.06 20.06 20.07 20.06 20.06 20.06 20.07 20.06 20.07 20.06 20.07 20.06 20.07 20.06 20.07 20.06 20.07 20.06 20.07 20.06 20.07	2007 2005 2015 2014 2010 2011 2016 2013 2016 2013 2007 2015 2010 2013 2006 2009 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2016 2017 2017 2017 2015 2016 2017 2017 2017 2017 2017 2017 2017 2017
2 2016828 pubmed 2 2016828 pubmed 2 2016828 pubmed 2 2016828 pubmed 1 2016828 pubmed 2 2016828 pubmed 2 2016928 pubmed	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y	y	n n y y synthesia/Comment r r r r r r r r r r r r r	Policy > Invest (R&D) Policy > Invest (R&D) Prices > Expenditures Policy (descriptive) Policy (descr	n N y n y n y n y n y n y n y n	2013 Source of medicine information and their reliability variatated by medicine users. Nutritus N, Ceffen N. Pherror WorkS1: 2007 De 2014 Marmaceutical pricing ond purchasing sources of MAKIT is Source M MAKIT is Source M. Nutritus N, Ceffen N. Pharmaceutical pricing ond purchasing medicine users. Nutritus N, Ceffen N. Pharmaceutical pricing ond purchasing medicines. Nutritus N, Ceffen N. Nutritus N, Ceffen N. Pharmaceutical pricing ond purchasing medicines. Nutritus N, Ceffen N. Nutrius N, Ceffen N. Nutrius N, Ceffen N.	296(588-44 (pa) 2007 Mer crete date:2007/50/56 [Frist author-Nikerh U 1165 - doi: 10.293/crete date:2005/60/10 [Frist author-Nikerh M 2134 Century 2134 C	0.6.6.2.2007 01.05.2005 16.0.1.2.005 16.0.1.2.005 04.08.2.010 2.005.2.016 04.08.2.011 2.005.2.016 01.05.2.016 01.05.2.016 01.05.2.015 01.05.2.015 01.05.2.015 01.05.2.015 02.04.2.015 07.05.2.015 2.005.2.015 2.008.2.016 2.2.008 2.009 2.007	2007 2005 2015 2014 2010 2011 2016 2013 2007 2015 2010 2013 2006 2015 2015 2015 2015 2015 2015 2015 2015
2 2016828 pubmed 2 2016828 pubmed 2 201711 Scyna 2 201711 Scyna 2 201711 Scyna 2 2016927 medine 2 2016927 medine 2 2016927 pubmed 2 2016928 pubmed 2 2016928 </td <td>Y Y Y Y</td> <td>У У У У У</td> <td>Y</td> <td>n n s s s s s s s s s s s s s</td> <td>Y Policy > Invest (R&D) n Prices > Expenditures y Policy (descriptive) y Policy (descriptive)</td> <td>n N Y n Y n Y n Y n Y n Y n Y n</td> <td>201921 Sources of medicine information and their reliability variatated by medicine users. Natiratis N, Gentellow Pherrow Works's 21, 2007 De 201921 Sources of medicine information and their reliability variatated by medicine users. Natiratis N, Gentellow Pherrow Works's 21, 2007 De 201921 Sources of medicine information and their reliability variatates (NAE) Natiratis N, Gentellow Pherrow Works's 21, 2007 De 201921 Sources of medicine information and their reliability variating medicines: a cross country comparison of the afford 21 Nets NA, Cameron A, Van de Porth Nellow IA, Langeron A, Van de Porth Nellow IA, Langeron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, 2018 De National N, 2018 De<</td> <td>290(5894, Gap 207 Me create date:2007/50/6 [Frist author:Niterin U 1165 - doi: 10.293/create date:2014/01/15 [Frist author:Niterin M 2131 Century 2132 Ce</td> <td>06.05.2007 01.05.2007 01.05.2006 16.0.12.004 99.92.010 04.08.2011 20.05.2016 14.0.0007 14.0.0007 15.07.2015 01.05.2010 01.05.2010 01.05.2010 01.05.2010 01.05.2010 01.05.2010 01.05.2010 01.05.2015 27.09.2013 2006 2006 2007 2007</td> <td>2007 2005 2015 2014 2010 2011 2016 2013 2007 2015 2010 2013 2006 2009 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2017 2017 2017 2017 2017 2017 2017 2017</td>	Y Y Y Y	У У У У У	Y	n n s s s s s s s s s s s s s	Y Policy > Invest (R&D) n Prices > Expenditures y Policy (descriptive)	n N Y n Y n Y n Y n Y n Y n Y n	201921 Sources of medicine information and their reliability variatated by medicine users. Natiratis N, Gentellow Pherrow Works's 21, 2007 De 201921 Sources of medicine information and their reliability variatated by medicine users. Natiratis N, Gentellow Pherrow Works's 21, 2007 De 201921 Sources of medicine information and their reliability variatates (NAE) Natiratis N, Gentellow Pherrow Works's 21, 2007 De 201921 Sources of medicine information and their reliability variating medicines: a cross country comparison of the afford 21 Nets NA, Cameron A, Van de Porth Nellow IA, Langeron A, Van de Porth Nellow IA, Langeron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, Cameron A, Van de Porth Nellow IA, 2018 De National N, 2018 De National N, 2018 De<	290(5894, Gap 207 Me create date:2007/50/6 [Frist author:Niterin U 1165 - doi: 10.293/create date:2014/01/15 [Frist author:Niterin M 2131 Century 2132 Ce	06.05.2007 01.05.2007 01.05.2006 16.0.12.004 99.92.010 04.08.2011 20.05.2016 14.0.0007 14.0.0007 15.07.2015 01.05.2010 01.05.2010 01.05.2010 01.05.2010 01.05.2010 01.05.2010 01.05.2010 01.05.2015 27.09.2013 2006 2006 2007 2007	2007 2005 2015 2014 2010 2011 2016 2013 2007 2015 2010 2013 2006 2009 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2017 2017 2017 2017 2017 2017 2017 2017
8 20106828 pubmed 20106828 pubmed 20106828 pubmed 20106828 pubmed 20106828 pubmed 20106828 pubmed 20106827 pubmed 20106827 pubmed 20106827 pubmed 20106828 pubmed 20106828 pubmed 20106828 pubme	У У У У У У У У У У У У У У У У У У У	Y Y Y Y Y		n n y y Synthesi/Comment n c c c c c c c c c c c c c	Y Policy > Invest (R&D) n Prices > Expenditures y Prices > Expenditures y Prices (descriptive)	n N y n y a y a y a y a y a y a	2019216 Source of medicine information and their reliability variatated by medicine users. Nutritus N, Ceffen N. Phenr World's X1: 2007 De 2019216 Binity and tradiced to garders on the cost effectiveness of MAKT in South Africa. Nutritus N, Ceffen N. All Socies N. 2019216 Binity and tradiced to garders on the cost effectiveness of MAKT in South Africa. Nutritus N, Ceffen N. All Socies N. 2019216 Bioing onlicities in Vietnam Nutritus N, Ceffen N. Nutritus N, C	296(568-44 (pa) 207 Mer crete date:2007/50/51 [Frist author-Niferh U 1167- doi: 10.297/610699 crete date:2016/07/01 [Frist author-Niferh U 2143 Century 2143 Century 2143 Century 2143 Century 2143 Century 2143 Century 2143 Century 2143 Century 2143 Century 2144 Century 2	0.65.2007 01.05.2005 16.0.12.005 09.09.2010 04.08.2011 20.05.2016 04.08.2011 20.05.2016 01.05.2010 15.07.2015 01.05.2010 01.02.2006 01.02.2006 01.02.2005 01.02.2016 27.09.2015 22.08.2016	2007 2007 2005 2015 2014 2014 2010 2011 2016 2017 2017 2015 2010 2013 2006 2009 2015 2016 2013 2016 2015 2016 2017 2015 2016 2017 2017 2017 2017 2017 2015 2016 2007 2015 2016 2007 2015 2016 2007 2015 2015 2015 2015 2015 2015 2015 2015
2 2016828 pubmed 2 2016828 pubmed 2 201711 Sopus 2 201711 Sopus 2 2016828 pubmed 2 2016927 pubmed 2 2016927 pubmed 2 2016928	У У У У	Y Y Y Y Y	×	n s s s s s s s s s s s s s	Y Policy > Invest (R&D) n Prices > Expenditures y Policy (descriptive)	n N y n y n y n y n y n y n y n	Marce Marce <th< td=""><td>296) 636 A4 (pa) 207 Me create date 207/30/05 [Fris author:Niterin U 1165 / doi: 10.297 / enete date.2014/07/15 [Fris author:Niterin M 2143 Centrary 2143 Centrary 2143 Centrary 2143 Centrary 2143 Centrary 2144 Centrary 2143 Centrary 2144 Centrary 2143 Centrary 2144 Centrary 2144</td><td>06.05.2007 01.05.2005 16.0.1.204 99.99.2010 04.08.2011 20.05.2016 14.02.2013 14.02.2013 14.02.2013 14.02.2013 10.05.2010 17.09.2013 08.02.2006 10.10.2009 02.04.2015 27.09.2013 2007 2007 2007 2007 2007 2007 2007 200</td><td>2007 2005 2015 2014 2010 2014 2010 2014 2010 2015 2016 2015 2015 2015 2015 2015 2015 2015 2015</td></th<>	296) 636 A4 (pa) 207 Me create date 207/30/05 [Fris author:Niterin U 1165 / doi: 10.297 / enete date.2014/07/15 [Fris author:Niterin M 2143 Centrary 2143 Centrary 2143 Centrary 2143 Centrary 2143 Centrary 2144 Centrary 2143 Centrary 2144 Centrary 2143 Centrary 2144	06.05.2007 01.05.2005 16.0.1.204 99.99.2010 04.08.2011 20.05.2016 14.02.2013 14.02.2013 14.02.2013 14.02.2013 10.05.2010 17.09.2013 08.02.2006 10.10.2009 02.04.2015 27.09.2013 2007 2007 2007 2007 2007 2007 2007 200	2007 2005 2015 2014 2010 2014 2010 2014 2010 2015 2016 2015 2015 2015 2015 2015 2015 2015 2015
2 2016823 pubmed 2 2016827 pubmed 2 2016827 pubmed 2 2016827 pubmed 2 2016823 pubmed 2 201		Y Y Y Y Y	y	n n y synthesi/Comment y source for the synthesi/Comment y Synthesi/Comment y Synthesi/Comment y Suthistical analysis - descriptive Statistical analysis - descriptive	Y Policy > Invest (IBLO) n Prices > Expenditures Y Policy (descriptive)	n N y n y N y a y a y a y a y a y a	Autors No. March U. Pear Works St. 2007 De Status No. Pear Works St. 2007 De Status N	298(5894 (5a) 207 Mar create date:2007/05/06 [Frist author:Nation N 157 - doi: 10.297/06 (207)/06 (207)/07 [Frist author:Nation N 2134 Century 2134 Centu	0.01.01.2007 01.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2014 20.05.2014 20.05.2014 20.05.2014 14.09.2007 15.07.2015 01.05.2010 01.05.2016 01.05.2016 27.09.2015 20.05.2015 20.05.2015 20.07 20.0	2007 2005 2015 2014 2010 2014 2010 2014 2010 2015 2015 2015 2015 2015 2015 2015
2 2016828 pubmed 2 2016828 pubmed 2 201711 Sopura 2 2016828 pubmed 2 2016827 pubmed 2 2016927 pubmed 2 2016927 pubmed 2 2016928 pubmed 2 2016		Y Y Y Y Y	y	n Spithesi/Comment Spithesi/Comment Economic model (analytic, empirical data) F Spithesi/Comment Spithesi/Co	Y Policy > Invest (R&D) n Prices > Dependitures y Policy (descriptive) y Policy (descriptive) y Noiry (descriptive)	т И У Л У Л У Л У Л У Л У Л У Л У Л	Yame Source of medicine information and their reliability variated by medicine users. Nature N, Center NA, Maria SA, Ma	296(584)4 (pa) 207 Me crede date:2007/05/05 [Frist author:Niterin U 11657, doi: 10.297 (crede date:2004/07/16] [Frist author:Niterin M 2114 Century 2124 Century 2134	0.6.08.2007 0.1.05.2005 16.0.1.2.044 09.09.2.010 0.4.08.2.011 20.05.2016 15.07.2013 15.07.2013 0.102.2006 10.10.2006 10.10.2006 10.10.2006 0.2.04.2015 07.05.2015 2.008.2014 0.2007 2.008.2014 0.70.2015	2007 2005 2015 2015 2014 2010 2011 2010 2011 2013 2015 2015 2015 2015 2015 2015 2015 2015
2 2016823 pubmed 2 2016827 pubmed 2 2016827 pubmed 2 2016825 pubmed 2 2016826 pubmed 2 2016828 pubmed 2 2016828 pubmed 2 2016828 pubmed 2 201	Y Y Y Y	Y Y Y Y Y Y		n n n n n n n n n n n n n n n n n n n	Y Policy > Invest (#&D) n Prices > Expenditures y Policy (descriptive)	• K Y • Y • Y • Y • Y • Y • Y • Y • Y • Y •	Autors Note March U. Perm Works X1: 2007 De Sources of medicine information and their reliability variated by medicine users. Nattras N, Gerlen No. March X1: 2007 De Marmaceutical price goldicis is Wetham Nattras N, Gerlen No. March X1: 2007 De Marmaceutical price goldicis is Wetham Nattras N, Gerlen No. March S1: 2007 De Marmaceutical price goldicis is Wetham Nayers TA. Knight R, Bought BE, Lewons I, Hende Nayers RA, Knight N, Bought BE, Lewons I, Hende N, Nayers TA. Knight R, Bought BE, Lewons I, Hende N, Nayers TA. Knight R, Bought BE, Lewons I, Hende N, Nayers TA. Knight R, Bought BE, Lewons I, Hende N, Nayers TA. Knight R, Bought BE, Lewons I, Hende N, Nayers TA. Knight R, Bought BE, Lewons I, Hende N, Nayers TA. Knight R, Bought BE, Lewons I, Hende N, Nayers TA. Knight R, Lewons Y, Nawer I, Hende N, Nawer J, Hende N, Nawer I,	2980 (588 - 4 (aba) 2007 Mar create date-2007/05/06 First author-Natires N 2140 (586 - 4 (aba) 2007 Mar create date-2007/05/06 First author-Natires N 214 (57 - 4 (bb) 1289/05/06) create date-2004/07/15 First author-Natires N 214 (57 - 4 (bb) 1289/05/06) create date-2004/07/15 First author-Natires N 645 Suppl 15.13 - 7 doi: 10.1937 / create date-2014/07/16 First author-Natires N 646 Suppl 15.13 - 7 doi: 10.1110/000 create date-2016/07/20 First author-Chana N 07 200 - 7 doi: 10.1110/000 create date-2015/07/20 First author-Chana N 07 200 - 7 doi: 10.1110/000 create date-2015/07/20 First author-Chana N 07 200 - 7 doi: 10.11110/000 create date-2015/07/20 First author-Chana N 07 200 - 4 doi: 10.11110/000 create date-2013/07/27 First author-Chapeshie DA 07 200 - 4 doi: 10.11110/000 create date-2013/07/27 First author-Chapeshie DA 07 200 - 4 doi: 10.11110/000 create date-2013/07/27 First author-Chapeshie DA 07 201 - 4 doi: 10.11110/010 create date-2013/07/27 First author-Parket D 07 201 - 4 doi: 10.11110/010 create date-2013/07/27 First author-Parket D 11.124 - 250. doi: 10.1110/010 create date-2013/07/27 First author-Parket D 11.247 - 250. doi: 10.1110/010 create date-2013 11.247 - 250. doi: 10.1110/010 create date-2013 11.247 - 250. doi: 10.1110/010 create date-2013 11.247 - 250. doi: 10.1110/010 cre	0.618.2007 0.105.2007 0.105.2006 16.0.1.2014 09.09.2010 0.4.08.2011 2.0.05.2016 14.09.2007 15.07.2015 0.105.2010 0.105.2010 0.105.2010 0.204.2015 2.006 2.007 2.00	2007 2005 2015 2015 2014 2010 2014 2010 2014 2011 2016 2013 2016 2015 2010 2009 2009 2015 2016 2010 2009 2015 2016 2017 2017 2017 2017 2017 2017 2017 2017
2 2010628 pubmed 2 2010628 pubmed 2 2010628 pubmed 2 2010628 pubmed 3 2010628 pubmed 2 2010627 medine 2 2010627 pubmed 2 2010628 pubmed 2 201	Y Y Y Y	Y Y Y Y Y	¥ ¥	n o o o o o o o o o o o o o	Y Policy > Invest (R&D) n Prices > Expenditures Y Prices > Expenditures Y Prices (descriptive) Y Prices (Prices Prices)	• 8 Y • Y 8 Y 8 Y 9 Y 9 Y 9 Y 9 Y 9 Y 9 Y 9 Y 9	Yame Source of medicine information and their reliability variatated by medicine users. Number U Perm WorkSit X2007 De 2019 Source of medicine information and their reliability variatated by medicine users. Nutratus N, Ceffen N All X156 Rs. 2005 Mole 2019 Marmaceutical pricing ond purchasing insisten soft MAXIF Source MIA Nutratus N, Ceffen N All X156 Rs. 2005 Mole 2019 Source of paramaceutical pricing and purchasing medicines: a cross country comparison of the alford4t NRINK A, Cameron A, Van de Port Neihol Paramaceutical Pricing ond purchasing medicines: a cross country comparison of the alford4t NRINK A, Cameron A, Van de Port Paramaceutical Pricing ond board hands parable in dimensional market. Occamel AA, Jane C, Taanock F,	296(584)4 (pa) 207 Me crete date:2007/50/6 first author:Niterit U 1167 - doi: 10.297 (crete date:2014/07/16 first author:Niterit M 2114 Century 2124 Century 2134	0.05.2007 01.05.2005 16.0.1.204 09.09.2010 04.08.2011 20.05.2016 15.07.2015 01.05.2016 01.05.2016 01.05.2016 01.05.2010 01.05.2010 01.05.2010 01.05.2010 02.04.2015 07.05.2015 22.008 2007 2007 2008 2008	2007 2005 2015 2014 2010 2011 2011 2011 2010 2011 2010 2017 2017
2 2016828 pubmed 2 2016828 pubmed 2 2016828 pubmed 2 2016828 pubmed 2 2016827 pubmed 2 2016927 pubmed 2 2016927 pubmed 2 2016927 pubmed 2 2016928 pubmed 2 201		Y Y Y Y Y Y	y y	n n s s s s s s s s s s s s s	Y Policy > Invest (R&D) n Prices > Expenditures Y Policy (descriptive)		Autors of medicine information and their reliability valuated by medicine users. Natura N, Gental Control Perm Works Str. 2007 De 30 Information of medicine information and their reliability valuated by medicine users. Natura N, Gental Control Natura N, Gental Con	290(589.4 (pa) 207 Me create date:207/50/6 [Frist author:Nutres N 1165 - doi: 10.297/6 - doi: 10.197/6 - doi: 10.197/7 - doi: 10.197/6 - doi: 10.197/7 - doi: 10.197/6 - doi: 10.197/7 - doi: 10.1077/7 - doi: 10.1077/7 - doi: 10.1077/7 - doi: 10.1077/7 -	0.6.08.2007 0.1.05.2007 1.6.0.1.2006 1.6.0.1.2006 0.4.08.2011 2.0.05.2016 1.4.0.2011 1.4.0.2011 1.4.0.2011 1.4.0.2011 1.4.0.2010 1.7.0.2015 0.1.05.2016 1.2.0.2006 0.2.0.4.2015 0.7.05.2015 2.006 2.2007 2.0	2007 2005 2015 2015 2014 2010 2011 2011 2011 2010 2013 2005 2015 2015 2015 2015 2015 2015 2015
2 2016828 pulmed 2 2016827 pulmed 2 2016827 pulmed 2 2016827 pulmed 2 2016828 pulmed 2 201	Y Y Y Y	Y Y Y Y Y Y		n n s s y synthesi/Comment y subtesi/Comment y subtesi/Comment y subtesi/Comment y subtesi/Comment y subtesi/Comment y subtesi/Comment y subtesi/Comment y subtesi/Comment y subtesi/Comment y subtesi/Comment y subtesi/Comment subtesi/	Yolicy > Invest (IBLO) Prices > Expenditures Prices > Prices Prices Prices > Prices Prices Prices > Prices Prices Prices > Prices Prices Prices Prices > Prices Prices Prices Prices > Prices Pric	• N • N • N • N • N • N • N • N	Josep March U. Perm Works 21, 2007 be Sources of medicine information and their reliability varianted by medicine users. Nattras N, Gerlen N.	29805484 (apa 2007 Mar create date:2007/05/06 [Frist author:Natires N 157 - doi: 10.2997/1680 Greet date:2005/07/16 [Frist author:Natires N 2134 Centrary 2134 Centrary	0.01.01.2007 01.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011 20.05.2014 20.05.2014 20.05.2014 20.05.2014 14.09.2007 15.07.2015 01.05.2010 01.05.2010 01.05.2016 27.09.2013 2007 2007 2007 2007 2007 2007 2007 200	2007 2005 2015 2014 2010 2011 2010 2011 2010 2010 2010
2 2016828 pubmed 2 2016828 pubmed 2 201711 Sopus 2 2016828 pubmed 2 2016827 pubmed 2 2016927 pubmed 2 2016928 pubmed 2 20169	Y Y Y Y	Y Y Y Y Y	y y	n n n n n n n n n n n n n n n n n n n	Y Policy > Invest (R&D) n Prices > Expenditures y Policy (descriptive) Y Policy VMIfer*** Y Policy (descriptive)	• N V • V • V • V • V • V • V • V •	Variants Source of medicine information and their reliability variated by medicine users. Natura N, Call Perm Works Str. 2007 De Variants Information of medicine information and their reliability variated by medicine users. Natura N, Call	296(589.4 (pa) 207 Me crede date:207/50/6 [Frist author:Naterin U 11657. doi: 10.397/140 crede date:2014/01/15 [Frist author:Naterin M 2114 Century 2124 Century 2134	0.6.08.2007 0.05.2007 1.6.0.1.204 0.909.2010 0.4.08.2011 2.0.05.2016 0.4.08.2011 2.0.05.2016 0.4.08.2011 2.0.05.2016 0.1.09.2017 0.1.09.2013 0.00.2006 10.1.0.2009 0.2.04.2015 0.705.2015 2.003 2.007 2.005 2.007 2.007 2.007 2.007 2.007 2.005 2.007 2.007 2.007 2.007 2.005 2.007 2.007 2.007 2.005 2.007 2.007 2.005 2.007 2.007 2.007 2.005 2.007 2.007 2.005 2.007 2.005 2.007 2.007 2.005 2.005 2.007 2.007 2.005 2.005 2.005 2.005 2.005 2.005 2.007 2.007 2.005	2007 2005 2015 2014 2010 2011 2010 2011 2010 2011 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2010 2015 2015
2 2016823 pubmed 2 2016827 pubmed 2 2016827 pubmed 2 2016823 pubmed 2 201		Y Y Y Y Y Y	y y	n y y synthesi/Comment y y synthesi/Comment y y synthesi/Comment y y synthesi/Comment y y statistical analysis - descriptive statistical analysis - descriptiv	Y Policy > Invest (R&D) n Prices > Expenditures y Policy (descriptive)	• K Y • Y • Y • Y • Y • Y • Y • Y • Y • Y •	Matrix II Marria U. Perm Works 21, 2007 De Source of medicine information and their relability varianted by module exercise. Nattras II, General A. Perm Works 21, 2007 De Marmaceutical price opticals in Vertam Nattras II, General A. Permanestical price opticals in Vertam Permanestical price opticals in Vertam Marmaceutical price opticals in Vertam Nattras II, General A. Nattras II, General A. Permanestical price opticals in Vertam Marmaceutical price opticals and vertaming medicines a conscurity comparison of the afford Vertam Nattras II, General A., Van & Ponter M. Permanestical price opticals in Vertam Permanestin Vertam Pe	290(5894, Gao 207 Mar create date-2070/50/6 [Fris author-Natires N 157, doi: 10.297/61005 Greet date-2050/50/1 [Fris author-Natires N 2131 Central 2132 Central 2133 Central 2132 Central 2132 Central 2132 Central 2133 C	0.618.2007 0.105.2007 0.105.2006 16.0.1.2014 09.09.2010 0.4.08.2011 2.0.05.2016 14.0.0.2007 15.0.7.2015 0.105.2010 0.7.2015 0.105.2010 0.7.0.5.2010 0.7.0.5.2010 0.7.0.5.2010 0.7.0.5.2010 0.7.0.5.2015 2.0000 2.0000 2.0000 2.0000 2.0000 2.0000 2.0000 2.00000 2.00000 2.00000 2.00000000	2007 2005 2015 2014 2010 2010 2010 2013 2017 2013 2017 2015 2010 2010 2007 2015 2015 2016 2015 2015 2015 2016 2017 2017 2017 2017 2017 2017 2017 2017
2 2010628 pubmed 2 2010628 pubmed 2 2010628 pubmed 3 2010628 pubmed 3 2010628 pubmed 3 2010627 pubmed 3 2010627 pubmed 2 2010628 pubmed 3 201	Y Y Y Y	Y Y Y Y Y	y y na	n o y Synthesi/Comment c c c c c c c c c c c c c	Y Policy > Invest (R&D) n Prices > Expenditures y Prices > Expenditures y Prices (descriptive) y Prices > Preces y Prices > Preces y Prices > Access* y Prices > Access* y Prices > Access*	N Y N	Yames Source of medicine information and their reliability variantee by medicine users. Nature N, Uetton Perm Works's X1207 De Yames exiting price of privance clipping and purchasing issues of MAKT is SAN MERA Nature N, Vetton IS, Nogened EL, Rows J, Nogenes AL, San S, Nogenes AL, San	296(584)4 (pa) 207 Me crede date:207/50/5 [Frist author:Niterit U 1167, doi: 10.297 dreet date:2014/07/15 [Frist author:Niterit M 2114 Century 2124 Century 2134 Centu	0.05.2007 01.05.2005 16.0.1.2.044 09.09.2010 04.08.2011 20.05.2016 15.07.2015 01.05.2016 01.05.2016 01.05.2016 01.05.2016 01.05.2016 01.05.2016 01.05.2016 01.05.2016 01.02.2006 02.04.2015 07.05.2015 27.09.2015 2.0007 2.0007 2.0008 2.0008 2.0007 2.0008 2.0008 2.0007 2.0008 2.0008 2.0007 2.0008 2.0008 2.0007 2.0008 2.0008 2.0007 2.0008 2.0008 2.0007 2.0008 2.0008 2.0007 2.0008 2.0008 2.0007 2.0008 2.0007 2.0008 2.0007 2.0008 2.0008 2.0007 2.0008 2.0008 2.0007 2.0008 2.0008 2.0007 2.0008 2.	2007 2005 2015 2014 2010 2011 2016 2011 2010 2011 2010 2010
8 2016828 pubmed 2016828 pubmed 2016827 2016827 pubmed 2016827 2016827 pubmed 2016827 2016828 pubmed 2016827 2016827 pubmed 2016827 2016828 pubmed 2016827 2016828 pubmed 2016828	Y Y Y Y	y y y y y	y y	n n s s s s s s s s s s s s s	Y Policy > Invest (R&D) n Prices > Expenditures y Policy (descriptive)	о К У О У О У О У О У О У О У О У О У О У О	Matrix II Marria U. Perm Worksit 2007 De Source of medicine information and their relability variated by medicine users. Nattras II, General Marcia Mattras III, General Marcia Mattras IIII, General Marcia Mattras IIII, General Marcia Mattras IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	290(5894, Gap 207 Mar create date.2007/50/6 [Fris author-Natires N 157, doi: 10.297/6 are date.2004/01/15 [Fris author-Natires N 213 Century 213	0.6.08.2007 0.1.05.2007 0.1.05.2006 16.0.1.2014 09.09.2010 0.4.08.2011 20.05.2016 14.0.2017 14.0.2017 14.0.2017 0.1.05.2010 17.0.9.2013 0.05.2010 0.204.2015 0.205.2016 0.204.2015 0.2007 2007 2007 2007 2007 2007 2007 20	2007 2005 2015 2014 2010 2010 2010 2010 2010 2010 2010
2 2016828 pubmed 2 2016828 pubmed 2 2016828 pubmed 3 2016828 pubmed 3 2016828 pubmed 3 2016827 pubmed 3 2016827 pubmed 3 2016827 pubmed 3 2016828 pubmed 3 201	Y Y Y Y	Y Y Y Y Y Y	y y	n n y y synthesi/Comment y y comment y y statistical analysis - discriptive y statistical analysis - discriptive y statistical analysis - discriptive statistical analysis - discriptive statistic	Y Policy > Invest (I&O) n Prices > Expenditures Noney (descriptive) Policy (descriptive) Y Policy > Proces Y Policy > Proces Y Policy (descriptive)	N N Y N	Autom Matrix IV Perm Works 21, 2007 be Sources of medicine information and their reliability variated by medicine users. Nattras IV, Gerlen N. Nattra IV, Gerlen N. Nattras IV, Gerlen N.<	290(589.4 (pa) 207 Me create date:207/50/6 [Frist author:Natires N 1915 Cate: 10.297 (Section 2017) (Section 2	0.05.2007 01.05.2005 16.0.1.2044 09.09.2010 04.08.2011 20.05.2016 01.05.2016 01.05.2016 01.05.2010 01.05.2010 01.05.2010 01.05.2010 01.05.2010 01.05.2010 01.05.2010 02.04.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 07.05.2015 09.05.2014 09.05.2014 09.05.2014 09.05.2015	2007 2005 2014 2017 2015 2014 2010 2010 2010 2010 2010 2015 2015 2015
2 2016828 pubmed 2 2016828 pubmed 2 2016828 pubmed 2 2016828 pubmed 2 2016827 pubmed 2 2016927 pubmed 2 2016927 pubmed 2 2016928 pubmed 2 201	Y Y Y Y	Y Y Y Y Y Y Y	Y Y	n n s s s s s s s s s s s s s	Y Policy > Invest (R&D) n Prices > Expenditures y Prices > Expenditures y Prices > Expenditures y Prices > Expenditures y Prices / Vertes		Matrix II Marria U. Perm Works's L2007 De Sources of medicine information and their relability varianted by medicine users. Nattras II, Genes M. Mattras II, Genes M. Mattras II, Genes M. Mattras III, Genes M. Mattras III, Genes M. Mattras III, Genes M. Mattras III, Genes M. Mattras IIII, Genes M. Mattras IIIII, Genes M. Mattras IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	290(5894 (pa) 207 Me create date:207/50/6 [Frist author:Nature IU 1167 - doi: 10.297/50 (Frist author:Nature II 2131 Centrary 2132 Centrar	0.6.05.2007 0.1.05.2005 16.0.1.204 99.99.2010 0.4.08.2011 20.05.2016 14.08.2011 20.05.2016 14.08.2011 14.08.2011 14.08.2010 17.08.2010 17.08.2010 07.05.2015 07.05.2015 07.05.2015 07.05.2015 20.09.2015 20.0012005 20.0012005 20.0012005 20.00120005 20.0010	2007 2005 2015 2014 2010 2010 2010 2010 2010 2010 2015 2015
2 2016828 pubmed 2 2016827 pubmed 2 2016827 pubmed 2 2016828 pubmed 2 201		Y Y Y Y Y Y Y	Y Y	n n n n n n n n n n n n n n	Y Policy > Invest (R&O) n Proces > Expenditures Y Policy (descriptive)	N N Y N	Matrix IV Matrix IV Perm Works 21, 2007 De Sources of medicine information and their reliability variantee by medicine users. Nattras IV, Gerlen N. Matrix 10, 2007 De Marmaceutical price opticals in Vertam Nattras IV, Gerlen N. Nattras IV, Gerlen N.<	2980.584.4 (apa 2007 Mar create date:2007/05/06 [Frist author:Nature N 157. doi: 10.2997.6005 create date:2004/07/16 [Frist author:Nature N 15.15 Create:10.15 Create date:2004/07/16 [Frist author:Nature N 15.15 Create:10.15 Create date:2004/07/16 [Frist author:Nature N 15.15 Create:10.15 Create date:2004/07/16 [Frist author:Openeting O 07.2007 0.000 (Frist a	0.618.2007 0.105.2005 16.0.1.2014 09.09.2010 04.08.2011 20.05.2014 04.08.2011 14.09.2007 15.07.2015 01.05.2010 01.05.2010 01.05.2010 01.05.2010 01.05.2010 01.04.2015 20.06 20.07 20.07 20	2007 2005 2014 2017 2015 2014 2010 2011 2010 2010 2010 2015 2015 2015
2 2010628 pubmed 2 2010628 pubmed 2 2010628 pubmed 2 2010628 pubmed 3 2010627 medine 2 2010627 medine 3 2010627 medine 3 2010627 pubmed 3 2010628 pubmed 3 201	Y Y Y Y	Y Y Y Y Y Y Y Y	y y	 Synthesis/Comment Second (analysis, empirical data) Economic model (analysis, empirical data) Second (analysis, empirical data) 	Y Policy > Invest (R&D) n Prices > Expenditures Y Policy (descriptive)	N N Y N	Mark Mark <th< td=""><td>290(589.4 (pa) 207 Me crede date:207/50/6 [Fits author:Naters N 1157. doi: 10.297. doi: 10.107 crede date:2014/01/15 [Fits author:Naters M 1214 Century 1215 Century 1</td><td>0.6.08.2007 0.0.5.2007 0.0.5.2005 16.0.1.2.004 09.09.2010 0.4.08.2011 20.05.2016 0.4.08.2011 20.05.2016 0.10.9.2017 0.01.001 0.01.001 0.01.001 0.01.2006 10.10.2006 10.10.2006 10.10.2006 10.10.2006 20.04.2015 20.07 2007 2007 2007 2007 2007 2007 200</td><td>2007 2005 2014 2015 2014 2010 2010 2010 2010 2010 2010 2010</td></th<>	290(589.4 (pa) 207 Me crede date:207/50/6 [Fits author:Naters N 1157. doi: 10.297. doi: 10.107 crede date:2014/01/15 [Fits author:Naters M 1214 Century 1215 Century 1	0.6.08.2007 0.0.5.2007 0.0.5.2005 16.0.1.2.004 09.09.2010 0.4.08.2011 20.05.2016 0.4.08.2011 20.05.2016 0.10.9.2017 0.01.001 0.01.001 0.01.001 0.01.2006 10.10.2006 10.10.2006 10.10.2006 10.10.2006 20.04.2015 20.07 2007 2007 2007 2007 2007 2007 200	2007 2005 2014 2015 2014 2010 2010 2010 2010 2010 2010 2010
8 2010828 pubmed 2010828 pubmed 2010828		y y y y y y y y y y y	y y	n n n n n n n n n n n n n n	Y Policy > Invest (#&D) n Prices > Expenditures Y Prices > Expenditures Y Prices > Expenditures Y Prices / Veces Y Prices / Veces / Veces	N N Y N	Mark Mark <th< td=""><td>2980(588-44, Equa 2007 Mar. create date:2007/50/65 First author:Nature M 1165 - doi: 10.293/create date:2014/01/15 First author:Nature M 213 Century create date:2014/01/15 First author:Nature M 213 Century create date:2014/01/15 First author:Nature M 268 Suppl 15:13:7 create date:2016/01/26 First author:Nature M 268 Suppl 15:13:8 create date:2016/01/26 First author:Opender 200 20:0-64 create date:2016/01/26 First author:Opender 201 20:0-17.27 create date:2016/01/26 First author:Opender 201 20:0-16. create date:2015/01/26 First author:Opender 202 20:0-4. create date:2015/01/26 First author:Opender 203 20:0-12.07 create date:2015/01/26 First author:Opender 203 20:0-12.07 create date:2013/01/27 First author:Paidet B 203 20:0-12.07 create date:2013/01/26 First author:Paidet B 203 20:0-12.07 create date:2013 create date:2013 create date:2013 203 20:13.09 create date:2013 create date:2014 create date:2014 203 20:13.09 create date:2013</td><td>0.05.8.2007 0.05.2007 0.05.2006 16.0.1.2014 09.09.2010 0.4.08.2011 20.05.2016 14.0.8.2011 14.0.8.2011 14.0.8.2011 14.0.8.2011 14.0.8.2011 14.0.8.2010 17.0.9.2013 0.0.5.2010 0.2.0.4.2015 14.0.6.2015 2.2.006 2.2.007 2.200</td><td>2007 2005 2014 2015 2014 2016 2016 2016 2016 2017 2016 2017 2017 2017 2017 2017 2017 2017 2017</td></th<>	2980(588-44, Equa 2007 Mar. create date:2007/50/65 First author:Nature M 1165 - doi: 10.293/create date:2014/01/15 First author:Nature M 213 Century create date:2014/01/15 First author:Nature M 213 Century create date:2014/01/15 First author:Nature M 268 Suppl 15:13:7 create date:2016/01/26 First author:Nature M 268 Suppl 15:13:8 create date:2016/01/26 First author:Opender 200 20:0-64 create date:2016/01/26 First author:Opender 201 20:0-17.27 create date:2016/01/26 First author:Opender 201 20:0-16. create date:2015/01/26 First author:Opender 202 20:0-4. create date:2015/01/26 First author:Opender 203 20:0-12.07 create date:2015/01/26 First author:Opender 203 20:0-12.07 create date:2013/01/27 First author:Paidet B 203 20:0-12.07 create date:2013/01/26 First author:Paidet B 203 20:0-12.07 create date:2013 create date:2013 create date:2013 203 20:13.09 create date:2013 create date:2014 create date:2014 203 20:13.09 create date:2013	0.05.8.2007 0.05.2007 0.05.2006 16.0.1.2014 09.09.2010 0.4.08.2011 20.05.2016 14.0.8.2011 14.0.8.2011 14.0.8.2011 14.0.8.2011 14.0.8.2011 14.0.8.2010 17.0.9.2013 0.0.5.2010 0.2.0.4.2015 14.0.6.2015 2.2.006 2.2.007 2.200	2007 2005 2014 2015 2014 2016 2016 2016 2016 2017 2016 2017 2017 2017 2017 2017 2017 2017 2017
8 20106828 pubmed 9 20106828 pubmed 2 2010682 pubmed 2 2010682 pubmed 3 2010682 pubmed 2 2010682 pubmed 3 2010682 pubmed 2 2		y y y y y y y y y y y y y y y	y y	n o y y synthesi/Comment y y comment y y y y y y y y y y y y y	Y Policy > Invest (IR&O) n Police > Expenditures No Police > Expenditures Y Policy (descriptive)	N N Y N	Matrix II. Matrix II. Perm Works 21: 2007 De Source of medicine information and their relability variated by medicine uero. Nattras II. Genes 14: 2007 De Nattras II. Genes 14: 2007 De Marmaceutical price opticals in Verteam Nattras II. Genes 14: 2007 De Nattras II. Genes 14: 2007 De Marmaceutical price opticals in Verteam Nattras II. Genes 14: Roughead E.L. encort I. Head Phology 14: 2007 DE Marmaceutical price opticals in Verteam Nattras II. Genes 14: Roughead E.L. encort I. Head Phology 14: 2007 DE Marmaceutical price opticals in Verteam on International II. Internation II. International II. Internation II. International II. Internation III. Internation IIII. Internation IIII. InternatiIIII. Internation IIII. I	290(584 (30) 207 Me create date:207/50/6 [Frist author:Nature N 157. doi: 10.297/6005 Greet date:205/6/0 [Frist author:Nature N 157. doi: 10.297/6 [Frist author:Openhale O 157. doi: 10.1007/6 [Frist author:Paret I 157. doi: 10.100	0.05.2007 0.05.2005 16.0.12.005 16.0.12.005 16.0.12.005 16.0.12.005 16.0.12.005 15.07.2015 0.05.2016 0.05.2016 0.05.2016 0.05.2016 0.05.2016 0.05.2016 0.05.2016 0.05.2016 0.05.2016 0.05.2016 0.05.2015 0.05.	2007 2005 2014 2015 2014 2016 2017 2017 2017 2017 2017 2017 2017 2017
8 2016828 pubmed 9 2016828 pubmed 1 2016827 pubmed 2 2016828 pubmed 2 201		Y Y Y Y Y Y Y Y Y	y y	n n s s s s s s s s s s s s s	Y Policy > Invest (R&D) n Prices > Expenditures y Prices > Expenditures y Prices > Expenditures y Prices > Expenditures y Prices / Expenditures y Prices / Expenditures y Prices / Expenditures y Prices / (descriptive) y Prices / (descriptive) y Prices / Verses	0 N Y 0	Markab Markab<	290(584) 4 (pa) 207 Me create date:207/50/6 [Frist author:Nature N 1167, doi: 10.297/6 (Frist author:Nature N 213 Century 213 Centur	0.05.2007 0.05.2007 0.05.2005 16.0.12.004 99.92.010 0.408.2011 20.05.2016 14.02.011 14.02.011 14.02.011 14.02.011 17.09.2013 0.05.2016 17.09.2013 0.05.2016 12.09.2016 0.204.2015 0.705.2015 0.205 2006 2007 2007 2007 2007 2007 2007 2007	2007 2005 2014 2015 2014 2016 2016 2016 2016 2017 2017 2017 2017 2017 2017 2017 2017
8 2010828 pubmed 9 2010828 pubmed 2010828 pubmed pubmed 2010828 </td <td></td> <td>Y Y Y Y Y Y Y Y Y Y Y</td> <td>y y</td> <td>n n s s s s s s s s s s s s s</td> <td>Y Policy > Invest (IBLO) n Prices > Expenditures Y Policy (descriptive) Nairy (descriptive) Nairy (descriptive) Y Policy > Prices Y Policy > Policy Y Policy implementation n Policy (descriptive)</td> <td>N N Y N</td> <td>Matrix IV Marris VI. Perm Works 21: 2007 De Sector of medicine information and their reliability variantee by Madrin South Markina Markin</td> <td>290(584) 4 (apa 207 Me create date-207/50/6 First author-Nitren U 1567 - doi: 10.297/50/509 - renet date-2014/01/5 First author-Nitren M 2131 Centru 2132 Centru 2132 Centru 2132 Centru 2132 Centru 2133 - doi: 10.103/ create date-2014/01/5 First author-Nitren M 2134 Centru 2134 Centru 213</td> <td>0.01.02.2007 01.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011 12.005.2014 04.08.2011 12.005.2014 04.08.2017 15.07.2015 01.05.2010 01.05.2010 02.04.2015 02.04.2015 02.04.2015 02.04.2015 02.04.2015 02.04.2015 02.04.2015 02.04.2015 02.04.2015 02.06 02.04.2015 02.06 02.04.2015 02.06 02.04.2015 02.06 02.04.2015 02.06 02.04.2015 03.06.2014 04.12.2030 05.2014 04.12.2030 05.05.2014 04.12.2031 05.05.2014 04.42.2015 05.05.2014 04.42.2015 05.05.2014 05</td> <td>2007 2005 2014 2015 2014 2015 2014 2016 2013 2016 2017 2015 2010 2015 2010 2015 2010 2015 2010 2015 2010 2015 2010 2015 2010 2015 2010 2015 2010 2015 2015</td>		Y Y Y Y Y Y Y Y Y Y Y	y y	n n s s s s s s s s s s s s s	Y Policy > Invest (IBLO) n Prices > Expenditures Y Policy (descriptive) Nairy (descriptive) Nairy (descriptive) Y Policy > Prices Y Policy > Policy Y Policy implementation n Policy (descriptive)	N N Y N	Matrix IV Marris VI. Perm Works 21: 2007 De Sector of medicine information and their reliability variantee by Madrin South Markina Markin	290(584) 4 (apa 207 Me create date-207/50/6 First author-Nitren U 1567 - doi: 10.297/50/509 - renet date-2014/01/5 First author-Nitren M 2131 Centru 2132 Centru 2132 Centru 2132 Centru 2132 Centru 2133 - doi: 10.103/ create date-2014/01/5 First author-Nitren M 2134 Centru 2134 Centru 213	0.01.02.2007 01.05.2007 01.05.2005 16.01.2014 09.09.2010 04.08.2011 12.005.2014 04.08.2011 12.005.2014 04.08.2017 15.07.2015 01.05.2010 01.05.2010 02.04.2015 02.04.2015 02.04.2015 02.04.2015 02.04.2015 02.04.2015 02.04.2015 02.04.2015 02.04.2015 02.06 02.04.2015 02.06 02.04.2015 02.06 02.04.2015 02.06 02.04.2015 02.06 02.04.2015 03.06.2014 04.12.2030 05.2014 04.12.2030 05.05.2014 04.12.2031 05.05.2014 04.42.2015 05.05.2014 04.42.2015 05.05.2014 05	2007 2005 2014 2015 2014 2015 2014 2016 2013 2016 2017 2015 2010 2015 2010 2015 2010 2015 2010 2015 2010 2015 2010 2015 2010 2015 2010 2015 2010 2015 2015
2 2010628 pubmed 2 2010628 pubmed 2 2010628 pubmed 2 2010628 pubmed 3 2010627 medine 3 2010627 medine 3 2010627 medine 3 2010627 medine 3 2010627 pubmed 3 2010628 pubmed 3 201		Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	y y	s s s s s s s s s s s s s s	Y Policy > Invest (R&D) n Prices > Expenditures y Prices > Expenditures y Prices > Expenditures y Prices > Expenditures y Prices / Veces y Prices / Veces* y Prices / Veces* y Prices / Veces* y Prices / Veces*	1 3 Y 4 Y 8 Y 8 Y 8 Y 8 Y 8 Y 8 Y 8 Y 8 Y 8 Y 8 Y 8 Y 8 Y 8 Y 8 Y 8 Y 8	Markab Markab<	2980.588.44 (pa) 207 Me create date.2007/50/6 [Frist author:Nature N 15.7 doi: 10.297.6083 create date.2007/50/6 [Frist author:Natures N 21.8 (cntrue) 21.9 (2016) 2016 (20	0.6.05.2007 0.05.2007 0.05.2005 16.0.1.2014 09.09.2010 0.4.08.2011 20.05.2016 0.4.08.2011 20.05.2016 0.10.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.20.4.2015 0.70.5.2015 0.20.5.2015 0.2007 2007 2007 2007 2007 2007 2007 20	2007 2005 2014 2015 2014 2015 2014 2016 2016 2016 2016 2017 2016 2017 2016 2017 2016 2017 2016 2017 2016 2017 2017 2017 2017 2017 2017 2017 2017
8 2010828 pubmed 9 2010828 pubmed 2010828 pubmed pubmed 2010829 pubmed pubmed 2010828 pubmed pubmed 2010828 </td <td></td> <td>Y Y Y Y Y Y Y Y Y Y Y Y Y Y</td> <td>y y</td> <td>n n s s s s s s s s s s s s s</td> <td>Y Policy > Invest (R&D) n Prices > Expenditures Y Prices > Expenditures Y Price > Expenditures Y Price y (descriptive) Y Price y (descriptive) Y Price y (descriptive) Y Price y (descriptive) Y Price y Prices Y Price y Vestare*** Y Price y Vestare***</td> <td></td> <td>Market Market U. Perm Works 1.200 De Bioleca of medicine information and their reliability variated by model neares. Nattras N, General Perm Works 1.200 De Bioleca of medicine information and their reliability variated by model neares. Nattras N, General N, Boogheral EL, General Heir N, Boogheral EL, Genel Heir N, Boogheral EL, Genel</td> <td>290(584, Capa 207 Mar create date:207/50/56 [Frist author:Nation N 157, doi: 10.297/56 [Frist author:Nation N 2131 Central 2131 Central 2131 Central 2132 Central 21</td> <td>0.05.8.2007 0.05.2007 0.05.2006 16.0.1.2014 09.09.2010 0.4.08.2011 20.05.2016 14.0.09.2010 14.0.09.2013 14.0.09.2013 0.05.2010 17.09.2013 08.02.2006 10.10.2009 02.04.2015 14.06.2015 27.09.2013 02.04.2015 2007 2007 2007 2007 2007 2007 2007 200</td> <td>2007 2005 2014 2015 2014 2015 2014 2016 2013 2016 2017 2015 2015 2016 2017 2015 2015 2015 2015 2015 2015 2015 2015</td>		Y Y Y Y Y Y Y Y Y Y Y Y Y Y	y y	n n s s s s s s s s s s s s s	Y Policy > Invest (R&D) n Prices > Expenditures Y Prices > Expenditures Y Price > Expenditures Y Price y (descriptive) Y Price y (descriptive) Y Price y (descriptive) Y Price y (descriptive) Y Price y Prices Y Price y Vestare***		Market Market U. Perm Works 1.200 De Bioleca of medicine information and their reliability variated by model neares. Nattras N, General Perm Works 1.200 De Bioleca of medicine information and their reliability variated by model neares. Nattras N, General N, Boogheral EL, General Heir N, Boogheral EL, Genel Heir N, Boogheral EL, Genel	290(584, Capa 207 Mar create date:207/50/56 [Frist author:Nation N 157, doi: 10.297/56 [Frist author:Nation N 2131 Central 2131 Central 2131 Central 2132 Central 21	0.05.8.2007 0.05.2007 0.05.2006 16.0.1.2014 09.09.2010 0.4.08.2011 20.05.2016 14.0.09.2010 14.0.09.2013 14.0.09.2013 0.05.2010 17.09.2013 08.02.2006 10.10.2009 02.04.2015 14.06.2015 27.09.2013 02.04.2015 2007 2007 2007 2007 2007 2007 2007 200	2007 2005 2014 2015 2014 2015 2014 2016 2013 2016 2017 2015 2015 2016 2017 2015 2015 2015 2015 2015 2015 2015 2015
8 20106828 pubmed 2010682 pubmed		y y y y y y y y y y y y y y y y y y y	y y	n o o o o v v v v v v v v v v v v v	Y Policy > Invest (IR&O) n Police > Expenditures N Police > Expenditures N Policy (descriptive) Y Policy Sector Y Policy Sector Y Policy (descriptive)	N N V N	Matrix I. Matrix I. Perm Works 1.200 De Backer of medicine information and their reliability variantee by Matrix II South Matrix I. Mattrix II. Medica I. Matrix I. Matrix II. MatriX	290(584 (30) 207 Me create date:207/50/6 [First author:Nature N 157. doi: 10.297/6005 Greet date:205/6/0 [First author:Nature N 157. doi: 10.297/6 (197. doi: 10.107/6 (197. doi: 10.107	0.63.2007 0.05.2007 0.05.2005 16.0.1.2014 09.09.2010 0.4.08.2011 20.05.2016 15.07.2010 0.10.2007 0.10.2007 0.20.2005 10.10.2009 0.20.4.2015 0.70.5.2015 0.2007 2.20	2007 2005 2014 2015 2014 2015 2014 2016 2016 2016 2016 2017 2016 2017 2017 2017 2017 2017 2017 2017 2017
8 2016828 pubmed 9 2016828 pubmed 1 2016828 pubmed 1 2016828 pubmed 1 2016827 medine 1 2016827 pubmed 1 2016827 pubmed 1 2016827 pubmed 1 2016827 pubmed 1 2016828 pubmed 2 201		Y Y Y Y Y Y Y Y Y Y Y Y Y	y y	n n n n n n n n n n n n n n	Y Policy > Invest (#&D) n Prices > Expenditures Y Prices > Expenditures Y Prices > Expenditures Y Prices > Expenditures Y Prices / Verses Y Prices	N Y N	Markab Markab<	290(584) 4 (pa) 207 Me create date:207/50/6 frist author:Nature N 1167 - doi: 10.297/6 (frist author:Nature N 213 (creater) 213 (creater	0.05.2007 0.05.2007 0.05.2005 16.0.1204 09.99.2010 0.405.2011 20.05.2016 14.0.2011 14.0.2017 14.0.2017 14.0.2017 0.05.2010 17.09.2013 0.05.2010 17.09.2013 0.05.2010 0.204.2015 0.05.2016 12.05.2016 12.05.2016 2.2006 2.2007 2.20	2007 2005 2005 2014 2015 2014 2015 2014 2015 2016 2017 2016 2017 2016 2017 2016 2017 2016 2017 2016 2017 2016 2017 2016 2017 2016 2017 2016 2017 2016 2017 2016 2016 2017 2016 2016 2016 2016 2016 2016 2016 2016
8 2010828 pubmed 9 2010828 pubmed 2 2010828 pubmed 2 2010828 pubmed 3 2010828 pubmed 2 2010827 medine 3 2010827 pubmed 2 2010827 pubmed 2 2010827 pubmed 2 2010828 pubmed 2 201		Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y	n n n n n n n n n n n n n n			Matrix IV Marris VI. Perm Works X1:200 De Biords of medicine information and their reliability variantee by MART in SAM MArian. Mattras IX, Gener SA, Maria KA, Sener SA, Maria KS, Marian KA, Sener SA, Marian SA, Marian K, Boughen JL, Ellows I, Hards NA, Sam SAM MART SAM MART SAM	290(584 (3a) 207 Mar create date:207/30/26 [Frist author:Nature N 157 doi: 10.297/36 (2a) 207 Mar create date:2014/01/26 [Frist author:Nature N 151 doi:10.107/36 (2a) 207 Mar create date:2014/01/26 [Frist author:Nature N 266 Suppl 1513 7. doi: 10.107/37 (2a) 207 Mar Create date:2010/01/26 [Frist author:Nature N 267 Suppl 1513 7. doi: 10.107/37 (2a) 207 Mar Create date:2010/01/26 [Frist author:Objected D 207 Jac 207 Mar Create date:2013/07/27 [Frist author:Partei L 207 Jac 207 Jac 207 Mar Create date:2013/07/27 [Frist author:Partei L 207 Jac 207 Jac 207 Mar Create date:2013/07/27 [Frist author:Partei L 207 Jac 207	0.018.2007 0.05.2007 0.05.2005 16.01.2014 09.09.2010 0.4.08.2011 2.005.2014 0.4.08.2011 12.005.2014 0.4.08.2007 15.07.2015 0.105.2010 0.105.2010 0.105.2010 0.204.2015 2.008.2015 2.008 2.009 2.008 2.008 2.009 2.008 2.008 2.009 2.009 2.009 2.009 2.009 2.009 2.009 2.009 2.009 2.009 2.009 2.009 2.	2007) 2005 2005 2004 2005 2004 2015 2014 2010 2010 2010 2010 2010 2010 2010
2 2010628 pubmed 2 2010521 pubmed 2 2010628 pubmed 2 2010628 pubmed 2 2010627 pubmed 2 2010627 pubmed 2 2010627 pubmed 2 2010628 pubmed 2 201		Y Y Y Y Y Y Y Y Y Y Y Y Y Y	y y	n	Y Policy > Invest (R&D) n Prices > Expenditures Maily (descriptive) Policy (descriptive) Y Policy (Markab Markab<	290(584) 4 (pa) 207 Me create date 207/30/06 [Fris author-Natres N 1157. doi: 10.297/207. doi: 10.1093/create date.2014/01/15 [Fris author-Natres N 213 Century 213 Cenury	0.05.2007 0.05.2007 0.05.2005 16.0.1.2014 99.99.2010 0.408.2011 20.05.2016 14.08.2011 20.05.2016 17.09.2013 0.05.2016 0.10.2006 10.10.2006 10.10.2006 10.10.2006 0.204.2015 0.705.2015 2.2006 2.2007 2	2007 2005 2005 2014 2015 2014 2015 2014 2015 2016 2015 2016 2015 2016 2015 2016 2016 2016 2016 2016 2016 2016 2016
8 2016828 pulmed 9 2016828 pulmed 2016828 pulmed pulmed 2016828 </td <td></td> <td>Y Y Y Y Y Y Y Y Y Y Y Y Y Y</td> <td>Y Y</td> <td>n n n n n n n n n n n n n n</td> <td>Y Policy > Invest (R&O) n Proces > Expenditures Y Proces > Expenditures Y Policy (descriptive) Nicy (replementation n Policy > Proces N Policy > Proces</td> <td></td> <td>Market Market U. Perm Works 1.200 De Bandward Perm Works 1.200 De Perm Works 1.200 De Perm Works 1.200 De Marmaceutical price policies in Wettam Nattras N. Genter N. Nattras N. Genter N. Permaceutical price policies in Wettam Marmaceutical price policies in Wettam Nattras N. Genter N. A. None P. Permaceutical price policies in Wettam Permaceutical price policies in Wettam Marmaceutical price policies in Wettam Nattras N. Genter N. A. Van de Perde N. Permaceutical Price policies in Wettam Marmaceutical price policies in Wettam Nattras N. Genter N. A. Van de Perde N. Permaceutical Price policies in Wettam Marmaceutical price policies in Wettam Nattras N. Genter N. Permaceutical Price policies Policie</td> <td>290(584, Capa 207 Mar. create: date:2077/50/6 First author:Nature N 157, doi: 10.297/6 author:Nature N 157, 207, 207, doi: 10.107/6 author:Nature N 157, 207, 207, doi: 10.107/6 author:Nature N 157, 207, 207, 207, 207, 207, 207, 207, 20</td> <td>0.6.18.2007 0.10.5.2005 16.0.1.2014 09.09.2010 0.4.08.2011 20.05.2014 0.4.08.2011 12.0052017 14.00.2007 15.07.2015 0.10.5.2010 0.7.02.015 0.10.5.2010 0.7.02.015 0.012.000 0.012.014 0.012.015 0.012.01</td> <td>2000 2000 2000 2001 2015 2014 2013 2016 2013 2016 2013 2016 2015 2015 2015 2015 2016 2017 2017 2016 2017 2016 2017 2016 2017 2016 2017 2016 2017 2017 2016 2017 2017 2017 2017 2017 2017 2017 2017</td>		Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y	n n n n n n n n n n n n n n	Y Policy > Invest (R&O) n Proces > Expenditures Y Proces > Expenditures Y Policy (descriptive) Nicy (replementation n Policy > Proces N Policy > Proces		Market Market U. Perm Works 1.200 De Bandward Perm Works 1.200 De Perm Works 1.200 De Perm Works 1.200 De Marmaceutical price policies in Wettam Nattras N. Genter N. Nattras N. Genter N. Permaceutical price policies in Wettam Marmaceutical price policies in Wettam Nattras N. Genter N. A. None P. Permaceutical price policies in Wettam Permaceutical price policies in Wettam Marmaceutical price policies in Wettam Nattras N. Genter N. A. Van de Perde N. Permaceutical Price policies in Wettam Marmaceutical price policies in Wettam Nattras N. Genter N. A. Van de Perde N. Permaceutical Price policies in Wettam Marmaceutical price policies in Wettam Nattras N. Genter N. Permaceutical Price policies Policie	290(584, Capa 207 Mar. create: date:2077/50/6 First author:Nature N 157, doi: 10.297/6 author:Nature N 157, 207, 207, doi: 10.107/6 author:Nature N 157, 207, 207, doi: 10.107/6 author:Nature N 157, 207, 207, 207, 207, 207, 207, 207, 20	0.6.18.2007 0.10.5.2005 16.0.1.2014 09.09.2010 0.4.08.2011 20.05.2014 0.4.08.2011 12.0052017 14.00.2007 15.07.2015 0.10.5.2010 0.7.02.015 0.10.5.2010 0.7.02.015 0.012.000 0.012.014 0.012.015 0.012.01	2000 2000 2000 2001 2015 2014 2013 2016 2013 2016 2013 2016 2015 2015 2015 2015 2016 2017 2017 2016 2017 2016 2017 2016 2017 2016 2017 2016 2017 2017 2016 2017 2017 2017 2017 2017 2017 2017 2017
8 20106828 pubmed 2010682 pubmed		Y Y Y Y Y Y Y Y Y	y y n		Y Policy > Invest (R&D) n Prices > Expenditures Y Prices > Expenditures Y Prices / Expenditures Y <td< td=""><td></td><td>Markab Markab Markab<</td><td>2900.586.4 (pap. 2007 Mer. create: date: 2007/05/06 [Frist author:Natures N 1016 57. doi: 10.293/ create: date: 2004/07/16 [Frist author:Natures N 2013 Control J. 2012 Area (J. 2014) (Prist author: Natures N 2013 Control J. 2012 Area (J. 2014) (Prist author: Natures N 2015 Control J. 2014) (Prist author: Control J. 2014) 2015 Control J. 2014 (Prist author: Control J. 2014) 2014 (Prist author: Control J. 2014) 2013 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2013 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2013 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2013 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2013 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2013 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2014 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2014 (Prist author: Parket Al. 2015) (Prist author: Parket Al. 2014) 2014 (Prist author: Parket Al. 2015) (Prist author: Parket Al. 2014) 2014 (Prist author: Parket Al. 2015) (Prist author: Parket Al. 2014) 2014 (Prist author: Parket Al. 2015) (Prist author: Parket Al. 2015) (Prist author: Parket Al. 2013) 2015 (Prist Al. 2014) (Prist author: Parket Al. 2013) 2014 (Prist Al. 2014) (Prist author: Parket Al. 2014) (Prist author: Parket Al. 2014) 2014 (Prist Al. 2014) (Prist author: Parket Al. 2014) (Prist author: Parket Al. 2014) 2015 (Prist Al. 2014) (Prist author: Parket Al. 2015) (Prist author: Parket Al. 2014) (Prist author: Parket Al. 2014) (Prist author: Parket Al. 2014) (Prist Al. 2</td><td>0.05.2007 0.05.2007 0.05.2005 16.0.12.004 99.92.010 0.4.08.2011 20.05.2016 0.4.08.2011 20.05.2016 0.10.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.20.4.2015 0.70.5.2015 0.20.6.2016 2.20.9.2015 0.20.5.2015 0.2007 2.</td><td>20070 20152 20154 20140 20154 20140 20154 20140 20154 20152</td></td<>		Markab Markab<	2900.586.4 (pap. 2007 Mer. create: date: 2007/05/06 [Frist author:Natures N 1016 57. doi: 10.293/ create: date: 2004/07/16 [Frist author:Natures N 2013 Control J. 2012 Area (J. 2014) (Prist author: Natures N 2013 Control J. 2012 Area (J. 2014) (Prist author: Natures N 2015 Control J. 2014) (Prist author: Control J. 2014) 2015 Control J. 2014 (Prist author: Control J. 2014) 2014 (Prist author: Control J. 2014) 2013 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2013 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2013 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2013 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2013 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2013 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2014 (Prist author: Control J. 2014) (Prist author: Control J. 2014) 2014 (Prist author: Parket Al. 2015) (Prist author: Parket Al. 2014) 2014 (Prist author: Parket Al. 2015) (Prist author: Parket Al. 2014) 2014 (Prist author: Parket Al. 2015) (Prist author: Parket Al. 2014) 2014 (Prist author: Parket Al. 2015) (Prist author: Parket Al. 2015) (Prist author: Parket Al. 2013) 2015 (Prist Al. 2014) (Prist author: Parket Al. 2013) 2014 (Prist Al. 2014) (Prist author: Parket Al. 2014) (Prist author: Parket Al. 2014) 2014 (Prist Al. 2014) (Prist author: Parket Al. 2014) (Prist author: Parket Al. 2014) 2015 (Prist Al. 2014) (Prist author: Parket Al. 2015) (Prist author: Parket Al. 2014) (Prist author: Parket Al. 2014) (Prist author: Parket Al. 2014) (Prist Al. 2	0.05.2007 0.05.2007 0.05.2005 16.0.12.004 99.92.010 0.4.08.2011 20.05.2016 0.4.08.2011 20.05.2016 0.10.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.10.5.2010 0.20.4.2015 0.70.5.2015 0.20.6.2016 2.20.9.2015 0.20.5.2015 0.2007 2.	20070 20152 20154 20140 20154 20140 20154 20140 20154 20152

4 20160828 pubmed								
	у	y		n		26803088 Rising Drug Prices and PBM Practices in the Spotlight. Rankin P, Baldwin P. Consult Pharm. 2016 Jan;31(1):56. doi: 10.4140/TCP.n.2(create date: 2016/01/24 first author: Rankin P	24.01.2016	2016
8 20160828 pubmed	У	y		n		26233041 Pharmaceutical policies: effects of financial incentives for prescribers. Rashidian A, Omidvari AH, Vali Y, Sturm H, O Cochrane Database Syst Rev. 2015 Aug 4;(8):CD006731.1 create date:2015/08/05 first author:Rashidian A	05.08.2015	2015
1 20160827 medline	у у			n		17244978 Antimicrobial price variation: conundrum of medical profession! Rataboli PV, Dang A. create date:2007/01/25 first author:Rataboli PV	25.01.2007	2007
4 20160828 pubmed	у	y		n		23042334 Proposal for San Francisco to negotiate drug prices makes waves. Raven K. Nat Med. 2012 Oct;18(10):1447. doi: 10.1038/nm1012-1 create date:2012/10/09 first author:Raven K	09.10.2012	2012
2 20160828 pubmed	y			y Economic model (analytic, empirical data) n Policy (descriptive	j y n	22433771 Antihypertensive drugs: a perspective on pharmaceutical price erosion and its impact on cost-effectivenes: Refoios Camejo R, McGrath C, Herings R, Mc Value Health. 2012 Mar-Apr;15(2):381-8. doi: 10.1016/j.j create date:2012/03/22 first author:Refoios Camejo R	22.03.2012	2012
2 20160828 pubmed	v			v Economic model (analytic) v Policy > Invest (RE	«D) n n	20864202 A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness. Refoios Cameio R. McGrath C. Herings R. Health Policy. 2011 Apr:100(1):18-24. doi: 10.1016/i.hea.create.date:2010/09/25 first author: Refoios Cameio R	25.09.2010	2010
5 20160828 pubmed	v			 Economic model (analytic, empirical data) n Policy (descriptive) 	a v n	23640368 Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer si Refoios Cameio R. McGrath C. Miraldo M. Ri Eur J Health Econ. 2014 May:15(4):439-45. doi: 10.1007/ create date:2013/05/04 first author: Refoios Cameio R	04.05.2013	2013
2 20172131 WebOfScience	v			v Systematic Review n Policy > diverse		SYSTEMATIC REVIEW ON THE IMPACTS OF STRICT PHARMACEUTICAL PRICE CONTROLS Relakis. J: Maniadakis. N: Kourlaba. G: Shen. VALUE IN HEALTH		2013
5 20160828 pubmed	v	v				23975702 The role of generic medicines and biosimilars in oncology in low-income countries. Renner L. Nkansah FA, Dodop AN. Ann Oncol. 2013 Seo.24 Suppl 5:v29-32. doi: 10.1093/an.create.date:2013/08/30 first author:Renner L	30.08.2013	2013
6 20160828 pubmed	v	v				27516088 Cost Effectiveness of the Long-Acting P(2)-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist D Reza Maleki-Yazdi M. Molimard M. Keininge Appl Health Econ Health Policy. 2016 Aug 11. [Epub ahea create date: 2016/08/16 first author: Reza Maleki-Yazdi M.	16.08.2016	2016
4 20160828 pubmed	,	,	v			26510275 Pressure mounts for measures to control drug prices Bire S Mod Health: 2015 Jul 27-45(30):12 No abstract available create date 2015/10/30 L first author: Bire S	30 10 2015	2015
7 20160828 pubmed	7		,	Economic model (analytic) v Policy (description		19620550 Accession the impact of slobel price interdemodencies Bichter & Bic	16.07.2008	2008
20100828 publied	y u			y Policy (descriptive;	y II	100000 Research in the control of the intervention of the second of the intervention of the intervention of the intervention of the second of the intervention of the intervention of the intervention of the intervention of the second of the intervention of the second of the intervention of the inte	10.07.2008	2008
3 20160828 publied	y y					21102111 demanying barriers to the availability and use of magnetism is applied injection in resource poor commissions. Nage Ac, eleo CA, min SA.	17.01.2010	2010
2 20160828 pubmed	y	y				2332252 Medical mapractice in connecticut: defensive medicine, real problem for a red herring - example of assessin kinic G, Howard T, Kolic U. Acta inform Med. 2012 Mar(2)(1):32-3.0011 (2014) [1] Tirst author: Kinic G	17.01.2013	2013
5 20160828 pubmed	y y					1396/224 Price dimensionand transparency in the global pharmaceutical marketplace. Know y UB. Pharmaceeconomics. 2009;23():051-8. Create date: 2005(07)(01) Trist author: Know y UB	01.07.2005	2005
11 20160918 pubmed	У	y				23804360 Lead me not into temptation: drug price regulation and dispensing physicians in Switzerland. Rischatsch M. Eur J Health Econ. 2014 Sep;15(1):697-708. doi: 10.1007, create date: 2013/07/191 trist author: Rischatsch M	19.07.2013	2013
8 20160828 pubmed	у у	_		n		23093876 A bibliometric study of publication patterns in access to medicines research in developing countries. Ritz LS, Adam T, Laing R. South Med Rev. 2010 Feb;3(1):2-6. Epub 2010 Feb 15. create date:2010/02/01 hrst author:Ritz LS	01.02.2010	2010
12 20160918 pubmed	у	Y		N		26532057 Reference Pricing For Laboratory Tests In The United States: Impact On Prices And Spending. Robinson J, Brown T, Whaley C. Value Health. 2015 Nov;18(7):A364. doi: 10.1016/j.jval.2: create date:2015/11/05 first author:Robinson J	05.11.2015	2015
12 20160918 pubmed	У	У		n		23918483 Increases in consumer cost sharing redirect patient volumes and reduce hospital prices for orthopedic surg Robinson JC, Brown TT. Health Aff (Millwood). 2013 Aug;32(8):1392-7. doi: 10.13 create date:2013/08/07 first author:Robinson JC	07.08.2013	2013
6 20160828 pubmed	У	y		n		25288418 Specialty pharmaceuticals: policy initiatives to improve assessment, pricing, prescription, and use. Robinson JC, Howell S. Health Aff (Millwood). 2014 Oct;33(10):1745-50. doi: 10. create date:2014/10/08 first author:Robinson JC	08.10.2014	2014
12 20160918 pubmed	У	y		n		22949452 Payers test reference pricing and centers of excellence to steer patients to low-price and high-quality provi Robinson JC, MacPherson K. Health Aff (Millwood). 2012 Sep;31(9):2028-36. doi: 10.1 create date:2012/09/06 first author:Robinson JC	06.09.2012	2012
12 20160918 pubmed	Y	Y		N		27554826 Association of Reference Pricing for Diagnostic Laboratory Testing With Changes in Patient Choices, Prices, Robinson JC, Whaley C, Brown TT. JAMA Intern Med. 2016 Sep 1;176(9):1353-9. doi: 10.101 create date:2016/07/28 first author:Robinson JC	28.07.2016	2016
12 20160918 pubmed	y	Y		N		27479594 Reference Pricing, Consumer Cost-Sharing, and Insurer Spending for Advanced Imaging Tests. Robinson JC, Whaley C, Brown TT. Med Care. 2016 Jul 29. [Epub ahead of print] create date:2016/08/02 first author:Robinson JC	02.08.2016	2016
2 20172131 WebOfScience	У			y Economic model (analytic) y Policy (descriptive	j y n	PHARMACEUTICAL PRICING UNDER UNCERTAINTY: RISK-SHARING CONTRACTS Rodriguez-Ibeas, R; Arizti, I; Antonanzas, F VALUE IN HEALTH		2011
6 20160828 pubmed	y y			n		24750542 Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use Rosenberg ST. Dev World Bioeth. 2014 Aug;14(2):83-91. doi: 10.1111/d create date:2014/04/23 first author:Rosenberg ST	23.04.2014	2014
2 20160828 pubmed	Y	v		n		27186235 Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Rosenthal ES, Graham CS. Infect Agent Cancer. 2016;11:24. doi: 10.1186/s13027-0: create date:2016/05/18 first author:Rosenthal ES	18.05.2016	2016
5 20160828 pubmed	y			y Statistical analysis - descriptive Y Prices (descriptive	.) y n	17970935 Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia an Roughead EE, Lopert R, Sansom LN. Value Health. 2007 Nov-Dec;10(6):514-20. create date:2007/11/01 first author:Roughead EE	01.11.2007	2007
4 20160828 pubmed	v		v			25853829 [Drug prices: how they are established and existing price control systems]. Rovira Forms J.	09.04.2015	2015
2 20160828 pubmed	v v					24603082 Pharmaceutical policy reform in the Russian Federation. Rudisil C. Vandoros S. Antoun JG. J. Health Polit Policy Law. 2014 Jun: 39(3):691-705, doi: 10.create date:2014/03/08 first author:Rudisil C	08.03.2014	2014
2 20160928 pubmed		W.				2/202220 Economic Evaluation of a Starrid-Elution Sinus Implant following Endorconic Sinus Surgary for Chronic Phic Burlowit 1 Smith T1 Otologonous Haad Nack Surg. 2014 May 5:151(2):350-261 create date:2014/05/02 L Fort author:9004991 L	07.05.2014	2014
2 20160020 publicu	· ·					24/2002 Cost affective costs, 20/4 affective costs, 20/4 affective costs and 20/4 affective costs, 20/4 affect	10.05.2014	2014
12 20160918 pubmed	7	,				12/05/20 Dublic hashb value of fixed-date combinations in the programmer and combination in	19.08.2014	2014
2 20160928 submod	y .	y				1992/2029 rows relation or the under Minimum regret and the discovery of the analysis of the a	22 10 2000	2008
2 20160828 pubmed	y y					19993030 metalline pince in unuan muzanimujue, a puulin meani and economic study of pharmacettical matrices and Kusso G y Micrake B. Pealith Policy Phan. 2010 Jarges Jarves, doi: 10.1033/htt (refet date:2009/10/22) Trist author:Russo G	22.10.2009	2009
 20160828 pubmed 20160828 pubmed 	y y					2332424 Low summary or summers in man, verywe une affordadiny (2000-2012): a time-serves and gen: Sarayani A, Kashidan A, Sondami K. Bish Upen: 2014 Oct 10;4[Upe0/2055; doi:10.1130/dm/cr48d date:2014/01/218] Trist author:Sarayani A, Kashidan A, Sondami K.	18.10.2014	2014
 zutouszs pubmed 	у у					1927/194 Tuwarus equinause nearin sare, ur/ug prices, and beyond. Saryanarayana k. Indian J Med Res. 2008 Apr;127(4):303-4. Review. No ab: create date:2008/06/26 first author:Satyanarayana K	20.0b.2008	2008
8 20160828 pubmed	γ			y Policy > Access*	n n	20575229 Impact of pharmaceutical regulation and policies on health system performance goals in Israel. Sax P, Shmueli A. Adv Health Serv Res. 2010;22:77-101. create date:2010/06/26 first author:Sax P	26.06.2010	2010
4 20160828 pubmed	γ		У	n		25980086 utesavers or kockbacks / Entices say patient-assistance programs help keep drug prices high. Schencker L. Mod Healthc. 2015 Mar 9;45(10):20-2. No abstract availa create date:2015/05/20 first author:Schencker L	20.05.2015	2015
12 20160918 pubmed	γ		У	n		15968483 [Drug utilization and pharmaceutical cost-containment in germany-perspectives 1 year after enactment of I Schlander M. Med Klin (Munich). 2005 Jun 15;100(6):314-24. German. create date:2005/06/22 first author:Schlander M	22.06.2005	2005
5 20160828 pubmed	У			y Synthesis/Comment y Policy (descriptive)	j y n	24171232 Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers. Schlette S, Hess R. Issue Brief (Commonw Fund). 2013 Oct;29:1-9. create date:2013/11/01 first author:Schlette S	01.11.2013	2013
2 20172131 Scopus	У	y		n		Comment on "pharmaceutical price discrimination and social welfare" (by Frank R. Lichtenberg) Schmalensee R.L. Capitalism and Society		2010
2 20160828 pubmed	У	y		n		16435758 The Balanced Scorecard versus Total Quality Management: which is better for your organization? Schwartz J. Mil Med. 2005 Oct;170(10):855-8. create date:2006/01/27 first author:Schwartz J	27.01.2006	2006
2 20160828 pubmed	Y		v	n		22961148 Straight talk with Mark Sculpher. Interview by Kate Ravilious. Sculpher M. Nat Med. 2012 Sep;18(9):1315. doi: 10.1038/nm0912-13 create date:2012/09/11 first author:Sculpher M	11.09.2012	2012
12 20160918 pubmed	y	v				17564580 Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme. Searles A, Jefferys S, Doran E, Henry DA. Med J Aust. 2007 Aug 20;187(4):236-9. Epub 2007 Jun 1: create date: 2007/06/15 first author: Searles A	15.06.2007	2007
12 20160918 pubmed	v	v				19563307 The PBS in a globalised world: free trade and reference pricing. Searles A. Aust Health Rev. 2009 Mav: 33(2):186-91. create date: 2009/07/01 first author: Searles A	01.07.2009	2009
2 20172131 Scopus	v v					Pharmaceutical Pricing Policy: A critique Selvarai S. Hasan H. Chokshi M. Senguota A. Economic and Political Weekly		2012
4 20160828 pubmed	v v					21455424 Medicine prices, availability and affordability in Sri Lanka. Senarathna SM. Mannapperuma U, Fernand Indian J Pharmacol. 2011 Feb: 43(1):60-3. doi: 10.4103/0j.create.date:2011/04/02 first author:Senarathna SM.	02.04.2011	2011
4 20160828 pubmed	, , ,					12299024 Neorbising antiretroviral drug prices: the experience of the Andean countries Sepane-Varnuer F. Bodriguez-Monguin B.	15.02.2007	2007
2 20160828 pubmed	, ,			Economic model (analytic empirical data) n Policy (descriptive	-) v n	2499025 Price-can Regulation Uncertainty and the Price Evolution of New Pharmaceuticals Shaiarizadeh & Holls & Health Econ 2015 Aug 2481966-72 doi:10.1002/hec.3. create date:2014/07/06 first author:Shaiarizadeh &	06.07.2014	2014
2 20100020 publica	y			Sumbaria (Commant		Product interval registration of the interval	00.07.2014	2014
2 20172131 Webbildence	y			y Policy (descriptive;	y II	INTELECTIONS OF DATIN AVERAGEN FOR THE AVERAGENCE FOR THE AVERAGENCE AVE	08.04.2016	2011
1 20160827 mediine	Y	Y				2/054040 Evaluating availability and price or essential medicines in Boston area (Massacrusters), output and an an and an	08.04.2016	2016
2 20172131 WebUtscience	Y	Y				A ROYEL ME HOU FOR COMBINING TREE CORRENT IS TIMATION APPROACHES TO PRAVMACEUTICAL PRIShendly, () WITCENT, C) POSITIAN VALUE IN HEALTH	24.05.2007	2010
5 20160828 pubmed	У	y				15/88/9 Urug importation and safety of drugs obtained from Canada. Shepherd M. Ann Pharmacother. 2007 Jul;41(7):1288-91. Epub 2007 J	21.06.2007	2007
12 20160918 pubmed	y			Economic model (analytic, empirical data) n Policy (descriptive)	y n	23389487 The impact of therapeutic reference pricing on innovation in cardiovascular medicine. Sheridan D, Attridge J. Pharmacoeconomics. 2006 Dec;24 Suppl 2:35-54. doi: 10. create date:2006/01/01 first author:sheridan D	01.01.2006	2006
6 20160828 pubmed	у у			n		23827980 Time trends and determinants of pharmaceutical expenditure in China (1990-2009). Shi L, Yang HY, Cheng G, Meng Q. Pharmaceconomics. 2014 Mar;32(3):257-64. doi: 10.10 create date:2013/07/06 first author:Shi L	06.07.2013	2013
12 20160918 pubmed	У	y		n		25321603 Is reference pricing the next big thing in payment reform? Shih T, Dimick JB. JAMA Surg. 2014 Dec;149[12]:1219-20. doi: 10.1001/jam create date:2014/10/17 first author:Shih T	17.10.2014	2014
8 20160828 pubmed	у у			n		25007076 Hospital preparedness in advance of the 2014 FIFA World Cup in Brazil. Shoaf K, Osorio de Castro CG, Miranda ES. Prehosp Disaster Med. 2014 Aug;29(4):409-12. doi: 10.11 create date:2014/07/10 first author:Shoaf K	10.07.2014	2014
2 20172131 Scopus	у у			n		Perceptions of general practitioners towards pharmaceutical price war and assessment medicines price var Siang T.C. Hassali M.A. Alrasheedy A.A. Sale¢ Journal of Medical Marketing		2014
12 20160918 pubmed	у	y		n		16097838 Pharmaceutical policy regarding generic drugs in Belgium. Simoens S, De Bruyn K, Bogaert M, Laekema Pharmacoeconomics. 2005;23(8):755-66. create date:2005/08/16 first author:Simoens S	16.08.2005	2005
1 20160827 medline	Y	v		n		19839067 Developing competitive and sustainable Polish generic medicines market. Simoens S. create date:2009/10/20 first author:Simoens S	20.10.2009	2009
4 20160828 pubmed	y	v				17877848 International comparison of generic medicine prices. Simoens S. Curr Med Res Opin. 2007 Nov;23(11):2647-54. create date:2007/09/20 first author:Simoens S	20.09.2007	2007
2 20160828 pubmed		v				21812796 What is the value for money of medicines? A registry study Simpens S I Clin Pharm Ther. 2012 Apr:37(2):182-6. doi: 10.1111/j.1 create date.2011/08/05 first author: Simpens S	05.08.2011	2011
12 20160918 pubmed	v	v				19450118 Generic medicine pricing in Europe: current issues and future perspective. Simoens S. J Med Econ. 2008;11(1):171-5. doi: 10.3111/136969908(create date: 2008/01/01 first author: Simoens S	01.01.2008	2008
12 20160918 pubmed	,	,				25152781 The Portuguese generic medicines market: a policy analysis	01 04 2009	2009
12 20160918 pubmed	,	,				24410552 Trends in generic prescribing and dispensing in Europe	01 07 2008	2008
4 20160828 pubmed	y	¥ 1				Tendor in general processing in control of the method of the second	21.01.2007	2007
3 20172121 Seemus	14					Todala regularia da la compare a menane ra compare	51.01.2007	2007
	У	,		-		A nounce on phannaceurus annung		2008
2 20172151 500pus	y y	,	y	n			45 40 2044	204.4
4 20160828 pubmed	у у у у		Y	n n		2331330 Effects of the watchina essential wedgets assessed and the processed and the	16.10.2014	2014
4 20160918 pubmed 12 20160918 pubmed	у у у у у		y	n n Y Economic model (analytic, empirical data) N Policy (descriptive)	y n	2227292 intercutor of histophical distance intercutor appending intercect. Towards a new numeration appending intercect. Towards and the intercutor appending intercect. Towards and the intercect appending intercect. Towards and the intercect appending intercect appending intercect appending intercect. Towards and the intercect appending	16.10.2014 16.09.2016	2014 2016
4 20160828 pubmed 12 20160828 pubmed 12 20160918 pubmed 12 20160918 pubmed	у у у у у	Y	y	n N Y Economic model (analytic, empirical data) N Policy (descriptive, N) y n	2521393 Erices to the Recently fording of Greece and Statement Recently fording of Greece and Recently fording of Greec	16.10.2014 16.09.2016 05.11.2015	2014 2016 2015
20160828 pubmed 20160918 pubmed 20160918 pubmed 20160928 pubmed 20160928 pubmed	у у у у у у	Y Y	Y	n N Economic model (analytic, empirical data) N Policy (descriptive N) y n	2357293 directs our de faloar activitation activitation metaleurity appetier in reacular galage activity. The metaleurity of galage activity and the metaleurity of galage activity and the metaleurity of galage activity. The metaleurity of galage activity activity of galage activity activity of galage activity activity of galage activi	16.10.2014 16.09.2016 05.11.2015 29.10.2013	2014 2016 2015 2013
2 20160828 pubmed 12 20160918 pubmed 12 20160918 pubmed 2 20160828 pubmed 2 20160828 pubmed 2 20160828 pubmed	у у у у у у у у	y y y	Ŷ	n n Y Economic model (analytic, empirical data) N Policy (descriptive N n) y n	2331339 citreds to the former citred and the product sprant metal and spra	16.10.2014 16.09.2016 05.11.2015 29.10.2013 02.07.2008	2014 2016 2015 2013 2008
20160328 pubmed 20160918 pubmed 20160918 pubmed 20160918 pubmed 20160828 pubmed 20160828 pubmed 20160828 pubmed	у у у у у у у у у	y y y	Y	n Y Economic model (analytic, empirical data) N Policy (descriptive N n n n n) y n	2321233 directs of une factorial estream metalicity system in reading system, in reading	16.10.2014 16.09.2016 05.11.2015 29.10.2013 02.07.2008 17.08.2016	2014 2016 2015 2013 2008 2016
2016/238 pubmed 2016/0318 pubmed 2016/0318 pubmed 2016/0318 pubmed 2016/0328 pubmed 2016/0328 pubmed 4 2016/0328 pubmed	у у у у у у у у у у	y y y y	та	n Y Economic model (analytic, empirical data) N Policy (descriptive N n n n n) y n	27510938 Pharmacerical Prior Park Control Difference Priority Internet Park Comparison and Reference Priority Internet Video Control Contro Control Control Control Control Co	16.10.2014 16.09.2016 05.11.2015 29.10.2013 02.07.2008 17.08.2016 05.04.2016	2014 2016 2015 2013 2008 2016 2016
20160328 pubmed 20160328 pubmed 20160318 pubmed 20160328 pubmed	У У У У У У У У У У У У У У	y y y y	y na y	n Economic model (analysis, empirical data) N Policy (descriptive n n n) y n	2351230 directs to the Halowing Careta Section and Careta Meeding (Figure 1) Press doil (L) 211 Press doil (16.10.2014 16.09.2016 05.11.2015 29.10.2013 02.07.2008 17.08.2016 05.04.2016 17.08.2005	2014 2016 2015 2013 2008 2016 2016 2005
20160828 pubmed 12 20160918 pubmed 12 20160918 pubmed 2 20160828 pubmed	У У У У У У У У У У У У У У	y y y y	y y	n Y Economic model (analytic, empirical data) N Policy (descriptive N N Y Y Conomic model (analytic) Y Policy > Proces) y n	275/2003 Pharmacenical Arbitras (Figure 10) Science 1, Marce 10,	16.10.2014 16.09.2016 05.11.2015 29.10.2013 02.07.2008 17.08.2016 05.04.2016 17.08.2005 26.01.2007	2014 2016 2015 2013 2008 2016 2016 2005 2007
2016023 pubmed 12 20160918 pubmed 12 20160918 pubmed 2 20160928 pubmed 2 20160828 pubmed	y y y y y y y y y y y y y	y y y	y y	n Economic model (analytic, empirical data) N Policy (descriptive K N N Policy descriptive Y Policy Policy Prices N Policy Disper N N Policy Disper N N N N N N N N N N N N N N N N N N N) y n n n y y	2351230 direct of the Constraint careful and exchange and	16.10.2014 16.09.2016 05.11.2015 29.10.2013 02.07.2008 17.08.2016 05.04.2016 17.08.2005 26.01.2007 30.07.2009	2014 2016 2015 2013 2008 2016 2016 2005 2007 2009
20100282 pubmed 20100282 pubmed 2010018 pubmed 2010018 pubmed 20100182 pubmed 20100282 pubmed 20100282 pubmed 20100282 pubmed 20100282 pubmed 20100282 pubmed 20100282 pubmed 20100318 pubmed 20100313 pubmed	y y y y y y y y y y y y y y	y y y	y y	n Y Economic model (analytic, empirical data) N Policy (descriptive N Y Y Economic model (analytic) Y Policy > Proces Policy >) y n n n n y	275:0932 Photomacurical Prior Pack And Prior Pack	16.10.2014 16.09.2016 05.11.2015 29.10.2013 02.07.2008 17.08.2016 05.04.2016 17.08.2005 26.01.2007 30.07.2009	2014 2016 2013 2008 2016 2016 2005 2007 2009 2011
2 2016/022 pubmed 2 2016/023 pubmed 2 2016/0318 pubmed 2 2016/0318 pubmed 2 2016/028 pubmed	y y y y y y y y y y y y y y	y y y y	y y	n Y Economic model (analytic, empirical data) V Policy (descriptive N n Y Conomic model (analytic) Y Policy > Press V Interrupted time arries study() N N Policy > Discy V V Statistical analysis - inductive (not RCT/NR N Policy > Press N N N N N N N N N N N N N N N N N N) y n n n y n y	2751938 Pharmaceutical Prices Subtract S, Pharaerzogut, Marchan S, Paraerzogut, Marchan S, Pa	16.10.2014 16.09.2016 05.11.2015 29.10.2013 02.07.2008 17.08.2016 05.04.2016 17.08.2005 26.01.2007 30.07.2009	2014 2016 2013 2008 2016 2005 2007 2007 2009 2011 2010
20160229, pubmed 20160229, pubmed 20160218, pubmed 20160218, pubmed 2016028, pubmed	y y y y y y y y y y y y y y	Y Y Y Y	y na y	Economic model (analytic, empirical data) N Policy (descriptive Policy - Policy - P) y n n y n y	2751938 Photometrical for Play is Greece. The strend of Different Polish. Subject X. Processious M. N. Processious M. Polis, A. Strend Polisher, A. Strend Polisher	16.10.2014 16.09.2016 05.11.2015 29.10.2013 02.07.2008 17.08.2016 05.04.2016 17.08.2005 26.01.2007 30.07.2009 15.05.2010 29.10.2014	2014 2016 2013 2008 2016 2006 2005 2007 2009 2011 2010 2014
4 2016/8258 pubmed 12 2016/938 pubmed 12 2016/938 pubmed 2 2016/928 pubmed 2 2016/928 pubmed 2 2016/928 pubmed 4 2016/928 pubmed 2 2016/928 pubmed 2 2016/928 pubmed 2 2016/928 pubmed 2 2016/928 pubmed 2 2016/928 pubmed 2 2016/928 pubmed 6 2016/928 pubmed	y y y y y y y y y y y y y y y y y	y y y y	Y Y	n Y Economic model (analytic, empirical data) N Policy (descriptive N N N N N N N N N N N N N N N N N N N) y n n n n y n y	27510933 Pharmacenical Arbitros (Page Page Page Page Page Page Page Page	16.10.2014 16.09.2016 05.11.2015 29.10.2013 20.07.2008 17.08.2016 17.08.2005 26.01.2007 30.07.2009 15.05.2010 29.10.2014 20.07.2010	2014 2016 2013 2008 2016 2005 2007 2009 2011 2010 2014 2010
2016/0258 pubmed 12 2016/0358 pubmed 12 2016/0358 pubmed 12 2016/0358 pubmed 2 2016/0258 pubmed	y y y y y y y y y y y y y y y y y y y	y y y y y y	Y na Y	Economic model (analytic), empirical data) N Policy (descriptive Policy - P) y a n n y a y	2750308 Photo Auditation planta on control space and con	16.10.2014 16.09.2016 05.11.2015 23.10.2013 02.07.2008 17.08.2016 05.04.2016 17.08.2005 26.01.2007 30.07.2009 15.05.2010 29.10.2014 24.07.2010	2014 2015 2013 2008 2016 2005 2007 2009 2011 2010 2014 2010 2014
2016/028 pubmed	y y y y y y y y y y y y y y y y y y y	y y y y y y y	y y	Economic model (analysis, empirical data) N Policy (descriptive Recommic model (analysis) V Policy Precision Economic model (analysis) V Policy Precision Recommic model (analysis) N Policy Precision Recommic model (analysis) N Policy Precision Policy Policy Policy Policy Policy Policy Policy Policy Policy Policy Policy Policy Policy Policy Poli) y n n n y n y	2750303 Pharmaceutical Project Search of Mitered Public Statistical Research of Mitered Public Proof Pable Health 2016 (18.6 with 2016) (2	16.10.2014 16.09.2016 05.11.2015 29.10.2013 20.07.2008 17.08.2016 17.08.2005 26.01.2007 20.07.2009 15.05.2010 29.10.2014 20.07.2010 20.07.2001 20.07.2001	2014 2016 2013 2008 2016 2005 2007 2009 2011 2010 2014 2010 2014 2010 2007 2007
2016/0259 pubmed 12 2016/0159 pubmed 12 2016/0158 pubmed	y y y y y y y y y y y y y y y y y y y	y y y y y y y	y na Y	Economic model (analytic, empirical data) N Policy (descriptive R P F F F F F F F F F F F F F	n n n y n y	2023080 The start of reference process of	16.10.2014 16.09.2016 05.11.2015 29.10.2013 20.07.2008 17.08.2016 17.08.2016 17.08.2016 17.08.2016 26.01.2007 30.07.2009 15.05.2010 23.10.2014 24.07.2010 20.07.2007 03.05.2011 09.07.2007	2014 2016 2013 2008 2016 2006 2007 2009 2011 2000 2014 2010 2014 2010 2017 2011 2010
2016/025: pubmed 12 2016/915: pubmed 12 2016/915: pubmed 12 2016/915: pubmed 2016/915: pubmed 2016/915: pubmed	y y y y y y y y y y y y y y y y y y y	Y Y Y Y Y Y Y	y na y	Economic model (analytic, empirical data) N Policy (descriptive Recommon model (analytic) V Policy - Policy - Statistical analysis - Inductive (not RCT/NR n Policy - Proces) y n n n n y n y	2753933 Symmetrical (Fig Picty & Greece: Transed to Offerent Polity, S.S. et House, M.S. et Hou	16.10.2014 16.09.2016 05.11.2015 29.10.2013 29.10.2013 20.07.2008 17.08.2016 05.04.2016 17.08.2016 26.01.2007 26.01.2007 20.07.2009 15.05.2010 24.10.2014 24.07.2010 20.07.2010 03.05.2011 03.07.2011 03.07.2011	2014 2016 2015 2013 2008 2016 2016 2005 2007 2009 2011 2010 2014 2010 2017 2011 2008 2011
2016/0259 pubmed 12 2016/0359 pubmed 12 2016/0358 pubmed	y y y y y y y y y y y y y y y y y y y	y y y y y y y	Y Y Y	Economic model (analytic, empirical data) N Policy (descriptive, N Policy (descriptive, N Policy - Prices N Policy - Prices Policy - Policy - Prices Policy - Policy - Pol	a a a a a a a a a a a a a a a a a a a	2753933 Pharmacentical Price Name of Different Politics Instances Control Market Policy 2005 (110, 110, 110, 110, 110, 110, 110, 110	16.10.2014 16.09.2016 05.11.2015 29.11.2015 29.11.2015 29.11.2015 17.08.2016 17.08.2016 17.08.2016 26.11.2007 30.07.2009 15.05.2010 29.11.2014 24.07.2010 20.07.2009 19.07.2028 19.07.2018 19.07.2028 19.07.	2014 2015 2013 2013 2016 2016 2005 2007 2009 2011 2010 2010 2011 2010 2011 2010 2011 2010 2011 2010
2016/025: pubmed 12 2016/915: pubmed 12 2016/915: pubmed 12 2016/915: pubmed 2016/025: pubmed 2016/025: pubmed	у у у у у у у у у у у у у у у у у у у	Y Y Y Y Y Y Y	y y y	Economic model (analysis, empirical data) N Policy (descriptive V Policy - Proces Interrupted time arrives tody (FS) N Policy - Proces Interrupted time arrives tody (FS) N Policy - Proces Datatical analysis - descriptive V Policy - Proces	n n n y n y	275393 Symmutocitical Priory Model: Same of Different Point. Symmutocitical Priory Model: Name of Different Point. Instrument Point Poin	16:10.2014 16:09.2015 16:01.2015 20:10.2013 20:00.2013 17:02.2016 17:02.2016 17:02.2019 15:05.2010 20:07.2009 20:07.	2014 2016 2015 2013 2008 2016 2006 2007 2007 2009 2011 2010 2007 2011 2010 2007 2011 2012 2007 2011 2014 2015
2016/0258 pubmed 2016/0358 pubmed 12 2016/0358 pubmed	У У У У У У У У У У У У У У У У У У У	y y v v y	Y Y Y	Economic model (analytic, empirical data) Ferrorenic model (analytic) F	n n n y n y n y	275393 Pharmacentical Project Section on a model of themes Point. Instance Section Market Section Section on a model of themes Point. Instance Section Market Section Section on a model of themes Point. 2753923 Sequences with the Recent Point on the Point Poin	16:10.2014 16:09:2016 05:11.2015 29:10.2013 02:07.2008 17:08.2016 05:04.2016 17:08.2005 26:01.2007 20:07.2009 15:05.2010 20:07.2009 10:07.2009 10:07.2009 10:07.2009	2014 2016 2015 2013 2008 2016 2005 2007 2009 2011 2010 2014 2010 2014 2010 2011 2010 2007 2011 2010 2011 2013 2011
2016/0258 pubmed 2016/0358 pubmed 12 2016/0358 pubmed 2016/0258 pubmed	У У У У У У У У У У У У У У У У У У У	y y y y	y y	Economic model (analytic, empirical data) N Policy (descriptive V Economic model (analytic) V Policy > Preces N Policy > Preces	n n n y n y	275303 Space Acceleration (Difference Price) Space Acceleration (Difference Price) Instance Control (Difference Price) Instance Control (Difference Price) 275303 Space Acceleration (Difference Price) Instance Control (Difference Price) Instance Contro (Difference Price) Instance	16 10, 2014 16 09 2016 05 11, 2015 29, 10, 2013 02, 07, 2008 17, 08, 2016 05, 04, 2016 17, 08, 2016 05, 04, 2016 17, 08, 2005 26, 01, 2007 29, 10, 2014 24, 01, 2014 24, 07, 2010 09, 07, 2008 19, 01, 2013 06, 05, 2011 21, 99, 2012 21, 99, 2012	2014 2016 2015 2013 2008 2016 2005 2007 2009 2011 2010 2014 2010 2007 2011 2010 2007 2011 2012 2003 2011 2013 2013 2014
20169255 pubmed 20169355 pubmed 2016935 pubmed 20172131 Scops 2016935 pubmed 20172131 Scops 2016935 pubmed 2016935 pubmed 2016935 pubmed	У У У У У У У У У У У У У У У У У У У	y y y y y	Y Y	Economic model (analysis, empirical dista) N Policy (descriptive P Policy Proces P Statistical analysis - descriptive Y Policy > Proces P Policy > Proces	a) y n n y n y n y n y n n	279309 Phantmachical fridge plays Greece: Theorem of Miterene Point. Set Jos C. Prosencetors Mitch Reserved. Transit Point P	16.10.2014 16.09.2016 05.11.2015 29.10.2013 02.07.2008 17.07.80.2016 06.04.2016 17.07.2008 17.07.2009 15.05.2010 29.10.2014 24.07.2010 20.07.2009 19.07.2008 19.07.2008 19.07.2018 19.07.20	2014 2016 2015 2013 2008 2016 2005 2007 2009 2011 2010 2010 2011 2000 2011 2008 2011 2001 2011 201
2016/025 pulmed 2016/015 pulmed 12 2016/015 pulmed 20	У У У У У У У У У У У У У У У У У У У	v v v v	Y N	Economic model (analytic, empirical data) N Policy (descriptive Y Economic model (analytic) Y Policy > Prees N Interrupted time arries study (7) Statistical analysis - inductive (not RCT/NR N Policy > Prees N Statistical analysis - descriptive Y Policy - Access*	n n n y n y	275938 Pharmacentical Price Name of Landon Land	16 10, 2014 16 03 2016 05, 11, 2015 23, 10, 2013 02, 07, 2008 17, 08, 2016 05, 04, 2016 17, 08, 2016 05, 04, 2016 17, 08, 2005 26, 01, 2007 26, 01, 2007 20, 07, 2008 19, 01, 2013 05, 05, 2011 21, 09, 2002 10, 02, 2004 10, 02, 02, 02, 02, 02, 02, 02, 02, 02, 0	2014 2016 2015 2013 2008 2016 2005 2007 2009 2011 2010 2014 2010 2014 2010 2014 2010 2013 2011 2015 2015 2012 2015
20160255 pubmed 20160355 pubmed 12 20160355 pubmed 20160285 pubmed 20	У У У У У У У У У У У У У У У У У У У	y y y y y y y	Y Y Y	Economic model (analytic, empirical deta) N Policy (descriptive V Policy - Prices interrupted time arrive study (IS) Policy - Prices Policy	n n n y n y n y n y	3793000 Photomacurital Process Character (Subted) and the defence Project in the defence Pr	16 10, 2014 16 09, 2016 05 11, 2015 23 1, 10, 2013 02 0, 2008 17 08, 2016 05 04, 2016 17 08, 2016 17 08, 2016 17 08, 2016 17 08, 2016 23 10, 2009 15, 05, 2010 24 0, 2020 24 0, 2020 24 0, 2020 24 0, 2020 24 0, 2020 25 0, 2007 26 0, 2017 26 0, 2017 27	2014 2016 2015 2013 2008 2016 2006 2007 2009 2011 2010 2011 2010 2011 2011 2011
2 20160325 pubmed 2 20160315 pubmed 12 20160315 pubmed 2 20160325 pubmed <t< td=""><td>Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y</td><td>Y Y Y Y Y Y</td><td>Y Y Y</td><td>Economic model (analytic, empirical dista) N Policy (descriptive V Economic model (analytic) Y Policy > Prices Interrupted time arries study ()TS N Policy > Prices Statistical analysis - inductive (not RCT/NR N Policy > Prices Statistical analysis - descriptive Y Policy > Access* Statistical analysis - descriptive Y Policy > Access*</td><td>a) y n n y n y n y</td><td>275393 Phasemacerical Arloy Degrad Genes: The and a Offeren Point. Instance Count of the Second Second</td><td>16:10.2014 16:02.2016 05:11.2015 23:10.2013 02:07.2008 17:08.2016 05:04.2016 17:08.2016 05:04.2016 17:08.2005 26:01.2007 21:10.2014 24:07.2009 15:05.2010 09:07.2008 09:07.2008 09:07.2008 10:03.2019 10:03.2019 10:03.2019</td><td>2014 2016 2015 2013 2008 2016 2016 2016 2016 2010 2011 2010 2011 2010 2007 2011 2010 2011 2001 2011 201</td></t<>	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y Y	Y Y Y	Economic model (analytic, empirical dista) N Policy (descriptive V Economic model (analytic) Y Policy > Prices Interrupted time arries study ()TS N Policy > Prices Statistical analysis - inductive (not RCT/NR N Policy > Prices Statistical analysis - descriptive Y Policy > Access* Statistical analysis - descriptive Y Policy > Access*	a) y n n y n y n y	275393 Phasemacerical Arloy Degrad Genes: The and a Offeren Point. Instance Count of the Second	16:10.2014 16:02.2016 05:11.2015 23:10.2013 02:07.2008 17:08.2016 05:04.2016 17:08.2016 05:04.2016 17:08.2005 26:01.2007 21:10.2014 24:07.2009 15:05.2010 09:07.2008 09:07.2008 09:07.2008 10:03.2019 10:03.2019 10:03.2019	2014 2016 2015 2013 2008 2016 2016 2016 2016 2010 2011 2010 2011 2010 2007 2011 2010 2011 2001 2011 201
2016/025; pubmed 2016/035; pubmed 12 2016/035; pubmed 2016/035; pubmed 2	Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y Y Y Y	Y Y Y	Economic model (analysis, empirical data) N Policy (descriptive V Policy Proces, n Policy > Proces, N Policy + Policy > Proces, N Policy + Policy	n n n y n y	37393 Symmutatical fright plays Greec. Transed to Miterark Bulk. Simplex Processing Mathematical Bulk From Pack Heath. 2014;18:24.001.218.001.2014;19:24.001.218.001.2014;19:24.0012014;19:24.0012014;19:24.001204;19:24.0012014;19:24.001204;19:24.0	16 10, 2014 16 09, 2016 05 11, 2015 29, 10, 2013 02, 02, 2008 17, 08, 2015 17, 08, 2015 17, 08, 2015 17, 08, 2015 29, 10, 2019 29, 10, 2014 24, 07, 2010 20, 07, 2007 10, 01, 2013 20, 07, 2007 10, 01, 2013 10, 01, 2013 10, 01, 2013 10, 01, 2013 10, 01, 2013 10, 01, 2013 10, 01, 2015 10, 0	2014 2016 2015 2013 2008 2016 2005 2007 2009 2011 2010 2014 2010 2017 2011 2010 2011 2011 2011 2011
20169252 pubmed 20169352 pubmed 20169352 pubmed 20169352 pubmed 20169352 pubmed 20169352 pubmed 20169352 pubmed 2016935 pubmed <td>Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y</td> <td></td> <td>Y Y Y</td> <td>Economic model (analytic, empirical dista) N Policy (descriptive V Economic model (analytic) Y Policy > Prices V Interrupted time series study (P) Statistical analysis - inductive (not RCT/NR n Policy > Prices Statistical analysis - inductive (not RCT/NR n Policy > Prices Statistical analysis - inductive (not RCT/NR n Policy > Prices) V Policy > Prices</td> <td>a) y n n y n y n y n y n n</td> <td>3 Provide Signary Greener: The stand of Miterene Point. Instrumentation Mitching Diary Greener: The stand of Miterene Point. Instrumentation Mitching Diary Greener: The stand of Miterene Point. Instrumentation Mitching Diary Greener: The stand of Miterener Point. Instrumentation Mitching Diary Greener: The Stand of Miterener Point. Instrumentation Mitching Diary Greener: The Stand of Miterener Point. Instrumentation Mitching Diary Greener: The Stand of Miterener Point. Instrumentation Mitching Diary Greener: The Stand of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Miterener: The Stand Of Miter</td> <td>16 10.2014 16 09.2016 05.11.2015 29.10.2013 02.07.2008 17.078.2016 17.078.2016 17.078.2016 17.078.2016 17.078.2017 20.077.2009 15.05.2010 29.10.2014 24.07.2010 29.10.2014 24.07.2010 29.077.2008 19.077.2010 20.07.2010</td> <td>2014 2016 2015 2013 2008 2016 2016 2016 2005 2007 2009 2011 2010 2014 2010 2013 2013 2013 2015 2015 2012 2015 2012 2015 2012 2015 2012 2014 2014</td>	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y		Y Y Y	Economic model (analytic, empirical dista) N Policy (descriptive V Economic model (analytic) Y Policy > Prices V Interrupted time series study (P) Statistical analysis - inductive (not RCT/NR n Policy > Prices Statistical analysis - inductive (not RCT/NR n Policy > Prices Statistical analysis - inductive (not RCT/NR n Policy > Prices) V Policy > Prices	a) y n n y n y n y n y n n	3 Provide Signary Greener: The stand of Miterene Point. Instrumentation Mitching Diary Greener: The stand of Miterene Point. Instrumentation Mitching Diary Greener: The stand of Miterene Point. Instrumentation Mitching Diary Greener: The stand of Miterener Point. Instrumentation Mitching Diary Greener: The Stand of Miterener Point. Instrumentation Mitching Diary Greener: The Stand of Miterener Point. Instrumentation Mitching Diary Greener: The Stand of Miterener Point. Instrumentation Mitching Diary Greener: The Stand of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Mitching Diary Greener: The Stand Of Miterener Point. Instrumentation Miterener: The Stand Of Miter	16 10.2014 16 09.2016 05.11.2015 29.10.2013 02.07.2008 17.078.2016 17.078.2016 17.078.2016 17.078.2016 17.078.2017 20.077.2009 15.05.2010 29.10.2014 24.07.2010 29.10.2014 24.07.2010 29.077.2008 19.077.2010 20.07.2010	2014 2016 2015 2013 2008 2016 2016 2016 2005 2007 2009 2011 2010 2014 2010 2013 2013 2013 2015 2015 2012 2015 2012 2015 2012 2015 2012 2014 2014
2016/0258 pubmed 2016/0358 pubmed 12 2016/0358 pubmed	У У У У У У У У У У У У У У У У У У У	Y Y Y Y Y Y Y	Y Y Y	Economic model (analytic, empirical data) N Policy (descriptive Y Economic model (analytic) Y Policy > Prees N Interrupted time arries study (ITS) Statistical analysis - inductive (ind RCT/NN N Policy > Prees N Statistical analysis - descriptive Y Policy > Po	n n n y n y n y	Partner Provide Signal Si	16 10, 2014 16 09 2016 05 11, 2015 20 1, 20 20 17 08, 2013 02 0, 7, 2008 17 08, 2016 17 08, 2016 17 08, 2016 17 08, 2016 26 0, 1, 2007 26 0, 1, 2007 26 0, 1, 2007 29 0, 2014 24 0, 2014 24 0, 2014 24 0, 2014 24 0, 2014 24 0, 2014 10 0, 2015 10 0, 2014 21 09, 2015 10 0, 2015 10 0, 2015 10 0, 2014 10 0, 2016 2014 2015 2016 2017 2016 2017 201	2014 2016 2015 2013 2008 2016 2006 2007 2007 2001 2010 2014 2010 2014 2010 2011 2011
20160255 pubmed 20160356 pubmed 12 2016038 pubmed 20160285 pubmed 20160858 pubmed 20160858 pubmed 20160858 pubmed 20160858 pubmed 20160858 pubmed 20160858 pubmed <td>Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y</td> <td></td> <td>Y N</td> <td>Economic model (analytic), empirical data) N Policy (descriptive M Policy - Policy</td> <td>a) y n n y n y n y n n n n</td> <td>Partner Provide State State Provide State State Provide State <th< td=""><td>16 10, 2014 16 09, 2016 05, 11, 2015 23, 10, 2013 02, 07, 2008 17, 08, 2016 17, 08, 2016 17, 08, 2016 17, 08, 2016 17, 08, 2017 24, 10, 2017 24, 10, 2014 24, 07, 2010 24, 07, 2010 24,</td><td>2014 2016 2015 2013 2008 2016 2016 2007 2009 2011 2010 2010 2011 2010 2011 2010 2011 2011 2013 2011 2015 2012 2015 2012 2016 2016 2016 2016 2016 2016 2016</td></th<></td>	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y		Y N	Economic model (analytic), empirical data) N Policy (descriptive M Policy - Policy	a) y n n y n y n y n n n n	Partner Provide State State Provide State State Provide State <th< td=""><td>16 10, 2014 16 09, 2016 05, 11, 2015 23, 10, 2013 02, 07, 2008 17, 08, 2016 17, 08, 2016 17, 08, 2016 17, 08, 2016 17, 08, 2017 24, 10, 2017 24, 10, 2014 24, 07, 2010 24, 07, 2010 24,</td><td>2014 2016 2015 2013 2008 2016 2016 2007 2009 2011 2010 2010 2011 2010 2011 2010 2011 2011 2013 2011 2015 2012 2015 2012 2016 2016 2016 2016 2016 2016 2016</td></th<>	16 10, 2014 16 09, 2016 05, 11, 2015 23, 10, 2013 02, 07, 2008 17, 08, 2016 17, 08, 2016 17, 08, 2016 17, 08, 2016 17, 08, 2017 24, 10, 2017 24, 10, 2014 24, 07, 2010 24,	2014 2016 2015 2013 2008 2016 2016 2007 2009 2011 2010 2010 2011 2010 2011 2010 2011 2011 2013 2011 2015 2012 2015 2012 2016 2016 2016 2016 2016 2016 2016
2016/025 pulmed 2016/015 pulmed 12 2016/015 pulmed 20	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y Y Y Y	Y Y Y	Economic model (analytic, empirical data) V Folicy (descriptive V Economic model (analytic) V Policy Press P Interrupted time arries study (ITS) V Policy Press P Interrupted time arries study (ITS) V Policy Press P Policy (descriptive V Policy Access V V Policy Access V Policy Ac	n n n y n y n y	2759308 Pharmacentical Price Name of Lange Allow Constructions	16 10, 2014 16 09 2016 05 11, 2015 23 10, 2013 02 07, 2008 17 08, 2015 17 08, 2015 17 08, 2015 17 08, 2015 17 08, 2015 26 01, 2007 2010, 2008 19 01, 2013 20 07, 2008 19 01, 2013 20 07, 2008 19 01, 2013 20 07, 2008 19 01, 2013 06 05, 2011 21 09, 2012 08 04, 2015 01, 03, 2001 10 01, 2015 10 02, 2008 10 01, 2015 10 02, 2008 10 01, 2015 10 01, 2015 10 02, 2008 10 01, 2015 10 01, 2015 10 02, 2008 10 02,	2014 2016 2013 2013 2008 2016 2005 2007 2009 2011 2010 2014 2010 2011 2011 2015 2015 2015 2015 2015
2016/025: pubmed 2016/035: pubmed 12 2016/035: pubmed 2016/025: pubmed	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	* * * *	× ×	Economic model (analysis, empirical data) N Policy (descriptive Policy - Process Interrupted time acrines tada/(ISS) V Policy - Proces Interrupted time acrines tada/(ISS) Policy - Process Interrupted time acrines tada/(ISS) Policy - Process Policy - Policy - Policy - Process Policy - Policy -) y n n v n y n y n n	3Process Standard Legisland Standard Legisland From Pack Instances	16 10, 2014 16 09, 2016 05 11, 2015 20 11, 2015 20 12, 2008 17 08, 2016 06 04, 2016 17 08, 2017 201, 2019 201, 2017 201, 2017 2017, 2017	2014 2016 2013 2013 2008 2016 2005 2007 2009 2011 2010 2011 2010 2011 2011 2011
20160255 pubmed 20160256 pubmed 20160258 pubmed 20160285 pubmed 20160828 pubmed	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	v v v v v v v v v v v v v v v v v v v	Y Y Y	Economic model (analytic, empirical dista) N Policy (descriptive V Economic model (analytic) V Policy > Prices N Policy > Prices N Policy > Prices Statistical analysis - descriptive V Statistical analysis - descriptive V Policy > Access* N Policy = Access* N	a) y n n y n y n y n n	3 Proceedings Sector Sector<	16 10.2014 16 03.2016 05.11.2015 23.10.2013 02.07.2008 17.08.2016 17.08.2016 17.08.2016 17.08.2016 17.08.2016 17.08.2016 17.08.2017 20.07.2009 15.05.2010 20.07.2009 19.01.2014 20.07.2009 19.01.2013 0.07.2009 19.01.2013 0.07.2010 20.04.2015 0.01.2016 10.07.2010 20.04.2015 10.07.2010 20.04.2015 10.01.2016 10.01.201	2014 2016 2015 2013 2008 2016 2007 2009 2011 2010 2014 2010 2017 2011 2008 2013 2011 2008 2013 2011 2015 2015 2015 2015 2010 2016 2010 2014 2016 2016 2016 2016 2016 2016 2016 2016
2016/025: pubmed 2016/025: pubmed 12 2016/025: pubmed	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	* * * *	Y Y Y	Economic model (analytic), empirical dicta) N Policy (descriptive V Economic model (analytic) V Policy - Proces. Interrupted time acress study (TS) N Policy - Proces. Interrupted time acress study (TS) N Policy - Proces. Statistical analysis - descriptive V Policy (descriptive Statistical analysis - descriptive V Policy - Access ¹ Statistical analysis - descriptive V Policy (descriptive Statistical analysis - descriptive V Policy (descriptive Statistical analysis - descriptive) y n n y n y n a	Partner Province with the Recently Care of the Section of the Sectin Sectin of the Section of the Sectin Section of the Section of	16 10.2014 16 09.2016 05 11.2015 29.10.2013 02.07.2008 17.08.2015 05.04.2016 17.08.2016 17.08.2015 17.08.2005 29.01.2017 29.10.2014 29.01.2017 29.01.2017 20.07.2009 10.01.2013 10.07.2010 10.01.2013 10.07.2010 10.07.2010 10.07.2010 10.07.2010 10.07.2010 10.07.2010 10.07.2010 10.07.2014 10.07.	2014 2016 2015 2013 2008 2006 2007 2009 2011 2010 2011 2010 2011 2011 2010 2011 2011 2011 2015 2011 2015 2012 2015 2012 2016 2014 2014 2016 2014 2016 2014 2016 2016 2017 2019 2016 2019 2016 2019 2016 2019 2016 2019 2016 2019 2016 2019 2016 2019 2016 2019 2016 2019 2016 2019 2016 2019 2016 2019 2016 2019 2016 2019 2019 2019 2019 2019 2019 2019 2019
20160255 pubmed 20160256 pubmed 12 20160285 pubmed 20160857 pubmed 20160858 pubmed </td <td>Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y</td> <td></td> <td>Y Y Y Y</td> <td>Economic model (analytic, empirical data) N Policy (description Conomic model (analytic) V Policy - Policy Economic model (analytic) V Policy - Policy Statistical analysis - description Statistical analysis - description V Policy - Policy -</td> <td>a a a y a a y a a y a a y a a y a a y a a a y a a a y a a a a a y a a a a a y a</td> <td>Processes Spectra Control (Spectra Contro)))</td> <td>16 10, 2014 16 09, 2016 05 11, 2015 29 1, 10, 2013 10, 20, 2008 11, 20, 2008 12, 20, 2008 14, 20, 2008 15, 20, 2008 15, 20, 2009 15, 20, 20, 2009 15, 20, 2009</td> <td>2014 2016 2015 2013 2008 2016 2007 2009 2011 2010 2011 2010 2011 2001 2011 2003 2011 2003 2011 2003 2011 2005 2012 2015 2015 2010 2016 2016 2016 2016 2016 2016 2016</td>	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y		Y Y Y Y	Economic model (analytic, empirical data) N Policy (description Conomic model (analytic) V Policy - Policy Economic model (analytic) V Policy - Policy Statistical analysis - description Statistical analysis - description V Policy -	a a a y a a y a a y a a y a a y a a y a a a y a a a y a a a a a y a a a a a y a	Processes Spectra Control (Spectra Contro)))	16 10, 2014 16 09, 2016 05 11, 2015 29 1, 10, 2013 10, 20, 2008 11, 20, 2008 12, 20, 2008 14, 20, 2008 15, 20, 2008 15, 20, 2009 15, 20, 20, 2009 15, 20, 2009	2014 2016 2015 2013 2008 2016 2007 2009 2011 2010 2011 2010 2011 2001 2011 2003 2011 2003 2011 2003 2011 2005 2012 2015 2015 2010 2016 2016 2016 2016 2016 2016 2016
20140255 pubmed 20140915 pubmed 12 20140915 pubmed 20140285 pubmed 20140828 pubmed 20140828 pubmed 20140828 pubmed 201408028 pubmed 2	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	* * * * * * * * *	Y Y Y Y	Economic model (analytic, empirical data) N Policy (descriptive V Economic model (analytic) V Policy - Proces N Enterrupted time arries study (TS) Statistical analysis - inductive (Ind RCT/NN N Policy - Proces N Statistical analysis - descriptive V Statistical analysis - descriptive V Policy - Proces N Statistical analysis - descriptive V Policy - Proces N Policy	y n n y n y n y n n n n n n	Processes Sensenzial Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-	16 10, 2014 16 09 2016 05 11, 2015 20 1, 20, 2008 17 08, 2016 17 08, 2016 17 08, 2016 17 08, 2016 17 08, 2016 17 08, 2016 20, 10, 2007 20, 10, 2007 20, 10, 2007 20, 10, 2007 20, 20, 2007 20,	2014 2016 2015 2013 2008 2016 2005 2007 2009 2011 2010 2010 2010 2010 2010 2010
20160255 pubmed 20160358 pubmed 12 20160385 pubmed 20160285 pubmed 20	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	v v v v v v v v v v v v v v v v v v v	Y n3 Y Y	Economic model (analytic, empirical data) N Policy (descriptive Economic model (analytic) Y Policy > Prices Interruptied time arrive study (IS) A Policy > Prices Interruptied time arrive study (IS) A Policy > Prices Statistical analysis - descriptive Y Policy (descriptive Statistical analysis - descriptive Y Policy descriptive Statistical analysis - descriptive Y Policy descriptive Y Policy (descriptive)	y n n y n y n y n y n y n	Process Pr	16 10, 2014 16 09, 2016 05, 11, 2015 23, 10, 2013 02, 07, 2008 17, 08, 2016 05, 04, 2016 17, 08, 2016 17, 08, 2017 24, 07, 2009 15, 05, 2010 24, 07, 2009 15, 05, 2010 24, 07, 2019 24, 07, 2016 24,	2014 2016 2015 2013 2008 2016 2007 2009 2011 2010 2010 2011 2010 2011 2010 2011 2010 2011 2011 2015 2015
20140255 pubmed 20140075 pubmed 12 20160785 pubmed 20160285 pubmed 20	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y	Economic model (analytic, empirical data) N Policy (descriptive V Economic model (analytic) V Policy Proces Policy Policy Proces Policy Proces Policy Policy Proces Policy Policy Proces Policy	n n n y n y n y	Partner Provide State Provide State<	16 10, 2014 16 09 2016 05 11, 2015 20 1, 2013 02 0, 7, 2008 17 08, 2015 17 08, 2015 17 08, 2015 17 08, 2015 17 08, 2015 29 0, 2014 29 0, 2014 29 0, 2014 20 0, 72 007 00, 05, 2011 20, 07, 2008 19 0, 2014 20, 72 007 00, 05, 2011 0, 07, 2008 19 0, 2012 0, 07, 2008 19 0, 2012 0, 07, 2008 19 0, 2012 0, 07, 2008 10 0, 2015 10 0, 2015 20 0, 20	2014 2015 2016 2016 2016 2016 2016 2016 2016 2016
20160255 pubmed 20160156 pubmed 12 20160185 pubmed 20160285 pubmed 20	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y		Y Y Y Y Y	Economic model (analysis, empirical data) N Policy (descriptive M Policy Prices Interrupted time errors tade/(IS) V Policy Prices Interrupted time errors tade/(IS) Prices Statistical analysis - descriptive Statistical analysis - descriptive N Policy (descriptive N Policy (descript) y n n y n y n y n n	Process Standard and Process Control of Network bank Standard And Process Control of Network bank Process Network Bank Process Control Network Process	16 10, 2014 16 09, 2016 05 11, 2015 20 1, 20 2008 17 08, 2016 05 04, 2016 17 08, 2016 18 09, 2016 19 09, 2017 10 09, 2019 10 01, 2015 10 09, 2009 10 01, 2016 10 09, 2009 10 01, 2016 10	2014 12016 2016 2016 2016 2016 2016 2016 201
20169252 pubmed 20169252 pubmed 12 2016928 pubmed 2016928 pubm	У У У У У У У У У У У У У У У У У У У		У У У У У У У	Economic model (analytic, empirical data) N Policy (descriptive V Economic model (analytic) V Policy > Prices N Policy - Pric	a a a a a a a a a a a a a a a a a a a	Partner <t< td=""><td>16 10.2014 16 09.2016 05.11.2015 29.10.2013 02.02.2008 17.08.2016 17.08.2016 17.08.2016 17.08.2016 17.08.2017 20.07.2009 15.05.2010 20.07.2009 15.05.2010 20.07.2009 19.01.2014 24.07.2010 20.07.2008 19.01.2014 24.07.2010 20.07.2008 19.07.2018 20.07.2010 20.07.</td><td>2014 2014 2016 2016 2016 2016 2016 2016 2016 2016</td></t<>	16 10.2014 16 09.2016 05.11.2015 29.10.2013 02.02.2008 17.08.2016 17.08.2016 17.08.2016 17.08.2016 17.08.2017 20.07.2009 15.05.2010 20.07.2009 15.05.2010 20.07.2009 19.01.2014 24.07.2010 20.07.2008 19.01.2014 24.07.2010 20.07.2008 19.07.2018 20.07.2010 20.07.	2014 2014 2016 2016 2016 2016 2016 2016 2016 2016
2016/025 pubmed 2016/035 pubmed 12 2016/035 pubmed 20	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	÷	Y Y Y Y Y	Economic model (analytic), empirical dicta) N Policy (descriptive P Economic model (analytic) Y Policy - Prices Interrupted time acres study (15) Policy - Prices Interrupted time acres study (15) Policy - Prices Statistical analysis - descriptive Statistical analysis - descrip) y n n y n y n y n n y n	Partner <t< td=""><td>16 10, 2014 16 09, 2016 05 11, 2015 20 11, 2015 20 12, 2008 17 /08, 2016 17 /08, 2016 17 /08, 2016 17 /08, 2016 17 /08, 2016 20 12, 2009 20 12, 2009 20 12, 2007 20 13, 2017 20 14, 2017</td><td>2014 4 2015 4 2015 2 2016 2 2017 2 2018 2 2018 2 2018 2 2018 2 2018 2 2019 2 20</td></t<>	16 10, 2014 16 09, 2016 05 11, 2015 20 11, 2015 20 12, 2008 17 /08, 2016 17 /08, 2016 17 /08, 2016 17 /08, 2016 17 /08, 2016 20 12, 2009 20 12, 2009 20 12, 2007 20 13, 2017 20 14, 2017	2014 4 2015 4 2015 2 2016 2 2017 2 2018 2 2018 2 2018 2 2018 2 2018 2 2019 2 20

20160828 pubmed 20160828 pubmed 20160828 pubmed	y y y	У	У	n n			2274907 Drug firms, call for changes to German law that limits drug prices. Tuffs A. BMJ. 2012 Feb 23:344:1483. doi: 10.1136/mit.elf48 A. create diste: 2012/01/01 [first author:Tuffra A. 2467748 The impact of generatinal number of generating and prices are the wrong target?. Turpin RG, Splem C, Pontes-Arrada A, Smales Biol. 2012 Feb 23:344:1483. doi: 10.1136/genic.create Biol.2012/01/01 [first author:Tuffra A. 2567748 The impact of generating interview on biologistram infection risk and costs. Turpin RG, Splem C, Pontes-Arrada A, Smales. Biol. 2012 Feb 23:344:1483. doi: 10.1038/genic.create Biol.2010/02/01 [first author:Tuffra A. 2563748 The impact of generating interview on biologistram infection risk and costs. Ubly, Seconer M. Mod Healthe. 2016 Myr.24(1813):30-1 No abstrat Awair create diste: 2016/07/02 [first author:Tuffra A 2582148 D/IEDEres in medicil desenderules excording to drug prices. Ueblisme H. Mod Healthe. 2016 Myr.24(1813):30-1 No abstrat Awair create diste: 2016/07/02 [first author:Tuffra A	01.03.2012 29.03.2014 02.07.2016 13.07 2006	2013 2014 201 201
20160828 pubmed	, v		У	y Statistical analysis - description	Y Policy (descriptive)	V D	24238023 The costs of new drugs compared to current standard treatment! Uive/ M. Schlegel C. Gunders Remult	19,11 2013	200
20160828 pubmed	<i>y</i>	v			roncy (descriptive)	<i>y</i>	1990/352 (The color in the index of content variables and balf to increase in children (Lines VII) (See State Stat	01.04.2005	200
20160918 pubmed	, v	,	v				23252350 A reference pricing system for Ireland. Usher C. Barry M. Expert Rev Pharmacoecon Outcomes Res. 2012 Dec:12/E create date:2012/12/21 first author:Usher C	21.12.2012	201
20160828 pubmed	y y		,	n			21839891 [International reference prices and cost minimization analysis for the regulation of medicine prices in Color Vacca C, Acosta A, Rodriguez I. Value Health. 2011 Jul-Aug;14(5 Suppl 1):S16-9. doi: 10.1 create date:2011/08/24 [rist author:Vacca C	24.08.2011	201
20160930 pubmed	y y	y					15870428 When will the U.S. flinch at cancer drug prices? Vanchieri C. J Natl Cancer Inst. 2005 May 4;97(9):624-6. No abstract a create date:2005/05/05 first author:Vanchieri C	05.05.2005	200
20172131 Scopus	У	у		n			Parallel trade and pharmaceutical prices: A game-theoretic approach and empirical evidence from the Euro Vandoros S. Kanavos P. World Economy		201
20172131 WebOfScience	У)	(n			DDES PHARMACEUTICAL PRICE REGULATION AFFECT THE ADOPTION OF GENERIC COMPETITION IN THE OL Variol, N; Costa+Font, J; McGuire, AJ VALUE IN HEALTH		201
20160918 pubmed	y Y			N			26532995 External And Internal Reference Pricing As Cost Containment Measures In Bulgaria. Vasileva M, Manova M, Marik V, Zidarova B, Value Health. 2015 Nov;18(7):A534. doi: 10.1016/j.jval.2: create date::2015/11/05 first author:Vasileva M	05.11.2015	201
20160828 pubmed	У	Y	_	n			27226843 Novel methodology for pharmaceutical expenditure forecast. Vataire AL, Cetinsoy L, AballA©a S, Rémuz J Mark Access Health Policy. 2014;2. doi: 10.3402/jmahp create date:2014/01/01 first author:Vataire AL	01.01.2014	201
20160828 pubmed	У	_	У	n			16927609 The economics of pharmaceutical price regulation and importation: refocusing the debate. Vernon JA, Golec JH, Hughen WK. Am J Law Med. 2006;32(2-3):175-92. No abstract availab create date:2006/08/25 first author: Vernon JA	25.08.2006	200
20160828 pubmed	У	y		n			1952613 Mathematical modeling and pharmaceutical pricing: analyses used to inform in-licensing and development. Vernon JA, Hughen WK, Johnson SJ. Health Care Manag SG. 2005 May;8(2):167-79. Create date: 2005/06/15] first author: Vernon JA	15.06.2005	200
20160828 pubmed	y .			Economic model (analytic)	y Policy > Invest (R&D)	n n	15366/3 Examining the link between price regulation and pharmaceutical R&D investment. Verificial Land Land Land Land Land Land Land Land	24.09.2004	200
20160827 mediine	y y			n			26200324 barriers to universal nearint coversage in Republic or involution and informal out-or van 1, receiver FG, Jobiente S, Negruta A, Mareti A, Habiente J.	12.08.2015	201
20160828 pubmed	y .	У		n			2/12310 A review of the value of innovation in innaves for COPU and astrima. Vircinow JL, Akota KA, Darda J, Dekruugen K, J Mark Access Health Policy. 2015;3: doi: 10.3402/(marp create date:2015/01/01 hist author:vircinow JL Akota KA, Darda J, Dekruugen KJ, J Mark Access Health Policy. 2015;3: doi: 10.3402/(marp create date:2015/01/01 hist author:vircinow JL Akota KA, Darda J, Dekruugen KJ, J Mark Access Health Policy. 2015;3: doi: 10.3402/(marp create date:2015/01/01 hist author:vircinow JL Akota KA, Darda J, Dekruugen KJ, J Mark Access Health Policy. 2015;3: doi: 10.3402/(marp create date:2015/01/01 hist author:vircinow JL Akota KA, Darda J, Dekruugen KJ, J Mark Access Health Policy. 2015;3: doi: 10.3402/(marp create date:2015/01/01 hist author:vircinow JL Akota KA, Darda J, Dekruugen KJ, J Mark Access Health Policy. 2015;3: doi: 10.3402/(marp create date:2015/01/01 hist author:vircinow JL Akota KA, Darda J, Dekruugen KJ, J Mark Access Health Policy. 2015;3: doi: 10.3402/(marp create date:2015/01/01 hist author:vircinow JL Akota KA, Darda J, Dekruugen KJ, J Mark Access Health Policy. 2015;3: doi: 10.3402/(marp create date:2015/01/01 hist author:vircinow JL Akota KA, Darda J, Dekruugen KJ, J Mark Access Health Policy. 2015;3: doi: 10.3402/(marp create date:2015/01/01 hist author:vircinow JL Akota KA, Darda J, Dekruugen KA, Darda J, Dekruugen KJ, J Mark Access Health Policy. 2015;3: doi: 10.3402/(marp create date:2015/01/01 hist author:vircinow JL Akota KA, Darda J, Dekruugen KA, Darda J, Dekruugen KJ, J Mark Access Health Policy. 2015;3: doi: 10.3402/(marp create date:2015/01/01 hist author:vircinow JL Akota KA, Darda J, Dekruugen KA, Darda J, Dekruugen KJ, J Mark Access Health Policy. 2015;3: doi: 10.3402/(marp create date:2015/01/01 hist author:vircinow JL Akota KA, Darda J, Dekruugen KA, Darda J, Dekruu	01.01.2015	201
20172151 Scopus	y .		Ŷ	Statistical analysis - industive (not RC	T/NR n Other (non Policy) > Other	¥ 0	rina maccular incling pointers in Aussiania virus Astronomic datarea Munar Science Sci	07 11 2015	201
20160828 pubmed	ý	v		0	,	,	24962537 Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services : Vogler S, Habimana K, Arts D. Health Policy. 2014 Sep:117(3):311-27. doi: 10.1016/i.he.create.date:2014/06/26 first author: Vogler S	26.06.2014	201
20160828 pubmed	y y	,		n			21495202 Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member 5 Vogler S, Habl C, Bogut M, Voncina L. Croat Med J. 2011 Apr 15;52(2):183-97. Review. create date:2011/04/16 first author:Vogler S	16.04.2011	201
20160828 pubmed	у			y Statistical analysis - descriptive	Y Prices (descriptive)	y n	26091603 Analysis of Medicine Prices in New Zealand and 16 European Countries. Vogler 5, Kilpatrick K, Babar ZU. Value Health. 2015 Jun;18(4):484-92. doi: 10.1016/j.jval. create date:2015/06/21 first author:Vogler S	21.06.2015	201
20160828 pubmed	У	y		n			25848546 Medicines discarded in household garbage: analysis of a pharmaceutical waste sample in Vienna. Vogler S, Leopold C, Zuidberg C, Habl C. J Pharm Policy Pract. 2014;7:6. doi: 10.1186/2052-3211-: create date:2014/01/01 first author:Vogler S	01.01.2014	20
20160828 pubmed	У			y Statistical analysis - descriptive	Y Prices (descriptive)	Y N	26670089 Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison stud Vogler S, Vitry A, Babar ZU. Lancet Oncol. 2016 Jan;17(1):39-47. doi: 10.1016/S1470-create date:2015/12/17 first author:Vogler S	17.12.2015	20
20160827 medline	У		y	n			26468397 The Pharmaceutical Pricing and Reimbursement Information (PPRI) network - a decade of exchange of info Vogler S, Zimmermann N, De Joncheere K create date:2015/10/05	05.10.2015	201
20160828 pubmed	У			y Synthesis/Comment	Y Policy (descriptive)	y N	26981252 Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. Vogler S, Zimmermann N, Ferrario A, Wirtz \ J Pharm Policy Pract. 2016;9:9. doi: 10.1186/s40545-016 create date:2016/03/17 first author:Vogler S	17.03.2016	201
20160828 pubmed	У			y Statistical analysis - descriptive	Y Prices (descriptive)	y n	2382678 The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of c Vogler S, Zimmermann N, Habl C, Mazag J. Cost Eff Resour Alloc. 2013 Jul 4;11(1):15. doi: 10.1186/1 create date:2013/07/06 first author:Vogler S	06.07.2013	201
20160828 pubmed	У			y Survey / (Structured) Interviews	y Prices (descriptive)	y n	2309389 Discounts and rebates granted to public payers for medicines in European countries. Vogler S, Zimmermann N, Habl C, Piessnegge South Med Rev. 2012 Jul;5(1):38-46. Epub 2012 Jul 23. create date:2012/10/25 first author:Vogler S	25.10.2012	201
20160828 pubmed	У			y Survey / (Structured) Interviews	 y Policy (descriptive) 	y n	2309388 Pharmaceutical policies in European countries in response to the global financial crisis. Vogler S, Zimmermann N, Leopold C, de Jon: South Med Rev. 2011 Dec;4(2):69-79. doi: 10.5655/smr.v create date:2012/10/25 first author:Vogler S	25.10.2012	201
20172131 Scopus	γ		У	n			Pharmaceutical proting and reimpursement information (PPR)-new PPRI analysis including Spain Voglet S. Espin J. Habl C. Pharmaceuticals Policy and Law		200
20172131 Scopus	у	У	_				The Pharmaceutocal Pricing and Relimburgement Information (PPRI) Initiative-Experiences from engaging w/ Voger 5, Leopold C, Zmmermann N, Habi C, Health Policy and Technology		201
20172131 Scopus 20160828 pubmed	y		У	Craticical application instruction of the	T/NP p Boliny Stime		rearmaceutos pricing in source Voger 5, warmaceutos prici	01.01.2014	201
20160918 pubmed	y			statistical analysis - inductive (not RC	TYPES II POLICY > Prices	n y	2200003 The encircular on using market regulation on primate sustainability of the chapter and providence for the chapter and providence for the chapter and primate sustainability of the chapter and	05.12.2011	201
20160918 pubmed	7)					2022/27 Treatment of paratice for the stress of the United Bit Mark Control (1997) (19	04.09.2010	201
20160828 pubmed	7)					Second guarantee second second and the intervention of the national execution methods with a second method and the intervention of the national execution methods with a second method and the intervention of the national execution methods are a second methods and the intervention of the national execution methods are a second methods and the intervention of the national execution methods are a second methods and the intervention of the national execution methods are a second methods and the intervention of the national execution methods are a second methods are a second methods and the intervention of the national execution methods are a second method methods are a second method method are a second method are a sec	26 11 2015	201
20160828 pubmed	, y						1578305 Price connection in the Chinese obstrate rule and a sector with the connect sector with the co	20.06.2006	201
20160828 pubmed	, , ,			D			1530931 The Chinese pharmaceutical market at the crossroads: pro-competition solutions to improve access, quality Wang YR. Appl Health Econ Health Policy. 2005;4(3):17-15. cross-tead-2005;11:73-11 first author: Wang YR	29.11.2005	200
20160828 pubmed	y y						20526904 Balancine medicine orices and business sustainability: analyses of pharmacy costs, revenues and profit she. Waning B. Maddix J. Soucy L. BMC Health Serv Res. 2010 Jul 13:10:205. doi: 10.1186/J.create.date:2010/07/16 first author: Waning B.	16.07.2010	201
20160827 medline	v v			n			20003422 Towards equitable access to medicines for the rural poor: analyses of insurance claims reveal rural pharma Waning B, Maddix J, Tripodis Y, Laing R, Leufkens HG, Gokhale M. create date:2009/12/17 first author:Waning B	17.12.2009	200
20172131 Scopus	y y			n			Pharmaceutical pricing in Egypt Wanis H. Pharmaceutical Prices in the 21st Century		201
20172131 WebOfScience	y y			n			COMPULSORY LICENSES FOR NON-COMMUNICABLE DISEASES: IMPLICATIONS FOR PHARMACEUTICAL PRIC Wasserman, M; Priest, VL VALUE IN HEALTH		201
20160828 pubmed	у		У	n			2529482 Campaigners warn that EU trade deal with US could threaten drug prices. Watson R. BMJ. 2014 Oct 7;349:g6098. doi: 10.1136/bmi.g6098. No create date:2014/10/09 first author:Watson R	09.10.2014	201
20160911 pubmed	У		y	n			17467498 Value-based pricing of drugs in the UK. Webb DJ, Walker A. Lancet. 2007 Apr 28;369(9571):1415-6. No abstract avail: create date:2007/05/01 first author:Webb DJ	01.05.2007	200
20160828 pubmed	У	Y		n			26533926 Impact of Grexit on Pharmaceutical Pricing: An International Reference Pricing Analysis. Weiss J, Hakim P, Kjeldgaard-Pedersen J, Dej Value Health. 2015 Nov;18(7):A701. doi: 10.1016/j.jval.2 create date:2015/11/05 first author:Weiss J	05.11.2015	201
20160918 pubmed	У	y		n			2003643 The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Wellman-Labadie O, Zhou Y. Health Policy. 2010 May;95[2-3]:216-28. doi: 10.1016/j.h create date:2009/12/29 first author:Wellman-Labadie O	29.12.2009	200
20160828 pubmed	у у			n			2493123 Exploration of approaches to adjusting brand-name drug prices in Mainland of China: based on comparisor Weng G, Han S, Pu R, Pan WH, Shi L. Chin Med J (Engl). 2014;127(12):2222-8. create date:2014/06/17 first author:Weng G	17.06.2014	201
20172131 Scopus	У	_	У	n			Pharmaceutical prices Wertheimer A. Journal of Pharmaceutical Health Services Research		201
20172131 Scopus	У	Y		n			The healthcare system and pharmaceutical prices in United States Wertheimer A.I. Huang MY. Pharmaceutical Prices in the 21st Century		201
20160828 pubmed	У	Y		n			25099307 Chronic conditions, transial burden and pharmaceutical pricing: insights from Australian consumers. White JA, Sav A, Kelly F, King MA, McMillan Australian Vol. 35(5):539-59. doi: 10.1017/j.14/create date:2019/08/UB Tirst author:Whitty JA	08.08.2014	2014
20160828 pubmed	y .	Y		n			180/059 should orug prices be negotated under part Dr. Writers nam P. Writers nam P. Heatin Art (WinWood). 2005 JUI-AU[27] (4):119-76, automo Create date: 10/31/06 (1):1151 automotiviticets nam P. 2002 FOR Create date: 10/31/06 (1):1151 automotiviticet nam P. 2002 FOR Create date: 10/31/06 (1):1151 automotiviticet nam P. 2002 FOR Create date: 10/31/06 (1):1151 automotiviticet nam P. 2002 FOR Create date: 10/31/06 (1):1151 automotiviticet nam P. 2002 FOR Create date: 10/31/06 (1):1151 automotiviticet nam P. 2002 FOR Create date nam P. 2002 FOR Create date nam P. 2002 F	10.08.2013	2001
20160828 pubmed	y .		na				23920/b [Increases in pharmaceutical expenditures of PH by monocional antibodies]. Will be: Versineerung simedial. 2013 Jun 1;55(2):51-3. German . Create date: 2015/05(2):05.10 Jun 1;55(2):05.10 Jun 1;55(2):05.	10.08.2013	201:
20160828 pubmed	y .	Y		n			2/18/3/2 Negotiating orug prices for weakare. Wienesky ok. Prestruct Hank Manage, 2010 Wie1/04/3/2/3/2/3. No asstra (reate date:2010/05/18 Tirst author: Wienesky Gk	18.05.2016	2010
20172131 WebUtscience	y .		y	n V Cara study	a Delina (description)		Pharmaceutral price regulation who have a splice using middless development arguments the same of entry Will M. Descent J. Zeullers Y. Crail B. And Haveh E. See Alex 1. Descent date 2010/11/01 [Exit subheabilitie M.	04.11.2010	200
20160931 publied	y .	v		Case study	y Policy (descriptive)	y II	2009339 Reducing uncertainty water-based pricing using evidence development agreements, are used to containe, wind wy resistori 0, zoement 1, or and 1, and	10.06.2005	201
20160828 pubmed	7	y	v				1988272 [Research to upon this much proceeding and the second sec	17 12 2008	200
20160827 medline	, ,		,	 Literature Beview (not systematic) 	v Prices > Access*	v n	2623055 Human rights and access to benatifis C treatment for neonle who inject drugs Wolfe D Lubmann N. Harris M. Momenshalbal & Albers F. Burne J. Swan T. create date:2015/08/02. [first author:Wolfe D	02.08.2015	201
20160828 pubmed	y y				,	,	26478624 Transitioning to a national health system in Cvorus: a stakeholder analysis of pharmaceutical policy reform. Wouters OJ. Kanavos PG. Bull World Health Organ. 2015 Sep 1:93(9):606-13. doi: 1 create date:2015/10/201 first author:Wouters OJ	20.10.2015	201
20172131 Scopus	v v			n			Effects of pharmaceutical price regulation: China's evidence between 1997 and 2008 Wu B. Zhang Q. Qiao X. Journal of the Asia Pacific Economy		201
20160828 pubmed	v v			n			24190661 Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals. Wu J, Xu J, Liu G, Wu J. Wu J, Xu J, Liu G, Wu J. Pharmacoeconomics. 2014 Mar;32(3):293-303. doi: 10.1 create date:2013/11/06 first author:Wu J	05.11.2013	201
20172131 Scopus	y y			n			To what extent are pharmaceutical prices determined by patents? A case study of oncology medicines in TI Yamabhai I. Smith R.D. Journal of Intellectual Property Rights		201
20160827 medline	y y			n			24754184 [Prudent use price controls in Chinese medicines market: based on statistical data analysis]. Yang G, Wang N, Huang LQ, Qiu HY, Guo LP. create date: 2014	2014	201
20160827 medline	у у						1995509 Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China. Yang H, Dib HH, Zhu M, Qi G, Zhang X. create date:2009/12/04 first author:Yang H		200
20172131 Scopus				n			Study of the pharmaceutical pricing and reimbursement policies in Sweden Yao L-X. Ma L. Zheng Q. Chinese Journal of New Drugs	04.12.2009	
	у	>	1	n				04.12.2009	201
20160828 pubmed	y y	y	(n n			2bbbbbb9 The case of pharmacist prescribing policy in Israel. Yariv H. Isr J Health Policy Res. 2015;4:49. doi: 10.118b/s13584-0_create date:2015/12/15 first author:Yariv H	04.12.2009	201 201
20160828 pubmed 20160828 pubmed	y y y	y	(n n y Interrupted time series study (ITS)	n Policy > Prices	n y	Zabobaby Incase of pharmaticity prescribing policy in trade. Yan VK. Isr J Health holicy Res. 2015;4:39:40 create date: 2015;1/21/21 Inst autor/creater of the set of pharmaticity prescribing policy in trade. 17/51920 Amatepuicity Exc. Yan topulos J. Eur J Health holicy Res. 2015;4:39:40 create date: 2017;0/171 [Inst autor/creater of the set of pharmaticity prescribe and the set of pharmaticity pharmati	15.12.2009 15.12.2015 11.07.2007	201 201 200
20160828 pubmed 20160828 pubmed 20160827 medline	y y y y	y	(n n y Interrupted time series study (ITS) y Synthesis/Comment	n Policy > Prices y Policy (descriptive)	n y y n	Zabebabel The ray H. Isr J Health Policy Res. 2015;4:4:3: doi: 10.1136/13:94/ Credit date.2017/11/1 [Inst author:Tarn H JS19920 Pharmaceutical princing and instruments reference from in Greece. Vfantopopulos J. Ear J Health Econ. 2008 Feb;9(1);87:97. create date.2017/11 [Inst author:Tarn H JS69209 Pharmaceutical Princes in the 21st Century: Springer International Publishing Switzerland 2015. Zaheer-Ud- Din Babar (ed) create date.2015 create date.2015	04.12.2009 15.12.2015 11.07.2007 2015	201 201 200 201
20160828 pubmed 20160828 pubmed 20160827 medline 20160828 pubmed	у у у у у у	y	(n n y Interrupted time series study (ITS) y Synthesis/Comment	n Policy > Prices y Policy (descriptive)	n y y n	Zabebabble The case of pharmatic prescripting policy in transit. Yan Vi. Sp1 Healt Molex (#e1.2015;42:44.00 CL1334;13:94) Create date:2015;7(12). [Inst author:Tarn Vi Displago Diamanencial princip and the multi-mu	04.12.2009 15.12.2015 11.07.2007 2015 30.05.2013	201 201 200 201 201
20160828 pubmed 20160828 pubmed 20160827 medline 20160828 pubmed 20160911 pubmed	у у у у у у у	y	,	n n y Interrupted time series study (ITS) y Synthesis/Comment n Y Economic model (analytic)	n Policy > Prices y Policy (descriptive) y Policy > Expenditures	n y y n N n	Zabebabe The rel M Str / Health Policy Heid, 2015;4:43:40 cit; 2015;4:13:44 cit; 2015;4:14:44 cit; 2015;2:14:44 cit;	04.12.2009 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016	201 201 200 201 201 201
20160828 pubmed 20160827 medline 20160827 medline 20160828 pubmed 20160911 pubmed 20160828 pubmed	у У У У У У У У	y	,	n n y Interrupted time series study (ITS) y Synthesig/Comment n Economic model (analytic) y Literature Review (not systematic)	n Policy > Prices y Policy (descriptive) y Policy (descriptive) y Policy (descriptive)	n y y n N n y n	Zabebabble The case of pharmatic prescripting policy in transit. Yan Yi, Yi Spil Team Policy Res 2015;42:44:00: 10.1334(13:94) Create date:2015;7(13). Inst author:Tarm H Displago Jammanecinical pricing and policy in the main terms in Greece. Yan Yi, K Spil Team Policy Res 2015;42:44:00: 10.1334(13:94) Create date:2015;7(13). Inst author:Tarm H Zabes/DBZ Pharmacenical Price and the main terms in Greece. Zaber-Ud-Gin Rabar (ed) Tarm H create date:2015;7(14). Inst author:Tarm H Zabes/DBZ Pharmacenical Price and the main terms in Greece. Zaber-Ud-Gin Rabar (ed) create date:2015 create date:2015;7(14). Inst author:Tarm H Zabes/DBZ Pharmacenical Price and the main terms research concerns. Zabes/DBR (MARM, MARM, NARMIGH, MARM, MA	04.12.2009 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005	201 201 200 201 201 201 201
20160828 pubmed 20160827 medline 20160827 medline 20160828 pubmed 20160911 pubmed 20160828 pubmed 20172131 Scopus	у у у у у у у у у	y y	,	n n Y Interrupted time series study (ITS) Y Synthesis/Comment n Y Economic model (analytic) Y Literature Review (not systematic) n	n Policy > Prices y Policy (descriptive) y Policy > Expenditures y Policy (descriptive)	n y y n N n y n	200-04000 The case of pharmatic prescripting policy in strate. Yan /K. Wai	04.12.2009 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005	201 201 201 201 201 201 200 200 201
2016/0828 pubmed 2016/0828 pubmed 2016/0827 medline 2016/0828 pubmed 2016/0911 pubmed 2017/2131 Scopus 2017/2131 Scopus	y y y y y y y y y	y y	<i>,</i>	n n y Interrupted time series study (ITS) y Synthesis/Comment n Y Economic model (analytic) y Literature Review (not systematic) n y Economic model (analytic)	n Policy > Prices y Policy (descriptive) y Policy > Expenditures y Policy (descriptive) y Policy (descriptive)	n y y n N n y n	2664-6400 The case of pharmatic prescripting policy in transit. Yar VI. Sp1 Healt Molex, Wei, 2015;44:36 CF 1213;4(1):344 CF 2014 CF 2014;1(1):151 Sp1 Healt Molex, Wei, 2015;44:36 CF 1213;4(1):344 CF 2014 CF 2014;1(1):151 266697827 Pharmacenical Prescription Policy International Publishing Switzerland 2015. Zah St, Bigle MA, Meen N, Nachidan A. Ceret delta: 2013;7(1):151 Sp1 Healt Molex, Wei, 2015;44:36 CF 2011;131;1(1):151 Sp1 Healt Molex, Wei, 2015;44:36 CF 2011;131;1(1):151 Ceret delta: 2013;7(1):151 Ceret delta: 2013;7(1):151 Sp1 Healt Molex, Wei, 2015;44:36 CF 2011;131;1(1):151 Ceret delta: 2013;7(1):151 Sp1 Healt Molex, Wei, 2015;44:36 CF 2011;131;1(1):151 Ceret delta: 2013;7(1):151 Ceret delta: 2013;7(2):151 Ceret	04.12.2009 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005	201 201 201 201 201 201 201 200 201 201
2016/822 pubmed 2016/822 pubmed 2016/822 pubmed 2016/822 pubmed 2016/931 pubmed 2016/931 pubmed 2016/931 scopus 20172131 Scopus 20172131 Scopus 20172131 Scopus	у у у у у у у у у у у у у у	y y	<i>,</i>	n n n n n n n n n n n n n n n n n n n	n Policy > Prices y Policy (descriptive) y Policy > Expenditures y Policy (descriptive) y Policy (descriptive)	n y n y n y n	240-64000 The case of plannatic prescripting policy in strat. Yan Yi, Kin Y	04.12.2009 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005 01.11.2014	201 201 201 201 201 201 201 201 201 201
20160822 pubmed 20160823 pubmed 20160827 medline 20160827 medline 20160828 pubmed 20160911 pubmed 20172131 Scopus 20172131 Scopus 20172131 Scopus 20172131 Scopus 20160828 pubmed	ү у у у у у у у у у у у у у у	y Y	,	n n n y Interrupted time series study (ITS) y Synthesid/Comment P Conomic model (analytic) y Economic model (analytic) p Economic model (analytic) n y Syntematic Review	n Policy > Prices y Policy (descriptive) y Policy Supenditures y Policy (descriptive) y Policy (descriptive) n Policy > Expenditures	n y y n N n y n N y n	2664-800 The case of pharmatic prescripting policy in transit. Yar VH. Sp1 Healt Proce (see 2015;4:4:4:4:0:10:11:4:1:1); [Init author:Tarm H 2666/372 Thermoschical princing and them systems research concerns. Yar VH. Sp1 Healt Proce (see 2015;4:4:4:0:0:11:13:4:1); [Init author:Tarm H 2666/372 Thermoschical Princing and Methy Systems research concerns. Zadd S, Bigde MA, Meem N, Nashidan A, Part Healt Sci. 2005;4:2:1; [Init author:Tarm H 2666/372 Thermoschical Princing and Methy Systems research concerns. Zadd S, Bigde MA, Meem N, Nashidan A, Part Healt Sci. 2005;4:2:1; [Init author:Tarm H 2666/372 Thermoschical Princing and Methy Systems research concerns. Zadd S, Bigde MA, Meem N, Nashidan A, Part Sci. 2013;4:3:2:4:4:0:1:10;17(Juorum Creet detac: 2013;7);27(J); [Init author:Tarm H 200930 Methods for the comparative valuation of Dynamic Dagroups Tests in Precision Medicine. Zanitis S, Bigde MA, Meem N, Nashidan A, Part Sci. 2013;4:12:4:4:4:0:1:10;17(J); [Init author:Tarm H 200930 Methods for the comparative valuation of Dynamic Dagroups Tests in Precision Medicine. Zanitis S, Bigde MA, Meem N, Nashidan A, Post One: 2013 May 22,8(5);66:515; doi: 10:377;/[Juorum Creet detac:2013;7(2);21] [Init author:Tarm H 200930 Methods for the comparative valuation of Dynamic Research examptions in diverse structure valuation of Dynamic Research examptions in Ambring Smith Research examptions in the structure research examptions in Ambring Smith Research examptinter A 200930 Methods for th	04.12.2009 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 01.11.2014	201 201 201 201 201 201 201 201 201 201
2010/02.8 pubmed 2016/02.8 pubmed 2016/02.8 pubmed 2016/03.2 pubmed 2016/03.1 pubmed 2016/03.8 pubmed 201721.3 Scopus 201721.3 Scopus 201721.3 Scopus 2016/03.8 pubmed 2016/03.8 pubmed 2016/03.8 OECD ilbrary	у у у у у у у у у у у у у у у у у у у	y y y		n n v Interrupted time series study (15) v Synthesiu/Comment n Economic model (analytic) v Literature Review (not systematic) n v Economic model (analytic) n v Systematic Review n	n Policy > Prices y Policy (descriptive) y Policy Sependitures policy (descriptive) y Policy (descriptive) n Policy Sependitures	n y y n N n y n	2404-0400 The case of pharmatic prescripting policy in transit. Year IK. War IK. WA	04.12.2009 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 04.11.2015	201 201 201 201 201 201 201 201 201 201
2016/328 pubmed 2016/828 pubmed 2016/828 pubmed 2016/828 pubmed 2016/928 pubmed 2016/928 pubmed 2016/928 pubmed 2016/928 pubmed 2016/928 pubmed 2016/928 pubmed	ў ў ў ў ў ў ў ў ў ў ў ў ў ў ў ў	y y y	Y	n n synthesiy/Comment Synthesiy/Comment Synthesiy/Comment Synthesiy/Comment Commit (analytic) Synthesiy/Commit (analytic) Syntematic Review	n Policy > Prices y Policy (descriptive) y Policy Sependitures policy (descriptive) y Policy (descriptive) n Policy > Expenditures	n y y n N n y n N y	2004-000 The case of pharmatic prescripting policy in transit. Yar VH. For I Head In Council (2014)	04.12.2009 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 04.11.2015 20.01.2010 07.10.2010	201 201 201 201 201 201 200 201 201 201
2016/02.8 pubmed 2016/02.8 pubmed 2016/02.7 medline 2016/02.8 pubmed 2016/02.8 pubmed 2017/2111 Scopus 2016/02.8 pubmed 2016/02.8 pubmed 2016/02.8 OFCD Ribrary 2016/02.8 OFCD Ribrary 2016/02.8 OFCD Ribrary 2016/02.8 OFCD Ribrary	ў ў ў ў ў ў ў ў ў ў ў ў ў ў	y y y	Y Y	n v termyted time series study (15) v sythesiy/Comment n t commit: model (analytic) u terrature Review (not systematic) n v systematic Review systematic Review n v systematic Review n v systematic Review	n Policy > Prices y Policy (descriptive) y Policy (descriptive) y Policy (descriptive) n Policy - Sapenditures	n Y y n N n y n y n	2420-6400 The case of pharmatic prescripting policy in transit. Yarvi K. For J Healt free Couples (2): 10: 10: 10: 10: 10: 10: 10: 10: 10: 10	04.12.2009 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 04.11.2015 20.01.2010 07.10.2010 07.12.2014	201 201 200 201 201 201 201 201 201 201
2010/028 pubmed 2010/027 medline 2010/027 medline 2010/027 medline 2010/021 pubmed 2010/021 pubmed 2017/2131 Scopus 2017/2131 Scopus 2010/028 pubmed 2016/028 pubmed 2016/028 OECD library 2016/028 OECD library 2016/028 pubmed 2016/028 pubmed	у у у у у у у у у у у у у у у у у у у	y y y	Y Y	n n y Interrupted Line zerles study (15) y Synthesi/Comment Synthesi/Comment Commit endod (saulytic) Literature Review (not systematic) G Systematic Review G Subsetime G Subsetime G Subsetime G Subsetime G Subsetime G Subsetime G Subsetime G Subsetime G Subsetime G Subsetime G Subsetime G Subsetime G Subsetime G Subsetime Su	n Policy > Prices y Policy (descriptive) y Policy (descriptive) y Policy (descriptive) n Policy (descriptive) y Policy (descriptive)	n y y n y n y n y n y n	2004-0400 The case of pharmatic prescripting packy in transit. Year He. Year	04.12.2009 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005 01.01.2005 01.11.2014 04.11.2014 04.11.2015 20.01.2010 07.10.2010 05.12.2014	201 201 201 201 201 201 201 201 201 201
2010/02/82 pulmed 2010/02/82 pulmed 2010/02/82 melline 2010/02/82 melline 2010/02/82 pulmed 2010/21/81 Scopus 2017/21/81 Scopus 2017/21/81 Scopus 2010/02/82 pulmed 2016/02/82 pulmed 2016/02/82 pulmed 2016/02/82 pulmed 2016/02/82 pulmed	у у у у у у у у у у у у у у	y y y	y y	n v termyted sins series study (15) v sythesiy/Comment n termone model (analytic) u terrature Review (not systematic) n v Systematic Review n s Systematic Review	n Policy > Prices y Policy (descriptive) y Policy (descriptive) y Policy (descriptive) n Policy > Expenditures y Policy (descriptive)	n y y n N n y n y	2404-040 The case of plannatic prescripting policy in transit. Yarry N. For J Head In Force 2006 (1997) (19	04.12.2009 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 01.11.2015 20.01.2010 07.10.2010 05.12.2014	201 200 201 201 201 201 201 201 201 201
2016/028 pubmed 2016/029 pubmed 2016/027 medline 2016/027 medline 2016/027 medline 2016/021 pubmed 2016/021 pubmed 2016/021 pubmed 2016/021 pubmed 2016/021 pubmed 2016/021 pubmed 2016/021 pubmed 2016/022 pubmed	А А А А А А А А А А А А А А А А А А А	y y y y	y y y	n v linterrugted time sortes study (15) v SynthesiyComment v Comment v Economic model (analytic) v Literature Review (not synthesis) v Economic model (analytic) v v Canomic model (analytic) v v v v v v v v v v v v v	n Policy > Prices y Policy (descriptive) y Policy (descriptive) y Policy (descriptive) n Policy (descriptive) y Policy (descriptive)	n y y n N n y n n y y n	2004-0409 The case of plannance prescripting packy in trans. Year He. 2004-0409 The case of plannance prescripting packy in trans. Year He. 2004-0409 The case of plannance prescripting packy in trans. Year He. 2004-0409 The case of plannance prescripting packy in trans. Year He. 2004-0409 The case of plannance prescripting packy in trans. Year He. 2004-0409 The case of plannance prescripting packy in trans. Year He. 2004-0409 The case of plannance prescripting packy in the case of plannance plannace plannace plannance plannance pl	04.1.2.2005 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005 01.11.2014 04.11.2014 04.11.2014 04.11.2014 04.11.2014 04.12.015 20.01.2010 07.10.2010	201 201 200 201 201 201 201 201 201 201
2015/08/29 pubmed 2015/08/29 pubmed 2016/08/29 pubmed 2016/08/29 pubmed 2016/08/29 pubmed 2016/08/29 pubmed 2016/08/29 pubmed 2016/08/29 QICO Library 2016/08/29 QICO Library	у у у у у у у у у у у у у у	y y y y y	y y y	n setempted sine series study (15) y setempted sine series study (15) y setempted sine series study (15) n transmitted (analytic) n y systematic Review (not systematic) n y Systematic Review n g Guideline Guideline	n Policy > Prices y Policy (descriptive) y Policy (descriptive) y Policy (descriptive) n Policy > Expenditures y Policy (descriptive)	n y y n N n y n n y y n	2404-040 The case of plannatic prescription goods of reader due to any strate. Year Nr. Nr. Ver Nr.	04.1.2.2019 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014	201 201 201 201 201 201 201 201 201 201
2016/028 pubmed 2016/027 medline 2016/027 medline 2016/027 medline 2016/027 medline 2016/027 medline 2016/028 pubmed 2016/028 pubmed 2016/028 pubmed 2016/028 pubmed 2016/028 pubmed 2016/028 pubmed 2016/028 pubmed 2016/028 pubmed 2018/027 pubmed 2018/027 pubmed 2018/027 pubmed	х х х х х х х х х х х х х х	y y y y y y	y y y	n v interrupted time sorne study (15) v SynthesiyComment v SynthesiyComment v Commit model (analytic) v Literature Review (not systematic) c Commit model (analytic) v Systematic Review n v Cadeline n n	n Policy > Prices v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) n Policy (descriptive) v Policy (descriptive)	n y n y n y n y n n y	2404-040 The case of planmatic prescription goicy in trans. Year He. 250320 Planmacenical priving of the main arrow of feedback and planmacenical priving of the main arrow of the planmacenical plan	04.1.2.2019 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005 01.01.2016 01.11.2014 04.11.2014 04.11.2016 07.10.2010 05.12.2014	201 200 201 201 201 201 201 201 201 201
2016/828 pubmed 2016/828 pubmed 2018/828 pubmed 2018/828 pubmed	Y Y Y Y	y y y y y	y y y	n sterngted line series study (15) y sterngted line series study (15) y sterngted line series study (15) r ternomic model (analytic) a conomic model (analytic) a systematic Review (not systematic) a systematic Review (not systematic) a systematic) a systematic) a systematic	n Policy > Prices y Policy (descriptive) y Policy (descriptive) y Policy (descriptive) n Policy > Expenditures y Policy (descriptive)	n y n N n y n y n y n y	Abbelake (In Ecale of plannatic prescripting policy in Institu Yarry K. For J Healt Institut, 400: 2013.94 (13:84) circle 40: 2013.94 (13:84	04.1.2.009 15.12.2015 11.07.2007 2015 30.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014	201 200 201 201 200 201 201 201 201 201
0.108.002 published 0.006027 published 0.006027 published 0.006021 published 0.006021 published 0.006021 published 0.006021 published 0.006021 published 0.006022 published 0.00602 published	У У У У	y y y y y y y	y y y	n v interrupted time sortes study (15) 2 SynthesiyComment 1 Conomic model (analytic) 2 Literature Review (not systematic) 4 Conomic model (analytic) 5 Conomic model (analytic) 5 Conomic model (analytic) 6 Conomic model (analytic) 7 Cadadone 1 Conomic model (analytic) 7 Cadadone	n Policy > Prices v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) n Policy > Expenditures v Policy (descriptive) v Policy (descriptive)	n y n N n y n y n	Added by the case of plannance prescripting placety in strate. Year H. Mark 1. For J Healt Index (<i>Apr.</i> 2013.44, 2013.44, 2013.11, 2014.2013.11, [1114.140:ch ⁻ Tarr H. Mark 1. 20269729 Benetic of plannance in Plannance	04.12.2009 15.12.2015 11.07.2007 2015 30.03.2015 20.02.2016 04.01.2005 01.11.2014 04.11.2015 20.01.2010 07.10.2010 07.10.2010	201 200 201 201 201 201 201 201 201 201
02158/028 pubmed 02158/028 pubmed 02158/028 pubmed 02158/028 pubmed 02158/028 pubmed 02158/028 pubmed 02172131 Scopus 02172131 Scopus 0216028 pubmed 0218027 pubmed 02188027 pubmed 02188027 pubmed	х х х х х х х х х х х х х х	y y y y y y	y y y	n netempted line series study (15) y Sythesis/Comment f Coronic model (nalytic) y Literature Review (not systematic) n y Systematic Review n y Coulorine y Coulorine y Coulorine y Coulorine n y	n Policy > Prices Y Policy (descriptive) Y Policy (descriptive) Y Policy (descriptive) n Policy > Expenditures Y Policy (descriptive)	n y y n N n y n y n	Abbelake (In Easter of plannates) Yar Nr. For J Healt Inco. 2006 (Feg) (13 - 200 -	0.11.2009 15.12.2015 11.07.2007 2015 2016 2	201 200 201 201 201 201 201 201 201 201
2010/0029 pulnmed 2010/0029 pulnmed	х х х х х х х х х х х х х х	y y y y y y	Y Y Y	n v trempeter time sories study (1%) y Synthesiy/Comment trempeter time model (analytic) v Literature Review (not systematic) v Literature Review (not systematic) v Gudeelne n v Gudeelne	n Policy > Prices v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) n Policy > Expenditures v Policy (descriptive) v Policy (descriptive)	n y n N n y n	Added by the case of plannance prescripting placing in strate. Year Nr. N. J. Expland in the case of plannance prescripting placing in strate. Year Nr. N. J. Added by the case of plannance prescripting placing in strate. Year Nr. N. J. Expland in the case of plannance prescripting placing in the case of plannance placing in the case of plannance placing prescripting placing in the case of plannance plan	04.12.2009 15.12.2015 11.07.2007 2015 30.05.2015 20.02.2016 04.01.2005 01.11.2014 04.11.2014 04.11.2015 20.01.2010 07.10.2010 05.12.2014	201 200 201 201 201 201 201 201 201 201
2015/02/8 pubmed 2015/02/8 pubmed 2016/02/8 pubmed	 У У	y y y y y y y	×	n starspeld line series study (15) y Systhesu/Comment r t Commic model (nav)r(c) y Linerature Review (not systematic) r s systematic Review o s output s outp	n Policy > Prices V Policy (descriptive) V Policy (Bescriptive) V Policy (Bescriptive) n Policy > Expenditures V Policy (descriptive)	n y y n y n y n y n	Aubele (a) It is clear of plannates, the processing project of the plannes, the	0.11.2009 15.12.2015 11.07.2007 2015 2016 2015 2016 2	201 201 200 201 201 201 201 201 201 201
0.00002 publicle 0.00002 publicle 0.00002 publicle 0.00002 publicle 0.00002 publicle 0.00002 publicle 0.00002 publicle 0.00002 publicle 0.00002 publicle 0.00002 publicle 0.000002 publicle	 У Y Y	y y y y y y y y	y y y y	n v trengeted time sories study (1%) y Synthesiy/Comment trengeted time sories study (1%) trengeted time sories study (1%) trengeted time sories study (1%) trengeted time sories study (1%) y Control time	n Policy > Prices v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) n Policy > Expenditures v Policy (descriptive) v Policy (descriptive)	n y y n N n y n n y	Added by the case of plannance prescripting packy in trans. Yan Hr. For J Real Index, 2013, 448, 402, 313, 344, 602, 313, 343, 113, 341, 113, 412, 344, 114, 114, 114, 114, 114, 114, 114	04.12.2005 15.12.2015 10.07.2007 20.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.12.2014	201 201 200 201 201 201 201 201 201 201
2015/02/8 pubmed 2015/02/8 pubmed	 Y Y	у У У У У У У У У У У У У У У	- - 	n starupted line series study (15) y Sythesis/Commet commerced (analytic) y Linearus Review (not systematic) a commerced (analytic) y Systematic Review y Subtematic Review a a a a b b	n Policy > Prices V Policy (descriptive) V Policy (descriptive) V Policy (descriptive) n Policy (descriptive) V Policy (descriptive)	n y N n Y n Y n Y	Abbelands In Case of plannance prescripting policy in Israel. Yar IV. K For I Media Trick 2002 For I Medi	0.1.1.2009 15.12.2015 11.07.2007 2015 2015 2015 2012 2012 2012 2012 2012 2012 2012 2012 2012 2015 2016 20 2016 20	201 201 200 201 201 201 201 201 201 201
0.1980/20 pubmed 0.0980/27 pubmed	У <p< td=""><td>у У У У У У У У У У У У У</td><td>v v</td><td>n v terrupted time series study (1%) v Synthesiy Comment v Corronic model (analytic) v Corronic model (analytic) v Corronic model (analytic) v Corronic Roview v Correct Roview</td><td>n Policy > Prices v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) n Policy (descriptive) v Policy (descriptive) v Policy (descriptive)</td><td>л 9 у 0 у 0 у 0 л у 0</td><td>Added by the case of plannatestic price of more software. Yarri N. For J Healt fields, doi: 10.139/11.094 (refer dist. 2017.1/13) Intel dist. 2007.1/13 Intel</td><td>0.1.1.2005 11.0.7.2007 11.0.7.2007 2015 20.05.2013 24.0.2.2016 0.1.0.1.2005 0.1.1.2016 0.1.0.2005 0.1.1.2014 0.1.1.2016 24.0.1.2010 0.7.1.0.2010 0.5.1.2.2014</td><td>201 201 200 201 201 201 201 201 201 201</td></p<>	у У У У У У У У У У У У У	v v	n v terrupted time series study (1%) v Synthesiy Comment v Corronic model (analytic) v Corronic model (analytic) v Corronic model (analytic) v Corronic Roview v Correct Roview	n Policy > Prices v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) n Policy (descriptive) v Policy (descriptive) v Policy (descriptive)	л 9 у 0 у 0 у 0 л у 0	Added by the case of plannatestic price of more software. Yarri N. For J Healt fields, doi: 10.139/11.094 (refer dist. 2017.1/13) Intel dist. 2007.1/13 Intel	0.1.1.2005 11.0.7.2007 11.0.7.2007 2015 20.05.2013 24.0.2.2016 0.1.0.1.2005 0.1.1.2016 0.1.0.2005 0.1.1.2014 0.1.1.2016 24.0.1.2010 0.7.1.0.2010 0.5.1.2.2014	201 201 200 201 201 201 201 201 201 201
0010828 pubmed 0010928 pubmed 0010928 pubmed 0010928 pubmed 0010828 pubmed 00108828 pubmed 00108888 pubmed 0010888 pubmed 001088 pubm	 У У	y y y y y y y y y	- 	n v interrupted time sortes study (15) v SynthesiyCommet v SynthesiyCommet v Commit model (analytic) v Commit model (analyti	n Policy > Prices v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) n Policy (descriptive) v Policy (descriptive)	а У У а Л а У а С у а С у а	Abbeland In Case of plannatic prescripting policy in trans. Yar Nr. N. For Nr. N. Displays Plannatic prescripting policy in trans. Yar Nr. N. For Neutron Science, 2017;21 [Inst Author: Tarm P. Displays Plannatic prescripting policy in trans. Zar Nr. N. For Neutron Science, 2017;21 [Inst Author: Tarm P. Displays Plannatic prescripting policy in trans. Zar Nr. N. For Neutron Science, 2017;21 [Inst Author: Tarm P. Displays Plannatic prescripting policy in trans. Zar Nr. N. For Neutron Science, 2017;21 [Inst Author: Tarm P. Displays Plannatic prescripting policy in trans. Zar Nr. N. For Neutron Science, 2017;21 [Inst Author: Tarm P. Displays Plannatic prescripting policy in trans. Zar Nr. N. For Neutron Science, 2015;24(1);2017;2017;2017;2017;2017;2017;2017;2017	04.17.2005 16.12.2015 10.07.2015 20.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014	201 201 201 201 201 201 201 201 201 201
0108028 pubmed 010808 pubmed 010	У У У У	у У У У У У У У У У У У У У У У У У У У	v v	n v eventset v synthesiyComment v synthesiyComment v commit model (analytic) v commit model (analytic) v commit model (analytic) v synthesis v synthesis	n Policy > Prices v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) n Policy > Expenditures v Policy (descriptive) v Policy (descriptive)	n ¥ Y n N n M n Y n Y n	Aude day In factor of partners process proces process process proces process process process process	0 8.12.2005 11.07.2007 2015 2005 2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2016 01.11.2016 05.12.2014	201 201 200 200 200 201 200 200 200 200
0103828 pubmed 0103827 molline 0105827 molline 0105828 pubmed 0105828 pubmed 0105828 pubmed 0105828 pubmed 0105828 pubmed 0105828 OLCO Library 0105828 OLCO Library 0105828 OLCO Library 0105828 OLCO Library 0105828 pubmed 0105828 pubmed 0105828 pubmed 0105827 pubmed 0105827 pubmed 0105827 pubmed 0105827 pubmed 0105827 pubmed	 У У	y y y y y y y y y y y		n v uterrupted time sories study (15) v SynthesiyCommet v SynthesiyCommet v Canonic model (analytic) v Canoni	n Policy > Prices v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) n Policy (descriptive) v Policy (descriptive)	n Y Y n N n Y n N Y N	Added by the class of plannacturp proceedings pland processing pland plan	04.17.2005 15.12.2015 10.07.2015 20.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014	20: 20: 20: 20: 20: 20: 20: 20: 20: 20:
0130828 pubmed 0130828 pubmed 0130828 pubmed 0130828 pubmed 0130828 pubmed 0130828 pubmed 0130828 pubmed 0130828 pubmed 0130918 pubmed 0130918 pubmed 0130918 pubmed 0130828 pubmed 013088 pubmed 01308 pubmed 01308 pubmed 01308 pubmed 01308 pubmed 01308 pubmed 01308 pub	У У	у У У У У У У У У У У У У У У У У У У У		n setempted time series study (1%) y synthesiy Comment n terrature Review (not systematic) n comment of (analytic) y Goomie model (analytic) y Systematic Review source of the systematic and the systematic of the systematic Review of the syst	n Policy > Prices V Policy (descriptive) V Policy & Expenditures V Policy > Expenditures N Policy < Expenditures V Policy (descriptive)	n y y n N n n y n y n	Abbel Me date of plannatestic price of management Varia Nr. Market Science Varia Nr. Market Science Abbel Me date of plannatestic price of management Varia Nr. Market Science Varia Nr. Market Science Abbel Me date of plannatestic price of management Varia Nr. Market Science Varia Nr. Market Science Abbel Me date of plannatestic price of management Varia Nr. Market Science Varia Nr. Market Science Abbel Me date of plannatestic price of management Varia Nr. Market Science Varia Nr. Market Science Abbel Me date of plannatestic price of management Varia Nr. Market Science Varia Nr. Market Science Abbel Me date of plannatestic price of management Varia Nr. Market Science Varia Nr. Market Science Abbel Me date of plannatestic price of management Varia Nr. Market Science Varia Nr. Market Science Abbel Me date of Market Competitions An Interfector burg Nr. Market Science Nr. Market Competitions An Interfector burg Nr. Market Science Nr. Market Competitions An Interfector burg Nr. Market Science Nr. Market Competitions An Interfector burg Nr. Market Science Nr. Market Competitions An Interfector burg Nr. Market Science Nr. Market Competitions An Interfector burg Nr. Market Science Nr. Market Competitions An Interfector burg Nr. Market Science Nr. Market Competitions An Interfector burg Nr. Market Science Nr. Market Competitions An Interfector burg Nr. Market Science Nr. Market Competitions An Interfector burg Nr. Market Science Nr	04.17.2009 115.12.2015 11.07.2007 2015 2005.2013 24.02.2016 01.01.2005 01.01.2005 01.11.2014 04.11.2014 04.11.2015 26.01.2010 07.10.2010 05.12.2014	200 200 200 200 200 200 200 200 200 200
11100220 publicity 01100220 publicity 0100028 pub	у у у у у у у у у у у у у у	• • • • • • • • • • • • • • • • • • •		n v unterrupted time series study (1%) v Synthesize(Commet t Coromic model (analytic) v Literature Review (not systematic) v Customic model (analytic) v Cu	n Policy > Prices v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) n Policy (descriptive) v Policy (descriptive)	л У У Л У Л О У Л О У Л У Л	Added in the case of plannance prescripting placely in trans. Year Nr. N. J. Explane of plannance prescripting placely in trans. Year Nr. N. J. Added in the case of plannance prescripting placely in trans. Year Nr. N. J. The case of plannance prescripting placely in trans. Year Nr. N. J. Added in the case of plannance prescripting placely in the case. Year Nr. N. J. The case of plannance prescripting placely in the case. Year Nr. N. J. Added in the case. The case. The case. Year Nr. N. J. The case. Year Nr. N. J. Added in the case. The case. The case. The case. Year Nr. N. J. Added in the case. The case. The case. The case. Year Nr. N. J. Added in the case. The case. The case. The case. Year Nr. N. J. Added in the case. The case. The case. The case. The case. The case. Added in the case. The case. The case. The case. The case. The case. Added in the case. Added in the case. Added in the case. The case. The case. <td>0.1.2.2015 11.1.2.2015 12.0.7.2015 20.05.2013 24.0.2.2016 0.1.0.2005 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014</td> <td>2020 2001 2002 2002 2002 2002 2002 2002</td>	0.1.2.2015 11.1.2.2015 12.0.7.2015 20.05.2013 24.0.2.2016 0.1.0.2005 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014	2020 2001 2002 2002 2002 2002 2002 2002
0108028 pubmed 010802	У У У У	у У У У У У У У У У У У У У У		n v terrepted time series study (1%) v synthesiy Comment v terrepted time series study (1%) v terr	n Policy > Prices V Policy (descriptive) V Policy (descriptive) V Policy (descriptive) n Policy > Expenditures V Policy (descriptive)	n y y n N n y n y n	Aude day In factor of partnerscharts price company in start. Yarry K. <	04.12.2005 11.07.2007 2005 2005 2005 2002 2002 2002 01.01.2005 01.01.2005 01.01.2005 01.01.2016 01.01.2015 20.01.2010 07.10.2010 07.12.2014	2000 2000 2000 2000 2000 2000 2000 200
0100026 published 0000027 published 0000028 published 0100028 publi	У Y Y	• • • • • • • • • • • • • • • • • • •	× ×	n v terminet time areas study (1%) y Synthesiz/Comment terminet areas study (1%) terminet areas study (1%) terminet areas study (1%) terminet areas study (1%) y Control (1%) synthesiz/Comment p Control (1%) synthesiz	n Policy > Prices v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) n Policy > Expenditures v Policy (descriptive)	а 9 у а у а у а у а у а	Added in the class of plannaccular prices (more galaxy in transf. Year Nr. N. J. For Year Nr. N. J. For Year Nr. N. J. Added in the class of plannaccular prices (more galaxy in transf.) Year Nr. N. J. The class of plannaccular prices (more galaxy in transf.) For Year Nr. N. J. Added in the class of plannaccular prices (more galaxy in transf.) Year Nr. N. J. The class of plannaccular prices (more galaxy in transf.) For Year Nr. N. J. Added in the class of plannaccular prices (more galaxy in transf.) Year Nr. N. J. The class of plannaccular prices (more galaxy in transf.) For Year Nr. N. J. Added in the class of plannaccular prices (more galaxy in transf.) The class of plannaccular prices (more galaxy in transf.) For Year Nr. N. Y. Added in the class of plannaccular prices (more galaxy in transf.) The class of plannaccular prices (more galaxy in transf.) For Year Nr. N. Y. Added in the class of plannaccular prices (more galaxy in transf.) The class of plannaccular prices (more galaxy in transf.) For Year Class of plannaccular plannaccular prices (more galaxy in transf.) For Year Class of plannaccular plan	04.12.2005 11.12.2015 11.07.2007 2015 20.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 05.12.2014	2010 2010 2010 2010 2010 2010 2010 2010
2019/02/2 pubmed 2019/02/2	У У	• • • • • • • • • • • • • • • • • • •		n v interrupted time sortes study (15) v SynthesiyComment r Commit model (analytic) v Extensive Root synthesis commit model (analytic) v Contention Root (analytic) v Contention Ro	n Policy > Prices y Policy (descriptive) y Policy (descriptive) y Policy (descriptive) n Policy (descriptive) y Policy (descriptive)	п ¥ У п Л п У п Л У п	Aude drag In <i>E</i> drag of plannaccicity prescriptions in Greece. Yarin K. Yarin K. Yarin K. Yarin K. Yarin K. Yarin K. Yarin K. Yarin K. Ya	04.17.2005 11.51.2.2015 10.07.2015 20.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 05.12.2014	2001 2002 2002 2002 2002 2002 2002 2002
0.1988/02 pubmed 0.09927 pubmed 0.09927 pubmed 0.09927 pubmed 0.09928 pub	У У У У У У У У У У У У У У	• • • • • • • • • • • • • • • • • • •	y y y	n v terrepted time series study (1%) y Synthesiy(Comment terrepted time series study (1%) terrepted time series study (1%) v Synthesiy(Comment v Conomic model (analytic) v Synthesiy(Comment v Conomic model (analytic) v Conomic model (analytic) v Context v Context n n n n n n n n n n n n n	n Policy > Prices v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) v Policy (descriptive)	п ¥ У п У п У п У п	Aude drag In class of glammachic prices (manual prices) ministration approximation prices (manual prices) ministration approximation approximation prices (manual prices) ministration approximation approximateprice approprime approximation approximation approximation app	0.1.2.2015 11.0.7.2007 11.0.7.2007 2015 20.0.5.2013 24.0.2.2016 0.1.0.1.2005 0.1.1.2016 0.1.0.2005 20.0.1.2010 0.7.1.0.2010 0.5.1.2.2014	2001 2002 2002 2002 2002 2002 2002 2002
2019/02/20 pubmed 2019/02/20	У У У У У У У У У У У У У У	• • • • • • • • • • • • • • • • • • •		n v interrupted time sortes study (1%) v SynthesiyCommet r Coromic model (analytic) v Literature Review (not synthesis) c Coromic model (analytic) v Cadeline n v Cadeline n n n n n n n n n n n n n	n Policy + Prices V Policy (descriptive) V Policy (descriptive) V Policy (descriptive) n Policy (descriptive) V Policy (descriptive)	а У У а Л У а Л У а У а	Added in the class of plannamental prescripting plants,	04.12.2005 11.51.2.2015 10.07.2015 20.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014	201 200 200 200 201 201 201 201 201 201
01010002 pubmed 0100002 pubmed 20160022 pubmed 20160022 pubmed 20160022 pubmed 20160022 pubmed 20160028 pubmed 20160028 pubmed 20160028 pubmed 20160028 pubmed 20160028 pubmed 20160028 pubmed 20180027 pubmed 20180027 pubmed 20180027 pubmed 20180027 pubmed 20180027 pubmed 20180028 pubmed 20180028 pubmed 20180028 pubmed 20180029 pubmed 201800000000000000000000000000000000000	У У У У У У У У У У У У У У У У У У У		y y y	n v terrepted time series study (1%) v Synthesiy Comment v Synthesiy Comment v Coromic model (analytic) v Coromic model (analytic) v Systematic Review (not systematic) v Coromic model (analytic) v Coromic model (analyt	n Policy > Prices v Policy (descriptive) v Policy (descriptive) v Policy (descriptive) n Policy (descriptive) v Policy (descriptive) v Policy (descriptive)	п ¥ У п У п У п У п	Aude drag In class of plannaccular prices (minutes) prices (minutes) (minute	04.12.2005 11.07.2007 2015 20.05.2013 24.02.2016 01.01.2005 01.01.2005 01.01.2005 20.01.2010 20.01.2010 07.10.2010 05.12.2014	201 202 200 200 201 201 201 201 201 201
0.00002 pudmet 0.00002 pudmet 0.000002 pudmet 0.000002 pudmet 0.00000000000000000000000000000000000	У У У У У У У У У У У У У У У У У У У			n v Unterrugated time sores study (1%) v Synthetic Commet v Synthetic Commet v Commet v Commet model (analytic) v Commet mo	n Policy > Prices V Policy (descriptive) V Policy (descriptive) V Policy (descriptive) N Policy (descriptive) V Policy (descriptive) V Policy (descriptive)	а У У а Л У а У а У а У а	Added The class of plannakes prescription (particle) Ym /r /r For J Healt Mode (particle) (04.17.2005 15.12.2015 10.07.2015 20.05.2013 24.02.2016 01.01.2005 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014 01.11.2014	201 201 200 201 201 201 201 201 201 201

4 20180827 pubmed								
	Ŷ	У		n			284/9840 New User Fee Agreements Aim at Ensuring Relief From High Drug Prices: But Trump's Budget Proposal Thire Barlas S. P 1, 2017 May;42(5):312-329. create date:2017/05/10 [hrst author:Barlas S	
4 20180827 pubmed	У	У		n			28381916 Republicans Resolve to Address High Drug Prices: Rhetoric Meets Reality With PPACA Replacement. Barlas S. P T. 2017 Apr;42(4):242-273. create date:2017/04/07 first author:Barlas S	
4 20180827 pubmed	У	y		n			29719363 White House Report on Drug Prices Is a Detailed Road Map: Price-Lowering Ideas Generated, Some Already, Barlas S. P T. 2018 May;43(5):259-286. create date:2018/05/03 first author:Barlas S	
5 20180827 pubmed	/ n						27549327 Misoprostol Vaginal Insert in Labor Induction: A Cost-Consequences Model for 5 European Countries-An Et Bierut A, DowgiaÅ, Ao-Smolarczyk J, PieniÄ Adv Ther. 2016 Oct; 33(10):1755-1770. Epub 2016 Aug 2: create date: 2016/08/24 first author: Bierut A	
2 20180827 pubmed	Y	v		n			29403372 Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Bochenek T, Abilova V, Alkan A, Asanin B, de Front Pharmacol. 2018 Jan 18;8:942. doi: 10.3389/fphar. create date: 2018/02/07 first author: Bochenek T	
2 20180828 sconus	· .						Systemic measures and legislative and organizational frameworks aimed at neverting or mitigating drug sk Bochenek T Abilova V Alkan A Asanin B Frontiers in Pharmacology	2018
2 20190928 WebOfScier							Sustaining Managuran and Janiglation and Drawningthing Tramaworks Amand at Prevaniting or Milination Drug. Bechanak T. Abilova V. Alkan A. Asanin B. EDONTLEDS IN DUADMACO LOGY	2019
4 20190927 submed							Systems measure and organization of guina account of the formation of the sector of th	2010
4 20180827 publied	Ŷ	y					2022/405 The weather changes in Oncompy ong Prices Aren the Matchine Care Acc. Bonadoar remain A Carron NV. Apprinteautic confrequences (2017/02/25) This addition. Bonadoar remain A	
6 20180827 pubmed	Ŷ			Y	Y	y n	29030022 (Managed Entry Agreements for Pharmacolucias in the Context of Adaptive Partways in Europe. Bouly JL, Sapede C, Garner S. Pront Pharmacol. 2018 Mar 27(5):200. doi: 10.3369/jphai create date:2018/04/11 [htts: author: bouly JL]	
11 20180828 pubmed	/ n						27350294 Reference pricing with endogenous generic entry. Brekke KR, Canta C, Straume OR. J Health Econ. 2016 Dec;50:312-329. doi: 10.1016/j.jheal create date:2016/06/29 first author:Brekke KR	
12 20180828 pubmed	/ n						27350294 Reference pricing with endogenous generic entry. Brekke KR, Canta C, Straume OR. J Health Econ. 2016 Dec;50:312-329. doi: 10.1016/j.jheal create date:2016/06/29 first author:Brekke KR	
8 20180828 pubmed	У	У		n			29493050 The impact of permissive and restrictive pharmaceutical policies on quetiapine dispensing: Evaluating a pol Brett J, Schaffer A, Dobbins T, Buckley NA, P Pharmacoepidemiol Drug Saf. 2018 Apr;27(4):439-446. d create date:2018/03/02 first author:Brett J	
2 20180827 pubmed	y	y		n			29073981 Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology fc Brixner D, Maniadakis N, Kalä ³ 2, Hu S, Shen Value Health Reg Issues. 2017 Sep;13:1-6. doi: 10.1016/j create date:2017/10/28 first author:Brixner D	
2 20180828 scopus	v v			n			Considering Multicriteria Decision Analysis (MCDA) Simple Scoring as an Evidence-Based HTA Methodology Brixner D., Maniadakis N., Kaló Z., Hu S., She Value in Health Regional Issues	2017
4 20180827 pubmed		v					29779693 A new strategy to reduce US drug prices Burki TK Lancet Opcial 2018 May 12, nij: S1470-2045(18)30374-7, create date: 2018/05/22 first author:Burki TK	
4 20190927 pubmed	,	,					20050551 Can drug prises with policy, bare's how Cairnet L Nature 2018 Apr;55(7700)-026 doi: 10.1039/dd1596-0.craste.deta::0119/0/0721 [in:t-author:Cairnet]	
3 20190929 scenus	, ,	y					2000/2 Cp ong pinta min point in canone mina di harmana andre and anno canone in canone in canone di harmana andre anno canone di harmana an Armana anno canone di harmana anno canone di harmana anno canone di harmana anno canone di harmana anno canone di	2017
2 20180828 scopus	/ "						2730469 A Comparative review of the phantacoeconomic goldenies in South Anna caraphina 3.C. Journal of Investical Economics	2017
2 20180827 pubmed	/ n						27564849 A comparative review of the pharmacoeconomic guidelines in South Africa. Carapinha JL. J Med Econ. 2017 Jan;20(1):37-44. Epub 2016 Aug 26. create date:2016/08/27 first author:Carapinha JL	
2 20180828 WebOfScier	/ n						27564849 A comparative review of the pharmacoeconomic guidelines in South Africa Carapinha, JL JOURNAL OF MEDICAL ECONOMICS	2017
2 20180828 scopus	У			Y	n	n y	Value Based Pricing of Pharmaceuticals in the US and UK: Does Centralized Cost Effectiveness Analysis Matt Comanor W.S., Schweitzer S.O., Riddle J.M., Review of Industrial Organization	2018
2 20180828 WebOfScier	/ n						Value Based Pricing of Pharmaceuticals in the US and UK: Does Centralized Cost Effectiveness Analysis Matt Comanor, WS; Schweitzer, SO; Riddle, JM; S REVIEW OF INDUSTRIAL ORGANIZATION	2018
12 20180828 pubmed	/ n						27025848 Factors influencing the variation in GMS prescribing expenditure in Ireland. ConwayLenihan A, Ahern S, Moore S, Cronir Health Econ Rev. 2016 Dec;6(1):13. doi: 10.1186/s13561: create date:2016/03/31 first author:ConwayLenihan A	
8 20180828 pubmed	Y	v		n			28793075 [Coordination between pharmaceutical services for integrated pharmacotherapy: the case of Catalonia]. Costa KS, Goldbaum M, Guayta-Escolies R, N Cien Saude Colet. 2017 Aug;22(8):2595-2608. doi: 10.155 create date:2017/08/10 first author:Costa KS	
8 20180828 pubmed	v	v		n			29160467 Pharmaceutical services in primary health care: interfederative agreement in the development of pharmacy Costa KS. Tayares NUL. Nascimento JMD Jú Rey Saude Publica. 2017 Nov 13:51/suppl 21:25. doi: 10.1 create date:2017/11/22 first author:Costa KS	
8 20180828 pubmed	,	ý					29160466 Pharmaceutical services in the primary health care of the Pravilian Unified Health System: advances and chi: Costa KS. Tavares NUL. Nascimento IMD Iãs: Rev Saude Publica. 2017 Nov 13-51 (suppl 2)-35. doi: 10.1.create date: 2017/1/22. first author: Costa KS	
8 20190928 pubmed	,	,					2844405 Promotion and remulsion search medicines: Brahlin comparative necreartive necreartive disconters EM Shadlen KC Dev Denom Salud Publics 2017 Apr 20:41-65 create date-2017/04/27 Strit authoride Conters EM	
0 20190927 submed	, ,	y					2011 Control of Contro	
5 20180827 publied	Ŷ			Y	1		25300650 Antibianity challenges to value head of which a bases, of phane beases, and cures. Data of the which is to be a set of the	
4 20180827 pubmed	y	Y		n			286/2324 High Generic Drug Prices and Market Competition: A Ketrospective Conditistuary. Dave CV, Resseneim AS, POX ER, Qiu Y, Hart, Ann Intern Med. 2017 Aug 1;16/(3):145-151. doi: 10./32 create date:2017/07/04 Trist author:Dave CV	
o 20180827 pubmed	у у			n			2820148/ Urug pricing and reimbursement decision making systems in Mongolia. Uorj G, Sunderland B, Sanjjav T, Uorj G, Gen J Pharm Policy Pract. 2017 Feb 27;10:11. doi: 10.1186/s4 create date:2017/03/07 first author:Dorj G	
2 20180827 pubmed	У	У		n			29033595 Drug tendering: drug supply and shortage implications for the uptake of biosimilars. Dranitsaris G, Jacobs I, Kirchhoff C, Popoviar Clinicoecon Outcomes Res. 2017 Sep 29;9:573-584. doi: create date:2017/10/17 first author:Dranitsaris G	
2 20180828 scopus	/ n						Drug tendering: Drug supply and shortage implications for the uptake of biosimilars Dranitsaris G., Jacobs I., Kirchhoff C., Popovi ClinicoEconomics and Outcomes Research	2017
2 20180828 WebOfScier	/ n						29033595 Drug tendering: drug supply and shortage implications for the uptake of biosimilars Dranitsaris, G; Jacobs, J; Kirchhoff, C; Popov CLINICOECONOMICS AND OUTCOMES RESEARCH	2017
2 20180828 scopus	v			Y	v	n n	Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes. Dunlop W.C.N., Staufer A., Levy P., Edwards. Health Policy	2018
2 20180827 nubmed	, v			v	v	y n	29567205 Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes Dunlop WCN. Staufer A, Levy P. Fidwards GI. Health Drilly 2018 May 129(5)-528-532. doi: 10.1016/il.jcreate.date.2018/03/24.if.ereate.date.	2010
2 20180828 WabOfSrim	, , ,				1	,	2952206 Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes. Dunion WCN: Statifer A Low-C High Market Link Draws With Draws With Link Draws With Draws With Link Draws With Link Draws With Link Draws With Link Draws With Draws With Link Draws With Draws Wit	2010
1 20100020 Web0/S0Er	,						Experience interviewe prevention of the service of	2018
4 20180827 pubmed	У	У		n			294446 // Lanada makes deal to reduce generic drug prices. Dyer 0. BMJ. 2018 Feb 14;3b0:k723. doi: 10.1136/bmj.k723. No: create date:2018/02/16 first author:Dyer 0	
8 20180828 pubmed	У	У		n			28543810 Policy objective of generic medicines from the investment perspective: The case of clopidogrel. Elek P, HarsAnyi A, Zelei T, Cstetneki K, Kall ^A Health Policy. 2017 May;121(5):558-565. doi: 10.1016/j.f create date:2017/03/28 first author:Elek P	
2 20180827 pubmed	у у			n			27697777 Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect eviden Elek P, TakÄjcs E, MerÄßsz G, KalÅ ² Z. Health Policy Plan. 2017 Apr 1;32(3):349-358. doi: 10.105 create date:2016/10/05 first author:Elek P	
2 20180828 scopus	/ n						27697777 Implication of external price referencing and parallel trade on pharmaceutical expenditure: Indirect eviden Elek P., Takács E., Merész G., Kaló Z. Health Policy and Planning	2017
2 20180828 WebOfScier	/ n						27697777 Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect eviden Elek, P; Takacs, E; Meresz, G; Kalo, Z HEALTH POLICY AND PLANNING	2017
8 20180828 pubmed	v v			n			28793073 Rational use of medicines, pharmaceuticalization and uses of methylphenidate. Esher A, Coutinho T. Cien Saude Colet. 2017 Aug;22(8):2571-2580. doi: 10.15! create date:2017/08/10 first author:Esher A	
2 20180828 scopus	/ 1						27995636 Managing the Rising Costs and High Drug Excenditures in Critical Care Pharmacy Practice Flannery A.H., Pandya K., Laine M.E., Almete Pharmacotherapy	2017
2 20190927 pubmed		v					22005526 Managing the Billing Costs and kink Drug Evanditures in Critical Care Dharmany Practice Elannery All Dandys K Laine ME Almater P. Dharmanycharany 2017 Jan-27/11-56-56 doi: 10.1002/nl.create.date.2016/12/21 first author: Elannery All	
2 20180827 publiked	Ŷ	y					2/35050 wanaging use koing costs and migri origi expendences in circular care internative reactions. Praintery Any Party R, Care MR, America N, Die Marco MB, Cost 2010, 12/21 Trist autority 21	2017
2 20180828 WebUrscler	/ n						2/393656 Managing the Keiing Losts and high Drug Expenditures in Critical Care Pharmacy Practice Frannery, AR; Pandya, K; Laine, ME; Almeter PharMacOTHERAPY	2017
2 20180827 pubmed	У		У	n			30030646 Pharmaceutical pricing conundrum: time to get nd of it? Garattini L Padula A. Eur J Health Econ. 2018 Jul 20. doi: 10.1007/s10198-018- create date:2018/07/22 hrst author:Garattini L	
9 20180827 pubmed	Y		У	n			29270834 Value-Based Pricing: L'Enfant Terrible? Garner S, Rintoul A, Hill SR. Pharmacoeconomics. 2018 Jan;36(1):5-6. doi: 10.1007/s-create date:2017/12/23 first author:Garner S	
9 20180827 pubmed	У	y		n			28869571 Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Econc Garrison LP, Towse A. J Pers Med. 2017 Sep 4;7(3). pii: E10. doi: 10.3390/jpm7(create date:2017/09/05 first author:Garrison LP	
5 20180827 pubmed	У			Y	y	y n	28721607 Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry-Defining the "Gooc Ghinea N, Little M, Lipworth W. J Bioeth Inq. 2017 Sep;14(3):401-410. doi: 10.1007/s116' create date:2017/07/20 first author: Ghinea N	
11 20180828 pubmed	Y			v	v	y n	28522031 [The French medecine pricing committee and the medicine economic policy: Rules and competences]. Giorgi D. Ann Pharm Fr. 2017 Sep;75(5):359-372. doi: 10.1016/j.pl create date:2017/05/20 first author:Giorgi D	
4 20180827 pubmed	v	v		n			29789291 Is Ontario adding drug prices to EMRs? Glauser W. CMAJ. 2018 May 22:190/201:E628-E629. doi: 10.1503/cm.create.date:2018/05/24 first author:Glauser W	
2 20180828 WebOfScience	, 	,		D			Stategies for nizing of pharmaceuticals and generics in developing countries Godman 8: Hassali Ma GARI IDURNAI-GENERICS AND BIOSIMII ARS INITIATIVE IDURNAI	2017
2 20190928 sconus	, ,			N.			Reference Drives with Clarity Demond for Demonstrately Concessor V Scandinguish Durral of Economics	2019
2 20180828 scopus	Ŷ			y .	Ŷ		Reference Prixing with leader behavior of Priamace utuals double and the Prixing of State Prixing and	2018
2 20180828 Web013clei	/ "						Reference in any winit leader behavior of internative country of the second sec	2018
5 20180827 pubmed	/ n						26944633 Private versus social incentives for pharmaceutical innovation. GonzAllez P, Macho-Stadler I, PAGrez-Castr J Health Econ. 2016 Dec;30:286-297. doi: 10.1016/j.jmeal.create.date:2016/03/06 [hrst author:GonzAllez P	
		v		n			28591520 Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law. Greene JA, Padula WV. N Engl J Med. 2017 Jul 13;377(2):101-103. doi: 10.1056/t create date:2017/06/08 first author:Greene JA	
4 20180827 pubmed	У	,						
4 20180827 pubmed 5 20180827 pubmed	y y	,		y	n	n y	28813502 Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic re Gronde IV, Uyi-de Groot CA, Pieters 1. PLoS One. 2017 Aug 1b;12[8]:e0182b13. doi: 10.13/1/joi create date:2017/08/17 first author:Gronde IV	
4 20180827 pubmed 5 20180827 pubmed 2 20180828 WebOfScience	y y y	y		n	n	n y	28813302. Addressing the challenge of high-princed prescription drugs in the era of precision medicine's systemator or Gronole UV UV-de Groot CA, Peters 1. PLoS One. 2017 Aug 15;1[2]:e0124613. doi:10.1371/joi/create.date.2017/08/12] Inst author:Sirone IV 2945211 Obviewing Public Health Instrumer. Through Philose Health Instrumer. Through Philose Health Instrumer. Through Philose Health Instrumer. Philose	2017
4 20180827 pubmed 5 20180827 pubmed 2 20180828 WebOfScience 4 20180827 pubmed	y y y	y y		n	n	n y	284132W, Addressing the challenge of Indeparted precision indus; in the era of precision mediane: A systematic r 6 formole IV, Uy-6 Groot CA, Peters T. 29465214 Delivering Public Health Insurance Through Private Plan Choice in the United States Gruber, J. 29467321 The DA Unapproved Drugs Initiative: An Observation Study of the Consequences for Drug Prices and Sh Gupta R, Dhrwas SJ, Sox ER, Ross JS.	2017
4 20180827 pubmed 5 20180827 pubmed 2 20180828 WebOfScience 4 20180827 pubmed 7 20180828 pubmed	y y y y	y y y		n n	n	n y	283.1240 Addressing the challenge of https-preced preception drugs in the era of precision mediane'. A systematic r L'oronde IV. Uy-le' Groot QL, Pele Son Die, 2017 Aug. 15; 21(8):e310.843.1 doi: 10.1371/joi create date:2171/08/17] Inst author:Groote IV 28494731. The FDA Unappreced Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Sin Gugle R, Dhrvas S, Fost R, Ross JK. 28494731. The FDA Unappreced Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Sin Gugle R, Dhrvas S, Fost R, Ross JK. 28494731. The FDA Unappreced Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Sin Gugle R, Dhrvas S, Fost R, Ross JK.	2017
4 20180827 pubmed 5 20180827 pubmed 2 20180828 WebOfScience 4 20180827 pubmed 7 20180828 pubmed 8 20180828 pubmed	у У У У У	y y y		n n	n	n y	283.1202 Addressing the champing of high aned precision for experimentary of a systematic ref Groups (V) Uyel corold CV, Height CV,	2017
4 20180827 pubmed 5 20180827 pubmed 2 20180828 WebOfScience 4 20180827 pubmed 7 20180828 pubmed 8 20180828 pubmed 4 20180828 pubmed	у У У У У О	y y y		7 n n	n	n y	2831-202 Addressing the challenge of https-preced preception drugs in the era of precision medicine. A systematic re Groube 1V, Uy-lee Groud De Agel 2845-214 Deleving the challenge of https-preced precestion drugs in the era of precision dreadone IV Uy-lee Groud De Agel 2845-213 The FDA Unappreced Drugs Initiative. An Observational Study of the Consequences for Drug Prices and Shi Guga RB, Dhruva SS, Foet RB, Rossi SJ, 2845-2845 The FDA Unappreced Drugs Initiative. An Observational Study of the Consequences for Drug Prices and Shi Guga RB, Dhruva SS, Foet RB, Rossi SJ, 2845-2856 Price Agel Drugs Initiative. An Observational Study of the Consequences for Drug Prices and Shi Guga RB, Dhruva SS, Foet RB, Rossi SJ, Poet RB, 2012 (2012) 10:10:10:11/11/1.11 create date: 2017/09/21 [Fits author:Guga R 2012 (2012) 10:10:10:11/11/1.11/1.11/1.11/1.11/1.11/	2017
4 20180827 pubmed 5 20180827 pubmed 2 20180828 WebOfScience 4 20180827 pubmed 7 20180828 pubmed 8 20180828 pubmed 4 20180827 pubmed 2 20180827 pubmed	У У У У И У У У У	y y y		7 n n	n	n y	283.1320, Addressing the challenge of high-index precision for adjust in the end a precision medicine. A systematic rel formal is 10, Voyle Coroll CA, Pade 1, 2013, Vag 16, 2118, 2013, 2	2017
4 20180827 pubmed 5 20180827 pubmed 2 20180828 Web05Science 4 20180828 pubmed 8 20180828 pubmed 8 20180827 pubmed 4 20180827 pubmed 2 20180827 pubmed	у у у у у у у у	y y y		7 n n	n	n y	Additudgi Additudgi <t< td=""><td>2017</td></t<>	2017
4 20180827 pubmed 5 20180827 pubmed 5 20180828 Web0fScience 4 20180828 pubmed 8 20180828 pubmed 8 20180827 pubmed 4 20180827 pubmed 2 20180827 pubmed 2 20180828 scopus	Y Y Y Y 7 7 7	Y Y Y		, , , ,	n	n y	288.1302 Addressing the challenge of https-inced precision into done. A systematic ref conde IV. Uy-los Cond CJ, Media Sci. 2017, Aug. 51, 218, 2012, 2013. doi: 10.1371/joi create atte: 2017/08/17 [Fitst author-Graph R] 289.4312 Addressing the challenge of https-inced precision into done. A systematic ref conde IV. Uy-los Cond CJ, Media Sci. 2017, Aug. 51, 218, 2012, 2013. doi: 10.1371/joi create atte: 2017/08/17 [Fitst author-Graph R] 289.4312 Merias Graph C, Magorove D, Magor	2017 2017
4 20180827 pubmed 5 20180827 pubmed 2 20180828 WebOfScience 4 20180827 pubmed 7 20180828 pubmed 8 20180828 pubmed 4 20180827 pubmed 2 20180827 pubmed 2 20180827 pubmed 2 20180828 scopus 2 20180828 WebOfScier	Y Y Y Y 7 7 7 7 7	y y y			n	n y	2811320 Addressing the changes of high sends precision for closes in the close is by closed on the clo	2017 2017 2017 2017
4 20180827 pubmed 5 20180827 pubmed 20180828 Web0/Science 4 20180827 pubmed 7 20180828 pubmed 8 20180828 pubmed 2 20180828 pubmed 2 20180827 pubmed 2 20180827 pubmed 2 20180828 scpus 2 20180827 pubmed 2 20180828 scpus 2 20180827 pubmed 2 20180828 scpus 2 20180827 pubmed	Y Y Y Y Y Y Y Y Y Y Y	y y y			n	n y	288.1320 Addressing the challenges of high-include inservation drugs in the and precision medicine. A systematic rel concel is U/yield concel U, yield	2017 2017 2017
4 20180827 pubmed 5 20180827 pubmed 2 20180828 WebO/Science 4 20180828 pubmed 7 20180828 pubmed 4 20180827 pubmed 4 20180827 pubmed 2 20180828 corpus 2 20180828 WebO/Scier 6 20180827 pubmed 5 20180827 pubmed	Y Y Y Y Y Y Y Y Y	Y Y Y	у		n	n y	288.120L Addressing the challing of high sends precision for closes in the closes. Could be addressing the challing of high sends precision for closes in the closes. No. Obs. 2017 Aug. 10; 2148; 201243.1 doi: 10.1171/join create date: 2017/08/11 [First author-closes the limited of high sends precision for closes. No. Obs. 2017 Aug. 10; 2148; 201243.1 doi: 10.1171/join create date: 2017/08/11 [First author-closes the limited of high sends precision for closes. No. Obs. 2017 Aug. 10; 2148; 201243.1 doi: 10.1171/join create date: 2017/08/11 [First author-closes the limited of high sends precision for closes. 2844213 Developer limited of high sends precision for closes. Precision 30: 00 (Precision 30: 00 (Prec	2017 2017 2017
4 2018/0827 pubmed 5 2018/0827 pubmed 2 2018/0828 Web/OfScience 4 2018/0827 pubmed 8 2018/0827 pubmed 4 2018/0827 pubmed 2 2018/0828 scopus 2 2018/0828 scopus 6 2018/0827 pubmed 5 2018/0827 pubmed 5 2018/0827 pubmed	y y y y y y y y y y	Y Y Y	у		n	n y	288.1320 Addressing the challenges of high-princed precision indicion with only in the and precision medicine. A systematic rel control IV, Uyi-le Control U, Vyi-le Contrecotte Contrecotte Contrecotte Control Contrecotte Control Control	2017 2017 2017
4 20180827 pubmed 5 20180827 pubmed 2 20180828 WebOlScience 4 20180828 pubmed 8 20180828 pubmed 4 20180827 pubmed 2 20180828 copus 2 20180828 copus 2 20180828 webOlScier 6 20180827 pubmed 5 20180827 pubmed 4 20180827 pubmed 4 20180827 pubmed	y y y y y y y y y y	y y y	¥	, , , , , , , , , , , , , , , , , , ,	n	n y	288.1320, Addressing the changes of high sends investigation on doors in the long is a systematic relicional (V, Uyle Grout CA, Marker SS, Fork RR, Boss), SA No. One. 2017 Aug. 10; 2108: 2018.241.34.00 No. One. 2017 Aug. 10; 2108: 2018 Aug. 2109; 2015 Aug. 2100; 2015 Aug. 2109; 2015 Aug. 2109; 2015 Aug. 2109; 2015 Aug. 2109	2017 2017 2017
4 2018027 pubmed 2 2018027 pubmed	y y y y y y y y y y y	y y y y	¥	, , , , , , , , , , , , , , , , , , ,	n	n y	2811202 Addressing the change of high paned precision frequencies in the data of precision medicine. No. One. 2017 Aug. 10; 1018; 0012431.40: 101171/join create date: 2017/03/11 [Fit author:Hot-Graph R 2984213 Addressing the change of high paned precision frequencies in the data of precision medicine. No. One. 2017 Aug. 10; 1018; 0012431.40: 101171/join create date: 2017/03/11 [Fit author:Hot-Graph R 2984213 Addressing the change of high paned precision frequencies in the data of high paned precision frequencies in the high paned precision frequenci frequencies in the high paned precision frequencies in	2017 2017 2017 2017
4 20180827 pubmed 5 20180827 pubmed 2 20180827 pubmed<	y y y y y y y y y y y y y y y y y	Y Y Y Y	¥	, , , , , , , , , , , , , , , , , , ,	n	n y	288.120L Addressing the challenge of high-sinced precision indicator. How have a differentiation in the one of precision medicine. A systematic relicional Conture, 1 (No. Ohe. 2017 Aug. 10; 2108:2012431. doi: 10.1171/j.j.c.reste atte: 2017/09/10 [First author:/ACRode C 289.421L believing the challenge of high-sinced precision indicator. How have in the control states Conture, 1 (No. Ohe. 2017 Aug. 10; 2108:2012431. doi: 10.1171/j.j.c.reste atte: 2017/09/10 [First author:/ACRode C 289.421L believing the challenge of high indices. And precision indicator. How have in Kicknood C (No. Ohe. 2017 Aug. 10; 2108:2012431. doi: 10.1171/j.j.c.reste atte: 2017/09/10 [First author:/KiCknood C 293.1221 bit (First author:/KiCknood C (No. Ohe. 2017 Aug. 10; 2108:201243. doi: 10.1171/j.j.c.reste atte: 2017/09/10 [First author:/KiCknood C 293.1232 bit (First author:/KiCknood C (How A) (First author:/KiCknood C (How A) (First author:/KiCknood C 293.1232 bit (First author:/KiCknood C (How A) (First author:/KiCknood C (How A) (First author:/KiCknood C 293.1242 bit (First author:/KiCknood C (How A) (First author:/KiCknood C (How A) (First author:/KiCknood C 293.1241 bit (First author:/KiCknood C (How A) (First author:/KiCknood C (How A) (First author:/KiCknood C 293.1241 bit (How A) (First author:/KiCknood C (How A) (First author:/KiCknood C (How A) (First author:/KiCknood C 293.1241 bit (How A) (First author:/KiCknood C (How A) (First author:/KiCknood C <	2017 2017 2017 2017
 20180227 pubmed 20180227 pubmed 20180227 pubmed 20180282 WebOTScince 20180282 pubmed 20180282 pubmed 20180828 pubmed 	y y y y y y y y y y y y y y y y	Y Y Y Y	y	, , , , , , , , , , , , , , , , , , ,	n	n y	2813124 Addressing the change of high anded precision indicions: a systematic r Groups (1), Up 44 cond CJ, Mag 10, 1248, 50, 1248, 50, 1248, 50, 1244, 126, 1248, 12	2017 2017 2017 2017
4 2018027 pubmed 2018027 pubmed 2018027 2018027 pubmed 2018027 2018028 pubmed 2018027 2018027 pubmed 2018027 2018027 pubmed 2018027 2018027 pubmed 2018027 2018027 pubmed 2018027 2018028 Pubmed 2018027 2018027 pubmed 2018027 2018028 Pubmed 2018027 2018028 Pubmed 2018028 2018028 Pubmed 2018027 2018028 Pubmed 2018028	y y y y y y y y y y y y y y y y y y y	Y Y Y Y	Ÿ	n n n n n n n	n	n y	Additional back construction for proceedings of high pands processing	2017 2017 2017 2017 2017 2017
4 2018022 pubmed 2 2018023 WebOTScine 2 2018028 WebOTScine 2 2018028 WebOTScine 2 2018028 pubmed 3 2018028 pubmed 4 20180828 pubmed 4 20180828 pubmed 2 2018088 pubmed 2 2018088 pubmed 2 2018088 pubmed 2 2018088 pubmed 2 2018088 pubmed 2 2 2 2 2 2	Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y	¥	n n n n n n n	n	a y	283.124 Addressing the change of high and a precision medicine. A systematic r Groub (V) Uybe CoreCL Vybe CoreCL Vyb	2017 2017 2017 2017 2017
4 2018027 pubmed 2 201	y y y y y y y y y y y y y y y y y y y	y y y y y	У		n	n y	2451230 Addressing the change of high and/or precision medicine in bytemate regimes for high and/or precision medicine. No. One. 2017 Aug. 10;1018;c012431.40:10.1137/job create date: 2017/037/s1 Text and	2017 2017 2017 2017 2017 2017 2017
4 2018027 pubmed 2 201	y y y y y y y y y y y y y y y y y y y	Y Y Y Y Y Y Y	Y	, , , , , , , , , , , , , , ,	n	n y	248.1240 Addressing the change of high-anced precision medicine. A systematic r Combine 1V, Uybe Comord L, Wybe Comord L, Wyb	2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 2 2018027 pubmed 2	y y y y y y y y y y y y y y	y y y y y y y y	¥		n	n y	2481320 Addressing the change of high anded precision medicine. For Sub Mark 2017, Sig 10, 120, 120, 120, 120, 120, 120, 120,	2017 2017 2017 2017 2017
4 20180227 pubmed 2 20180227 pubmed 2 2018027 pubmed 2018027	y y y y y y y y y y y y y y y y y y y	y y y y y y	Y		r	y A	243.120 Addressing the changes of high sends investigation on eclones: A systematic re Consol (V, Oyke Consol (V, Marka 10, 2148, e012441, doi: 10.1171/joi create date: 2017/09/10 [Fits author:Graph IV] 244.210 Betwing the changes of high investigation on eclones: A systematic re Consol (V, Oyke Consol (V, Marka 10, 2148, e012441, doi: 10.1171/joi create date: 2017/09/10 [Fits author:Graph IV] 244.211 Betwing the changes of high investigation and the change on and analysis of high investigation and investigation in the long of high investigation and investigatin and investign and investigatin and investigation and	2017 2017 2017 2017 2017
4 20180227 pubmed 2 20180227 pubmed <td< td=""><td>У У У У У У 7 0 7 7 7 7 7 7 7 7 7 7 7 7</td><td>y y y y y y y y</td><td>Y</td><td>0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0</td><td>ň</td><td>а у</td><td>2431243 Addressing the change of high anded precision medicine. Cuber. 2431243 Addressing the change of high anded precision medicine. Cuber. 2431244 Addressing the change of high anded precision medicine. Cuber. 2431245 Addressing the change of high anded precision medicine. Cuber. 2431245 Addressing the change of high anded precision. Cuber. 2431245 Addressing the change of high anded precision. Cuber. 2431245 Addressing the change of high and precision. Cuber. 2431245 Addressing the change of high and precision. Cuber. 2431245 Addressing the change of high and precision. Cuber. Cuber. 2431245 Addressing the change of high and precision. Cuber. Cuber. Cuber. 2431245 Addressing the change of high and precision. Cuber. Cuber. Cuber. Cuber. 2431245 Addressing the change of high and precision. Cuber. Cuber.</td><td>2017 2017 2017 2017 2017</td></td<>	У У У У У У 7 0 7 7 7 7 7 7 7 7 7 7 7 7	y y y y y y y y	Y	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ň	а у	2431243 Addressing the change of high anded precision medicine. Cuber. 2431243 Addressing the change of high anded precision medicine. Cuber. 2431244 Addressing the change of high anded precision medicine. Cuber. 2431245 Addressing the change of high anded precision medicine. Cuber. 2431245 Addressing the change of high anded precision. Cuber. 2431245 Addressing the change of high anded precision. Cuber. 2431245 Addressing the change of high and precision. Cuber. 2431245 Addressing the change of high and precision. Cuber. 2431245 Addressing the change of high and precision. Cuber. Cuber. 2431245 Addressing the change of high and precision. Cuber. Cuber. Cuber. 2431245 Addressing the change of high and precision. Cuber. Cuber. Cuber. Cuber. 2431245 Addressing the change of high and precision. Cuber.	2017 2017 2017 2017 2017
4 20180227 pubmed 2 20180227 pubmed 4 20180227 pubmed 2 20180227 pubmed <td< td=""><td></td><td>, у ү ү ү ү ү</td><td>×</td><td></td><td>×</td><td>х х</td><td>Addressing the change of high and precision for controls in the data of precision medicine. No. Unit 2017 Aug. 13, 113, 113, 124, 125, 113, 124, 124, 124, 124, 124, 124, 124, 124</td><td>2017 2017 2017 2017 2017</td></td<>		, у ү ү ү ү ү	×		×	х х	Addressing the change of high and precision for controls in the data of precision medicine. No. Unit 2017 Aug. 13, 113, 113, 124, 125, 113, 124, 124, 124, 124, 124, 124, 124, 124	2017 2017 2017 2017 2017
4 2038027 pubmed 2038027 pubmed 2038027	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	· · · · · · · · · · · · · ·	Y		×	х у	2813120 Addressing the changeprotect proception drives in the care of procession medicine. A systematic rel concept.	2017 2017 2017 2017 2017
4 2018027 pubmed 2 2018028 pubmed 2 2018028 pubmed 2 2018028 pubmed 2 201	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	У У У У У У У У У У У У У У У У У У У	×	n n n n n n n n n n n n n n n n n n n	×	а у	2431243 Addressing the change of high anded precision medicine. Column 2431243 Addressing the change of high anded precision medicine. Column 2431243 Addressing the change of high anded precision medicine. Column 2431243 Addressing the change of high anded precision medicine. Column 2431243 Market State (Column) Column Column 2431244 Market State (Column) Column Column Column 2431245 Market State (Column) Column Col	2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 2018027 2018027 pubmed 2018027 2018027 pubmed 2019027 2019027 pubmed 2019027	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	v v v v	Y		×	а у	2813120 Addressing the change of high and precision mechanics is systematic ref formal (V) Uybe CoreCL Vybe CoreCL V	2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 2 20180227 pubmed <td< td=""><td></td><td>Y Y Y Y Y Y Y Y Y Y Y Y</td><td>v</td><td>0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0</td><td>r</td><td>а т</td><td>2431243 Addressing the change of high and/or perception drugs in the and perception drugs in the state of perception drugs in</td><td>2017 2017 2017 2017 2017 2017 2017 2017</td></td<>		Y Y Y Y Y Y Y Y Y Y Y Y	v	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	r	а т	2431243 Addressing the change of high and/or perception drugs in the and perception drugs in the state of perception drugs in	2017 2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 20180227 20180227 pubmed 2018027 20180227 pubmed 20180227 20180228 pubmed			¥		×	· •	Addressing the change of high and precision frequencies in webcome is vypermeter for most in the addression medicine No. Dise. 2017 Aug. 10; 1014 doi:10.111//p.0.1 core at the change of high and precision frequencies in the addression frequencies is addressing for the addressi	2017 2017 2017 2017 2017 2017
4 2018027 pubmed 2018027 pubmed 2018027		y y y y y y y	Y	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	×	y A	2813124 Addressing the change of high anded perception drives in the card perception drives in the close in the United State Cuber 2813124 Addressing the change of high anded perception drives in the Card in the United State Cuber 2813124 Addressing the change of high anded perception drives in the United State Cuber 2813124 Addressing the change of high anded perception drives in the United State Cuber 2813124 Addressing the change of high and perception drives in the United State Cuber 2813125 Addressing the change of high and perception drives in the United State Cuber 2813125 Addressing the change of high and perception drives in the United State Feed State S	2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 2 20180227 pubmed 4 20180227 pubmed 2 20180227 pubmed <td< td=""><td></td><td>У У У У У У У У У У У У У У У У У У У</td><td>×</td><td></td><td>r</td><td>у А</td><td>2431242 Addressing the change of high and parced precision medicine. Column 2431243 Addressing the change of high and parced precision medicine. Column 2431243 Addressing the change of high and parced precision medicine. Column 2431243 Addressing the change of high and parced precision medicine. Column 2431243 Addressing the change of high and parced precision medicine. High and pa</td><td>2017 2017 2017 2017 2017 2017</td></td<>		У У У У У У У У У У У У У У У У У У У	×		r	у А	2431242 Addressing the change of high and parced precision medicine. Column 2431243 Addressing the change of high and parced precision medicine. Column 2431243 Addressing the change of high and parced precision medicine. Column 2431243 Addressing the change of high and parced precision medicine. Column 2431243 Addressing the change of high and parced precision medicine. High and pa	2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 2018027 2018027 pubmed 2019027 2018027 pubmed 2019027 2018028 pubmed 2019027 2018027 pubmed 2019027 2019027 pubmed 2019027 2019028 pubmed 2019028 2019028 pubmed 2019028		y y y y y y y y	Y		Y	х У Х	Abstraction Advancessing the charge of high parked perception mices in the ord perception in the line of the control in Upber Contro Upber Control In Upber Contro Upber Control In Upber C	2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 2 20180227 pubmed <td< td=""><td></td><td>Y Y Y Y Y Y Y Y</td><td>Y</td><td></td><td>r Y</td><td>y a</td><td>Jam 1200 Addressing the change of high anded perception drugs in the ad perception drugs in the state of perception drugs in the state drugs in the state of p</td><td>2017 2017 2017 2017 2017 2017 2017</td></td<>		Y Y Y Y Y Y Y Y	Y		r Y	y a	Jam 1200 Addressing the change of high anded perception drugs in the ad perception drugs in the state of perception drugs in the state drugs in the state of p	2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 20180227 20180227 pubmed 2018027 2018027 pubmed 2018027 2018027 pubmed 2018027 2018027 pubmed 2018027 2018027 pubmed 2018027 2018028 Pubmed 2018027 2018027 pubmed 2018027 2018028 pubmed 2018028 2018028 pubmed 2018		y y y y y y y	Y			y 4	Jamps 20 Addressing the change of high and price provide routes in the addression medicine. No. Disk. 2017 Aug. 10, 2018 (2018.04.04.00.01117//no.10.02018 (2018.04.04.00.0017/2018) Jamps 20 Income in the change of high and price provide routes in the high and price provide routes in the high and price price price high and price price high and price price price high and	2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 2018027 2018027 pubmed 2018027 2018028 WebOfSicros 2018027 2018027 pubmed 2018027 2018028 WebOfSicros 2018027 2018028 WebOfSicros 2018027 2018027 pubmed 2018027 2018028 WebOfSicros 2018027 2018028 Pubmed 2018028 2018028 Pubmed 2018028 2018028 Pubmed 2018028 2018028 Pubmed 2018028 2018028 Pubmed 20180		v v v v v v v v v v v v v v v v v v v	Y		r Y	х у у л	Jam 1200 Addressing the change of high anded perception drives in the card perception drives in the drive driv	2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 2 20180227 pubmed 2 2018022 pubmed 2 2018022 pubmed 2 2018022 pubmed 2 2018022 pubmed 4 2018022 pubmed 4 2018022 pubmed 4 2018022 pubmed 2 2					Y	у А	Jam Juss Juss Juss Juss Juss Juss Juss Jus	2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 2018027 2018027 pubmed 2018027 2018027 pubmed 2019027 2019027 pubmed 2019027 2019028 pubmed 2019027 2019028 pubmed 2019027 2019028 pubmed 2019027 2019028 pubmed 2019027		· · · · · · · · · · · · · · · · · ·	v		r Y	а у у а	Additional functional processing of high and procession in controls in the set of procession in control in Upbe Control Lyaps Control in Control in Upbe Control Lyaps Control in Contro Control in Control in Control in Control in Control in C	2017 2017 2017 2017 2017 2017
4 20180227 pubmed 2 20180227 pubmed <td< td=""><td></td><td>Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y</td><td>Y</td><td>а а а а а а а а а а а а а а а а а а а</td><td>r Y</td><td>у л</td><td>Jam Jack Jack Bernel Bernel and a precision medicine 14 vytemater ter formole 140. Upbe Control V, Upbe</td><td>2017 2017 2017 2017 2017 2017 2017</td></td<>		Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	а а а а а а а а а а а а а а а а а а а	r Y	у л	Jam Jack Jack Bernel Bernel and a precision medicine 14 vytemater ter formole 140. Upbe Control V, Upbe	2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 2018027 2018027 pubmed 2018027 2018028 Pubmed 2018027 2018027 pubmed 2018027 2018028 Pubmed 2018028			y y		Y	у х у х	Addressing the change of high and a precision medicine. No. Date. 2017, Aug. 19, 2108, 2012, Aug. 2014,	2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 2018027 2018027 pubmed 2018027 2018028 pubmed 2018027 2018027 pubmed 2018027 2018027 pubmed 2018027 2018027 pubmed 2018027 2018027 pubmed 2018027 2018028 Pubmed 2018027 2018027 pubmed 2018027 2018028 Pubmed 2018028 2018028 Pubmed 2018027 2018028 Pubmed 2018027 2018028 Pubmed 2018027 2018028 Pubmed 2018027		× × × × × × × × × × × × × ×	y y		r Y	х х у л	Jam Sub Addressing the change of high and a precision medicine. Cubers Cubers Cubers Set Sub Addressing the change of high and precision medicine. Cubers Cubers Cubers Set Sub Addressing the change of high and precision medicine. Fig. Set	2017 2017 2017 2017 2017 2017 2017
4 2018022 pubmed 2018022 pubmed 2018022 whend 2018022 bubmed 2018022 pubmed 2018022 pubmed 2018022 pubme			Y		r	у А	Justices will be changed of high and a precision medicine. Custors. <	2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 2018027 2018027 pubmed 2019027 2018028 pubmed 2019027 2018027 pubmed 2019027 2018028 pubmed 2019027			Y		r Y	у ,	Mathews (b) is charged in plane and precision in excerning in plane and precisi	2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 2 2018027 pubmed 3 2018027 pubmed 2 2018027 pubmed 2 2018027 pubmed 3 2018027 pubmed 3 2018027 pubmed 3 2018027 pubmed 3 2018027 pubmed		Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y	а а а а а а а а а а а а а а а а а а а	r	y a	Justices Addressing the change of high aread parced procession medicine. Note Show 2017 Aug. bj. 2018, 001241, 3 doi: 10.1171/jo.er tote show 2017/SKI 5 Note Show 2017 Aug. bj. 2018, 001241, 3 doi: 10.1171/jo.01200 27860000 Inclusion Control Note Show 2017 Aug. bj. 2018, 001241, 3 doi: 10.1171/jo.01200 Note Show 2017 Aug. bj. 2018, 001241, 3 doi: 10.1171/jo.01200 27860000 Inclusion Note Show 2017 Aug. bj. 2018, 001241, 3 doi: 10.1171/jo.01200 Note Show 2017 Aug. bj. 2018, 001241, 3 doi: 10.1171/jo.01200 2786000 Inclusion Note Show 2017 Aug. bj. 2018, 001241, 3 doi: 10.1171/jo.01200 Note Show 2017 Aug. bj. 2018, 001241, 3 doi: 10.1171/jo.01200 2786000 Inclusion Note Show 2017 Aug. bj. 2018, 001241, 3 doi: 10.1171/jo.01200 Note Show 2017 Aug. bj. 2018, 00124, 3 doi: 10.1171/jo.01200 2786100 Inclusion Note Show 2017 Aug. bj. 2018, 00124, 3 doi: 10.1171/jo.01200 Note Show 2017 Aug. bj. 2018, 00124, 3 doi: 10.1171/jo.01200 2786100 Inclusion Note Show 2017 Aug. bj. 2018, 00124, 3 doi: 10.1171/jo.01200 Note Show 2017 Aug. bj. 2018, 00124, 3 doi: 10.1171/jo.01200 2786100 Inclusion Note Show 2017 Aug. bj. 2018, 00124, 3 doi: 10.1171/jo.01200 Note Show 2017 Aug. bj. 2018, 00124, 3 doi: 10.1171/jo.01200 2786100 Inclusion Note Show 2017 Aug. bj. 2018, 00124, 3 doi: 10	2017 2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 2018027 2018027 pubmed 2018027 2018028 Pubmed 2018027 2018027 pubmed 2018027 2018028 pubmed 2018028 2018028 pubmed 2018027			Y		Y	у х У х	Addressing the change of high and a procession medicine. Note State of Control Note State of Contro Note State of Control	2017 2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 2018027 20180227 pubmed 20180227 20180227 pubmed 2018		Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	¥ ¥		r	а у у а	Abstraction Additionality the challenge of the phone of a percent of percent of percent of a percent of a percent of a percent of a pe	2017 2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 2018028 pubme			Y		r	y A	Additional for determines of hep-brends are structures in the process of hep-brend are structures of hep-brend are structures. How Structures in the hep-brend are structures. Additional for determines of hep-brends are structures. How Structures in the hep-brend are structures. How Structures in the hep-brend are structures. Additional for determines of hep-brends are structures. How Structures. How Structures. How Structures. Additional for determines of hep-brends are structures. How Structures. How Structures. How Structures. Additional for determines of hep-brends are structures. How Structures. How Structures. How Structures. Additional for determines of hep-brends are structures. How Structures. How Structures. How Structures. Additional for determines of hep-brends are structures. How Structures. How Structures. How Structures. How Structures. Additional for determines of hep-brends and structures. How Structures. </td <td>2017 2017 2017 2017 2017 2017 2017 2017</td>	2017 2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 2018027 2018027 pubmed 2019027 2018028 pubmed 2019027 2018027 pubmed 2019027 2018027 pubmed 2019027 2018027 pubmed 2019027 2019027 pubmed 2019027 2019028 pubmed 2019027 2019027 pubmed 2019027 2019027 pubmed 2019027 2019028 pubmed 2019027		Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y		r Y	а у у а	Matheway	2017 2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 20180227 pubmed 20180227 pubmed 2018027 pubmed 2018027 pubmed 2018027 pubmed 2018028 pubmed 2018027 pubmed 2018027 pubmed 2018027 pubmed 2018028 pubmed 2018027 pubmed 2018027 pubmed 2018027 pubmed 2018027 pubmed 2018027 pubmed 2018027 pubmed 2018027 pubmed 2018028 pubmed 2018027 pubmed 2018027 pubmed 2018027 pubmed 20180282 pubmed 2018082		Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y		r Y	y a	Additional the functional hash process frameworks in the set of process fram	2017 2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 2018027 pubmed 2018028 pubmed 2018027 pubmed 2018028 pubme			¥		Y	у л	Balaccian (and backening the finite data in the case of process manages manag	2017 2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 201		Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	y		r	а у	Mathematic Back and the change on large dress program and an large dress and the face of a control is control is of a control is of a control is of a control is of a c	2017 2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 20180227 pubmed 2018028 pubme			Y		r	y A	Ball Date Advances due to change and programmed programmed and programm	2017 2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 2 20180227 pubmed 2 2018027 pubmed 2 2			Y		T T	y A	Additional glue clustered in lange drock glue procession and south and so	2017 2017 2017 2017 2017 2017 2017 2017
4 20180227 pubmed 2 2018027 pubmed			Y		T	y a y a	Alternal Balance Advanced, the shared and share rate and procession.And we have the shared and share rate and share rate and shared	2017 2017 2017 2017 2017 2017 2017 2017
4 20180227 Jubined 20180227 Jubined Jubined 2018027 Jubined Jubined 2018028 Jubined Jubined 2018027 Jubined Jub			Y	а а а а а а а а а а а а а а а а а а а	T	у х У х	Mathewayee Addressing the channess of they are due discription within the origin procession. Non-Res (No. Performance) Non-Res (No. Performance) Mathewayee Mathewayee Non-Res (No. Performance) Non-Res (No. Performance) Non-Res (No. Performance) Mathewayee Mathewayee Non-Res (No. Performance) Non-Res (No. Performance) Non-Res (No. Performance) Mathewayee Non-Res (No. Performance) Non-Res (No. Performance) Non-Res (No. Performance) Non-Res (No. Performance) Mathewayee Non-Res (No. Performance) Non-Res (No. Performance) Non-Res (No. Performance) Non-Res (No. Performance) Mathewayee Non-Res (No. Performance) No-Res (No. Performance) Non-Res (No. Pe	2017 2017 2017 2017 2017 2017 2017 2017

4 20180827 pubmed	У		У	n			2800974 Drug prices: How do we get to a better place? Lexchin J CMAL 2017 Jun 12;189(2);1792-F93. doi: 10.1503/rm.create date:2017/06/14 [rist author:Lexchin J Drug prices: How do we get to a better place? Link D/ Cate Al	
2 20180827 pubmed	y y	Ŷ					2599700 Trainip doministree ruling concept states for ingris states in	
2 20180828 scopus	y n						28207060 Do national drug policies influence antiretroviral drug prices? Evidence from the Southern African Develop Liu Y, Galárraga O. Health Policy and Planning	2017
2 20180828 WebOfScier	y n						28207060 Do national drug policies influence antiretroviral drug prices? Evidence from the Southern African Develop Liu, Y; Galarraga, O HEALTH POLICY AND PLANNING	2017
8 20180828 pubmed	у у			n			29527335 Applying a health system perspective to the evolving Farmå[cia Popular medicines access programme in Br Luiza VL, Chaves LA, Campos MR, Bertoldi Al BMJ Glob Health. 2018 Feb 7;2[Suppl 3]:e000547. doi: 1(create date:2018/03/13 first author:Luiza VL	
2 20180827 pubmed	γ			y .	n	y n	29039214 Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment. Mahlich J, Kamae I, Sruamsiri R. Expert Rev Pharmacoecon Outcomes Res. 2018 Jun;18(3 create date:2017/10/19 first author:Mahlich J	
2 20180828 scopus 2 20180828 WebOfScier	y n						29039214 Pharmaceutical pricing in Japan: market evidence for meumatoid artificitis treatment Manino J, kamae L, situaman R. Expert Review or Pharmacoeconomics and Outcomes Research 20030116 Imarmaceutical pricing in Japan: market evidence for meumatoid artificitis treatment Manino J, kamae L, Stataman R. Expert Review or Pharmacoeconomics and Outcomes Research	2018
2 20180827 pubmed	y 11	v		n			2767362 Pharmaceutical Prices Row Non-Cure? Mance D. Amee D. Mance	2010
2 20180828 scopus	y y			n			Access to high cost medicines in low and middle income countries – examples from India Mandal S.C., Mandal M. Pharma Times	2017
8 20180828 pubmed	У			y .	y	y n	28545440 Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income s Maniadakis N, Kourlaba G, Shen J, Holtorf A, BMC Health Serv Res. 2017 May 25;17(1):371. doi: 10.11 create date:2017/05/27 first author:Maniadakis N	
12 20180828 pubmed	y n		_				27593281 Patients' knowledge and attitude towards therapeutic reference pricing system in Slovenia. MarĂ'etko N, Kos M. Int J Clin Pharm. 2016 Oct;38(5):1301-10. doi: 10.1007/s: create date:2016/08/10 first author: MarĂ'etko N	
2 20180827 pubmed	У		У	n			28661288 The Prescription Drug Pricing Moment: Using Public Health Analysis to Clarify the Fair Competition Debate (Marciarille AM. JLaw Med Ethics. 2017 Mar;45(1 supp)]:45-49. doi: 10.1 create date:2017/07/01 [first author:Marciarille AM	2017
5 20180827 pubmed	y II			n			2000/1206 The rescription in the	2017
4 20180827 pubmed	y y	v		n			27793813 Popular measure in California ballot targets drug prices. McCarthy M. BMJ. 2016 Oct 28;355:15830. doi: 10.1136/bmij.i5830. No. create date:2016/10/30 first author:McCarthy M	
6 20180827 pubmed	y	y		n			28660496 Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins. McRae I, van Gool K, Hall J, Yen L. Appl Health Econ Health Policy. 2017 Oct;15(5):625-634. create date::2017/07/01 first author:McRae I	
4 20180827 pubmed	γ			y .	n	y n	28473888 Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Eu: Medic G, Korchagina D, Young KE, Toumi M, J Mark Access Health Policy. 2017 Apr 10;5(1):1299665. c create date:2017/05/06 first author:Medic G	
9 20180827 pubmed	У	y		n			29714590 Incremental Cost-Effectiveness Ratio and Net Monetary Benefit: Promoting the Application of Value-Based Messori A, Trippoli S. Ther Innov Regul Sci. 2018 Jan 1:2168479018769300. do create date:2018/05/02 [first author:Messori A	
5 20180827 pubmed	y n			~	v	V D	28350905 Reimoursed Price of Orphan Drugs: Current strategies and Potential Improvements. Mincarone P, Leo CG, Salana S, Sarria-Sami (Value Realth Genomics, 2017/2011); F.8. doi: 10.1159/00 (Teate date:2017/2011) [F15 author:Mincarone P and CG, Salana S, Sarria-Sami (Value Realth Genomics, 2017/2011); F.8. doi: 10.1159/00 (Teate date:2017/2011) [F15 author:Mincarone P and CG, Salana S, Sarria-Sami (Value Realth Genomics, 2017/2011); F.8. doi: 10.1159/00 (Teate date:2017/2011) [F15 author:Mincarone P and CG, Salana S, Sarria-Sami (Value Realth Genomics, 2017/2011); F15 author:Mincarone P and F15 author:Mincar	
6 20180827 pubmed	ý	y		n	,	,	29284064 Policies for biosimilar uptake in Europe: An overview. Moorkens E, Vulto AG, Huys J, Dylst P, Godm PLoS One. 2017 Dec 28;12(12):e0190147. doi: 10.1371/jr.create.date:2017/12/29 first author:Moorkens E	
2 20180828 scopus	y n						28238340 Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory heal Morgan S.G., Vogler S., Wagner A.K. Health Policy	2017
2 20180827 pubmed	У	y	_	n			30041827 An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable Morgan SG, Good CB, Leopold C, Kaltenboer Health Policy. 2018 Jul 21. pii: S0168-8510[18]30246-X. d create date: 2018/07/26 first author: Morgan SG	
2 20180827 pubmed	γ		y	n			2823830 Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory heal Morgan SG, Vogler S, Wagner AK. Health Policy. 2017 Apr;121(4):354-362. doi: 10.1016/j.h. create date:2017/02/28 first author:Morgan SG	2047
2 20180828 WebUtscier 6 20180827 pubmed	y n			×	v	v n	2823390 rayers experiences with continential pharmaceutical price discounts: A survey or public and statutory or guery, sy wagers, and the statutory of the sta	2017
9 20180827 pubmed	ý		v	n	,	,	28975551 Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water. Neyt M. Pharmacoeconomics. 2018 Jan; 36(1):1-3. doi: 10.1007/s create date:2017/10/05 first author:Neyt M	
9 20180827 pubmed	y	y		n			29991102 Value-Based Pricing of Disease-Modifying Therapies for Multiple Sciencesis: Is This Mission Possible? Ngorsuraches S. S D Med. 2018 Mar;71(3):134-135. No abstract available. create date:2018/07/11 first author:Ngorsuraches S	
4 20180827 pubmed	у у			n			28453716 Inflated medicine prices in Vietnam: a qualitative study. Nguyen TA, Knight R, Mant A, Razee H, Broo Health Policy Plan. 2017 Jun 1;32(5):647-656. doi: 10.109 create date:2017/04/30 first author:Nguyen TA	
5 20180827 pubmed	γ	y		n			27882835 Health Care Costs for Patients with Heart Failure Escalate Nearly 3-Fold in Final Months of Life. Obi EN, Swindle JP, Turner SJ, Russo PA, Alta J Manag Care Spee Pharm. 2016 Dec;22(12):1446-1456. create date:2016/11/25 [first author:Obi EN	
8 20180828 pubmed 4 20180827 pubmed	Y	v		Y	n	y n	29478875 Variations in on-prescription drug consumption and expenditure: Determinants and policy implications. Otto M, Armen P, Jommi C. Health Policy. 2018 Jun; 1220/514-620. doi: 10.1010/j.hr create date:2018/02/17 J Irist authors:Policy and Participation and expenditure: Determinants and policy implications. Otto M, Armen P, Jommi C. Health Policy. 2018 Jun; 1220/514-620. doi: 10.1010/j.hr create date:2018/02/17 J Irist authors:Policy and Participations. Otto M, Armen P, Jommi C. Health Policy. 2018 Jun; 1220/514-620. doi: 10.1010/j.hr create date:2018/02/17 J Irist authors:Policy and Participations. Otto M. Armen P, Jommi C. Health Policy. 2018 Jun; 1220/514-620. doi: 10.1010/j.hr create date:2018/02/17 J Irist authors:Policy and Participations. Otto M. Armen P, Jommi C. Health Policy. 2018 Jun; 1220/514-620. doi: 10.1010/j.hr create date:2018/02/17 J Irist authors:Policy and Participations. Otto M. Armen P, Jommi C. Health Policy. 2018 Jun; 1220/514-620. doi: 10.1010/j.hr create date:2018/02/17 J Irist authors:Policy and Participations. Otto M. Armen P, Jommi C. Health Policy. 2018 Jun; 1220/514-620. doi: 10.1010/j.hr create date:2018/02/17 J Irist authors:Policy and Participations. Otto M. Armen P, Jommi C. Health Policy. 2018 Jun; 1220/514-620. doi: 10.1010/j.hr create date:2018/02/17 J Irist authors:Policy and Participations. J Policy and Participat	
4 20180827 pubmed	y v	y v					2259587 Justifying high drug prices within the context of value: Biologics versus generics. Patterson ME, Rosenfelt DJ. Res Social Adm Pharm. 2018 Feb;14(2):121-123. doi:10.1101/101/2111/21.2017/03/061 First author.Patterson ME	
7 20180828 pubmed	y n		-				28699779 Indication-specific pricing of pharmaceuticals in the US healthcare system. Pearson SD, Dreitlein WB, Henshall C, Towse J Comp Eff Res. 2017 Jul;6(5):397-404. doi: 10.2217/cerc.create date:2017/07/13 first author:Pearson SD	
6 20180827 pubmed	У	y		n			28699779 Indication-specific pricing of pharmaceuticals in the US healthcare system. Pearson SD, Dreitlein WB, Henshall C, Towse J Comp Eff Res. 2017 Jul;6(5):397-404. doi: 10.2217/cer-i: create date:2017/07/13 first author: Pearson SD	
2 20180828 WebOfScier	y n			_			2999300 Pandora's Prescription: The Pharmaceutical Priving vs. Cost Conundrum Pederson, T FASEB JOURNAL	2017
6 20180827 pubmed	У			Y .	У	y n	29470724 Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Impro Persson U, Norlin JM. Appl Health Econ Health Policy. 2018 Apr;16(2):157-165. create date:2018/02/23 [first author:Persson U	
6 20180827 pubmed	y v v			y D	Ŷ	y n	285/9445 Value-eased pricing and the end or pharmaceutca pricing as we know it r A case study on sofaretend and as vertica pricing. A sub-asset pricing and the end or pharmaceutca pricing as we know it r A case study on sofaretend and as vertica pricing. A sub-asset pricing and the end or pharmaceutca pricing as we know it r A case study on sofaretend and as vertica pricing. A sub-asset pricing and the end or pharmaceutca pricing as we know it r A case study on sofaretend and as vertica pricing. A sub-asset pricing and the end or pharmaceutca pricing as we know it r A case study on sofaretend and as vertica pricing. A sub-asset pricing as the end or pharmaceutca pricing as	
9 20180827 pubmed	y n						2857943 Value-Based pricing and the end of pharmaceutical pricing as we know it? A case study on sorafenib and ax Petrou P. Pharmacol Res. 2017 Oct;124:160-163. doi: 10.1016/j.ph create date:2017/06/06 first author: Petrou P	
2 20180828 WebOfScier	y n						28579443 Value-Based pricing and the end of pharmaceutical pricing as we know it? A case study on sorafenib and ax Petrou, P PHARMACOLOGICAL RESEARCH	2017
2 20180828 scopus	y n						Higher pharmaceutical public expenditure after direct price control: Improved access or induced demand? Prada S.L., Soto V.E., Andia T.S., Vaca C.P., M Cost Effectiveness and Resource Allocation	2018
2 20180827 pubmed	у у			n			2950733 Higher pharmaceutical public expenditure after direct price control: improved access or induced demand? Prada SJ, Soto VE, Andia TS, Vaca CP, Morale Cost Eff Resour Alloc. 2018 Mar 2;16:8. doi: 10.1186/s12 create date.2018/03/07 first author:Prada SJ	2010
2 20180828 WebUtscler 2 20180828 scopus	y n	v					2900353 higher pharmaceutical public expensionare after direct phote control: improved access or induced demandri Prada, 3; yaca, Uer, Mort LOST EFFELTIVENESS AND RESUMUE ALLOCATION RED Sounding & surgers Kein stands in singer & control: improved access or induced demandri Prada, 3; yaca, Uer, Mort LOST EFFELTIVENESS AND RESUMUE ALLOCATION RED Sounding & surgers Kein stands in singer & control: improved access or induced demandri Prada, 3; yaca, Uer, Mort LOST EFFELTIVENESS AND RESUMUE ALLOCATION RED Sounding & surgers Kein stands in singer & control: improved access or induced demandri Prada, 3; yaca, Uer, Mort LOST EFFELTIVENESS AND RESUMUE ALLOCATION RED Sounding & surgers Kein stands in singer & control: improved access or induced demandri Prada, 3; yaca, Uer, Mort LOST EFFELTIVENESS AND RESUMUE ALLOCATION RED Sounding & surgers Kein stands in singer & control: improved access or induced demandri Prada, 3; yaca, Uer, Mort LOST EFFELTIVENESS AND RESUMUE ALLOCATION RED Sounding & surgers Kein stands in singer & control: improved access or induced demandri Prada, 3; yaca, Uer, Mort LOST EFFELTIVENESS AND RESUMUE ALLOCATION RED Sounding & surgers Kein stands in stands in singer & control: improved access or induced demandri Prada, 3; yaca, Ver, Andria, 15, yaca, Uer, Mort LOST EFFELTIVENESS AND RESUMUE ALLOCATION RED Sounding & surgers Kein stands in stand	2018
2 20180828 WebOfSciend	e y	v					PHARMACEUTICAL PROFESSION THE UNITED STATES VERSUS EUROPE: HOW DO DIFFERENT TYPES OF US PRIC Reinaud, F; Ando, G; Lockwood, C VALUE IN HEALTH	2017
4 20180827 pubmed	ÿ	y		n			27832870 Drug prices threaten the NHS. Ress M, Levi J, McDonald D, Piears J, Gothan Lancet. 2016 Nov 26;388(10060):2603-2604. doi: 10.101/ create date:2016/11/12 first author:Ress M	
6 20180827 pubmed	y n						27516088 Cost Effectiveness of the Long-Acting P2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Du: Reza Maleki-Yazdi M, Molimard M, Keininge Appl Health Policy. 2016 Oct;14(5):579-94. d create date:2016/08/16 first author: Reza Maleki-Yazdi M	
2 20180828 WebOfScier	y n	_					A systematic review of pharmaceutical pricing policies in developing countries Rida, NA; Ibrahim, MIM; Babar, ZUD; Owusu JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH	2017
4 20180827 pubmed	Y	Y		n			2008995 Will Courts Allow States to Regulate Drug Prices? Robertson C. N Engl J Med. 2018 Aug 8. doi: 10.1016/NELMp1810432. create date:2018/05/93 First author:Nobertson C	
4 20180827 pubmed	y y	y v		n			2900/022 Value-based Pricing and Patient Access for Spectanty Urigs. Roomson L, novems, Pearson SU. Javae-based Pricing and Patient Access for Spectanty Urigs. Provide the Access for Spectanty Urigs. Provide the Access for Spectanty Urigs. Biological A	
2 20180827 pubmed	y V	y v					2897020 Innovative Contracting for Pharmaceuticals and Medical's Sets-Price Rule. Sachs R. Badlev N. Lakdavalla DN. J Health Polity Class 2018 Feb 143(11):518 Feb 143(11):518(11):518(11):518(11):518(11):518(11):518(11):518(11):518(11):518	
2 20180828 scopus	ý	ý		n			Innovative contracting for pharmaceuticals and medicaid's best-price rule Sachs R., Bagdey N., Lakdawalla D.N. Journal of Health Politics, Policy and Law	2018
2 20180828 WebOfScier	y n						28972020 Innovative Contracting for Pharmaceuticals and Medicaid's Best-Price Rule Sachs, R; Bagley, N; Lakdawalla, DN JOURNAL OF HEALTH POLITICS POLICY AND LAW	2018
4 20180827 pubmed	y y			n	_		27832869 Uncontrollable medicine prices in Pakistan. Saleem F, Hassali MA, Iqbal Q, Baloch M, Shi Lancet. 2016 Nov 26;388(10060):2602. doi: 10.1016/S01. create date:2016/11/12] first author:Saleem F	
2 20180827 pubmed	Y			Y .	Y	y n	2963292 Policies and availability of orphan medicines in outpatient care in 24 European countries. Samola K, Abnoen K, Martkainen JL, Timoni Eur J Clin Pharmacol. 2018 Jul; 44(7):895-902. doi: 10.100 create date:2018/04/11 trist author:samola K	2018
2 20180828 Scopus 2 20180828 WebOfScier	y D			Y	Ŷ	y n	Police and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in 24 european countries and availability of prohammetricines in outpatient care in outpatient care in 24 european count	2018
4 20180827 pubmed	,	v		n			29800027 An Incomplete Prescription: President Trump's Plan to Address High Drug Prices. Sarpatwari A, Avorn J, Kesselheim AS. JAMA. 2018 Jun 19;319[23]:2373-2374. doi: 10.1001/jarr.create.date:2018/05/26 first author:Sarpatwari A	
11 20180828 pubmed	y n						28605615 Cancer Drugs: An International Comparison of Postlicensing Price Inflation. Savage P, Mahmoud S, Patel Y, Kantarjian H. J Oncol Pract. 2017 Jun;13(6):e538-e542. doi: 10.1200/JC create date:2017/06/13 first author:Savage P	
2 20180827 pubmed	У	y		n			28605615 Cancer Drugs: An International Comparison of Postlicensing Price Inflation. Savage P, Mahmoud S, Patel Y, Kantarjian H. J Oncol Pract. 2017 Jun;13(6):e538-e542. doi: 10.1200/JC create date:2017/06/13 first author:Savage P	
2 20180828 scopus	y n						28605615 Cancer drugs: An international comparison of postilensing price inflation Savage P, Mahmoud S, Patel Y, Kantarjan J Journal of Oncology Practice 3805615 Cancer drugs: An international Comparison of postilensing price inflation Figure 1 - Dealth V, Kantarjan J, Journal of Oncology Practice	2017
2 20180828 Web013clei	y II						28000031 Calific Drillogi. All international Contigention in Constantiation in Vision Entry in Mainton of Vision Entry in Mainton	2017
4 20180827 pubmed	y y		v	n			28671371 Problematic Jumps in Drug Prices and What You Can Do. Shaughnessy AF. Am Fam Physician. 2017 Jul 1;96(1):16-18. No abstract av. create date:2017/07/04 first author: Shaughnessy AF	
5 20180827 pubmed	y	У					28982809 Understanding the health economic burden of patients with tuberous sclerosis complex (TSC) with epilepsy Shepherd C, Koepp M, Myland M, Patel K, M BMJ Open. 2017 Oct 5;7(10):e015236. doi: 10.1136/bmj: create date:2017/10/07 first author:Shepherd C	
4 20180827 pubmed	γ	v		n				
2 20180828 scopus		,		n			29989905 Nevada Pushes For Transparency On Diabetes Drug Prices. Silverman E. Manag Care. 2018 Jun;27(6):18. create date:2018/07/11 first author:Silverman E	
ZUISUSZ7 pubmed	y n	,		n n	-		2998995 Nevida Public for Transparency On Diabetes Drug Prices. Silverman E. Manag Care. 2018 Jun;27(6):18. create date-2018/07/11 [first author:Silverman E Drug Policy—The Cetch Republic Sicopi J. Value in Health Regional Issues	2017
2 20180828 WebOffrien	y n y	,		n n	Ŷ	y n	Symphysic Name Circle Name Circle Manage Circle Control of the Circle Digr Pelloy—The Circle Republic Slough J. Value Health Reg Issues. 2017 Sept 21:55-58. doi: 10.1011 create date 2018/10/21 [Inst author:Sloveman E 2007 BD Drug Pelloy—The Circle Republic. Slough J. Value Health Reg Issues. 2017 Sept 21:55-58. doi: 10.1011 create date 2018/10/2018 [Inst author:SlovepÅ] J 2019 BD Drug Pelloy The Circle Republic. Slough J. Value Health Reg Issues. 2017 Sept 21:55-58. doi: 10.1011 create date 2017/10/28 [Inst author:SlovepÅ] J Drug Pelloy The Circle Republic. Scrub G. Fox APT Republic Scrub G. Fox APT Republic. Scrub G. Fox APT Republic.	2017
2 20180828 WebOfScient 2 20180828 scopus	y n y be y y n	y		n n y	Ÿ	γ n	2959950 Nexdia Publis for Transparency On Diabetes Drug Prices. Silveman E. Manag Carc. 2018 Juni;27(b;18. create date:2018/07/11 [first author:Silveman E Drug Policy - The Crech Republic. Socupi J. Value Health Regional Issue create date:2018/07/11 [first author:Silveman E Drug Policy - The Crech Republic. Socupi J. Value Health Regional Issue create date:2018/07/11 [first author:Silveman E Public Health Instrument with Monopolistical Competitive Providers and Optional Spot Sale Socupi J. Value Health Regional. Socupi J. Public Health Instrument with Monopolistical Competitive Providers and Optional Spot Sale Socupi J. Socupi J. Socupi J. Socupi J. Sale Socupi J. Socupi J. Socupi J. Socupi J. Socupi J. Socupi J. Socupi J. Socupi J. Socupi J. Socupi J.	2017 2018 2017
2 20180828 WebOfScient 2 20180828 scopus 2 20180827 pubmed	y n y ze y y n y	y y		n n n	¥	y n	Spessible Name (arr. 2018 Jun;27(b):18. Name (arr. 2018 Jun;27(b):18. Create date-2018/07(11 [Infs.author:Shemma E] Dip RP/07_mbC (chr Republic) Sioupi 1. Maine (arr. 2018 Jun;27(b):18. Create date-2018/07(11 [Infs.author:Shemma E] 2007 BP Dip RP/06 yn the Corth Republic. Sioupi 1. Value Health Regional susse 2008 Internet Filter Hamannee with Monopalitating Competitive Providers and Optional SpotSate Sores, G. Geard, T.R. BioDWR4.0F (2000 MCMAANX55 Socie 1.01-01-create date-2017/01/28 [Infs.author:ShoupA],1 2004 Internet Filter Hamannee with Monopalitating Competitive Providers and Optional SpotSate Sores, G. Geard, T.R. BioDWR4.0F (2000 MCMAANX55 Socie 1.01-01-create date-2017/01/28 [Infs.author:ShoupA],1 2004 Internet Filter With Soldbard(rifeginarism Competitive Providers and Optional SpotSate Sores, G. Geard, T.R. Rol Sove: 2017 and 12(1):e10:9401.e10-1171/jour create date-2017/01/24 [Infs.author:Shamper,IT. 2004 Internet Filter With Soldbard(rifeginarism Competitive P) Statimeer,IT. Rossis S. Liver,Sh. Giaver, R [Infs.author:Shamper,IT. Rol Sove: 2017 and 12(1):e10:9401.e10-1171/jour create date-2017/01/24 [Infs.author:Shamper,IT.	2017 2018 2017
2 20180828 WebOfScient 2 20180828 scopus 2 20180827 pubmed 2 20180828 WebOfScier	y n y ce y y n y y n	y y		n n n	¥	y n	Systems Namag Carce 2018 Junit 2/101 Ling Contrast Carce 2018 Junit 2/101 Ling Contreat Carce 2018 Junit 2/101 Ling Con	2017 2018 2017 2017
2 20180828 WebOfScienc 2 20180828 scopus 2 20180827 pubmed 2 20180827 pubmed 2 20180827 pubmed 2 20180827 pubmed 2 20180827 pubmed	y n y y n y n y n y n	y y	у	n n Y n	Y	y n	Sensition Name (arr. 2018 Aur.2/[0:18] Center data 2018/(0/11] Instrumt for any and the sensitivity of any any any any and the sensitity any and any any any any an	2017 2018 2017 2017
2 20180828 WebOfScience 2 20180828 scopus 2 20180827 pubmed 2 20180827 pubmed 7 20180827 pubmed 4 20180827 pubmed	y n y y n y n y y	y y	у	n n n n		y n y n	Symphone Name (arr. 2018 Jun;27(6):18. Center Alter 2018 /07/11 [Inst author:Sheeman E Big Palloy-The Cach Republic Skoup I. Maine (arr. 2018 Jun;27(6):18. reste date:2018/07/11 [Inst author:Sheeman E 2019 Big Palloy - The Cach Republic Skoup I. Wale Health Registrate: 2017 Seg 13:55:58. doi: 10.1011 create date:2018/07/11 [Inst author:Sheeman E 2019 Big Palloy - The Cach Republic Skoup I. Value Health Registrate: 2017 Seg 13:55:58. doi: 10.1011 create date:2017/07/12 [Inst author:ShaepA] I 2019 Big Palloy - The Cach Republic Sarek, G. Stee, G. Republic E1008/UA (JF CACMCA UAV/SS & POLCY 2019 Big Palloy - The Cach Republic Sarek, G. Stee, G. Republic PLOB/UA (JF CACMCA UAV/SS & POLCY 2019 Big Palloy - The Cach Republic Sarek, G. Stee, G. Republic PLOB/UA (JF CACMCA UAV/SS & POLCY 2019 Big Palloy - The Cach Republic Satemert, T. Rosol S, LicertA, Sceare I PLOB (JE CACMCA UAV/SS & POLCY) 2019 Big Palloy - The Cach Republic Satemert, T. Rosol S, LicertA, Sceare I PLOB (JE CACH = CACH REPUBLIC) 2019 Big Palloy - The Cach Republic Satemert, T. Rosol S, LicertA, Sceare I PLOB (Sate Tach Tach Republic) 2019 Big Palloy - The Cach Republic Satemert, T. Rosol S, LicertA, Sceare I PLOB (Sate Tach Tach Republic) Sateteeeeeeeeeeeeeeeeeeeeeeeeeeeeee	2017 2018 2017 2017
2 20180828 WebOfScient 2 20180828 scopus 2 20180827 pubmed 2 20180827 pubmed 2 20180828 WebOfScier 9 20180827 pubmed 4 20180827 pubmed 1 2 20180828 pubmed	y n y te y y n y y y y y y	y y y	У	n N N N	r I	y n	System Revente Current System Systema Current Systema Manag Carren 2018 Janz 27(6):18. order date-2018/07(11 [refs.arbitor). 2019 Reg Fuely Inde Current Regulation. Stoapa A Manag Carren 2018 Janz 27(6):18. order date-2018/07(11 [refs.arbitor). 2019 Reg Fuely Inde Current Regulation. Stoapa A Value Headth Regulations. Order Headth Systema A 2019 Reg Fuely Inde Current Regulation. Stoapa A Value Headth Regulations. Stoapa A 2019 Rel Exclusion. Stoapa A Stoapa A Rel Current Systema A Stoapa A 2019 Stoapa A Stoapa A Stoapa A Rel Current Systema A Stoapa A 2019 Stoapa A Stoapa A Stoapa A Rel Current Systema A Stoapa A 2019 Stoapa A Stoapa A Stoapa A Rel Current Systema A Stoapa A 2019 Stoapa A Stoapa A Stoapa A Rel Current Systema A Stoapa A 2019 Stoapa A Stoapa A Stoapa A Rel Current Systema A Stoapa A 2019 Stoapa A Stoapa A	2017 2018 2017 2017
2 20180828 WebOfScient 2 20180827 pubmed 2 20180827 pubmed 2 20180827 pubmed 7 20180827 pubmed 4 20180828 pubmed 12 20180828 pubmed 7 20180828 pubmed 12 20180828 pubmed 7 20180828 pubmed	y n y y n y n y y n y y y	y y y	Ÿ	* * *		y n y n	Bends Publis for Tangapering On Dialeo Drag Prices. Simema E. Manag Care. 2018 Janz, 27(6):18. Create date-2018/07(11) [Frit author:Sheema E. 010 Prior Prior Core Regulation. Simema E. Sime E. Sime E. Sime E.	2017 2018 2017 2017
2 20180828 WebO/fscienc 2 20180827 scpuus 2 20180827 pubmed 2 20180828 WebO/fscienc 2 20180827 pubmed 7 20180828 pubmed 4 20180827 pubmed 12 20180828 pubmed 7 20180828 pubmed 12 20180828 pubmed 12 20180828 pubmed 4 20180827 pubmed	у п у у п у л у у у у у у у у	y y y	¥	n 9 0 0 0 0 0 0 0 0 0 0 0 0 0	• •	y n y n	Bends hunds for franzpiers(n) Dialogits Drug Prices. Simema E. Manag Care. 2018 Junz/2016 Jung. Crede Adea/2016 JULG Franzpiers 2019 Proje Price Deck Pepublic. Sicolay J. Value Head Hingdown Lasse Sicolay J. Value Head	2017 2018 2017 2017
2 20180828 WebOSScience 2 20180828 scopus 2 20180827 pubmed 2 20180828 pubmed 2 20180827 pubmed	у п у у п у п у л у у у у у у у	y y y y	v		• •	y n y n	Bendra Junks for Tanagarency On Dalace Drag Prices. Simema E. Manage Cance Diala Auge Tanagarency On Dalace Drag Prices. Simema E. Manage Cance Diala Auge Tanagarency Diala Cance Diala Diala Auge Tanagarency Diala Diala Cance Diala Diala Cance Diala	2017 2018 2017 2017
2 20180828 WebOfScient 2 20180827 pubmed 2 20180827 pubmed 2 20180827 pubmed 9 20180828 WebOfScier 9 20180827 pubmed 10 20180827 pubmed 12 20180828 pubmed 12 20180828 pubmed 12 20180828 pubmed 2 20180827 pubmed	γ п ce γ γ п γ η γ γ γ γ γ γ γ γ γ γ γ γ γ	y y y y		n y n n y n y		y n y n	Parts Remark E. Re	2017 2018 2017 2017
2 2018/828 WebOScene 2 2018/828 copust 2 2018/828 copust 2 2018/828 WebOScene 7 2018/828 pubmed 2 2018/828 pubmed 4 2018/828 pubmed 4 2018/828 pubmed 4 2018/827 pubmed 5 2018/827 pubmed 2 2018/827 pubmed 2 2018/827 pubmed	γ п *e γ γ η γ η γ η γ γ γ γ γ γ γ γ γ γ γ γ γ	y y y y y		n Y N N Y N N Y N N N Y		y n y n y n	Pages Revanda Punks for Transprency On Dalace Drag Prices. Seman E. Revanda Punks for Transprency On Dalace Drag Prices. Seman E. Revanda Punks for Transprency Drag Prices. Reveada Punks for Transprency Drag Prices. Seman E. Reveada Punks for Transprency Drag Prices. Reveada Punks for Transprency Drag Punks for Transprency Drag Prices. Seman E. Seman E	2017 2018 2017 2017
2 2018/08/28 Web/OfScience 2 2018/08/28 copust 2 2018/08/27 pubmed 2 2018/08/27 pubmed 2 2018/08/28 pubmed 4 2018/08/27 pubmed 2 2018/08/28 pubmed 4 2018/08/27 pubmed 2 2018/08/27 pubmed 2 2018/08/27 pubmed 2 2018/08/27 pubmed 2 2018/08/27 pubmed 2 2018/08/27 pubmed 2 2018/08/27 pubmed	γ п 2000 γ γ η γ η γ η γ γ γ γ γ γ γ γ γ γ γ γ γ	у У У У У	Y	n Y n n Y n Y Y		y n y n y n	Pages Revandary Junity and Prantypiers (2010) Revandary Strength Revandary Strength <th< td=""><td>2017 2018 2017 2017</td></th<>	2017 2018 2017 2017
2 2018/023 WebOTScient 2 2018/023 Keopus 2 2018/023 Pubmed 2 2018/023 Pubmed 3 2018/023 Pubmed 4 2018/023 Pubmed 7 2018/023 Pubmed 7 2018/023 Pubmed 5 2018/023 Pubmed 5 2018/023 Pubmed 2 2018/023 Pubmed 2 2018/023 Pubmed 2 2018/023 Pubmed 2 2018/023 Pubmed	у п 22 у Л 32 у Л 34 37 37 37 37 37 37 37 37	y y y y y	×	n Y n N Y N N Y N N N Y		y n y n y n	Parses Names Cance Names Cance <t< td=""><td>2017 2018 2017 2017 2017</td></t<>	2017 2018 2017 2017 2017
2 2018/08/28 WebOTScient 2 2018/08/28 Gooput 2 2018/08/28 pubmed 2 2018/08/27 scopus	у п у 7 22 у 7 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	y y y y y		n 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	r r r	y n y n	Parses Revands Punkter Strangerency On Daketo Bruge Process Steman E. Manage Care 2018 Junz (276) (116) Center Care 2018 Junz (276) (116) Center Care 2018 Junz (276) 2007 Poil Poil Poil y Into Confer Republic Stoop (116) Stoop	2017 2018 2017 2017 2017 2017 2017
2 2018/023 WebOTScient 2 2018/023 keopus 2 2018/023 pubmed 2 2018/023 pubmed 4 2018/023 pubmed 4 2018/023 pubmed 7 2018/023 pubmed 5 2018/023 pubmed 5 2018/023 pubmed 2 2018/023 scopus	у п у п 22 у п у п у п у п у п у п у п у п	y y y y y		n y n y y n n y	•	y n y n y n	Joseph Standard Manuag Lance 2018 Junit 2018 Jun	2017 2018 2017 2017 2017 2017 2017 2017 2017
2 2018/028 WeeOfScene 2 2018/028 coopus 2 2018/028 pubmed 2 2018/027 pubmed 2 2018/027 pubmed 2 2018/027 pubmed 2 2018/027 pubmed 2 2018/027 pubmed 2 2018/027 pubmed 2 2018/028 coopus 2 2018/028 coopus 2 2018/028 voopus 2 2018/028 voopus 2 2018/028 voopus	у п у 2 3 3 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5	y y y y y		n 9 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	•	y n y n y n	Bends hunds for franzgenergy On black bin Dig Netzen. Manuag Cance 2018 Junz 27(b): 1.0. medic 2018 Junz 27(b): 1.0. <thmedic 1.0.<="" 2018="" 27(b):="" junz="" th=""> medic 2018(</thmedic>	2017 2018 2017 2017 2017 2017 2017 2017 2017 2017
2 2018/023 WeeOfScient 2 2018/023 keeOfScient 2 2018/023 pubmed 2 2018/023 pubmed 2 2018/023 pubmed 3 2018/023 pubmed 4 2018/027 pubmed 5 2018/023 pubmed 5 2018/023 pubmed 2 2018/023 pubmed 2 2018/023 pubmed 2 2018/023 pubmed 2 2018/023 pubmed 2 2018/023 keepuis 2 2018/023 keepuis 2 2018/023 keepuis 2 2018/023 keepuis 2 2018/023 keepuis	у п 	y y y y y		n 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	•	y n y n y n	Joseph Solution Manual Solution Manual Solution Constraints 1000000000000000000000000000000000000	2017 2018 2017 2017 2017 2017 2017 2017 2017
2 2016/023 WebOTScent 2 2018/023 Keopus 2 2018/023 pubmed 2 2018/023 webOTScent 2 2018/023 webOTScent 2 2018/023 pubmed 2 2018/023 webOTScent 2 2018/023 pubmed	у п у 22 у 7 у у у у у у у у у у у у у	y y y y y		n 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	•	y n y n y n	Bends hulls for franzpiers() to flaste Drag Process Simma E. Mang Care 2018 Junz (2018) Center 2018 Junz (2018) 100 Process Franz (1000 Process) Simma E. Maine Care 2018 Junz (2018) Simma E. Maine Care 2018 Junz (2018) 100 Process Franz (1000 Process) Simma E. Maine Care 2018 Junz (2018) Simma E. Maine Care 2018 Junz (2018) Simma E. Junz (1000 Process) Simma E. Junz (1000 Process) Jun	2017 2018 2017 2017 2017 2017 2017 2017 2017 2017
2 2018/023 WeeOfScient 2 2018/023 KeeOfScient 2 2018/023 pubmed 2 2018/023 pubmed 4 2018/023 pubmed 4 2018/027 pubmed 4 2018/027 pubmed 5 2018/023 keeOfScien 5 2018/023 keeOfScien 5 2018/023 pubmed 5 2018/023 pubmed	у п у у γ γ γ γ γ γ γ γ γ γ	Y Y Y Y Y Y		n 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	•	y n y n y n	Best Manual for any period programme for any period prog	2017 2018 2017 2017 2017 2017 2017 2017 2017 2017
2 2016/023 WebOTScene 2016/023 WebOTScene 2016/023 Koopus 2016/023 Pubmed 2016/023 Pubmed	у п у 7 у 7 у 7 у 7 у 7 у 7 у 7 у 7	Y Y Y Y Y Y		n n n Y N N Y n n N Y N N N Y N	•	y n y n y n	Bends hulls for franzgency Dn Daket Drag Proces. Simma E. Mang Canc Disk Jung Zipping. Center Disk Jung Zipping. 2007 B0 Proj Proce Creck Pegadia. Singa Jung Zipping. Singa Jung Zipping. Singa Jung Zipping. 2007 B0 Proj Proce Creck Pegadia. Singa Jung Zipping. Singa Jung Zipping. Singa Jung Zipping. 2007 B0 Proce Proce Pegadia. Singa Jung Zipping. Singa Jung Zipping. Singa Jung Zipping. 2008 B0 Proce Pegadia. Singa Jung Zipping. Singa Jung Zipping. Singa Jung Zipping. 2008 B0 Proce Pegadia. Singa Jung Zipping. Singa Jung Zipping. Singa Jung Zipping. 2008 B0 Proce Pegadia. Singa Jung Zipping. Singa Jung Zipping. Singa Jung Zipping. 2009 B0 Proce Pegadia. Singa Jung Zipping. Singa Jung Zipping. Singa Jung Zipping. 2009 B0 Proce Pegadia. Singa Jung Zipping. Singa Jung Zipping. Singa Jung Zipping. 2009 B0 Proce Pegadia. Singa Jung Zipping. Singa Jung Zipping. Singa Jung Zipping. 2009 B0 Proce Pegadia. Singa Jung Zipping. Singa Jung Zipping	2017 2018 2017 2017 2017 2017 2017 2017 2018
2 2018/023 WebOfScent 2 2018/023 KebOfScent 2 2018/023 pubmed 2 2018/023 pubmed 4 2018/023 pubmed 4 2018/023 pubmed 7 2018/023 pubmed 7 2018/023 pubmed 7 2018/023 pubmed 2 2018/027 pubmed 2 2018/027 pubmed 2 2018/023 pubmed	у п у у у у у 7 у 7 у 7 у 7 у 7 у 7			n 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9		y n y n y n	Best Manual Construction Second Seco	2017 2018 2017 2017 2017 2017 2017 2017 2017 2017
2 2016/023 WebOTScene 2016/023 WebOTScene 2016/023 WebOTScene 2016/023 Pubmed 2016/023 Pubmed	Υ η γ γ γ γ γ γ γ γ γ γ	y y y y y y y y y		n n n n y n y n n y n n y n n y n n		y n y n y n	Bend Audie for Transprency On Diale Drag Process Simma E. Manage Cance 2014 Auge Cancel 2014 Auge Cancee 2014 Auge Cancel 2014 Auge Cancel 2014 Auge Canc	2017 2018 2017 2017 2017 2017 2017 2017 2018
2 2018/023 WebOfScent 2 2018/023 Keopus 2 2018/023 pubmed 2 2018/023 pubmed 2 2018/023 pubmed 4 2018/027 pubmed 2 2018/028 scopus 2 2018/028 pubmed 2 2018/028 pubmed	У п 22 У 7 У 7 У 7 У 7 У 7 У 7 У 7 У 7	y y y y y y y y y y y		n n 7 n n 7 7 n 7 7 n 7 7 n 7 7 7 7 7 7		y n y n y n	P398 Manual Andrahas for Sampage Park (Display Register) Manual Sampage Park (Display	2017 2018 2017 2017 2017 2017 2017 2017 2017 2018
2 20160828 WebOfScent 2 20180828 pubmed 2 20180827 pubmed 2 20180828 scopus 2 20180828 webOfScent 2 20180828 webOfScent 2 20180828 scopus 2 20180828 scopus 2 20180828 scopus 2 20180828 scopus	Y л Y 7	y y y y y y y y y y y y y y y y		n n n n n y n n y n n y n n y y n n n y y n n n y y n n n y y n n n y n n n y n		y n y n y n	Jose Solution Jose Solution Jose Solution Jose Solution Jose Solution 1998 Non-Proceed Register Solution Meet Solution	2017 2018 2017 2017 2017 2017 2017 2017 2018
2 2018/08/28 WeeOfScient 2 2018/08/28 (webOfScient 2 2018/08/27 pubmed 2 2018/08/27 pubmed 4 2018/08/27 pubmed 4 2018/08/27 pubmed 4 2018/08/27 pubmed 2 2018/08/28 (webOfScient 2 2 2018/08/28 (webOfScient 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Υ η 22 24 37 4 37 4 4 4 4 4 4 4 4 4 4 4 4 4	y y y y y y y y y y y y y y y y y		n n n n n y n y n n y n n n n n n n n n	•	y n y n y n	Best Manual for any period programme (manual period p	2017 2018 2017 2017 2017 2017 2017 2017 2017 2017
2 2018/0828 WebOfScent 2 2018/0828 pubmed 2 2018/0827 pubmed 2 2018/0828 pubmed 2 2018/0827 pubmed 2 2018/0828 pubmed	У л Y У Y л Y ۲ Y ۲ Y ۲ Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y Y Y Y Y Y		n n n n n n y n n n n n n y y n n n n n	•	y n y n y n	Page 30 Manual Sec 2000, 2	2017 2018 2017 2017 2017 2017 2017 2018
2 2018/08/28 WebeOfScient 2 2018/08/28 scopus 2 2018/08/27 pubmed 2 2018/08/27 pubmed 2 2018/08/27 pubmed 2 2018/08/27 pubmed 4 2018/08/27 pubmed 4 2018/08/27 pubmed 7 2018/08/27 pubmed 2 2018/08/27 pubmed 2018/08/27 pubmed <td> Y A Y Y</td> <td>y y y y y y y y y y y y y y y y y y</td> <td></td> <td>n n 7 0 0 7 7 7 0 7 7 0 7 7 0 7 7 7 7 7</td> <td></td> <td>y n y n y n</td> <td>Beak Manual Social Sociel Social Social</td> <td>2017 2018 2017 2017 2017 2017 2017 2017 2018</td>	 Y A Y Y	y y y y y y y y y y y y y y y y y y		n n 7 0 0 7 7 7 0 7 7 0 7 7 0 7 7 7 7 7		y n y n y n	Beak Manual Social Sociel Social	2017 2018 2017 2017 2017 2017 2017 2017 2018

